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Abstract 
 
The central goal of this dissertation is to evaluate the feasibility of lipidic cubic phase gels 
(LCPs) and their dispersed nanoparticles (cubosomes) as self-assembled nanoreactor 
scaffolds for heterogeneous catalysis, and to design and develop such systems. This novel 
approach exploits, among other things, the very large lipid/water interface of LCPs, thereby 
performing efficient aqueous chemistry that takes place in the structured aqueous channels 
of the mesophases. Since LCPs can be doped with guest lipids without losing their three-
dimensional architecture, such materials have a large potential for designing tailor-made 
functional biomaterials. Finally, these materials can coexist with any amount of excess water, 
thereby making them ideal matrices for heterogeneous reactions. Thus, research in this 
direction is necessary and opens exciting new avenues to discoveries in materials science 
and technology.  
Functionalization of LCPs and cubosomes was achieved using various approaches. Lipidic 
proline-derived organocatalysts were designed, synthesized, and incorporated into the 
mesophases, and the kinetics and stereochemistry of a model aldol reaction was 
investigated. The kinetics of the model aldol reactions are tunable by modifying the diameter 
of the aqueous channels. Similarly, lipidic Pt-catalyst were synthesized and used as additives 
in LCPs to hydrolyze phosphate-ester derived pesticides that are structurally related to 
chemical warfare agents such as sarin. Palladium nanoparticles (PdNPs), known to be 
synthesized in the aqueous compartment of LCPs at ambient conditions, were used to 
catalyze Suzuki-Miyaura cross coupling reactions. Interestingly, catalysis is only possible if 
the aqueous channels of the LCPs are being enlarged after PdNP synthesis. This allows for 
an “on demand” on/off switching of the Suzuki-Miyaura cross coupling. Additionally, attempts 
to immobilize enzymes electrostatically and via lipidic modification were made. 
An additional goal of this thesis was to synthesize a small library of cyclopropanated lipids as 
building blocks of mesophases with novel properties. The mesophases of these compounds 
exhibit remarkable low temperature phase behavior, which was investigated in a joint project 
with the group of Prof. Raffaele Mezzenga at the ETH. Most importantly, confined water in 
LCPs of the doubly cyclopropanated lipid DCPML was shown to remain liquid down to -11 
°C, rendering these materials interesting for various biochemical and biophysical 
investigations of systems that are unstable at ambient temperatures. 
A third project was launched in collaboration with the group of Prof. Dr. Dr. med. Daniel 
Eberli at the University Hospital Zurich to develop cubosomes which enable controlled 
oxygen release and delivery to anoxic muscle cells. To this end, lipidic pyridone 
endoperoxides were synthesized and incorporated in cubosomes. Preliminary data indicate 
that such host-guest cubosomes could affect cellular reactivity to hypoxia by providing 
oxygen to the cells. 
 
 
Zusammenfassung 
 
Das zentrale Ziel dieser Dissertation ist, die Evaluation der Machbarkeit lipidischer kubischen 
Phasen (LCPs) und deren dispergierten Nanopartikel (Cubosomes), als selbstassemblierte 
Nanoreaktor-Gerüste für die heterogene Katalyse zu prüfen und solche Systeme zu planen 
und zu entwickeln. Dieses neue Konzept nutzt, unter anderem, die grosse Lipid-Wasser-
Oberfläche aus, um effiziente wässrige Synthesen in den strukturierten wässrigen Kanälen 
der Mesophasen durchzuführen. Da LCPs mit Additiv-Lipiden versehen werden können, 
ohne die dreidimensionale Architektur zu verlieren, haben diese Materialien grosses 
Potential, um massgeschneiderte, funktionale Biomaterialien herzustellen. Zudem sind LCPs 
in Anwesenheit von überschüssigem Wasser stabil, was aus diesen Materialien ideale 
Matrizen für heterogene Katalyse macht. Forschung in diese Richtung ist erforderlich und 
eröffnet neue, spannende Wege und Entdeckungen in Materialwissenschaften und Technik. 
 
Die Funktionalisierung der LCPs und Cubosomes wurde auf verschiedenen Wegen erreicht. 
Lipidische prolinverwandte Organokatalysatoren wurden entworfen, synthetisiert und in die 
Mesophasen eingebaut um die Kinetik und die Stereochemie einer Model-Aldol-Reaktion zu 
untersuchen. Die Kinetik dieser Model-Aldol-Reaktion konnte durch Modifikation der 
Durchmesser der wässrigen Kanäle gesteuert werden. 
Pt-Katalysatoren wurden hergestellt und, ähnlich wie zuvor, in die Mesophasen eingebaut 
um Phosphatester mit kampfstoffähnlicher Struktur wie z.B. Sarin, zu hydrolysieren und 
unschädlich zu machen. Palladium-Nanopartikel, die bekanntlich in den wässrigen Kanälen 
von LCPs unter Umgebungsbedingungen gebildet werden, wurden für die Katalyse von 
Suzuki-Miyaura-Kreuzkupplungen verwendet. Interessanterweise ist die Katalyse nur 
möglich, wenn die wässrigen Kanäle nach der Palladium-Nanopartikel-Synthese vergrössert 
werden. Dies ermöglicht, die Reaktion mit einem “Schalter“ bei Bedarf an- oder 
auszuschalten. Zusätzlich wurden Versuche gemacht, um Enzyme in den Mesophasen 
elektrostatisch oder via lipidische Modifikation zu immobilisieren. 
Ein zusätzliches Ziel dieser Arbeit ist es, eine Serie von cyclopropylierten Lipiden als 
Bestandteile von Mesophasen mit neuen Eigenschaften zu synthetisieren. Die Mesophasen 
dieser Verbindungen zeigen aussergewöhnliche Eigenschaften bei tiefen Temperaturen. 
Diese Eigenschaften wurden in einem gemeinsamen Projekt mit der Gruppe von Prof. 
Raffaele Mezzenga an der ETH untersucht. Dabei wurde in den LCPs des 
zweifachcyclopropylierten Lipids DCPML “confined water“ gefunden, also Wasser, das in 
sehr wenig Raum eingeengt ist und das trotz Temperaturen von bis -11 °C nicht einfriert. 
Dies macht diese Materialien interessant für biochemische und biophysikalische 
Untersuchungen von Systemen, welche bei Raumtemperatur nicht stabil sind. 
Ein drittes Projekt wurde in Kollaboration mit der Gruppe von Prof. Dr. Dr. med. Daniel Eberli 
vom Universitätsspital Zürich gestartet, um Cubosomes zu entwickeln, die eine kontrollierte 
Abgabe und Zufuhr von Sauerstoff zu anoxischen Muskelzellen ermöglichen. Hierfür wurden 
lipidische Pyridonendoperoxide synthetisiert und in Cubosomes eingebaut. Erste Daten 
deuten darauf hin, dass diese Cubosomes die zelluläre Reaktivität dieser Zellen auf Hypoxia, 
durch die Sauerstoff-Zufuhr beeinflussen. 
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Chapter 1  
1.1 General Introduction  
1.1.1 Lipids – prelude 
 
Lipids are fascinating molecules, and they are the building blocks of lipidic mesophases which 
are the core of this thesis. Before structure, properties, preparation and applications of lipidic 
mesophases will be introduced and discussed, a short general overview of these mesophase 
building blocks will be provided. 
Lipids are considered as biological substances that are insoluble in water due to their 
hydrophobic or amphiphilic nature. Natural lipids can be composed of two different 
biosynthetic subunits, which are ketoacyl and isoprene moieties.1 They can be divided into 
eight groups:  
 
• Fatty acids consist of a hydrocarbon chain and a carboxylic acid head group. These 
two moieties render fatty acids amphiphilic, though insoluble in water. The 
hydrocarbon chain length can vary from 4 to 24 carbons and can be either saturated 
or unsaturated.2  
• Glycerolipids have a glycerol head group that can bear one to three fatty acid 
substituents attached via ester bonds. These lipids function as energy storage for 
mammals. Hydrolysis of the ester group is the initial step in fat digestion.2 
• Phospholipids bear a phospho-glycerol head group. They play important roles in lipid 
bilayer of cells and in cell signaling.3 
• Sterol lipids are important elements of membranes. Cholesterol is the most prominent 
representative of this class of lipids. Steroids are derived from a fused four ring 
framework and play important roles as hormones.4 
• Saccharolipids are esters of fatty acids and a monosaccharide.  
• Sphingolipids are a broad class of lipids derived from the amino acid serine and 
contain a phosphate group. 
• Prenol lipids are isoprene derived lipids. They are synthesized via the mevalonic acid 
pathway.5  
• Polyketides  
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Figure 1: Structures of monoolein, a glycerolipid; oleic acid, a fatty acid; cholesterol, a sterol lipid; and 
1,2-Distearoyl-sn-glycero-3-phospho-rac-(1-glycerol), a phospholipid. 
 
The class of glycerolipids plays a central role in this thesis, with monoolein (MO) as their 
representative, responsible for the unique architecture of lipidic cubic phases discussed in the 
research herein. Examples of the classes of fatty acids, phospholipids and sterol lipids have 
been used as additives to modify the properties of the lipidic mesophase applied in this thesis. 
Thus, for example, the aqueous channel radii were enlarged to enable electrostatic 
interactions with enzymes. 
Mammals transform carbohydrates, if an excess is available, to triglycerides. This process is 
called lipogenesis. Fatty acid synthases polymerize and reduce acetyl-CoA building blocks, 
whereas sterol and prenol lipids are built up from reactive isopentenyl pyrophosphates.5 The 
metabolic process of lipid digestion is called ß-oxidation. After a sequence of 
dehydrogenation, hydration and oxygenation, a ß-keto acid is formed which is cleaved by 
thiolysis to generate acetyl-CoA.2 
Historically, lipids were divided into two categories: solid and fluid greases. This definition was 
refined and a classification into oils, greases, tallow, waxes, resins, balsams and essential oils 
was introduced.6 William Prout realized in 1827 that fats, together with carbohydrates and 
proteins are an essential part of human and animal’s nutrition.6 Triglycerides, phospholipids 
and cholesterol are among the most represented fats in food and are needed to enable the 
uptake of hydrophobic vitamins.2 Mammals, humans included, cannot produce all the required 
lipids: linoleic acid and α-linolenic acid for example, are essential and need to be directly 
absorbed from diet.2 Additionally, phospholipids, are a major element of biological 
membranes, like the cellular plasma membrane. Such membranes are responsible for the 
compartmentalization in cells by spatial separation of different organelles. Furthermore, lipids 
play an important role in cell signaling. Activation of G protein-coupled receptors occurs upon 
lipid signaling,7–9 whereby several lipid classes are involved in cell signaling processes.10 
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1.1.2 Lipidic self-assembly  
 
Hydrated lipids tend to aggregate and form self-assembled structures. The major driving force 
for amphiphilic self-assembly is the hydrophobic effect, which leads to the minimization of the 
interface between the hydrocarbon tails of the amphiphile and water molecules. The ensuing 
supramolecular structures can feature different phases, depending on molecular shape, 
concentration, temperature and pressure, whereas their complexity reaches from one-
dimensional (lamellar Lα, micellar L) over two-dimensional (hexagonal, H) to more complex 
three-dimensional (cubic, Q) morphologies (Figure 2). This phenomenon is referred to as lipid 
polymorphism.11,12 The ratio of the molecular volume, length of the lipidic chain and the head 
group area determines the packing parameter and as follows the curvature of the lipidic 
bilayer.13  
 
Figure 2: A) The profiles of a liposome, a micelle and a lipidic bilayer. Reprinted with permission from 
Ref. 12. B) Schematic illustration lipidic self-assembled structures, depending on the packing 
parameter P, which depends on the molecular volume (v), the area of the head group (a), and the 
length of the molecule (l). Reprinted with permission from Ref. 13. 
 
 
1.1.3 Lipidic cubic phases 
 
Lyotropic liquid crystals (LLCs) are liquid crystals that are located between the liquid and solid 
state of matter, and are often referred to as the “fourth state of matter”. Lipidic cubic phases 
(LCPs) are a special form of LLCs that form spontaneously upon mixing water and lipids, and 
possibly a small amount of additive, in a certain ratio given by the phase diagram (Figure 3). 
2 ISRN Pharmaceutics
Liposome
Micelle
Bilayer sheet
Figure 1: Aspects of liposomes and micelles. A representation of
the steric organization of a liposome (left) and a micelle (right).
Liposomes have a lipidic bilayer (bottom) whereas micelles are
constructed only by one lipid layer that has its apolar section turned
inwards while its polar heads interact with the environment. As a
result, the enclosed space in micelles is much more confined to that
available in liposomes.
provide for an upgraded biopharmaceutical profile through
reduced toxicity and favourable pharmacokinetic behaviour
and an improved therapeutic index in comparison to the
free-form drug.
3. Physiochemistry of Liposomes
The eﬃcacy of liposomes as a colloidal storage and carrier
system for biologically drastic substances greatly depends on
the physiochemical properties of their membranes and the
nature of the enclosed agent. The former include their size,
surface charge, lipidic organization, and chemical constitu-
tion, among others [6]. Hereinafter follows a generalized
presentation of the physical and chemical traits of liposomes.
3.1. Chemical Traits. Liposomes are composed of lipids.
Lipids are amphiphile biomolecules that have either a
charged or neutral polar head and at least one hydrophobic
aliphatic chain. They are generally immiscible to aqueous
solutions but very soluble to organic solvents. Although there
are many types of lipids, liposomes are mainly consisted
of phospholipids that have a hydrophilic head and two
apolar hydrophobic chains (Figure 2). When dispersed in
aqueous solutions, their steric organization aims tominimize
the interactions between the hydrophobic chains and water
molecules, thus spontaneously forms bilayer membranes, the
liposomes [7]. Inside these membranes, ions or molecules
can be encapsulated, provided that they are present during
the formulation process. The final arrangement of lipids
Hydrophobic tail
Hydrophilic headAqueous solution
Figure 2: The fundamental organization of liposomes. In this figure
one can observe the fundamental organization of liposomes with
one bilayer and the direction that phospholipids adopt in order to
form it.
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Figure 3: Departmental structure and charge distribution of a
typical phosphoglyceride. On the left is the polar phosphoric group
esterified to the hydroxyl group of an alcohol. On the right is the
apolar aliphatic chains esterified to the central moiety, which is a
glycerol.
depends on their concentration, temperature, and geometric
form.
3.1.1. Anatomy of a Phospholipid. A typical phospholipid is
divided into four sections (Figure 3) [8]:
(1) the fatty acid section,
(2) a moiety onto which the fatty acids can be attached,
(3) a phosphate group,
(4) an alcohol attached to the phosphate.
The fatty acid section acts as a hydrophobic fence while
the remaining part of the molecule is hydrophilic and can
thus interact with the aqueous surrounding of the liposome.
The moiety onto which the fatty acids can be attached is usu-
ally glycerol but can also be sphingosine [9, 10]. Laboratory
liposomal formulation uses glycerol-based phospholipids,
also called phosphoglycerides. Glycerol’s hydroxyl groups of
C1 and C2 are each esterified to the carboxyl group of a
fatty acid. The C3 hydroxyl group is esterified to a phosphate
group which is in turns esterified to the hydroxyl group of
an alcohol. This alcohol group usually belongs to choline,
serine, and glycerol but can be also provided from inositol or
This journal is the Owner Societies 2011 Phys. Chem. Chem. Phys., 2011, 13, 19195–19205 19197
The phase space of lipi s encompasses both lamellar and
curved structures, and topologies of a high genus number
may also arise. We shall return to curved lipid aggregates
below and discuss how they relate to curvature stress fields and
the lateral pressure profile of lipid bilayers.
Lipids in the planar, lamellar phase display a number of
phase transitions of which the so-called main phase transi-
tion is the most important one in relation to the lateral,
molecular organization of the bilayer, although in some lipid
bilayers other transitions separate diﬀerent solid phases, in
particular the so-called rippled phase.26 The main phase
transition takes the bilayer from a low-temperature solid-
ordered phase t a high-temperature liquid-disordered
phase. The main phase transition is a first-order transition27
but for certain lipids the transition is close to a critical
point28–30 which implies that the transition is associated with
strong precursor fluctuation eﬀects that manifest themselves
in anomalies in various response functions, such as specific
heat, mechanical moduli (bending modulus, area compr ssion–
expansion modulus), sound velocity etc.20 The fluctuation-
induced softening of the bilayer in the transition region31
correlates with anomalies in e.g. passive permeability and
partitioning of solutes.32,33
Most importantly, the main phase transition and the underlying
collective phenomena are the source of lateral organization and
density fluctuations of the bilayer, e.g. in the form of macroscopic
phase separation and lateral compositional fluctuations in the
case of binary mixtures and multi-component systems. This
leads to both static and dynamic heterogeneity on various
length scales, depending on the correlation length of the lipid
fluctuations.27,34 It has been known for a long time that these
phenomena result in the occurrence of diﬀerentiated regions in
the plane of the membrane in the form of lipid domains.27,35–37
Lipid domains have been found in a wide range of lipid bilayer
mixtures,38–49 e.g. by the use of various microscopy techniques,
in particular atomic force micr scopy and fluorescence
microscopy. Some examples are shown in Fig. 2. Previous
variance in the size of the reported domains in diﬀerent models
of the same systems, e.g. supported bilayers and giant unilamellar
vesicles, seems now to have been clarified by taking into account
the possible interaction between the bilayer of the support for
planar layers and the coupling b tween the bilayer curvature
and the line tension of the domains in curved bilayers.50
The phase equilibria in multi-component lipid bilayers can
imply solid and liquid phases, as well as solid–solid, solid–liquid,
as liquid–liquid phase separation.51 Coexisting fluid phases in a
Fig. 1 Schematic illustration of lamellar and non-lamellar lipid aggregates formed by self-assembly processes in water.24 The diﬀerent structures
have diﬀerent senses of curvature and are arranged in accordance with the value of the phenomenological molecular packing parameter, P = n/al,
where n is the molecular volume, a is the cross-sectional area of the head group, and l is the length of the molecule.
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They are gel-like and stable materials with a well-defined 3-dimensional nanostructure and 
exhibit two non-intercommunicating aqueous channel system. LCPs are thermodynamically 
stable in excess of water and show a combination of other useful properties: optical 
transparency, biocompatibility, deformability, and adhesivity to hydrophilic as well as 
hydrophobic surfaces. Another important property of LCPs for the realization of the project 
described herein is the ability to host a wide variety of guest lipids with a broad range of 
properties.14–16 Guest lipids, often also referred to as additives, usually have an amphiphilic 
character or are hydrophobic since they otherwise would be dissolved in water and washed 
away. Such additives can be small or large, positively or negatively charged or neutral, and 
can bear any conceivable functional groups and moieties, such as chromophores, photo 
switches or catalysts.  
Monoolein (MO) is the best-studied lipid that forms LCPs. It consists of a glycerol headgroup 
coupled through an ester bond to an oleyl chain (Figure 1). The phase behavior of the 
MO/water system and the structure and properties of the ensuing mesophases is well 
described in literature (Figure 3).17 Such phase diagrams have been constructed by 
systematically varying temperature and hydration degree of this binary system. The phases 
and their transitions were identified using small angle X-ray scattering (SAXS), differential 
scanning calorimetry (DSC) and microscopy.18–22  
 
 
Figure 3: Binary phase diagram of monoolein and water with representation of the various phases. 
Abbreviations: FI, fluid isotropic phase; HII, inverted hexagonal phase; Lα , lamellar liquid crystalline 
phase; Lc, lamellar crystal phase. Reprinted with permission from Ref. 17.  
 
Upon hydration at room temperature, MO exhibits phase transitions from lamellar crystalline 
(Lc) to lamellar liquid crystalline (Lα) in which lipids can laterally diffuse due to the increased 
water content. Further increase of water gives rise to a reorganization of the lamellar phase 
Whilst the repeat dispenser greatly facilitated the in meso method,
it was still a manual setup with limits to the number of trials that one
person could comfortably and reproducibly set up at a sitting. The
need to automate the process was obvious. With the assistance of A.
Peddi and Y. Zheng, engineers at The Ohio State University where
the original work was carried out, we were able to perform a proof-of-
principle robotics exercise employing LabView-controlled motorized
translation stages operating and supporting a micro-syringe and a
crystallization plate. The prototype was used to demonstrate that the
viscous mesophase could be dispensed automatically and wells filled
in such a way that eventually yielded crystals. This was sufficient to
secure funding for a robot, which was custom-designed and built to
our specifications (Cherezov et al., 2004).
The in meso robot has two arms programmed to move simulta-
neously. One dispenses the viscous protein-laden mesophase, while
the other dispenses precipitant. Typical volumes used are 30–50 nl
mesophase (consisting of 12–20 nl protein solution and 18–30 nl
monoolein) and 600–800 nl precipitant solution. Custom 96-well glass
sandwich plates were designed which take several minutes to fill using
an eight-tip robot. The robot enables the precise and accurate setting
up of in meso crystallization trials with picolitre to microlitre volumes
of mesophase in high-throughput mode and, if required, under
challenging conditions of reduced temperature and controlled
lighting. Given the success of the in meso robot, several are currently
in use in laboratories throughout the world. Variations on the original
design, in which tip alignment is performed automatically and in
which precipitant is handled by disposable tips, are now commercially
available. Another uses a 96-tip liquid-dispensing head to deliver
IYCr crystallization series
8 Caffrey ! Lipid cubic phase or in meso method Acta Cryst. (2015). F71, 3–18
Figure 5
Temperature–composition phase diagram of the monoolein–water system determined under conditions of use in the heating and cooling directions from 20"C. A schematic
representation of the various phase states is included, in which coloured zones represent water. The liquid crystalline phases below #17"C are undercooled and metastable
(Qiu & Caffrey, 2000). Abbreviations: FI, fluid isotropic phase; HII, inverted hexagonal phase; L!, lamellar liquid crystalline phase; Lc, lamellar crystal phase. Reprinted with
permission from Caffrey (2009). Copyright (2009) Annual Reviews.
Figure 6
The cubic phase is viscous and sticky; it has the consistency of thick toothpaste. The
particular toothpaste used in this figure contains small white crystals. This is exactly
what is sought when in meso crystallization trials are set up. The inset shows crystals
of the integral membrane light-driven proton pump bacteriorhodopsin growing in
the lipid cubic phase. The analogy between the toothpaste and the crystal-laden
mesophase is obvious.
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forming an Ia3d phase, a low-hydration bicontinuous cubic phase, which transforms to a 
higher-hydration bicontinuous cubic phase, denoted Pn3m phase. Upon further hydration, this 
phase does not dissolve, and is stable in excess of water. At low hydration and high 
temperatures, an isotropic fluid (FI) is formed. Upon raising the temperature to 85°C at a 
water content greater than 15%, phase transition from a bicontinuous cubic (Ia3d or Pn3m) to 
the inverse hexagonal phase (HII) takes place. This hexagonal phase, like the Pn3m cubic 
phase, is stable in excess water. The phenomenon of lipid polymorphism renders these 
materials interesting for application in diverse fields of science and technology.  
3,7,11,15-Tetramethyl-1,2,3-hexadecanetriol, usually called phytantriol (PT), is a synthetic 
lipid that is often used as a cosmetic ingredient because of its positive effects on moisture 
retention in the skin and enhancing penetration of panthenol, vitamins and amino acids.23 The 
mesophases of PT are, besides the ones of MO and monolinoleate, of the few that can be 
considered as safe to use in drug delivery applications.23 The phase behavior of the PT and 
water system is very similar to the one of MO and water. Noteworthy is the fact that the PT 
phase diagram is based on a mixture of stereoisomers. A major difference, however, is the 
lower hydration degree and smaller lattice parameter of the Pn3m cubic phase at excess 
water conditions as compared to MO.24 This is a disadvantage from our perspective, as in this 
project we plan to use LCPs as nanoreactors for catalysis. To that end, the chemical reactions 
in these systems should take place in the confined aqueous compartments, in which a 
maximal water proportion and aqueous channel diameter are certainly advantageous. 
Additionally, the lower hydration degree leads to a more viscous cubic phase. The absence of 
the ester group in PT is the main structural difference as compared to MO, resulting in PT 
being chemically much more stable than MO, since ester groups are prone to hydrolysis at 
strongly basic or acidic conditions. The same is true for in vivo applications in the presence of 
digestive enzymes. 
 
Figure 4: Phytantriol (PT) and water binary phase diagram and molecular structure of phytantriol. 
Abbreviations: L2, inversed micellar phase; HII, inverced hexagonal phase; Lα , lamellar liquid crystalline 
phase. Reprinted with permission from Ref. 23.  
This journal is c The Royal Society of Chemistry 2012 Chem. Soc. Rev., 2012, 41, 1297–1322 1299
that may more correctly be classified as ‘burst’ release
carriers.32,33 As a matrix for the controlled and/or sustained
release of hydrophilic ingredients, the QII microstructure is
also non-ideal as there are water channels open to the outside
aqueous media.34,35 Particle coating technologies are being
developed to try to ameliorate this feature.22,36 In this regard,
hexosomes w ich comprise infinitely long, hexagonally close
packed water cylinders, enclosed within a hydrophobic matrix,
may oﬀer a diﬀerent solution. LCCDs produced from a
discontinuous (inverse) micellar cubic phase, that comprises
discrete micelles isolated from the external environment
(Fd3m)37–39 oﬀer another alternative and have also shown
early romis for delivery (Fig. 4).40
The list of other (non-ionic) amphiphiles that exhibit the
requisite lyotropic phase behaviour is expanding and include
glycolipids 41–47 alkyl glycerates,48,49 urea (urea-like)50,51 and
mono-/di-ethanolamides.52–55 The QII, and to lesser extent HII
lyotropic liquid crystalline phase and their LCCDs have been
t e prime focu for development in this area. Despite the
growing interest in such ‘‘soft’’ materials, surprisingly little
consideration has been given to the systematic design and
synth sis of new amphiphiles. As a scientific community, our
understanding of surfactant and lipid phase science is still
evolving, albeit rapidly and in the quest to rationally
design novel mesophase systems, the challenge remains to
deconvolute the relationship between structure, composition,
and function. This critical review provides engineering guide-
lines for the design of ‘dilutable’ lyotropic liquid crystal phases
with two- and three-dimensional geometries from surfactants
and lipids. Specifically, we examine the requirements of
monolayer curvature, packing frustration, headgroup
hydrophilicity/functionality, paired with tail group hydro-
phobicity and fluidity, that combine to enable non-lamellar
self-assembly architectures. We examine the impact of these
considerations upon the phase behaviour of diverse classifica-
tions of surfactants and lipids with the view to providing
engineering guidelines for the design and synthesis of new
amphiphiles. For the purposes of this review, we will primarily
restrict ourselves to simple binary amphiphile–water systems
which form inverse cubic and/or hexagonal nanoarchitectures.
In the main, focus will be directed towards single chained,
non-ionic amphiphiles.
Inverse (Type II) lyotropic liquid crystalline
mesophases
The understanding of phase behaviour and the interconver-
sion between mesophases, in response to hydration and/or
external stimuli has been well described. In particular, the
structure of the HII phase and non-lamellar transitions
of biological based lipids have been described15 as has the
Fig. 2 Monoolein, the magic lipid showing the QDII (Pn3m) inverse bic tinu u phase stable in excess water.
Fig. 3 Temperature composition phase diagrams of (a) GMO
(re-drawn from ref. 60) and (b) phytantriol (re-drawn from ref. 30).
The chemical structure and 3D ball and stick representations are
superposed on the phase diagrams.
Pu
bli
sh
ed
 on
 05
 O
cto
be
r 2
01
1. 
Do
wn
loa
de
d b
y U
niv
ers
ity
 of
 Z
uri
ch
 on
 05
/11
/20
15
 10
:04
:48
. 
View Article Online
HO
OH
HO
Chapter 1 
 
 
 
6 
Bicontinuous cubic phases can adopt different defined space group geometries. The aqueous 
channels in the double gyroid cubic phase (Ia3d) possess a three-fold junction (Figure 5A), 
whereas the double diamond cubic phase (Pn3m) has a four-fold junction (Figure 5B), and the 
primitive cubic phase (Im3m) even a six-fold (Figure 5C).19,25 Notably, the Im3m cubic phase 
is not present in the MO/water phase diagram (Figure 3), however it is formed with other lipids 
or if additives are applied to MO cubic phases.26 
 
Figure 5: Topological Representation of the three bicontinuous cubic phases. Aqueous channels are 
colored in blue and green and the lipidic bilayer is colored yellow. A) Ia3d double gyroid cubic phase, B) 
Pn3m double diamond cubic phase, and C) Im3m primitive cubic phase.  
 
Even though these cubic phases show different three-dimensional structures, they share 
several properties. They consist of a curved lipidic bilayer that forms an infinite periodic 
minimal surface with zero mean curvature that is encompassed by two identical, but non-
intersecting water channel systems. Furthermore, lipids can diffuse laterally within its 
compartment whereas water can do so within the channels and to excess water reservoirs, if 
present.27  
The geometrical models of the cubic phases can be used to calculate the aqueous channel 
radii. The water-lipid interface in the bicontinuous cubic phase is assumed to be parallel to the 
minimal surface.28 The geometry and the lattice parameter a are determined by SAXS 
measurements and knowing the lipid volume fraction of the sample ϕ, the length of the lipid 
tail, l, can be calculated by solving the following cubic equation29: 
 Φ = 2$% &'()* + ,- ./ &'()* -                     (1) 
 
  
8 
 
 
lipid and water molecules can diffuse within their respective molecular compartments, and 
water can diffuse between the channels and an excess reservoir (21). A discontinuous cubic 
structure, which consists of reverse micelles packed in cubic crystalline domains (Fd3m) has 
also been intensely studied (8).  
 
         
Figure 4. Re resentation of the top logy of the three bicontinuous cubic phases with particul r attention
to the aqueous channel geometry. The water channels are depicted in blue and green, while the lipidic 
bilayer is colored in gold-yellow. A) Ia3d double gyroid cubic phase, B) Pn3m double diamond cubic 
phase, and C) Im3m primitive cubic phase. 
 
Geometrical con iderations can be used in or er to alculate the aqueous channel radius. For
the inverse bi ontinuous cubic phases, the water-lipid interface is assumed to be p rallel to the 
underlying minimal surface (TPMS) (22). By knowing from SAXS measurements the geometry 
and the lattice parameter a, and knowing the lipid volume fraction of the sample ϕ, the length 
of the lipid tail, l, can be calculated by solving the following cubic equation (23): 
 
Φ = 2𝐴0 (
𝐿𝑙𝑖𝑝
𝑎
) + 4
3
𝜋𝜒 (
𝐿𝑙𝑖𝑝
𝑎
)
3
                     (3) 
 
where 𝐴0 is the area of the surface in the unit cell in which the lattice parameter is equal to 
unity, and 𝜒 is the Euler-Poincare characteristic. Depending on the specific cubic phase they 
have the following values: 𝐴0 = 3.091 and 𝜒 = −8 for Ia3d; 𝐴0 = 1.919 and 𝜒 = −2 for 
Pn3m; and 𝐴0 = 2.345 and 𝜒 = −4 for Im3m. For the radius of the aqueous channels, r the 
following equations are valid for the Ia3d, Pn3m and Im3m phases, respectively (19): 
A B C 
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where $% is the area of the surface in the unit cell in which the lattice parameter is equal to 
unity, and / is the Euler-Poincare characteristic. Depending on the specific cubic phase they 
have the following values: $% = 3.091	and / = −8 for Ia3d; $% = 1.919	and / = −2 for Pn3m; 
and $% = 2.345	and / = −4	for Im3m. For the radius of the aqueous channels, r the following 
equations are valid for the Ia3d, Pn3m and Im3m phases, respectively20: 
 : = 0.248; − <=>?                       (2a) : = 0.391; − <=>?                       (2b) : = 0.3055; − <=>?                     (2c) 
 
 
1.1.4 Cubosomes 
 
In addition to their use as bulk gels, LCPs can be dispersed in water by ultra-sonication, 
forming nanoparticles that are denoted as cubosomes. Both LCPs and cubosomes exhibit a 
periodic, three-dimensional aqueous channel network and a very large lipid/water interfacial 
area (ca. 400 m2 g-1 lipid).30 Whereas bulk LCPs are malleable and can be attached to various 
surfaces due to their solid consistency and adhesive properties, cubosome nanoparticles 
dispersions have low viscosity and their appearance is comparable to the one of milk. Their 
typical particle size varies from 100 to 800 nm and can be determined by dynamic light 
scattering. The same method can be used to determine the polydispersity index of the 
particles. Cubosomes exhibit identical packing arrangement and phase identity to those of the 
parent gel LCP.31 Because of their very large ratio of surface area to volume, cubosomes tend 
to aggregate to form thermodynamically stable bulk LCPs. To overcome this, their surfaces 
need to be kinetically stabilized.32 Pluronics,33 are the most frequently used stabilizers for 
such systems. In Figure 9, cryo-transmission electron microscopy image shows catalytic 
cubosomes that were used to catalyze aldol reactions (see Chapter 2). A more detailed 
description of cubosomes as drug delivery system will be provided in the introduction to 
Chapter 9. In this project, cubosomes were loaded with lipidic endoperoxides and delivered to 
anoxic cells which, upon controlled oxygen release might be supplied with the latter. 
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Figure 9: Cryo-transmission electron microscopy image of catalytic cubosomes with a Pn3m 
symmetry. Cubosomes need to be stabilized with a polymer, leading to a lamellar surrounding. 
Catalytic cubosomes will be described in Chapter 2. 
 
 
1.1.5 Hexagonal phases  
 
In the hexagonal phase, six cylinders consisting of a lipidic monolayer are packed in 
hexagonal symmetry. MO, for example shows an inverse hexagonal phase (HII) in which the 
head groups of the lipids point inwards and the hydrophobic tails protrude to the external 
surface, thereby confining the aqueous channels.34 MO shows the HII phase at high 
temperatures of 70-100°C, which is typical for hydrated monoacylglycerols.22 HII phases are 
highly curved and thus the hydrophobic chains are densely packed. This is only possible at 
higher temperatures where hydrogen bonding between water and the lipid head groups are 
weaker as compared to lower temperatures. The weaker hydrogen bonding leads to a 
decrease in the hydration sphere that allows for an optimized packing. In contrast, normal 
hexagonal phases (HI) are typically formed by detergents in water dispersions. 
 
 
Figure 6: Schematic representation of A) normal (HI), and B) inverse hexagonal phases (HII) formed 
upon self-assembly of lipids in water at certain conditions. Polar head groups are shown in red, apolar 
chains are shown in grey. Reprinted with permission from Ref. 34.  
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𝑟 = 0.248𝑎 − 𝐿𝑙𝑖𝑝                       (4a) 
𝑟 = 0.391𝑎 − 𝐿𝑙𝑖𝑝                       (4b) 
𝑟 = 0.3055𝑎 − 𝐿𝑙𝑖𝑝                     (4c) 
 
1.5 Hexagonal phas  
In the hexagonal symmetry, lipidic monolayers form cylinders that are organized in a hexagonal 
packing arrangement. Monoacylglycerols usually present an inverse hexagonal phase, with the 
water confined into cylinders formed by the polar headgroups of lipids, while the hydrophobic 
tails protrude into the external interface of the aggregates (24). For hydrated monoacylglycerols 
the HII phase appears at high temperatures (70-100 °C), as is the case for MO (20). These 
systems are highly curved and the lipidic chains are densely packed and stressed. To overcome 
the free energy related to the lipidic chain stress, the curvature required from the lipid molecular 
sha e needs to be optimized. For these systems, the lipidic we ge sha e increases at high 
temperature when H-bonds betwe n the lipid’s polar head groups and water molecule  are 
broken. This loss f hydration sphere results in decrease of the head group cross sectional area.  
 
       
Figure 5. Schematic representation of A) normal, and B) inverse hexagonal phases formed from 
aggregation of lipid molecules in the presence of water. Polar head groups are shown in red, apolar 
chains are shown in grey. The highly curved lipidic monolayers constitute cylinders that are organized 
in a hexago al packing arrangement. In the normal phase, the water is confined to the external interface 
of the cylindrical aggregates, while in the inverse phase the cylinders constitute the aqueous channels. 
Reproduced with permission from (25). 
A B 
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1.1.6 Applications of LCPs  
 
Due to their unique properties LCPs find applications in a very wide range of fundamental- 
and applied fields. Landau and Rosenbusch introduced LCPs for the solubilization, 
stabilization, and crystallization of membrane proteins. The implementation of this novel 
concept led to an explosion in solved membrane protein structures and had therefore a 
significant impact on structural biology and biomedicine.14 The use of LCPs as drug delivery 
systems is a promising approach, thus research in this field is steadily expanding. LCPs with 
customized properties like negative or positive charged surfaces have been developed. The 
resulting electrostatic interactions with a charged drug allow for modified drug-release 
behavior.35,36 The development of stimuli responsive lipidic materials has the potential to lift 
the drug delivery field to a higher level. Temperature has a major effect on the mesophase 
symmetry, which on the other hand affects the release of a drug. Temperature induced 
switching of the mesophase symmetry enables controlled drug release.37,38 The use of pH-
responsive LCPs exploits the changes in pH in different regions of the human body. Thus, 
phase transitions can be induced by protonation or deprotonation of pH sensitive additives. 
Negrini et al. for example, used a linoleic acid-based system to deliver phloroglucinol to the 
intestine. The low pH in the stomach induced a phase transition to a HII phase leading to a 
reduced drug release, which was increased again in the intestine at higher pH (Figure 7).39  
 
 
Figure 7: Schematic representation of the proposed pH-responsive drug delivery mechanism across 
the gastrointestinal tract. The lipidic nanoparticles have a cubic symmetry (Im3m) at pH 7, whereas the 
low pH in the stomach (pH 2), induces a phase transition to a reverse hexagonal phase (HII). Due to the 
slower diffusion in HII phases, the drug release is reduced. In the intestine at pH 7, the phase transition 
is inverted back to bicontinuous cubic (Im3m), enabling efficient release of the drug. Reprinted with 
permission from Ref. 39.  
 
Published: March 31, 2011
r 2011 American Chemical Society 5296 dx.doi.org/10.1021/la200591u | Langmuir 2011, 27, 5296–5303
ARTICLE
pubs.acs.org/Langmuir
pH-Responsive Lyotropic Liquid Crystals for Controlled Drug Delivery
Renata Negrini and Raﬀaele Mezzenga*
Food and Soft Materials Science, Institute of Food, Nutrition and Health, Eidgen€ossische Technische Hochschule Z€urich (ETH Z€urich),
Schmelzbergstrasse 9, CH-8092 Z€urich, Switzerland
bS Supporting Information
’ INTRODUCTION
Stimuli!responsive drug delivery systems have a very unique
behavior because they can undergo suitable changes in response
to speciﬁc environmental ﬂuctuations or imposed variations of
control parameters. Although many types of stimuli have been
considered, such as exposure to light, magnetic and electric ﬁelds,
or changes in the pH, ionic strength, or temperature, most of the
literature has focused on temperature and pH.1 In situ variations
of the temperature are typically limited by the livability of tissues
in living organisms and can usually be achieved only via external
controllable temperature sources.2 On the other hand, pH
changes arise naturally within the human body, which makes
this parameter an ideal self-regulatory stimulus capable of
directing the response of the carrier to a deﬁned tissue or cellular
compartment.3,4 Up to now, stimuli!responsive drug delivery
systems have been nearly exclusively designed using synthetic
polymers. These systems have found potential applications in the
biomedical and pharmaceutical ﬁeld, where low dosage may
allow for non-natural compounds, but they cannot be used in
food applications, where only non-toxic food-grade molecules
and macromolecules, such as lipids, proteins, or polysaccharides,
can be employed.5,6
Noncharged polar lipids, such as monoglycerides or zwitter-
ionic phospholipids, are valuable candidates for drug delivery
systems because of their capacity to self-assemble in the presence
of water into a variety of reversed lyotropic liquid crystals (LLCs),
depending upon temperature, composition, pressure, ionic strength,
and other variables.7!9 A widely investigated system is that of
unsaturated monoglycerides, such as monoolein or monolinolein,
which have been shown to form reversed LLCs in the presence of
excess water.10!14 A particularly desirable feature of these
systems is the presence of thermodynamically stable aqueous
channels15,16 organized in either a three-dimensional (3D)
bicontinuous structure in the cubic phases or a one-dimensional
(1D) parallel way in the hexagonal phases,17 while the lipid tails
occupy the region in between the channels, which makes these
systems suitable nanocarriers for both hydrophilic and hydro-
phobic drugs.18!25 Despite the interesting topological character-
istics of reversed LLCs, however, only a very limited number of
studies on possible stimuli!responsive mechanisms of interest
for drug delivery have been published26!30 and their practical
relevance, in particular for oral drug delivery, has been mostly
limited by the instability of monoglycerides during the digestion
process.31
Because the release of hydrophilic drugs from LLCs is known to
be a diﬀusion-controlled process regulated by both the size of the
Received: February 15, 2011
Revised: March 15, 2011
ABSTRACT: We present a food-grade lyotropic liquid crystal
system, capable of responding to pH variations with a reversible
switch in both the structure and physical properties. The system,
which is composed by monolinolein and linoleic acid (97:3 wt %
ratio) in the presence of excess water at 37 !C and 150 mM ionic
strength, is speciﬁcally designed to reversibly change from a Im3m
reverse bicontinuous cubic phase to a HII reverse columnar
hexagonal phase, when changing the pH from neutral (pH 7)
to acidic (pH 2) conditions, to simulate intestine and stomach
conditions, respectively. The pH responsiveness is provided by
the linoleic acid, which, being a weak acid (pKa≈ 5), is essentially
in the deprotonated charged state at pH 7 and mainly protonated
and neutral at pH 2, imposing changes in the critical packing
parameter (CPP) of the lyotropic liquid crystal. The use of this
system as an eﬃcient controlled-release delivery vehicle is
demonstrated on the model hydrophilic drug phloroglucinol,
by both release and diﬀusion studies at diﬀerent pH, as followed
by ultraviolet!visible (UV!vis) spectroscopy. The Im3m cubic phase at pH 7 is sh wn to release 4 times faster than theHII phase at
pH 2, making this system an ideal candidate for oral administration of drugs for targeted delivery in intestine or colon tracts.
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By adding photochromic compounds to LCPs, light responsive materials can be obtained. 
Aleandri et al. incorporated a lipidic photoswitch into dye-loaded mesophases. The light 
induced trans-cis isomerization of a lipidic azo-benzene derivative leads to disrupted lipid 
packing and therefore faster release of the dye.40 Finally, electromagnetic energy can be 
applied as an external trigger. For example, magneto-responsive lipidic materials were used 
to macroscopically align lamellar and hexagonal phases, by incorporating magnetite 
nanoparticles to the system.41 Apart from drug delivery systems, lyotropic liquid crystals have 
been used as biosensors and diagnostic platforms. Director distortion or crystallization based 
liquid crystal biosensors have been developed.6,42 Crystallization based biosensors were used 
to monitor a birefringence signal that occurred upon crystallization of an enzymatic product in 
the LCP.43 Finally, LCPs find application as food emulsifiers.44  
 
 
1.1.7 Modification of aqueous channel diameters 
 
The water channel diameter is of importance for the above-mentioned applications of lipidic 
mesophases such as drug delivery and release or membrane protein crystallization.45 
Therefore, several research groups have identified compounds which act as swelling agents 
when added to the LCP. Angelov et al. found that octyl glycoside can swell MO-based LCPs 
at excess water conditions.46 Diglycerol monooleate and sucrose stearate have been shown 
to enlarge the channels of monolinolein systems, inducing a phase transition from a Pn3m to 
a Im3m cubic phase (Figure 8).45,47 Engblom et al. showed that distearoylphosphatidylglycerol 
increases the aqueous channels of MO LCPs.6 A very efficient swelling strategy was 
developed by Tyler et al. who used a two-step procedure to swell MO phases at 40°C by first 
adding cholesterol and then anionic lipids.48  
 
 
Figure 8: Illustration of aqueous channel swelling upon increasing the sugar ester concentration and 
phase transition from Pn3m to Im3m cubic phase. Reprinted with permission from Ref. 45. 
 
To sum up, swelling of LCPs aqueous channels is a useful tool to tune the release of 
incorporated compounds or to affect protein crystallization.49,50 The available know-how on 
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modifications of water channel diameter is significant for this thesis, as it allows us to control 
the kinetics of reactions carried out within LCPs or cubosomes. 
 
 
1.1.8 Non-lipid based thermotropic and lyotropic liquid crystals 
 
A brief introduction to the non-lipid based liquid crystals is provided here in order to complete 
the picture of the field of liquid crystals. These are often referred to as LCs in the literature. 
LCs revolutionized the area of display technology where they are being applied in televisions, 
cameras, mobile phones and laptops. Furthermore, LCs are used in materials science, 
nanoscience and in medicine.51–53 Additionally, LCs are supramolecular models based on 
many noncovalent secondary interactions like hydrogen and halogen bonding or π-stacking 
and play therefore an important role from a fundamental research point of view.54 Essentially, 
LCs can be divided into two groups, based on how their respective phase transitions are 
induced: lyotropic or thermotropic.54 Thermotropic LCs are achieved by changing the 
temperature of a mesogen in its pure state, either by heating a crystalline solid of a mesogen 
or cooling an isotropic liquid (Figure 10). Upon heating, the mesogens lose their positional-, 
but not their orientational ordering, which upon further heating vanishes as well. In contrast, 
lyotropic LCs (LLCs) require a solvent and mesogens undergo phase transitions upon 
changing their concentration. Common LLCs display nematic, lamellar, columnar and cubic 
phases.  
 
Figure 10: Schematic illustration of different liquid crystal phases observed upon heating from the solid 
state. In the smectic phases (SmC and SmA), positional and orientational ordering is mostly retained. 
Upon further heating, a phase transition to nematic (N) takes place, in which the positional ordering is 
lost and only orientational ordering is maintained, which upon further heating vanishes as well. 
Reprinted with permission from Ref. 54. 
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nematic, N, and exhibits solely orientational order of the long axis of rod-like molecules, while disk-like
molecules, so called discotic, can show nematic phases as well. The spatial and temporal average
of this long axis is called the director, n. At lower temperatures smectic pha es are lso observed,
which, in addition to orientational order, also exhibit one- or two-dimensional positional order of the
molecules centres of mass. Depending on the degree and nature of order, a whole range of different
smectic phases can be distinguished, with the simplest being the smectic A phase with one-dimensional
positional order and the di cto in directio of the smectic layer ormal. If the di ector, which at the
same time is the optic axis of the syste , is inclined to the layer normal, one speaks of the smectic C
phase (see Figure 1).
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Figure 1. Sche atic illustration of different liquid crystal (LC) phases observed on heating fro the
crystalline tate. At first, positional ordering is partially maintained in the sm ctic phases, SmC nd
SmA, together with orientational order of the long molecular axis of often rod-shaped molecules.
On further heating, positional order is lost at the transition to the nematic phase, which solely exhibits
orientational order. Eventually, at the clearing point, all liquid crystalline order is lost and the isotropic
liquid is reached. For simplicity, only rod-like molecules are depicted in the figure, but other molecular
shapes exist as well, such as disc-like or bent-core materials, which exhibit liquid crystalline behavior.
These phases are called the fluid smectic phases, with hexatic phases and higher ordered phases to
follow at even lower temperature [7]. The order thus increases with decreasing temperature, while the
symmetry is reduced. An important parameter in the description of LC phases is the orientational
order parameter, S2, which in its simplest description takes the form:
S2 = hP2(cosJ)i = h3cos
2J  1
2
i (1)
where P2 is the second Legendre polynomial and J the angle between the long axis of an individual
molecule and th director. The order parameter changes as a functio of temperature, dependence
which is schematically shown in Figure 2.
1.2. Lyotropic Liquid Crystals
Lyotropic LCs [8,9] on the other hand are observed when changing the concentration of a shape-
or property anisotropic dispersant in an isotropic solvent. Often, lyotropic phases are observed as
a function of concentration of amphiphilic molecules in water or other solvents, as schematically
shown in Figure 3. Below the critical micelle concentration, cmc, the amphiphiles are molecularly
dispersed in the solvent, but at larger concentrations form micelles, which can be of the spherical, disk
or rod-like type, depending on the molecular shape. At even higher concentrations, these micelles
aggregate to ordered structures and can form hexagonal, cubic or lamellar phases, also of the inverse
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Metal complexes exhibiting thermotropic or lyotropic liquid crystalline behavior are referred to 
as metallomesogens. Luminescent metallomesogens are very attractive materials for 
OLEDs,51,55 Pt-metallomesogens have been used as fluorescent probes for the detection of 
Hg2+, Zn2+, Cd 2+ and Pd2+ and liquid crystalline metallofullerenes have been applied for bulk 
heterojunction solar cells.56,57 
Whereas surfactant and lipid-based LLCs have been studied to a great extent, leading to in-
depth knowledge of the self-assembly behavior, other LLC forming compound classes like 
chromonics are underexplored. LLCs in organic (or nonaqueous) media have rarely been 
studied.58 Kölbel et al. reported rod-like rigid amphiphiles displaying lyotropic smectic and 
columnar liquid crystalline phases in glycerol.59 The phase behavior of Gemini surfactants in a 
protic ionic liquid has revealed a reverse hexagonal phase.60 Fullerene derivatives often show 
thermotropic LC behaviour, but when modified with bisphenyl groups bearing long alkyl 
chains, lyotropic hexagonal columnar phases were obtained.61 A very promising approach is 
to transfer the chiral, nematic and photonic properties of cellulose nanocrystals to other 
materials, e.g. polymers or mesoporous silica.62,63  
Research on thermotropic LCs has reached much higher levels of sophistication as compared 
to non-lipid-based LLCs. Thus, smart stimuli-responsive materials based on thermotropic LCs 
have been developed. Such tailor-made materials are in high-demand and have been used 
for almost every conceivable application. Several LCs displaying photostimulated isothermal 
phase transitions, based on different molecular switches have been reported.54 Chiral nematic 
LCs that allow for helical chirality inversion upon photoswitching,64 and metallomesogens 
showing different symmetries based on the coordinating metal have been developed.65 These 
materials have potential applications in photonics, holographic optical data storage, self-
healing materials, sensors and as polarizers.54  
 
 
1.2 Rationale of this research 
1.2.1 Lipidic material 
 
As mentioned above, lipidic mesophases have been applied in a wide range of demanding 
purposes in different fields of science ranging from materials science, food science to 
nanomedicine. However, to the best of our knowledge, lipidic mesophases have not been 
functionalized and used as catalytic systems. Given the plethora of fascinating properties and 
characteristics of lipidic mesophases, particularly of the lipidic cubic phases, we embarked on 
a research program aimed at using such biomaterials as frameworks for the immobilization of 
catalysts in organic reactions. This novel approach exploits, among other things, the large 
lipid/water interface to perform efficient aqueous chemistry, taking place in the aqueous 
channels of the mesophases. Because lyotropic liquid crystals have a large potential for 
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designing tailor-made materials, research in this direction is necessary and will open exciting 
new avenues to discoveries in materials science. The next paragraph will introduce briefly the 
field of aqueous chemistry and its development over the past decades, since this thesis 
combines materials science of lipidic mesophases with aqueous chemistry.  
 
 
1.2.2 Aqueous organic chemistry 
 
Breslow’s discovery of the positive effect of water on the reaction rate and selectivity of Diels-
Alder reactions in the 1980s is commonly considered as the “Big Bang” in aqueous organic 
synthesis.66 In this pioneering work, Rideout and Breslow showed that several Diels-Alder 
reactions can be significantly accelerated when water was used as the solvent (Scheme 1). 
The reaction of cyclopentadiene and butenone in 2,2,4-trimethylpentane was shown to be 
700-fold slower as compared to the same reaction in water.67 They rationalized that the 
hydrophobic effect was responsible for the strong rate enhancement. Later it has been shown 
that, in addition to the hydrophobic effect, also hydrogen bonding between water and the 
substrates in the transition states plays an important role, as water acts in a similar mode as 
Lewis-acids do.68  
 
 
Scheme 1: Diels-Alder reaction of cyclopentadiene and butenon or acrylonitrile and of anthracene-9-
carbinol and N-Ethylmaleimide, used by Rideout and Breslow to show the accelerative effect of water 
on these reactions. Adapted from Ref 67. 
 
This work has initiated widespread interest in this field, and the repertoire of chemical 
transformations that can efficiently be carried out in water is ever growing. In addition to the 
Diels-Alder reaction, Michael-type additions, allylation reactions, cyclopropanation, cross 
coupling reactions, oxidations and reductions, as well as aldol-type reactions - to mention just 
a few examples - have been reinvented in aqueous medium.66 However, the poor solubility of 
many small molecules in water and the negative effect of water on certain chemical 
transformation might be the main reason why water was not considered as a useful solvent 
R
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for organic reactions until recently. This is inconsistent with the fact that many very desirable 
synthetic targets, e.g. nucleotides, peptides and carbohydrates are well soluble in water.66 
Chemists have developed different strategies to circumvent the solubility problem of building 
blocks. The use of a cosolvent, often DMF, DMSO or alcohols is one method to increase the 
solubility, although it is controversial.66,69 By varying the pH of a solution, charges can be 
added to ionizable compounds which can substantially increase the solubility of the solute.66 A 
very efficient approach is the use of surfactants which leads to a compartmentalization of the 
reaction, which locally increases the concentration of reaction partners and therefore has 
beneficial impact on many reactions.70–72 Finally, hydrophilic auxiliaries, for example some 
ethylene glycol-units, can be covalently attached to insoluble compounds which ideally can be 
cleaved afterwards.66,73 
Generally, using water as a solvent is very desirable since it is environmentally sustainable, 
nontoxic and cheap. However, the mere use of water as a solvent does not automatically lead 
to “greener” processes, as was already pointed out by several authors.69,74 The process needs 
to be evaluated in its entirety and factors such as substrate- and catalyst production, work-up 
and purification of products, as well as recycling of the catalyst need to be considered. 
Regarding these problems, our approach provides a number of promising features: The 
reaction takes place in water or buffer, and work-up comprises only freeze drying followed by 
purification by chromatography, if required. Furthermore, the modified LCPs and cubosomes 
can be reused without any catalyst recycling process, and no extraction or chromatographic 
process is necessary.  
 
 
1.2.3 Catalyst immobilization 
 
The immobilization of catalysts is beneficial for many reasons; the recovery and recycling of 
often tediously synthesized catalysts from homogeneous systems is challenging. Various 
heterogeneous systems have been developed to allow for easy catalyst recovery. 
Furthermore, the immobilization of a catalyst can have positive effects on its long-term 
stability, this is especially the case for enzymes.75 In some cases, catalyst immobilization can 
even alter the outcome of the reaction, e.g. inverting the stereoselectivity of the products.76 
Other catalysts, like elemental metals, require an immobilization matrix and are not applicable 
otherwise. A widely used and established example is palladium on carbon that is used for 
hydrogenation reactions in academia and industry. 
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1.3 Objectives  
 
With the introduction of lipidic cubic phase as immobilization matrices for catalysts in organic 
chemistry we plan to add a novel and versatile material to the list of catalyst immobilization 
platforms. Lipidic mesophases have a plethora of properties that make these materials 
suitable nanocatalysts. The large surface area of ca. 400 m2 g-1 lipid30 between the aqueous 
channels and the lipidic bilayer promises efficient catalysis. The diameter of the aqueous 
channels can be controlled and tuned, not only during the mesophase preparation process 
but also at later stages, even while catalysis is ongoing. This allows to modify the kinetics of 
the reactions carried out within these materials on-demand. Lipidic mesophases are formed 
upon self-assembly, therefore the production process is simpler as compared to many other 
immobilization materials, since only mixing of lipids and water followed by centrifugation and 
equilibration is needed. Cubosomes need to be sonicated, therefore an additional working 
step is required. Another advantage is the fact that these materials enable application in a 
dual mode: As bulk mesophases or as nanoparticle dispersions, depending on the set-up 
requirements. Finally, this approach is very general, and in principle many different catalyst 
types can be incorporated, ranging from organocatalysts, metal-compex catalysts, palladium 
nanoparticles and enzymes.  
The goal of this thesis is to introduce lipidic cubic phases and cubosomes as a novel platform 
for catalysis, and to investigate the influence of these biomaterials on the chemical reactions 
carried out therein. This will be achieved as follows: 
 
• Suitable model reactions, with the focus on organocatalyzed and metal-complex 
catalyzed reactions, will be chosen to provide an initial proof of principle. 
• The respective catalysts will to be designed, synthesized and the catalyst-containing 
mesophases will be characterized by small angle X-ray scattering (SAXS) and 
dynamic light scattering (DLS).  
• The effect of structural modifications of the catalysts on the catalytic performance will 
be investigated.  
• These in-meso reactions will be investigated in terms of kinetics, stereochemistry, 
substrate scope and the influence of aqueous channel swelling on the reaction rates. 
• Cubosomes and LCPs exhibit identical internal cubic symmetry, but their external 
features may vary significantly, as cubosomes are stabilized nanoparticles and have a 
larger outer surface as compared to bulk LCP. The impact of these differences on 
catalysis will be investigated. 
• The scope of catalyst types will be expanded to palladium nanoparticles and enzymes. 
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Beside mesophase catalysis, which is the main project of this thesis, three additional 
subprojects have been carried out: 
 
• Synthesis of enantiopure phytantriol and comparison of the ensuing LCPs with the one 
of commercially available phytantriol, which is a mixture of isomers. 
• Synthesis of a small library of cyclopropanated lipids, their assembly into mesophases 
and their material investigation at sub-zero temperatures (Collaboration with the group 
of Prof. Dr. Raffaele Mezzenga from the Department of Health Sciences and 
Technology at the ETH) This is a continuation of an existing project.77 
• Synthesis of lipidic endoperoxides and their incorporation into cubosomes in order to 
develop a nanocarrier that enables delivery of oxygen-releasing compounds to anoxic 
muscle cells followed by controlled oxygen release to increase the survival of 
transplanted tissue (Collaboration with the group of Prof. Dr. Dr. med. Daniel Eberli at 
the University Hospital Zurich) 
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Lipidic mesophases as novel nanoreactor scaffolds for organocatalysts: 
Heterogeneously catalyzed asymmetric aldol reactions in confined water 
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 2.1 Introduction 
 
Nature has evolved enzymes to catalyze a plethora of reactions very efficiently and highly 
stereoselectively in aqueous environment and under mild conditions. Organocatalysis relies 
on small organic molecules to mimic nature´s sophistication without having to synthesize 
large protein assemblies. However, the recovery and recycling of potentially valuable 
catalysts from homogeneous systems is challenging. Various heterogeneous systems have 
been developed to allow easy catalyst recovery. Thus, organocatalysts have been 
immobilized on mesoporous silica1, on polymer supports2, on crystalline metal-organic 
frameworks3, on covalent organic frameworks4 or on cloth5.  
In addition to these solid supported systems, the applicability of lipidic self-assembly in 
micellar and vesicular catalysis is a large research field, as the use of surfactants is an 
efficient approach to conduct chemical reactions in water. Numerous processes have been 
developed that are competitive or even superior, in terms of yield, selectivity and catalyst 
recycling to their equivalents in organic solvents.6 Furthermore, in some examples the 
reaction was conducted under energy-saving conditions.7 Vesicles have been widely used to 
study enzymatic reactions. Their tunable size and lipid composition render them not only 
attractive membrane model systems, but also a platform for other catalysts.8–11 König et al. for 
example, used vesicles to catalyze hydrolytic cleavage of organophosphates with amphiphilic 
zinc complexes.12,13 In contrast to liposomal and micellar systems, only a few examples of 
chemical reactions carried out using lipidic mesophases are known. Mezzenga et al. studied 
enzyme kinetics of horseradish peroxidase (HRP) in different mesophase types.14,15 Watzke et 
al. showed that a Maillard reaction was more efficient in lipidic cubic phase (LCP) medium 
than in bulk water.16  
LCPs, are liquid crystalline biomaterials that form spontaneously upon mixing water and lipid 
molecules in a well-defined composition and temperature range given by the phase diagram.17 
The driving force for such amphiphilic self-assembly is the hydrophobic effect, which leads to 
the minimization of the interface between hydrocarbon tails of the amphiphile and water. 
LCPs are gel-like, stable biomaterials whose nanostructure depends on the specific lipid 
molecular structure. The latter is packed into a spatially curved lipid bilayer encompassing two 
identical but non-intercommunicating aqueous channel systems. Significantly, LCPs can be 
doped with various additive molecules, thereby functionalizing them by design.18 These 
complex biomaterials find application in a wide range of fundamental and applied fields such 
as drug delivery,19,20 membrane biology,21,22 biodevices,23 and food emulsifiers.24 LCPs are 
thermodynamically stable in excess of water and show a combination of useful properties: 
optical transparency, biocompatibility, deformability, and adhesivity to hydrophilic as well as 
hydrophobic surfaces, which allows their application on practically any surface. 
Monoolein (MO, Figure 1) is the best-studied and most widely used lipid that forms LCPs. In 
addition to their use as gels, LCPs can be dispersed in water by ultra-sonication, forming 
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nanoparticles that are denoted as cubosomes. The surface of cubosomes needs to be 
stabilized, typically with a polymeric additive, in order to prevent reassembly of the 
nanoparticles into the thermodynamically stable bulk LCP.25 Both LCPs and cubosomes 
exhibit a periodic, three-dimensional aqueous channel network and a very large lipid/water 
interfacial area (ca. 400 m2 g-1 lipid).26 
Whereas the above-mentioned examples have used LCPs merely as reaction medium, our 
approach entails the judicious modification of LCPs and cubosomes by design, thereby 
forming host-guest molecular systems that are intrinsically catalytically active. MO as the host 
lipid is responsible for the molecular architecture and properties of the biomaterial whose 
specific geometries can be used to host the guest lipid catalyst. The latter is “semi-
immobilized” in the bilayer, and orientated at the large interface between the aqueous and the 
lipidic compartments, exposing its catalytic site towards the aqueous subphase. Such “semi-
immobilization” denotes the free lateral diffusion of the catalyst within the curved lipidic 
bilayer. Figure 1 illustrates the concept of these designed catalytic mesophases. 
 
Figure 1: Schematic representation of the experimental set up (upper left), structure of the host guest 
LCP (upper middle), and the principle of catalytic LCPs (upper right). The LCP, composed of host MO 
lipids (pink), guest lipid-modified organocatalyst (dark blue) and water, is placed in a specially designed 
holder and overlaid with an aqueous solution (upper left). The reaction, catalyzed by the blue lipidic 
catalysts, takes place at the lipid-water interface of the catalytic mesophase. 
 
In addition to the large surface area of LCPs, these biomaterials offer several additional 
features which facilitate their application as efficient matrices for heterogeneous catalysis: The 
aqueous pores communicate freely with the overlay bulk water, thus avoiding the need for 
substrate diffusion across membranes. Mesophases can be used as bulk LCPs or in 
dispersed form as cubosomes, as both are thermodynamically stable in excess water. Thus, 
1 2
3 4
5
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depending on the requirements, either an adhesive gel or dispersion can be employed. 
Furthermore, both experimental set-ups allow simple catalyst recycling. Preparation of the 
mesophase is simple and fast and the lattice parameters as well as the geometry can be 
tuned at will by either using specific additives, or by controlling environmental parameters 
such as hydration, temperature,17 pH,20,27 or ionic strength28 of the aqueous medium. A 
fundamental requirement for the broad applicability of such mesophases as nanoreactor 
scaffolds in organic chemistry is their ability to host a wide variety of guest lipids with a broad 
range of properties,18,27,29 allowing to conduct different catalytic reactions.  
In this study, we report the first organocatalytic reaction conducted in designed host-guest 
LCPs and cubosomes as new class of self-assembled nanoreactor scaffolds, and analyze 
their effect on catalysis. The organocatalyzed aldol reaction between water-soluble aldehydes 
and cyclohexanone was chosen as a model reaction, as this reaction is one of the most 
important carbon-carbon bond forming reactions for the generation of β-hydroxycarbonyl 
moieties,30–32 being responsible for the biosynthesis of carbohydrates, keto acids and some 
amino acids.33 Enzymes catalyze these reactions very efficiently and highly stereoselectively 
in water under mild conditions. These are all very desirable attributes for chemical processes. 
However, although enzymes have been applied in synthesis, they usually suffer of limited up-
scale compatibility.34 The use of organocatalysts in order to mimic nature is therefore a very 
elegant approach. One of the first organocatalysts that was introduced was proline.35 
However, in contrast to enzymes, proline-catalyzed aldol reactions are usually carried out in 
polar organic solvents such as DMF or DMSO, and addition of large amounts of water led to 
decrease in reaction rate and stereoselectivity.36–38 This drawback could be overcome if a 
proline-derived catalyst, instead of proline itself is applied.39–41  
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2.2 Results and discussion 
2.2.1 First generation lipidic aldol organocatalysts 
 
It has been shown that aldol reactions in water catalyzed by proline-derivatives with free 
carboxylic acid are usually slow and their enantio- and diastereo-selectivity is poor. However, 
if the reaction occurs in confined space and the catalytic system provides a molecular 
environment comparable to a hydrophobic pocket of an enzyme, good results can be 
obtained.42 We hypothesized that a similar situation would be achieved in the confined 
aqueous channels of the LCPs. Therefore catalysts 9 and 13 were synthesized according to 
previously reported procedures.18 Catalyst 9 has been synthesized with two different methods: 
By a Steglich-esterification and by esterification using oleylchloride as the activated carboxylic 
acid species (Scheme 1, top panel). The product was obtained by both approaches in low 
yield, probably due the lowered nucleophilicity of the secondary alcohol and rather short 
reaction times. Additionally, the amide derivative was also synthesized, since ester tend to 
hydrolyze (Scheme 1, bottom panel). The Boc-protecting group of 8 and 12 was cleaved 
under acidic conditions using TFA in CH2Cl2. 
 
 
 
Scheme 1: Syntheses of lipidic catalysts 9 and 13 Conditions: a) Oleic acid, DCC (1.1 eq), DMAP (0.1 
eq) CH2Cl2 / DMF 4:1, r.t. b) DIPEA, CH2Cl2, 0°C c) TFA / CH2Cl2 (1:4), 0°C, d) EDC (1.1 eq), DMAP 
(0.1 eq) CH2Cl2 / DMF 4:1, r.t.. 
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The amide as well as the ester derivative (9 and 13) could be incorporated into MO-based 
LCPs at a content of up to 10 % (w/w) of the lipid. These LCPs were subsequently used to 
perform the very first catalysis experiments with LCPs. As a model aldol reaction 4-nitro-
benzaldehyde (14) and cyclohexanone (3) was used (Scheme 2).  
 
 
Scheme 2: First LCP catalysis experiment using 4-nitro-benzaldehyde 14 and cyclohexanone (3) as 
the substrate pair. Conditions: 4 days at room temperature with 30 mol % catalyst and 2 eq 
cyclohexanone. 
 
The reaction was very sluggish and after four days, only traces of product were detected. 
Thus, the choice of both the catalyst and the substrates was not ideal, and needed to be 
optimized. As already mentioned, better results can be expected if the proline carboxylic acid 
is derivatized, for example to an amide. The aldol reaction of 4-nitro-benzaldehyde and 
cyclohexanone is the benchmark aldol reaction in literature, however, for our system it is not 
suitable due to the low solubility in water. Less lipophilic substrates will probably lead to better 
reaction rates since they do not accumulate in the lipidic compartments of the LCP.  
 
 
2.2.2 Second generation lipidic aldol organocatalyst  
2.2.2.1 Synthesis of lipidic prolineamido-glycoside catalyst 
 
In order to implement the gained insights from the first experiments, a new, LCP compatible 
organocatalyst was designed. Catalyst 24, reported by Tsutsui’s et al. catalyzes aldol 
reactions of carbohydrates efficiently,43,44 and served as inspiration. The carbohydrate moiety 
possesses several advantages. Firstly, the hydroxyl groups stabilize the transition state of the 
aldol reaction.43 Secondly, the sugar acts as a linker between the lipidic chain and the 
catalytically active proline moiety, pushing the proline further into the aqueous channel of the 
mesophase, which might lead to easier contact between catalyst and substrates. Thirdly, 
carbohydrate-derived lipids are known to swell the aqueous channels of mesophases.45–47 
Furthermore, the primary alcohol of the carbohydrate moiety offers a good synthetis 
opportunity to install the lipidic chain.  
The starting point of the synthesis was the commercially available N-Acetyl-D-glucoseamine 
(16), which was treated with MeOH/Dowex to methylate the anomeric position and obtain an 
anomeric mixture of α- and ß-methyl glucoside.48 The ratio of the two anomers was 
determined by 1H-NMR to be 2:1 and they could easily be separated by column 
OH
NO2
OO
NO2
O
H
LCP
yield: traces
3 14 15
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chromatography to obtain pure 17. After cleaving the acetyl protecting group with barium 
oxide, the free amine 18 was coupled to Boc-L-proline (19) using DCC/DMAP to obtain Boc-
protected proline glycoside 20. Attempts to improve the yield of this step failed. The oleic 
chain was installed at the carbohydrate moiety by selective oxidation of the primary alcohol to 
the aldehyde49 and subsequent reductive amination using oleyl amine and NaCNBH3 to 22, 
which was treated with TFA to obtain catalyst 23. The unlipidated catalyst 24, to be used as 
reference catalyst, was synthesized directly from Boc-protected proline glucosamine 20 
(Scheme 3). 
 
 
Scheme 3: Synthesis of lipidic aldol organocatalyst 23 and its unlipidated version 24. Conditions: a) 
MeOH, Dowex, reflux; b) BaO, H2O, reflux; c) Boc-L-Proline (1 eq) DCC (1 eq), DMAP (1 eq), DMF, r.t.; 
d) TEMPO, TCC, DMF, 0°C; e) Oleylamine (1 eq) MeOH, r.t., 1h; f) NaCNBH3 (1.3 eq), MeOH, r.t., g) 
TFA, DCM, 0 °C. 
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2.2.2.2 Substrate screening with reference catalyst 24 
 
In order to find suitable, i.e. robust and water-soluble aldol substrates for mesophase 
catalysis, a screening of various aromatic and non-aromatic candidates was performed. The 
results are summarized in Table 1.  
 
Table 1: Screening of different aldol substrate pairs using reference catalyst 24. 
Entry Donor Acceptor Outcome Remarks 
1 
  
Reaction completed Works only freshly distilled 
4 
  
Reaction completed - 
5 
  
No product formation - 
6 
  
No product formation - 
7 
  
No product formation - 
8 
  
57 % conversion Reaction time: 3 d 
9 
  
Reaction completed - 
10 
  
Reaction completed - 
11 
  
No reaction Reaction time: 5 d 
12 
  
Reaction completed - 
13 
  
Reaction completed - 
14 
  
No product formation - 
15 
  
No product formation - 
16 
  
No product formation - 
17 
  
Traces of product 
formed 
- 
18 
  
Traces of product 
formed 
Reaction time: 3 d, mainly aldehyde 
dimer detected 
19 
  
65 % conversion - 
20 
  
No reaction Reaction time: 3d 
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21 
  
No reaction pH 12 (not soluble at neutral pH) 
22  
 
No reaction Reaction time: 3d 
23   No reaction Reaction time: 3d, at 40°C 
24   
Traces of product 
formed 
Reaction time: 2d, mainly aldehyde 
dimer detected 
25   No reaction Reaction time: 5d 
26  
 
Reaction completed - 
27 
  
28 % conversion Reaction time: 8d 
Conditions: Reactions carried out at room temperatures with 30 mol % catalyst 24 and 2 eq of donor. 
Monitored by 1H-NMR. 
 
Even though the substrate screening was restricted to water-soluble compounds only, several 
suitable substrate pairs, aromatic and non-aromatic, have been found. 2,2-dimethyl-1,3-
dioxan-5-one (DDO) and 2,3-O-isopropylidene-glyceraldehyde (IGA) was found to be a good 
substrate pair to start with, since both are highly water-soluble and showed good results in the 
screening (Table 1, entry 1). Furthermore, studying carbohydrate syntheses with this new 
system would distinguish our work from many other reported aldol studies.1,4,39,50–54 
 
 
2.2.2.3 LCP catalysis with substrates DDO and IGA and catalyst 23 
 
For initial experiments, LCPs including catalyst 23 was placed at the bottom of an NMR tube 
and the substrate solution was added on top. Product formation was detected by 1H-NMR and 
ESI-MS, and the reaction was completed after four days. Because of the specific geometry 
used, the surface area between the bulk water and the LCP in a NMR tube is not very large 
(0.13 cm2). We thus designed special metal holders with significantly larger surface area 
(3.14 cm2) to be used in further experiments. Since stirring is not possible, the reaction 
mixture had to be gently shaken. With this improved set-up, the reaction rate could be 
significantly accelerated; the reaction was completed after ca. 36 hours. However, during 
further investigations it has been shown that the initial results were hard to reproduce. One 
problem was the erratic decomposition, i.e. deprotection of the hydroxyl groups of the 
substrates, which occurred despite buffering the system at pH 7.4. Furthermore, the reaction 
rates varied substantially, from 36 hours to several days to complete the reaction, while in 
some cases the reaction did not even start. Catalyst deactivation after incorporation into the 
LCP is another scenario that cannot be excluded, although no experimental evidence was 
encountered. 
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Despite these drawbacks, these initial results proved the feasibility of this project; to use LCPs 
as a novel platform for catalysis. However, the choice of substrates and lipidic catalyst was 
still not ideal, and needed to be further optimized to obtain detailed information on how LCPs 
influence catalysis in terms of kinetics and stereochemistry. 
 
 
2.2.3 Third generation lipidic aldol organocatlaysts 
2.2.3.1 Design and syntheses of the catalysts, preparation of catalytic LCPs 
and comparison of their performances in LCPs 
 
Even small amounts of added guest catalysts can affect significantly the structural and 
dynamic properties of the ensuing host mesophases.18,27,29,55 The size of the aqueous 
channels, the curvature of the bilayer and the geometry of the LCP can be controlled by 
judicious modifications of the lipidic chains and head group region of the additive. To that end, 
six different proline-derived lipidic catalysts were designed and synthesized (Scheme 4). 
Modifications were introduced at the lipidic chain and at the linker that connects the proline 
headgroup to the lipidic chain(s), thereby obtaining catalysts with one (2, 23 and 26) or two 
(27, 28 and 29) lipidic chains, saturated (26 and 27) and unsaturated (2, 23, 28 and 29), as 
well as catalysts in which the proline is linked to the lipids via an amide (2, cn and 10), an 
amine (7 and 8) or an amide with a carbohydrate as a spacer (9).  
Starting from Boc-L-proline (19) catalysts 2, 26 and 29 were obtained after EDC/DMAP 
coupling with the corresponding amines and Boc-deprotection. The same procedure was 
applied for catalyst 27, before the corresponding amide was reduced using LiAlH4.56 Catalyst 
7 was obtained after reduction of 29. Dioleylamine (31) was synthesized in two steps: oleyl 
alcohol (30) was converted to the corresponding bromoalkene,57 and subsequent alkylation of 
oleylamine afforded dioleylamine (31) (Scheme 4, box).58 Starting from Boc-protected 24, 
catalyst 9 was obtained after selective oxidation of the primary alcohol to the aldehyde using 
TEMPO,49 and subsequent reductive amination using oleylamine and NaCNBH3 before the 
Boc-protection group was cleaved with trifluoroacetic acid (TFA). To evaluate the catalytic 
results, water-soluble compound 24 (synthesized according to the literature)59 was used as a 
reference catalyst, thereby providing a comparison between the model reaction carried out in 
our heterogeneous lipidic systems and a model reaction under homogeneous conditions.  
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Scheme 4: Syntheses of lipidic catalysts 2, 23, 26, 27, 28, 29 and water-soluble reference catalyst 11. 
Conditions: a) Oleylamine, EDC (1.1 eq), DMAP (0.1 eq) CH2Cl2 / DMF 4:1, r.t. b) CH2Cl2 / TFA 4:1, 0°C 
c) Stearylamine (1.1 eq), EDC (1.1 eq), DMAP (0.1 eq) CH2Cl2 / DMF 4:1, r.t. d) Dioleylamine (1.1 eq), 
EDC (1.1 eq), DMAP (0.1 eq) CH2Cl2 / DMF 4:1, r.t. e) Didodecylamine (1.1 eq), EDC (1.1 eq), DMAP 
(0.1 eq) CH2Cl2 / DMF 4:1, r.t. f) LiAlH4, THF, 0°C 2 h then reflux 20 h g) TEMPO, TCC, DMF, 0°C h) 
Oleylamine (1 eq), MeOH, r.t. 1h then NaCNBH3 (1.3 eq). i) P(Ph)3 (1.1 eq), CBr4 (1.1 eq.), DCM, 0°C, 
j) Oleylamine (1 eq), K2CO3 (0.3 eq), DMSO, 80°C.  
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With this range of catalysts in hand, the effects of molecular modifications of the catalyst 
additive on the synthetic performance of the designed host-guest LCPs were investigated. In 
the literature, the aldol reaction between water-insoluble 4-nitrobenzaldehyde and 
cyclohexanone is used as a model- and benchmark reaction for catalytic systems based on 
proline derivatives.30,37,39,52 However, for catalysis in LCPs and cubosomes, water-soluble 
substrates are required to facilitate diffusion of substrate from the bulk water into the pores of 
the mesophase material. To this end, water-soluble aldehyde 4a was synthesized (see 
paragraph 2.4.2 for procedure). An ethylene glycol unit was installed to increase water 
solubility (ca. 30 mmol/L or 6 g/L, and a ClogP value of -0.625 compared to 0.309 for 4-
nitrobenzaldehyde (derived from ChemDraw Ultra, version 13)). The aldol reaction of 
aldehyde 4a and cyclohexanone (3) serves as model reaction to study catalysis in LCPs and 
cubosomes. The conversions and the diastereomeric ratios were obtain from an 1H-NMR. A 
section of a spectrum from a reaction control is depicted in Figure 2. Catalytic mesophases 
were prepared such that the lipid-modified catalyst is laterally immobilized in the bilayer, 
exposing the catalytic moiety towards the aqueous compartment. The phase identity and 
lattice parameters of the mesophases were established by small angle x-ray scattering 
(SAXS). The catalytic performance of these designed LCPs was compared with those of the 
water-soluble catalyst 24 and of the lipidic catalyst 2 without LCP, which forms polydisperse 
micellar particles. Table 2 summarizes the results of the catalyst screening on the model aldol 
reaction of aldehyde 4a and cyclohexanone (3).  
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Figure 2: Section of a 1H-NMR spectrum from a reaction control sample. Conversion and d.r. could 
easily be determined, no side product was formed.  
 
Catalysts 2, 23 and 29 with an amide bond between the proline and the lipidic chain deliver 
higher yields as compared to the tertiary amine catalysts 27 and 28. Mase et al. reported that 
tertiary amine and amide catalysts bearing decanyl chains show similar catalytic activity in an 
aqueous emulsion.39 This fact indicates that the difference in activity between LCPs that 
contain catalyst 28 and 29, whose structures differ only in the mode of linking of the lipidic 
chains to the head group, is due to different embedding into the lipidic bilayer. This 
phenomenon can be rationalized by considering that the amide moiety is more polar than the 
tertiary amine, thereby enhancing the accessibility for the water-soluble substrates at the lipid-
water interface, whereas the tertiary amine derivatives are likely incorporated deeper in the 
lipidic bilayer. The aqueous channel diameters were calculated from the fully hydration lines 
of the respective LCPs containing the lipid-modified catalysts (2, 23, 27, 28, 29), which were 
determined by SAXS.  
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Table 2: Comparison of the catalytic efficiencies of the various LCP and non-LCP conditions used for 
the model aldol reaction of aldehyde 4a with cyclohexanone (3). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Conditions: Reactions were carried out in special, home built metal holders (see experimental section) 
at room temperature with PBS buffer (1X) at pH 7.4, 2 eq of ketone, 30 mol % of catalyst. Holders were 
shaken at 330 rpm during the reaction to ensure optimal mixing. Conversions were determined by 1H-
NMR integrals. a Catalyst 2 was dispersed by sonication in PBS 1X without addition of MO. b Catalyst-
free LCPs were used. Aqueous channel diameters were calculated from SAXS parameters as shown in 
the experimental section. 
 
The data shown in Table 2 indicate that the lipidic structure of the catalyst and the aqueous 
channel size have a strong effect on the performance of the system. LCPs containing catalyst 
23 with the carbohydrate-prolinamide head group exhibit the largest lattice parameter with an 
aqueous channel diameter of 5.11 nm. As the larger aqueous pores enable faster diffusion of 
water-soluble species, and the sugar moiety acts as an additional hydrophilic linker which 
ensures that the catalytic site is well exposed to water soluble substrates, we expected this 
catalyst to show superior performance. This was, however, not the case (cf. Table 2): the best 
result in terms of yield was obtained using catalyst 2, which has a very simple structure that 
can be obtained within two synthetic steps. This indicates that already the simpler amide 
derivatives are well exposed to the aqueous compartments to catalytically transform the 
substrates. In order to compare the LCP-based catalysis with a homogeneously catalysed 
one, the aldol reaction was conducted with catalyst 24 (Table 2, entry 7). The model reaction 
with this water-soluble catalyst was rather sluggish, yielding 65 % conversion after 48 h, 
which did not increase significantly even after 60 h. In contrast, a dispersion of catalyst 2 in 
1X PBS converted the substrates very efficiently to the products (Table 2, entry 6): Within 4 h, 
Entry Catalyst Time [h] Conv. [%] Water channel 
diameter [nm] 
SAXS spectra 
q = [Å-1] 
1 2 48 81 4.73 
 
 
 
 
 
2 28 48 71 4.63 
3 27 48 42 4.70 
4 23 48 75 5.11 
5 29 48 78 4.29 
6a 2 4h 98 - 
7 24 48 65 - 
8b - 72 0 - 
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98 % of the starting material was consumed and transformed to the products. This is probably 
due to the catalyst’s higher accessibility for the substrate as compared to the confined 
geometry in LCPs, in which the substrates need to diffuse from the overlay solution into the 
catalytic sites within the mesophase, and products need to diffuse out. However, a drawback 
of the dispersion set-up is the difficult recovery of the catalyst, which is much simpler and 
more efficient in the case of LCP-based catalysis. As expected, the control experiment with 
pure MO-water LCP, i.e. without catalyst did not show any catalytic activity (Table 2, entry 8). 
Catalyst 26 did not form LCPs with the required catalyst loading  
 
 
2.2.3.2 Controlling catalytic activity by tuning the LCPs  
 
To study the impact of the unit cell size, and related aqueous channel diameter on the 
reaction rate, three types of MO-based LCPs were tested (Table 3): PBS-hydrated LCP 
(LCP A, aq. channel diameter of 4.73 nm), HEPES-hydrated LCP (LCP B, aq. channel 
diameter of 4.65 nm), and HEPES-hydrated LCP which has been additionally doped with the 
strong swelling agent cholesterol (LCP C, aq. channel diameter of 5.71 nm).60 All LCPs 
contained 5% w/w catalyst 2 (relative to the total weight of the LCP), which was chosen for 
this study as it exhibited the best performance in the screening experiments (Table 2). The 
amount of LCP was varied to adjust the catalyst loading to 7.5, 15 and 30 mol % of catalyst 2, 
and their catalytic efficiency compared using the model aldol reaction of aldehyde 4a and 
cyclohexanone (3). The catalyst loading refers to the mol % of catalyst with respect to the 
aldehyde used. The results are summarized in table 2.  
Comparison of the catalytic efficiency of LCP C (Table 2, entries 7-9) with that of LCP B 
(Table 2, entries 4-6) indicates that a combination of buffer, additives (e.g. cholesterol) and 
aqueous channel size affect the catalytic conversion rate: LCP C, with the largest aqueous 
channel diameter of 5.71 nm, allows higher conversion at all catalyst loadings compared with 
LCP B with an aqueous channel diameter of 4.65 nm. These systems can be directly 
compared, as in both regimes the model reaction runs in HEPES buffer and the only 
difference is the added swelling agent cholesterol in LCP C. In contrast, the model reaction 
with LCP A takes place in PBS buffer. Experiments with water-soluble catalyst 24 revealed 
that the effects of the buffer on the model reaction are not negligible: it was shown that the 
conversion of the reaction in PBS buffer is significantly higher as compared to the identical 
reaction in HEPES buffer (65 % vs. 41 % after 48 h). Interestingly, this tendency was reversed 
when the model reaction was carried out in LCPs. The conversion of the model aldol reaction 
with HEPES-containing LCP B (table 2, entries 4-6) and LCP C (Table 2, entries 7-9) was 
higher than with PBS-containing LCP A (Table 3, entries 1-3) after 48 h. In case of LCP C, 
this finding can be rationalized by the larger aqueous channels determined by SAXS 
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(diameter of 5.71 nm). In the case of LCPs A and B, these are however comparable (4.73 vs. 
4.65 nm).  
The reaction progress in these three media, LCP A, B and C with catalyst loading of 30 mol % 
(Table 3, entries 1, 4 and 7) are depicted in Figure 3. The highest conversion of 95 % after 
48 h was obtained using medium C with 30 mol % catalyst loading (Table 3, entry 7), followed 
by medium C with 15 mol % catalyst loading (Table 3, entry 8) and medium B with 30 mol % 
catalyst loading (Table 3, entry 4), both with 85 % conversion after 48 h. The experiments 
using medium A (Table 3, entry 1-3) show lowest conversion. Remarkably, medium C with 
15 mol % catalyst loading (Table 3, entry 8) is more efficient than medium A with 30 mol % 
catalyst loading (Table 3, entry 1) and equally efficient as medium B with 30 mol % catalyst 
loading (Table 3, entry 4) despite the lower catalyst loading. The reaction progress of these 
three entries is shown in Figure 3.  
 
  
Chapter 2 
 
 
 
37 
Table 3: Comparison of the catalytic efficiencies of LCPs with different aqueous channel diameters as 
function of increasing catalyst loading. The model aldol reaction of cyclohexanone (3) with aldehyde 4a 
in different LCPs at varied catalyst loadings was investigated. 
Conditions: Reactions were carried out in special, home built metal holders (see experimental part) at 
room temperature with PBS buffer pH 7.4, 2 eq of ketone. The holders were shaken at 330 rpm during 
the reaction to ensure optimal mixing. a Determined by SAXS. b Determined by 1H-NMR. Medium 
legend: A) PBS 1X. B) HEPES 25 mM. C) HEPES 25 mM, cholesterol doped LCP. 
 
 
 
Figure 3: Progress of the aldol reaction of cyclohexanone 3 with aldehyde 4a in different LCP systems 
(determined by 1H-NMR). Comparison of the four LCP media A, B and C with 30 mol % cat. loading 
and medium C with 15 mol % cat. loading. 
  
Entry Medium Cat.-ldg.  
[mol %] 
Conv.b 
[%] 
Aq channel 
diameter a [nm] 
SAXS spectra 
q = [Å-1] 
1  30 81  
 
2 A 15 72 4.73 
3  7.5 63  
4  30 85  
5 B 15 75 4.65 
6  7.5 67  
7  30 95  
8 C 15 85 5.71 
9  7.5 71  
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Phytantriol-based LCPs 
In addition to the above described MO-based LCP systems, also phytantriol (PT) LCPs have 
been investigated. PT shows a similar phase diagram like MO (see introduction, page 5). The 
lower degree of hydration and smaller lattice parameter of the Pn3m cubic phase at excess 
water conditions, as compared to MO, is the major difference between these systems.61 This 
is a disadvantage from our perspective since diffusion of the substrate into the LCPs aqueous 
channels is slowed down, as can be seen in Figure 4. Commercial PT is a mixture of 
stereoisomers. In order to obtain LCPs that are composed of homochiral lipids, S,S-PT and 
R,R-PT have been synthesized. The synthesis of these PTs and attempts towards chiral 
recognition of small molecules with these homochiral PT-LCPs are described in Chapter 7. 
Preliminary data indicate that the phase diagrams of enantiopure PTs differs from commercial 
PT, which consists of four stereoisomers. Therefore, we prepared S,S-PT, R,R-PT and 
racemic-PT based catalytic LCPs containing catalyst 2 with 40 mol % to perform our model 
aldol reaction and compare the kinetics (Figure 4) and stereochemistry. We proposed that the 
chiral surfaces of these LCPs influence the preorganization of the substrates and thus affect 
the stereochemical outcome of the reaction. However, neither the reaction rates nor the 
stereochemistry was found to be significantly different for one of the three PT-LCPs, as shown 
in Figure 4.  
 
 
Figure 4: Progress of the aldol reaction of cyclohexanone 3 with aldehyde 4a in three different 
phytantriol LCP systems with catalyst 2 (determined by 1H-NMR). Comparison of LCP media consisting 
of racemic PT, S,S-PT and R,R-PT with 40 mol % cat. loading.  
 
In summary, the reaction rate is strongly dependent on the type of LCP. By changing 
parameters such as buffers or by using additives, catalytic LCPs can be modified such that 
the kinetics of the reactions performed therein can be tuned. Additionally, the influence of the 
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buffer (HEPES vs. PBS) on the reaction rate needs to be taken into account. In a reference 
system with water-soluble catalyst 24, the model reaction was found to proceed faster in PBS 
than in HEPES buffer.  
The isolated yields were between 50 and 91%. Catalytic LCPs delivered the product even at a 
low catalyst loading of 7.5 mol % and with only two equivalents of cyclohexanone (3), which is 
low as compared to examples in literature where often 5 equivalents50,52 or more were used.51  
 
 
2.2.3.3 Cubosomes  
 
Whereas bulk LCPs are malleable and can be attached to various surfaces due to their solid 
consistency and adhesive properties, they can alternatively be dispersed to form cubosome 
nanoparticles. The latter exhibit identical packing arrangement and phase identity to those of 
the parent gel LCP, but their viscosity is much lower.62 Because of their very large ratio of 
surface area to volume, cubosomes tend to aggregate to form thermodynamically stable bulk 
LCPs. To overcome this, their surfaces need to be kinetically stabilized.63 Pluronics,64 are the 
most frequently used stabilizers for such systems. The most efficient stabilizer was found to 
be Pluronic F108 (PF 108),63 which was consequently used in this study. Such self-assembled 
fluid dispersions thus allow running reactions in classical reaction flasks using stirring, and 
therefore potentially increase reaction rates. These two options of reaction media, bulk LCP 
and cubosomes offer a high degree of flexibility in the choice of the experimental set-up. 
Furthermore, this study delivers information about the differences and similarities in 
performance in terms of reaction rate.  
 
 
2.2.3.4 Cubosome preparation and characterization 
 
Cubosomes were prepared by mixing MO with the appropriate amount of catalyst. 
Subsequently, the lipid mixture was hydrated with a PF 108-containing buffer solution (cf. 
experimental section for more detail). The total lipid and PF 108 concentrations were 33.0 and 
1.65 mg/mL, respectively.  
Three types of cubosomes were investigated: Cubosomes A were hydrated with PBS 1X and 
adopted a Pn3m cubic phase, cubosomes B, hydrated with HEPES 25 mM buffer exhibited an 
Im3m cubic phase and cubosomes C, which are hydrated with HEPES 25 mM buffer and 
contain cholesterol (15 % w/w) as swelling agent form coexistence of Pn3m and Im3m cubic 
phase. The hydrodynamic diameter of the cubosomes was determined by dynamic light 
scattering (DLS) and varied from 133 - 177 nm, and no significant change in the particle size 
before and after the aldol reaction of cyclohexanone (3) and water-soluble aldehyde 4a was 
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observed. Thus, the influence of mesophase geometry on the kinetics of the catalytic reaction 
conducted in these media was investigated. 
 
 
Figure 5: Representative cryo-TEM images of cubosomes dispersed in PBS 1X (A) and HEPES (B) 
buffers, respectively. SAXS pattern of cubosomes dispersed in PBS (C, orange, Pn3m) and HEPES (D, 
blue, Im3m) buffers, respectively. The sketches of the repeating units for the Pn3m (inset in top panel) 
and the Im3m symmetries (inset in bottom panel) were obtained as level surfaces of the nodal 
approximations reported in65. 
 
Results of the catalytic experiments are summarized in table 3. As in the LCP case, the best 
results were obtained with cubosomes C with a catalyst loading of 30 mol % (Table 4, entry 
7). The conversion exceeded 80 % in less than 10 h of reaction time (Figure 6), with complete 
conversion being achieved after 48 h. With a catalyst loading of 15 mol %, the conversion 
similarly exceeded 80 % in less than 10 h, while after 48 h 86 % conversion was obtained. 
The conversion of cubosomes C with 15 mol % catalyst (Table 4, entry 8) was comparable to 
the cubosomes A with 30 mol % (Table 4, entry 1) and with cubosomes B with 30 mol % 
(Table 4, entry 4). Cubosomes B with 30 mol % (Table 4, entry 4), exceeded 80 % of 
conversion in less than 10 h of reaction time (Figure 6), and after 48 h, conversion was 90 % 
(Table 4, entry 4). The isolated yields ranged between 65 and 94%. Catalytic cubosomes 
delivered the product even at a low catalyst loading of 7.5 mol %.  
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Table 4: Comparison of the catalytic efficiencies of cubosomes with different geometries as function of 
increasing catalyst loading. The model aldol reaction of cyclohexanone (3) with aldehyde 4a was 
investigated 
Entry Cubosomes Space groupa Size [nm] PDI Cat.-ldg. [mol %] Conv.b [%] 
1     30 85 
2 A Pn3m 174 ± 2 0.17 15 73 
3     7.5 48 
4     30 90 
5 B Im3m 177 ± 2 0.19 15 71 
6     7.5 60 
7     30 100 
8 C Pn3m/Im3m 133 ± 1 0.17 15 86 
9     7.5 65 
Conditions: Reactions carried out at room temperature with PBS buffer pH 7.4, 2 eq of ketone. 
Reaction time 48 h a Determined by SAXS. b Determined by 1H-NMR. Cubosome type legend: A) PBS 
1X. B) HEPES 25 mM. C) HEPES 25 mM, cholesterol doped LCP. All dispersions were stabilized with 
1.65 mg/mL PF-108. 
 
 
Figure 6: Progress of the model aldol reaction of cyclohexanone (3) with aldehyde 4a carried out in 
cubosomes A, B and C (determined by 1H-NMR). 
 
LCP experiments were carried out in special, home-built metal holders with an interfacial area 
between the overlay bulk water and the LCP surface (“outer interfacial area”) of ca. 0.0003 m2 
per 100 mg LCP (see experimental section for pictures of our set-up). In contrast, assuming 
spherical geometry and monodisperse cubosome particle size of 200 nm, the interfacial area 
between the latter and bulk water is ca. 3 m2 per 100 mg, which is 4 orders of magnitude 
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larger. Based on these considerations one would expect the cubosomes to be catalytically 
much more efficient than bulk LCPs. Interestingly, this is not the case, and the reaction rates 
of the model aldol reaction in LCPs and cubosomes are comparable (after 48 h). Possible 
explanation for this effect is the stabilization mechanism of cubosomes. As was demonstrated 
by Larsson et al.66 and Demurtas et al,67 cubosomes exhibit a perfect bicontinuous cubic 
phase geometry at the inner part, while at the outside lamellar attachments are present, which 
can be seen in Figure 5A and 5B. Consequently, the aqueous pores are not directly 
accessible from bulk water as the lamellar structure at the outside forms a barrier for the 
substrates to diffuse to the catalytic sites inside the cubosomes. Comparison of the 
conversion rate of the catalytic LCPs vs. cubosomes at various time points (Figure 6) shows 
significantly faster initial reaction rates in the cubosome systems. It seems thus that there is 
an advantage of the large outer interfacial area of cubosomes at the beginning of the reaction, 
despite the lamellar attachments which function to some extent as a barrier. Figure 7 
illustrates this finding. We can conclude that the outer interfacial area has only a minor impact 
on the overall conversion rate, and diffusion inside the aqueous channels, once the substrates 
have entered, is rate limiting. This interpretation is supported by the fact that mesophases 
with different water channel diameters show different conversion rates (for example Table 3, 
entry 4 and 7).  
 
 
Figure 7: Comparison of the conversion rate of the model aldol reaction of cyclohexanone (3) with 
aldehyde 4a after 5 and 48 h (orange and blue, respectively) of catalytic LCPs (left) and cubosomes 
(right). 
 
 
2.2.3.5 Stereochemistry and substrate scope 
 
Following the demonstration of the applicability of catalytic cubosomes and LCPs as novel 
nanoreactor scaffolds for organocatalysis, we set out to investigate the stereochemistry and 
substrate scope of such reactions, which was extended by two unactivated aldehydes: 
benzaldehyde (4b) and 3-(2-hydroxyethoxy) benzaldehyde (4c). The experiments described 
A B C A B C
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above (Table 2 - 4) showed good diastereoselectivity (up to 87:13, table 4, entries 1 - 14) but 
only moderate enantioselectivity (67-89 % e.r.). Comparable low enantioselectivities were 
also obtained when conditions known from literature39 Table 5, entries 21 and 22) were 
applied and buffer was used instead of water. The low enantioselectivity might be a result of 
the relative high buffer concentrations (HEPES 25 mM, PBS 1X). As was shown in the 
literature,39 higher enantioselectivities can be obtained when trifluoroacetic acid (TFA) is used 
as an additive. To that end, a TFA-salt of the catalyst was formed. At higher buffer 
concentrations, there is a stronger salt competition, leading to the loss of the TFA salts of the 
catalysts. However, reducing the buffer concentrations led indeed to significantly better 
enantioselectivities (Table 5, entries 15 - 20), while the performance of catalysts 27 and 28 
was significantly reduced. Catalyst 29 delivered similar results to 2. Lowering the pH resulted 
in significant decrease in reaction rates, and using water instead of buffer led to much less 
stable mesophases. The best conditions were obtained using PBS 0.1X buffer, resulting in 
e.r.’s up to 93 %, which is comparable to examples of prolinederivative-catalyzed asymmetric 
aldol reactions between nitro-benzaldehydes and cyclohexanone (3) in aqueous 
systems.39,51,53,54,68,69 This system decreased the reaction rate as compared to the more 
concentrated buffer conditions (Table 5). There is no significant difference in terms of e.r. if 
the catalyst loading is changed (Table 5, entries 1 - 3). The enantiomers were assigned 
indirectly, by comparing the aldol products synthesized with catalytic mesophases and 
literature known reference catalysts by NMR and HPLC chiral stationary phase.  
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Table 5: Aldol reactions of cyclohexanone (3) with aldehydes 4a, 4b and 4c performed in catalytic mesophases.  
 
Entry Cat. Medium Aldehyde Time e.r.a (%) anti / synb Conv.a [%] 
1 2 A 4a 48 78 81 / 19 81 
2c 2 A 4a 48 75 81 / 19 72 
3d 2 A 4a 48 77.5 82 / 18 63 
4 2 A 4a 20 84 86 / 14 57 
5 27 A 4a 48 71 73 / 27 42 
6 28 A 4a 48 68 77 / 23 71 
7 23 A 4a 48 72 87 / 13 75 
8 2 B 4a 60 73 85 / 15 83 
9 2 B 4be 72 77 66 / 34 42 
10 2 B 4ce 96 89 71 / 29 35 
11 2 C 4a 20 71 86 / 14 78 
12 2 D 4a 48 67 85 / 15 90 
13 2 E 4a 48 73 87 / 13 95 
14 2 F 4a 48 70 82 / 18 100 
15 2 G 4a 60 93 80 / 20 62 
16 2 G 4a 48 92 88 / 12 39 
17 23 G 4a 96 72 82 / 18 79 
18 29 G 4a 60 92 86 / 14 35 
19 2 G 4be 72 92 90 / 10 8 
20 2 H 4a 60 91 90 / 10 55 
21 2 H 4a 60 91 90 / 10 60 
22 2 I 4a 4 69 77 / 23 98 
23 2 J 4a 4 80 79 / 21 99 
24 24 K 4a 48 70 76 / 14 65 
Conditions: Reactions were carried out at room temperature, 2 eq of ketone, 30 mol % of catalyst. a Determined 
by chiral-phase HPLC analysis for anti-product b Determined by 1H-NMR. c 15 mol % of catalyst. d 7.5 mol % of 
catalyst. e 3 eq of ketone, 40 mol % catalyst Medium legend: A) PBS 1X LCP. B) PBS 1X cubosomes (Cubosomes 
A). C) HEPES 25 mM LCP. D) HEPES 25 mM cubosomes (Cubosomes B). E) HEPES 25 mM, cholesterol doped 
LCP. F) HEPES 25 mM, cholesterol doped cubosomes (Cubosomes C). G) PBS 0.1X LCP. H) PBS 0.1X 
cubosomes (Cubosomes D). I) Dispersion of 2 in PBS. J) Dispersion of 2 in HEPES 25 mM. K) Solution of 24 in 
PBS 1X.  
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2.2.4 Recycling 
Catalytic LCPs as well as catalytic cubosomes can be reused up to five times without loss of 
activity. This is consistent with similar conclusions drawn on in-meso enzymatic reactions run 
over multiple cycles.70 In the case of the catalytic LCPs, the aqueous phase containing the 
crude product can be decanted, and the LCP rinsed with the corresponding buffer. 
Subsequently, a new substrate solution can be added as an overlay to the LCP. To recycle 
catalytic cubosomes, the dispersion is filtered, a new stabilizer solution is added, and the 
sonication process is repeated.  
 
2.2.5 Synthesis of various substrates and nornicotine reference catalyst 
Many of the substrates used in this chapter had to be synthesized first, either because they 
were not commercially available or their supply was too expensive. Substrates 34 and 37 
were not commercially available in satisfying quality. The syntheses will be briefly discussed. 
 
2.2.5.1 Carbohydrate derived substrates 
2,3-O-isopropylidene-glyceraldehyde (34) was synthesized in two synthetic steps from D-
mannitol (32) according to a reported procedure (Scheme 4A). To that end, D-mannitol (32) 
was diketalized using 2,2-dimethoxypropane under basic conditions and SnCl2 as a Lewis 
acid to obtain diacetonide 33. In a second step, the carbon-carbon bond between the vicinal 
diols of 33 was oxidatively cleaved using NaIO4 to obtain the final product 34.71 2,2-dimethyl-
1,3-dioxan-5-one (37) was obtained in two similar synthetic steps (Scheme 4B). 
Tris(hydroxymethyl)aminomethane was protected with 2,2-dimethoxypropane under acidic 
conditions. The amino alcohol 36 was subsequently transformed to ketone 37 by oxidative 
cleavage with NaIO4.72 Glyceraldehyde-3-phosphate (39) was synthesized from D-fructose-6-
phosphate (38) in one step after treatment with periodic acid (Scheme 4C).73 
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Scheme 4: Syntheses of 2,3-O-isopropylidene-glyceraldehyde (34), 2,2-dimethyl-1,3-dioxan-5-one (37) 
and glyceraldehyde-3-phosphate (39). Conditions: a) SnCl2, pyridine, glyme, reflux. b) NaIO4, CH2Cl2, 
0°C. c) pTSA, DMF, r.t. d) NaIO4, KH2PO4, H2O, 0°C. e) H5IO6, H2O, 0°C. 
 
 
2.2.5.2 Synthesis of aromatic aldehyde 4a 
 
Since aldol reactions with substrates 34 and 37 turned out to be very difficult, a more stable 
alternative was needed. 4-nitrobenzaldehyde, together with cyclohexanone is used as 
benchmark aldol reaction in literature. However, 4-nitrobenzaldehyde is hardly soluble in 
water. Therefore, aldehyde 4a was designed, which bears an ethylene glycol unit that renders 
the compound water-soluble (Scheme 5). Furthermore, the hydroxyl moiety could be 
phosphorylated to further increase the hydrophilicity.  
 
 
Scheme 5: Synthetic route to water-soluble aldehyde 4a. Conditions: a) Ethylene glycol, pTsOH, 
toluene, reflux. b) Ethylene glycol, PPh3, DIAD, THF, 55 °C. c) pTsOH, acetone/water 9:1, 55°C.  
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Compound 40 is an ideal starting material for the planned synthesis because the ethylene 
glycol moiety can be installed at the phenol group using a Mitsunobu reaction74 once the 
aldehyde was protected. Acetal 42 was then deprotected using pTsOH.  
 
 
2.2.5.3 Towards intramolecular aldol reactions in LCPs 
 
Diffusion of the substrates from bulk water into the aqueous channels where the catalyst is 
located is one of the rate determining steps for chemical reactions carried out in mesophases. 
It would be interesting to compare the kinetics of an intermolecular with an intramolecular 
aldol reaction in mesophases, in which only one substrate molecule needs to diffuse into the 
water channel system to get in contact with the catalyst. In contrast to organocatalytic, 
intermolecular aldol reactions, its intramolecular version is much less well developed and, to 
the best of our knowledge, no organocatalytic, intramolecular aldol reactions in aqueous 
medium have been reported. One of few targets is the isochroman-1-one heterocyclic unit. 
Fronert and co-workers75 addressed this topic using proline and proline derived catalysts in 
organic solvents (Scheme 6).  
 
 
Scheme 6: Intramolecular aldol reaction of 43 forming isochroman-1-one derivative 44.75 
 
Having this substrate as a starting point in mind, two new water-soluble and activated 
analogues 52 and 53 have been designed (Scheme 7). The synthesis of 2-formyl-5-
nitrobenzoic acid 47 was developed by Zhang et al.76 This compound was also used in the 
previously described substrate screening for intermolecular aldol reactions, albeit no product 
was formed (Table 1, entry 20). 
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Scheme 7: Synthesis of 2-formyl-5-nitrobenzoic acid 47 and attempts to synthesize substrates 52 and 
53, which would enable intramolecular aldol reactions. Conditions: a) NBS, AIBN, benzene, reflux. b) 
H2O, reflux. c) Ethylene glycol, pTsOH, toluene, reflux. d) Dihydroxy acetone, EDC, DMAP, DMF, r.t. e) 
1,5-dihydroxypentane-2,4-dione EDC, DMAP, DMF, r.t.. 
 
 
The esterification of 2-formyl-5-nitrobenzoic acid was found to be much more challenging than 
expected (Scheme 7). The coupling with dihydroxy aceton using DCC/DMAP and EDC/DMAP 
did not work, neither in DMF nor in CH2Cl2 as the solvent. Dihydroxy aceton is commercially 
available in dimeric form. In order to obtain the monomer, an aqueous solution has to be 
prepared and stored for a few hours, before it is lyophilized and can be used. Remaining 
water from the lyophilisation could be an explanation for the failed esterification experiments.  
 
 
2.2.5.4 Nornicotine reference catalyst 
 
In order to have a second water-soluble reference catalyst in hand, nornicotine was 
synthesized and the resolution of the enantiomers was carried out according to a reported 
procedure. The synthesis started with a Steglich esterification of commercially available 5-
bromo-nicotinic acid (54) with ethanol, followed by base catalyzed condensation with N-
vinylpyrrolidone. After acid catalyzed hydrolysis, decarboxylation and cyclization, imine 56 
was obtained, which was reduced by NaBH4 to 5-bromonornicotine (57). The chiral resolution 
of this racemic mixture was achieved by treatment with the chiral organic acid 3,3,3-trifluoro-
2-methoxy-2-phenylpropanoic acid (MTPA) and subsequent crystallization.77 Both 
nornicotine enantiomers were obtained after treating of bromo-nornicotine using n-BuLi and 
water at -78 °C.  
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Scheme 8: Synthesis of R- and S-nornicotine 58a and 58b by chiral resolution by crystallization of the 
MTPA salts of bromo-nornicotine 53 and subsequent debromination. Conditions: a) EtOH (1 eq), DCC 
(1 eq), DMAP (0.1 eq); b) NaH (1.33 eq), Vinylpyrrolidone (1.1 eq), THF, reflux. c) H2O, conc. HCl; d) 
NaOH 10%; e) NaBH4 (2.3 eq), MeOH/AcOH 5:1, -40°C. e) NaBH4, methanol/acetic acid (8:2), -40°C. f) 
Crystallisation with the corresponding MTPA salt. g) nBuLi, THF, -78 °C. 
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2.3 Conclusions 
 
Host-guest lipidic mesophases were established as novel nanoreactor scaffolds for 
heterogeneous organocatalysis. Five proline-based lipidated catalysts were designed, 
synthesized and laterally immobilized into LCPs and cubosomes. The resulting catalytic lipidic 
mesophases were tested for a model asymmetric aldol reaction in confined aqueous buffers 
with three different aldehydes. The influence of the chemical structure of the catalysts on the 
phase identity and on the lattice parameter of the lipidic mesophases was established and 
correlated with the performance of various catalyst-mesophase systems. Both LCPs and 
cubosomes constitute efficient catalytic systems with good diastereo - and enantioselectivity. 
These readily prepared, biocompatible, sustainable and benign systems can be recycled at 
least five times without loss of activity. The novel catalytic lipidic mesophase systems present 
two modes of use with distinct features: Whereas gel-like bulk LCP is malleable and can 
adhere to any surface, fluid cubosome dispersions can be used in a classical reaction flasks. 
Significantly, the reaction rate of the model aldol reaction could be controlled by modifying 
catalytic LCPs and cubosomes using cholesterol as an additive. The approach presented 
herein is general, and in principle various types of (organo)catalysts may be used, including 
lipidic metal complexes. However, the system has also limitations, as it is restricted to 
aqueous chemistry, and the reactions need to be run at rather low concentrations of water-
soluble substrates, in order not to disrupt the self-assembled lipidic structure of the 
mesophase. In conclusion, while catalysis in homogeneous systems has been developed to 
high sophistication, and immobilized catalysts on surfaces have been studied in great detail, 
the use of lipidic cubic phases as nanoreactor scaffolds for catalysts is novel. This remarkable 
and highly versatile mesophase material allows the tuning of various physical and chemical 
parameters, such as channel size, hydration, phase geometry interface charge, thereby 
providing exciting new avenues to be explored in catalysis in confined space. 
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2.4 Outlook 
 
The reaction rates of the studied aldol reaction with both catalytic LCPs and cubosomes might 
be increased by applying massive swelling of the aqueous channels, according to a reported 
procedure.78 Furthermore, the substrate scope needs to be extended to render catalytic LCP 
and cubosomes a more general tool for aqueous chemistry. Therefore, the attempts to 
synthesize carbohydrates need to be optimized. The same is true for the intramolecular aldol 
reaction. The stereochemistry of our model aldol reaction is moderate, however there is room 
to improve. Our system in its present form does not allow to catalyze water-insoluble 
compounds, as they accumulate in the lipidic compartment of the mesophases which 
destabilizes them. This problem is being addressed by developing catalytic LCPs made of 
polymerizable lipids. Since the polymerizable acroyl moieties in of these lipids are situated 
just the headgroup, enrichment of hydrophobic compounds in the lipidic compartment might 
be reduced (see Chapter 6).  
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2.5 Experimental section 
 
General Information  
1-Monooleoyl-sn-glycerol C18:1 (monoolein, MO) was purchased from Nu-Chek Prep, Inc. 
(MN, USA), and phosphate buffer solution (PBS (1X) pH 7.4) was purchased from Invitrogen. 
Phytantriol was purchased from DSM. N-(3- dimethylaminopropyl)-N′-ethylcarbodiimide 
hydrochloride (EDC) was purchased from TCI, and all other reagents and solvents were 
purchased from Sigma Aldrich. All chemicals and solvents were used as received, unless 
otherwise stated. Reactions were carried out under an inert atmosphere of argon in dry 
solvents. Dichloromethane was degassed with argon and purified by passage through 
activated alumina solvent column (MC Brown solvent system) prior to use. Column 
chromatography was performed using silica gel Merck 60 (particle size 0.040–0.063 mm). 
Analytical thin- layer chromatography (TLC) was performed using Merck pre-coated silica gel 
plates 60 F254; visualization by UV absorption and/or by dipping in a solution of KMnO4 (1 g), 
K2CO3 (2 g) in H2O (100 mL) and subsequent heating. 1H-NMR spectra were recorded on a 
Bruker AV2-500 (500MHz) spectrometer. Chemical shifts are given in parts per million (ppm) 
relative to the internal standard TMS (δ = 0 ppm). Coupling constants J are expressed in Hz 
and multiplicities are abbreviated as follows: s (singlet), br (broad), d (doublet), t (triplet), q 
(quadruplet), quint (quintet), m (multiplet). 13C-NMR chemical shifts are reported relative to the 
solvent residual peaks: CDCl3 = 77.00 ppm. Mass spectra were recorded by the Mass 
Spectroscopy Service of UZH on Finnigan MAT95 MS, BrukerLC MS and Finnigan TSQ700 
MS machines.  
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2.5.1 Synthesis 
2.5.1.1 General procedures 
 
Amide coupling: 
To a stirred solution of BOC-L-proline (500 mg, 2.32 mmol, 1 eq) in 50 mL of a mixture of dry 
CH2Cl2 and dry DMF (1:1) was added EDC (466 mg mg, 3.00 mmol, 1.3 eq) and DMAP 
(28 mg, 0.232 mmol, 0.1 eq) at 0 °C under an inert atmosphere. The solution was stirred for 1 
h at 0 °C and then the corresponding amine (3.48 mmol) was added dropwise over a period of 
10 min. The reaction mixture was stirred for 14 h at room temperature and then CH2Cl2 
(50 mL) was added, the mixture was washed with a saturated solution of NaHCO3. The 
organic phase was separated and the aqueous phase was extracted with CH2Cl2 (50 mL). 
The combined organic phases were washed with brine and dried over MgSO4. The solvent 
was removed and the crude product was purified by column chromatography. The solvent 
was evaporated to afford the corresponding products. 
 
Boc-deprotection: 
Boc-protected catalysts (0.43 mmol) were dissolved in CH2Cl2 (10 mL), cooled to 0°C and 
trifluoro acetic acid (TFA) (3 mL) was added slowly. The solution was stirred for 3 h at 0°C 
while the reaction was monitored by TLC. Upon completion of the reaction, the solvent was 
evaporated in vacuo. In order to remove residual TFA, CH2Cl2 (3 x 3 mL) was added and 
evaporated.  
 
Amide reduction: 
The corresponding amide (1.1 mmol, 1 eq) was dissolved in THF (10 mL) and slowly added to 
a suspension of LiAlH4 (141 mg, 3.7 mmol, 3.4 eq) in THF (10 mL) at 0°C. The reaction 
mixture was then heated up to reflux for 20 h. After cooling down to 0°C, saturated Na2SO4 
solution was added and the mixture was filtrated. After removal of the solvent in vacuo, the 
crude product was purified by column chromatography. The tertiary amine was then treated 
with CH2Cl2/TFA (3:1) to obtain the product as TFA salts. 
 
Aldol reaction using catalytic lipidic cubic phases (LCPs) 
Previously prepared LCP (containing 0.0071 mmol, 66 mg MO and corresponding buffer, LCP 
preparation as described on page 15) was put on homemade metal holders (Figure 8) and the 
plastic container for the aqueous phase was attached. Subsequently, a solution of the desired 
aldehyde 4a, 4b or 4c (0.0235 mmol, 1 eq) and cyclohexanone (3) (4.6 mg, 0.047 mmol, 
2 eq) in 2 mL of the desired buffer at pH 7.4 (PBS 1X, HEPES 25 mM, PBS 0.1X) was 
carefully poured on top of the catalytic LCP. The reaction set-up was gently shaken on a 
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laboratory shaker. The reaction was monitored by 1H-NMR. After completion of the reaction, 
the aqueous phase was removed and the LCP rinsed with 2 mL of corresponding buffer. The 
aqueous phases were extracted with EtOAc (5 x 3 mL). The combined organic phases were 
washed with brine and dried over MgSO4. The solvent was removed and the crude product 
was purified by column chromatography (silica gel, cyclohexane/EtOAc) to obtain the aldol 
products.  
 
Figure 8: Homemade metal holders for aldol reactions catalyzed by LCPs. Left: Empty metal holder 
with indentation for LCP, plastic container for the aqueous overlay and cap. Centre: LCP loaded metal 
holder. Left: Prepared set-up for aldol reactions catalyzed by LCPs. 
 
Aldol reaction using catalytic cubosomes 
Aldehyde 4a, 4b or 4c (0.0235 mmol, 1 eq) and cyclohexanone (3) (4.6 mg, 0.047 mmol, 
2 eq) were added to previously prepared cubosomes (0.0071 mmol catalyst, 66 mg MO, and 
2 mL of the corresponding buffer, cubosome preparation as described on page 15) and the 
reaction mixture was stirred. The reaction was monitored by 1H-NMR. After completion of the 
reaction, the cubosome were separated from the aqueous phase by centrifugation with 
vivacon 500 filter and the lipidic part was rinsed with 2 mL of the corresponding buffer. The 
aqueous phases were extracted with EtOAc (5 x 3 mL). The combined organic phases were 
washed with brine and dried over MgSO4. The solvent was removed and the crude product 
was purified by column chromatography (silica gel, cyclohexane/EtOAc) to obtain the aldol 
products. 
 
 
Figure 9: Set up for aldol reaction using catalytic cubosomes. 
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2.5.1.2 First generation catalysts 
 
Synthesis of 8 ((2S,4R)-1-(tert-butoxycarbonyl)-4-(oleoyloxy)pyrrolidine-2-carboxylic 
acid)18 
 
 
A) To a solution of oleic acid (6) 90% (271 mg, 0.865 mmol, 1 eq) in DCM (5 ml), DMAP 
(106 mg, 0.865 mmol, 1 eq), DCC (217 mg, 0.95 mmol, 1.1 eq) and (2S,4R)-1-(tert-
butoxycarbonyl)-4-hydroxypyrrolidine-2-carboxylic acid (7) (200 mg, 0.865 mmol, 1 eq) was 
added. The suspension was allowed to stir for 2 days at room temperature at which time it 
was filtrated, and after addition of DCM (5 mL), washed with brine (2x). The organic phase 
was dried over MgSO4 and the solvents evaporated. The crude product was purified by 
column chromatography (hexane/EtOAc 1:1, 1% acetic acid) to afford the product as a yellow 
oil (123 mg, 0.25 mmol, 32%). 
	
B) To a stirred solution (2S,4R)-1-(tert-butoxycarbonyl)-4-hydroxypyrrolidine-2-carboxylic acid 
(7) (200 mg, 0.86 mmol, 1.0 eq), DIPEA (0.86 mL) in anhydrous CH2Cl2 (10 mL) was cooled 
to 0 °C and treated dropwise with a solution of oleyl chloride (10) (361 mg, 1.2 mmol, 1.4 eq) 
in DCM (5 mL). The ice bath was removed and the reaction mixture was stirred until no more 
starting material was observed by TLC. The reaction mixture was poured into brine and 
extracted three times with CH2Cl2. The combined organic phases were washed with brine, 
dried over MgSO4 and concentrated under reduced pressure. The residue was purified by 
column chromatography on silica gel to obtain the product as a yellow oil (107 mg, 0.22 mmol, 
25 %).  
Analytical data were identical with the values reported in literature.18 
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Synthesis of catalyst 9 ((2S,4R)-4-(oleoyloxy)pyrrolidine-2-carboxylic acid)18 
 
 
 
Catalyst 9 was obtained after Boc-deprotection of 8 according to the general procedure as a 
yellow oil in quantitative yield. 
Analytical data were identical with the values reported in literature.18 
 
 
Synthesis of 12 ((2S,4R)-1-(tert-butoxycarbonyl)-4-oleamidopyrrolidine-2-carboxylic 
acid)18 
 
 
To a solution of oleic acid (6) 90% (271 mg, 0.865 mmol, 1 eq) in DCM (5 ml), DMAP (11 mg, 
0.087 mmol, 0.1 eq), EDC (182 mg, 0.95 mmol, 1.1 eq) and (2S,4R)-4-amino-1-(tert-
butoxycarbonyl)pyrrolidine-2-carboxylic acid (11) (200 mg, 0.865 mmol, 1 eq) was added. The 
suspension was allowed to stir for 10 h at room temperature at which time it was filtrated, and 
after addition of DCM (5 mL), washed with brine (2 x 5 mL). The organic phase was dried over 
MgSO4 and the solvents evaporated. The crude product was purified by FC (hexane/EtOAc 
1:1, 1% acetic acid) to obtain the desired product as a slightly yellow oil (330 mg, 0.692 mmol, 
80 %). 
Analytical data were identical with the values reported in literature.18 
 
Synthesis of catalyst 13 ((2S,4R)-4-oleamidopyrrolidine-2-carboxylic acid)18  
 
 
 
Catalyst 13 was obtained after Boc-deprotection of 12 according to the general procedure as 
a yellow oil in quantitative yield.Analytical data were identical with the values reported in 
literature.18 
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2.5.1.3 Second and third generation catalysts 
 
 
 
Scheme 9: Overview of the syntheses of lipidic catalysts 2, 23, 26, 27, 28, 29 and water-soluble 
reference catalyst 11. Conditions: a) Oleylamine, EDC (1.1 eq), DMAP (0.1 eq) CH2Cl2 / DMF 4:1, r.t. 
b) CH2Cl2 / TFA 4:1, 0°C c) Stearylamine (1.1 eq), EDC (1.1 eq), DMAP (0.1 eq) CH2Cl2 / DMF 4:1, r.t. 
d) Dioleylamine (1.1 eq), EDC (1.1 eq), DMAP (0.1 eq) CH2Cl2 / DMF 4:1, r.t. e) Didodecylamine 
(1.1 eq), EDC (1.1 eq), DMAP (0.1 eq) CH2Cl2 / DMF 4:1, r.t. f) LiAlH4, THF, 0°C 2 h then reflux 20 h. 
g) TEMPO, TCC, DMF, 0°C h) Oleylamine (1 eq), MeOH, r.t. 1h then NaCNBH3 (1.3 eq). i) P(Ph)3 
(1.1 eq.), CBr4 (1.1 eq), DCM, 0°C. j) Oleylamine (1 eq), K2CO3 (0.3 eq), DMSO, 80°C.  
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Synthesis of 17 (N-((3R,4R,5S,6R)-4,5-dihydroxy-6-(hydroxymethyl)-2-
methoxytetrahydro-2H-pyran-3-yl)acetamide)59 
 
 
 
N-Acetyl-D-glucosamine (16) (1.0 g, 4.5 mmol, 1 eq) was dissolved in MeOH (25 mL) before 
Dowex 50W X8, 50-100 mesh (0.2 g) was added. The reaction mixture was refluxed for 20 h, 
filtrated, the solvent evaporated in vacuo to give crude product (α/β mixture of anomers 2:1). 
The crude product was purified by flash chromatography (EtOAc/MeOH 8:2-6:4) to obtain the 
title compound as colorless solid (800 mg, 3.38 mmol, 75 % α-anomer)  
Analytical data were identical with the values reported in literature.59 
 
 
Synthesis of (18) ((2R,3S,4R,5R,6S)-5-amino-2-(hydroxymethyl)-6-methoxytetrahydro-
2H-pyran-3,4-diol)59 
 
 
N-Acetyl-D-methoxyglucoseamine (17) (1.0 g, 3.95 mmol, 1 eq) was dissolved in H2O (30 mL) 
and the pH was adjusted to 13 by adding BaO. The reaction mixture was stirred at reflux for 
12 h. The reaction mixture was cooled to room temperature before the white precipitate was 
filtered off. Subsequently, the water was removed by lyophilisation and the desired product 
was obtained as a colorless solid in quantitative yield. 
Analytical data were identical with the values reported in literature.59 
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Synthesis of 20 ((S)-tert-butyl 2-(((2S,3R,4R,5S,6R)-4,5-dihydroxy-6-(hydroxymethyl)-2-
methoxytetrahydro-2H-pyran-3-yl)carbamoyl)pyrrolidine-1-carboxylate) 
 
 
 
Boc-L-proline (19) (2.13 g, 10 mmol, 1 eq), DCC (2.04 g, 10 mmol, 1 eq) and DMAP (0.12 g, 1 
mmol, 0.1 eq) in DMF (125 mL) was stirred at 0°C for 1 h. To this mixture, 18 (1.9 g, 10 mmol, 
1 eq) was added. After an additional hour at 0 C°, the ice bath was removed und the mixture 
was stirred for 30 h at room temperature. The mixture was filtrated and the solvent 
evaporated. Purification by flash chromatography (EtOAc/MeoH 9:1-8:2) delivered pure the 
product as a yellow, sticky solid (1.56 g, 4 mmol, 40 %). 
Analytical data were identical with the values reported in literature.59 
 
 
Synthesis of 24 ((S)-N-((2S,3R,4R,5S,6R)-4,5-dihydroxy-6-(hydroxymethyl)-2-
methoxytetrahydro-2H-pyran-3-yl)pyrrolidine-2-carboxamide) 
 
 
 
Reference catalyst 24 was obtained after Boc-deprotection of 20 according to the general 
procedure as a yellow oil in quantitative yield. 
Analytical data were identical with the values reported in literature.59 
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Synthesis of 22 ((S)-tert-butyl 2-(((2S,3R,4R,5S,6R)-4,5-dihydroxy-2-methoxy-6-(((Z)-
octadec-9-en-1-ylamino)methyl)tetrahydro-2H-pyran-3-yl)carbamoyl)pyrrolidine-1-
carboxylate)49,79  
 
 
To a stirred solution of the proline carbohydrate 20 (300 mg, 0.77 mmol, 1 eq) in DMF 
(130 mL), NaHCO3 (1.93 g, 94.4 mmol and TEMPO (3 mg, 0.02 mmol, 0.26 eq) was added. 
After cooling to 0°C, TCC (111 mg, 0.483 mmol, 0.63 eq) was added. The reaction mixture 
was stirred for 7 h at 0°C, the white precipitate was filtered off and solvent was removed 
under vacuum. The remaining yellow oil was immediately used for the next step (since the 
aldehyde is prone to decomposition). Crude aldehyde was dissolved in MeOH (70 mL) and 
oleylamine (227 mg, 0.847 mmol, 1.1 eq) was added and stirred at room temperature. The 
reaction was monitored by TLC. After 2 h, the imine formation was completed. Subsequently, 
NaCNBH3 (53.2 mg, 0.847 mmol 1.1 eq) was added and the reaction mixture was stirred at 
reflux for 5 h. After cooling the reaction mixture to room temperature, EtOAc (100 mL) was 
added and the organic layer was washed with brine, dried over MgSO4 and concentrated 
under vacuo. The crude product was purified by flash chromatography (EtOAc/ MeOH). The 
product was obtained as sticky and slightly yellow solid (251 mg, 0.393 mmol, 51%). 
1H NMR (500 MHz, Chloroform-d) δ 5.37 – 5.23 (m, 2H), 4.56 (d, J = 3.1 Hz, 1H), 4.26 – 4.13 
(m, 1H), 4.09 – 3.92 (m, 1H), 3.69 – 3.54 (m, 2H), 3.53 – 3.34 (m, 2H), 3.29 (s, 3H), 3.18 – 
3.00 (m, 1H), 2.98 – 2.91 (m, 2H), 2.79 – 2.63 (m, 1H), 2.24 – 1.75 (m, 8H), 1.59 – 1.48 (m, 
2H), 1.40 (s, 9H), 1.32 – 1.12 (m, 20H), 0.81 (t, J = 6.7 Hz, 3H). 13C NMR (126 MHz, CDCl3) 
d 174.12, 171.30, 130.14, 129.94, 98.83, 80.71, 73.84, 68.38, 61.29, 60.56, 55.63, 53.77, 
50.85, 49.75, 47.36, 46.79, 32.09, 29.95, 29.89, 29.71, 29.66, 29.55, 29.50, 29.44, 28.52 
(3C), 27.40, 22.86, 14.30. HRMS (ESI [M + H]+) m/z: calcd for (C35H66N3O7) 640.48953, found 
640.48947. 
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Synthesis of catalyst 23 ((S)-N-((2S,3R,4R,5S,6R)-4,5-dihydroxy-2-methoxy-6-(((Z)-
octadec-9-en-1-ylamino)methyl)tetrahydro-2H-pyran-3-yl)pyrrolidine-2-carboxamide) 
 
 
 
Catalyst 23 was obtained after Boc-deprotection of 22 according to the general procedure as 
a yellow oil in quantitative yield. 1H NMR (500 MHz, DMSO-d6) δ 8.80 – 8.51 (m, 2H), 5.43 – 
5.26 (m, 2H), 4.63 (d, J = 3.3 Hz, 1H), 4.21 (s br, 1H), 3.81 – 3.66 (m, 2H), 3.50 (t, J = 9.6 Hz, 
1H), 3.33 (s, 3H), 3.31 – 3.16 (m, 3H), 3.12 (t, J = 9.2 Hz, 2H), 3.08 – 3.00 (m, 1H), 2.97 – 
2.89 (m, 2H), 2.33 – 2.23 (m, 1H), 2.02 – 1.81 (m, 8H), 1.68 – 1.52 (m, 2H), 1.34 – 1.18 (m, 
20H), 0.85 (t, J = 6.6 Hz, 3H). 13C NMR (126 MHz, DMSO-d6) δ 168.64, 129.64, 129.59, 
98.09, 72.26, 69.97, 67.96, 55.23, 53.87, 48.05, 47.49, 45.80, 31.28, 29.85, 29.14, 29.08, 
29.04, 28.82, 28.68 (2C), 28.58, 28.55, 28.48, 26.62, 26.56, 25.93, 25.08, 23.50, 22.09, 
13.94. HRMS (ESI [M + H]+) m/z: calcd for (C30H58N3O5) 540.43710, found 540.43743. 
 
 
Synthesis of 60 ((S,Z)-tert-butyl 2-(octadec-9-en-1-ylcarbamoyl)pyrrolidine-1-
carboxylate 
 
 
Boc-protected compound 60 was synthesized according to the general procedure for the 
amide coupling. The crude product was purified by column chromatography (silica gel, 
cyclohexane/EtOAc 4:1). The product was obtained as a slightly yellow oil (784 mg, 
1.74 mmol, 75 %). 1H NMR (500 MHz, DMSO-d6) δ 7.78 (s), 7.69 (s), 5.39 – 5.28 (m, 2H), 
4.04 – 3.95 (m, 1H), 3.40 – 3.33 (m, 1H), 3.30 – 3.23 (m, 1H), 3.10 – 2.92 (m, 2H), 2.12 – 
1.90 (m, 4H), 1.85 – 1.67 (m, 3H), 1.44 – 1.17 (m, 34H), 0.85 (t, J = 6.8 Hz, 3H). 13C NMR 
(126 MHz, DMSO) δ 172.13, 153.29, 129.59, 78.21, 59.82, 46.41, 38.39, 31.24, 31.06, 29.24, 
29.09, 29.06, 28.97 (2C), 28.92, 28.79, 28.73, 28.65, 28.55 (2C), 28.10, 27.97 (2C), 26.53, 
26.34, 23.11, 22.06, 13.90. HRMS (ESI [M + Na]+) m/z: calcd for (C28H52N2O3Na) 487.38701, 
found 487.38674.  
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Synthesis of catalyst 2, ((S,Z)-N-(octadec-9-en-1-yl)pyrrolidine-2-carboxamide (TFA salt)  
 
 
 
Catalyst 2 was obtained after Boc-deprotection of 60 according to the general procedure as a 
yellow oil in quantitative yield. 1H NMR (500 MHz, DMSO-d6) δ 8.52 (s, 1H), 5.37 – 5.28 (m, 
2H), 4.16 – 4.09 (m, 1H), 3.29 – 3.03 (m, 4H), 2.31 – 2.24 (m, 1H), 2.01 – 1.75 (m, 6H), 1.45 
– 1.38 (m, 2H), 1.32 – 1.19 (m, 22H), 0.85 (t, J = 7.0 Hz, 3H). 13C NMR (126 MHz, DMSO) δ 
167.81, 129.60, 59.01, 45.56, 40.00, 38.85, 31.32, 29.65, 29.17, 29.12, 29.08, 29.04, 28.89, 
28.87, 28.79, 28.72, 28.62, 26.63, 26.59, 26.30, 23.56, 22.12, 13.92. HRMS (ESI [M + H]+) 
m/z: calcd for (C23H45ON2) 365.35264, found 365.35290. 
 
 
Synthesis of 61 (S)-tert-butyl 2-(octadecylcarbamoyl)pyrrolidine-1-carboxylate 
 
 
The title compound was synthesized according to the general procedure for the amide 
coupling. The crude product was purified by column chromatography (silica gel, EtOAc). The 
solvent was evaporated to afford a slightly yellow oil (670 mg, 1.83 mmol 79%). 
1H NMR (500 MHz, Chloroform-d) δ 6.86 (s), 5.99 (s), 4.51 (t, J = 5.0 Hz), 4.44 – 4.32 (m), 
4.18 (s, 1H), 3.56 – 3.00 (m, 4H), 2.41 – 1.70 (m, 4H), 1.66 – 1.58 (m, 4H), 1.56 – 1.49 (m, 
1H), 1.39 (s, 9H), 1.32 – 0.97 (m, 30H), 0.81 (t, J = 6.9 Hz, 3H). 13C NMR (126 MHz, 
Chloroform-d) δ 172.39, 171.78, 157.67, 156.90, 80.23, 48.87, 47.04, 39.32, 33.96, 31.87, 
29.64 (4C), 29.60 (4C), 29.54, 29.48, 29.30, 29.24, 28.33, 26.82, 25.62, 24.94, 22.63, 14.06. 
HRMS (ESI [M + H]+) m/z: calcd for (C28H55O3N2) 467.42072, found 467.42136. 
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Synthesis of catalyst 26 ((S)-N-octadecylpyrrolidine-2-carboxamide) 
 
 
 
Catalyst 26 was obtained after Boc-deprotection of 56 according to the general procedure as 
a yellow oil in quantitative yield. 1H NMR (500 MHz, Chloroform-d) δ 7.80(s, 1H), 3.40 – 3.09 
(m, 4H), 3.05 (t, J = 7.2 Hz, 1H), 2.42 – 2.31 (m, 1H), 2.03 – 1.92 (m, 2H), 1.91 – 1.76 (m, 
3H), 1.72 – 1.63 (m, 2H), 1.60 – 1.34 (m, 6H), 1.18 (s, 32H), 0.81 (t, J = 6.9 Hz, 3H). 13C NMR 
(126 MHz, Chloroform-d) δ 168.28, 59.44, 50.00, 46.50, 41.11, 40.34, 39.46, 33.36, 33.29, 
31.91, 30.38, 29.69, 29.65, 29.59, 29.50, 29.35, 29.28, 29.21, 29.11, 28.36, 25.32, 24.72, 
22.68, 14.10. HRMS (ESI [M + H]+) m/z: calcd for (C23H47ON2) 367.36829, found 367.36849. 
 
 
Synthesis of 31 ((Z)-di((Z)-octadec-9-en-1-yl)amine)58 
 
 
 
To a stirred mixture of oleylamine (800 mg, 3.0 mmol) in DMSO (20 mL) and K2CO3 (150 mg, 
1.10 mmol), oleylbromide 62 (100 mg, 3.0 mmol) was added and the reaction mixture was 
heated to 80°C for 20 h. After cooling to room temperature, the mixture was filtered and water 
was added (50 mL). The mixture was extracted with CH2Cl2 (3 x 50 mL), and the combined 
organic phases were washed with brine and dried over MgSO4. The solvent was removed and 
the crude product was purified by column chromatography (silica gel, cyclohexane/EtOAc 1:1) 
to afford the product as a slightly yellow oil (141 mg, 0.273 mmol, 81%). 1H NMR (500 MHz, 
CDCl3) δ 5.32 – 5.24 (m, 4H), 2.51 (t, J = 7.3 Hz, 4H), 1.97 – 1.86 (m, 4H), 1.44 – 1.36 (m, 
8H), 1.32 – 1.13 (m, 44H), 0.81 (t, J = 6.8 Hz, 6H). 13C NMR (125 MHz, CDCl3) δ 129.91 (2C), 
129.83 (2C), 50.20 (2C), 32.60 (2C), 31.90 (2C), 30.24 (2C), 29.77 (2C), 29.69 (2C), 29.65, 
29.57 (2C), 29.52 (2C), 29.50 (2C), 29.31 (2C), 29.25, 29.17, 29.10, 27.43 (2C), 27.20 (2C), 
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22.68 (2C), 14.10 (2C). HRMS (ESI [M + H]+) m/z: calcd for (C36H72N) 518.56593, found 
518.56610. 
 
 
Synthesis of 62 ((Z)-1-bromooctadec-9-ene)57  
 
 
 
Oleyl alcohol (2.0 g, 7.4 mmol, 1 eq) and triphenylphosphine (2.1 g, 8.2 mmol, 1.1 eq) were 
dissolved in CH2Cl2 (40 mL) and cooled to 0°C. Subsequently, tetrabromomethane (2.72 g, 
8.2 mmol, 1.1 eq) was added in portions. The reaction mixture was stirred for 2 h at 0°C 
before the solvent was evaporated and the crude product was purified by column 
chromatography (silica gel, cyclohexane/EtOAc 4:1) to afford the product as a colourless 
liquid (2.4 g, 6.6 mmol, 89 %). 1H NMR (500 MHz, CDCl3) δ 5.33 – 5.25 (m, 2H), 3.34 (t, J = 
6.9 Hz, 2H), 1.98 – 1.87 (m, 4H), 1.78 (quint, J = 7.0 Hz, 2H), 1.39 – 1.32 (m, 2H), 1.30 – 1.14 
(m, 20H), 0.81 (t, J = 6.8 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 129.99, 129.74, 34.00, 32.83, 
31.91, 29.77, 29.70, 29.53, 29.33 (3C), 29.17, 28.74, 28.17, 27.22, 27.16, 22.69, 14.11.  
HRMS (EI [M]+) m/z: calcd for (C18H35Br) 330.19167, found 330.19126. 
 
 
Synthesis 63 of ((S)-tert-butyl 2-(di((Z)-octadec-9-en-1-yl)carbamoyl)pyrrolidine-1-
carboxylate)  
 
 
The title compound was synthesized according to the general procedure for the amide 
coupling. The crude product was purified by column chromatography (silica gel, EtOAc). The 
solvent was evaporated to afford a slightly yellow oil (262 mg, 0.367 mmol, 79 %). 1H NMR 
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(500 MHz, CDCl3) δ 5.32 -5.23 (m, 4H), 4.51 – 4.32 (m, 1H), 3.60 – 3.47 (m, 1H), 3.44 – 3.05 
(m, 9H), 2.15 – 1.87 (m, 10H), 1.81 – 1.72 (m, 2H), 1.63 – 1.14 (m, 55H) 0.81 (t, J = 6.8 Hz, 
6H). 13C NMR (126 MHz, CDCl3) δ 172.17, 153.90, 130.05, 129.92, 129.78, 129.64, 79.50, 
56.43, 47.81 (2C), 46.96, 46.85, 46.79, 46.53, 32.59, 31.89 (2C), 31.37, 30.36, 29.76 (2C), 
29.72, 29.65 (2C), 29.51 (2C), 29.41, 29.31 (3C), 29.18, 28.51 (4C), 27.69, 27.20 (2C), 27.00 
(2C), 24.20, 23.33, 22.67 (2C), 14.10 (2C). HRMS (ESI [M + H]+) m/z: calcd for (C46H87O3N2) 
715.67112, found 715.67138. 
 
 
Synthesis of catalyst 29 ((S)-N,N-di((Z)-octadec-9-en-1-yl)pyrrolidine-2-carboxamide) 
 
 
 
Catalyst 10 was obtained after Boc-deprotection of 63 according to the general procedure as 
a yellow oil in quantitative yield. 1H NMR (500 MHz, CDCl3) δ 5.35 – 5.22 (m, 4H), 4.74 (s (br), 
1H), 3.55 – 3.29 (m, 3H), 3.23 – 3.07 (m, 3H), 2.50 – 2.42 (m, 1H), 2.16 – 2.07 (m, 1H), 2.00 
– 1.86 (m, 8H), 1.85 – 1.77 (m, 1H), 1.60 – 1.41 (m, 4H), 1.32 – 1.14 (m, 45H), 0.81 (t, J = 6.8 
Hz, 6H). 13C NMR (126 MHz, CDCl3) δ 167.91, 130.00 (2C), 129.70 (2C), 57.98, 47.41, 46.81, 
46.39, 32.60, 31.89 (2C), 30.31, 29.75 (2C), 29.71, 29.68, 29.65, 29.51 (2C), 29.43, 29.34, 
29.31 (3C), 29.25, 29.23, 29.20, 29.15, 28.55, 27.21 (2C), 27.17, 27.15, 26.86, 26.73. 25.17, 
22.67 (2C), 14.09 (2C). HRMS (ESI [M + H]+) m/z: calcd for (C41H79ON2) 615.61869 found 
615.61827 
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Synthesis of catalyst 28 ((Z)-N-((Z)-octadec-9-en-1-yl)-N-((S)-pyrrolidin-2-
ylmethyl)octadec-9-en-1-amine) 
 
 
Catalyst 28 was synthesized according to the general procedure for the amide reduction from 
catalyst 29. The crude product was purified by column chromatography (silica gel, 
cyclohexane/EtOAc 2:1) to afford the product as a slightly yellow oil (59.7 mg, 0.100 mmol, 61 
%). 1H NMR (500 MHz, CDCl3) δ 5.44 – 5.15 (m, 4H), 3.61 – 3.38 (m, 1H), 3.15 – 2.92 (m, 
3H), 2.47 – 2.21 (m, 4H), 2.02 – 1.72 (m, 8H), 1.55 – 1.01 (m, 53H), 0.81 (t, J = 6.8 Hz, 6H). 
13C NMR (126 MHz, CDCl3) δ 129.93 (2C), 129.81 (2C), 56.11, 54.17, 44.79, 32.61 (2C), 
31.90 (2C), 29.85 - 29.45 (17C), 29.31 (2C), 29.18, 28.84, 27.45, 27.21 (2C), 26.84, 24.11, 
22.68 (2C), 14.11 (2C). HRMS (ESI [M + H]+) m/z: calcd for (C41H81N2) 601.63943, found 
601.63925. 
 
 
Synthesis of 64 ((S)-tert-butyl 2-(didodecylcarbamoyl)pyrrolidine-1-carboxylate  
 
 
 
The title compound was synthesized according to the general procedure for the amide 
coupling. The crude product was purified by column chromatography (silica gel, 
cyclohexane/EtOAc 4:1). The solvent was evaporated to afford a slightly yellow oil (1.02 g, 
1.85 mmol, 83 %). 1H NMR (500 MHz, CDCl3) δ 4.59 – 4.41 (m, 1H), 3.66 – 3.54 (m, 1H), 
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3.50 – 3.13 (m, 5H), 2.21 – 1.97 (m, 2H), 1.89 – 1.77 (m, 2H), 1.70 – 1.37 (m, 11H), 1.35 – 
1.19 (m, 38H), 0.88 (td, J = 6.9, 2.1 Hz, 6H). 13C NMR (125 MHz, CDCl3) δ 172.17, 153.91, 
79.52, 56.43, 56.09, 47.81, 46.86, 46.81, 46.53, 31.90 (2C), 31.36, 30.37, 29.61 (2C), 29.59, 
29.58 (2C), 29.54 (2C), 29.32 (2C), 28.51 (3C), 27.90, 27.68, 27.02, 26.97, 24.20, 23.33, 
22.67 (2C), 14.10 (2C). HRMS (ESI [M + H]+) m/z: calcd for (C34H67O3N2) 551.51462, found 
551.51505. 
 
 
Synthesis of 65 ((S)-N,N-didodecylpyrrolidine-2-carboxamide)54 
 
 
 
Catalyst 60 was obtained after Boc-deprotection of 59 according to the general procedure as 
a yellow oil in quantitative yield. 
Analytical data according to Arivalagan et al.54 
 
 
Synthesis of catalyst 27 ((S)-N-dodecyl-N-(pyrrolidin-2-ylmethyl)dodecan-1-amine)56  
 
 
 
Catalyst 27 was synthesized according to the general procedure for the amide reduction from 
60. The crude product was purified by column chromatography (silica gel, cyclohexane/EtOAc 
2:1) to afford the product as a slightly yellow oil (292 mg, 0.670 mmol, 63 %). 1H NMR (500 
MHz, CDCl3) δ 3.60 (quint, J = 6.9 Hz, 1H), 3.29 – 3.12 (m, 2H), 2.60 – 2.25 (m, 6H), 2.19 – 
1.52 (m, 1H), 1.48 – 1.09 (m, 6H), 0.81 (t, J = 6.9 Hz, 1H). 13C NMR (126 MHz, CDCl3) δ 
60.34, 55.99, 54.16, 54.10, 45.29, 31.85 (2C), 29.55 (2C), 29.53 (2C), 29.42 (2C), 29.34 (2C), 
29.30, 29.28 (2C), 29.05 (2C), 26.64 (2C), 23.73, 23.15, 22.64 (2C), 14.06 (2C). HRMS (ESI 
[M + H]+) m/z: calcd for (C29H61N2) 437.48293, found 437.48325. 
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2.5.1.4 Synthesis of substrates  
 
Synthesis of 33 ((1S,2S)-1,2-bis((R)-2,2-dimethyl-1,3-dioxolan-4-yl)ethane-1,2-diol)71 
 
 
 
To a mixture of D-Mannitol (32) (20 g, 0.11 mol, 1 eq), 2,2-dimethoxypropane (32 ml, 
0.26 mol, 2.4 eq) and glyme (50 mL), tin(II) chloride (20 mg, 0.1 mmol) was added and the 
mixture was heated to reflux until a clear solution was obtained (ca. 1 h). The solution was 
refluxed for another 30 min before cooling to room temperature. Pyridine (24 μl, 0.3 mmol) 
was added. The solvent was removed in vacuo the crude product was purified by flash 
chromatography (ethylacetate/cyclohexane 1:1 - pure ethylacetate) to obtain the desired 
product as colorless solid (15.7 g, 60 mmol, 54 %). 
Analytical data were identical with the values reported in literature.71 
 
 
Synthesis of 34 ((R)-2,2-dimethyl-1,3-dioxolane-4-carbaldehyde)71 
 
 
 
Diacetonide 33 (1 g, 4 mmol, 1.0 eq) was dissolved in CH2Cl2 (15 mL) and saturated aqueous 
NaHCO3 (0.36 mL) was added to the flask. Solid NaIO4, (1.6 g, 7.6 mmol, 1.9 eq) was 
subsequently added portion wise during a 20-min period while the reaction mixture was 
vigorously stirred. The reaction was allowed to proceed for 2 h while the temperature was 
kept below 30 °C by means of an ice bath. The white precipitate was filtered off and the 
solvent evaporated. The crude product was purified by bulb-to-bulb distillation (5 mbar, 
100°C) to give aldehyde 34 as a colourless liquid (700 mg, 5.4 mmol, 67 %). 
Analytical data were identical with the values reported in literature.71 
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Synthesis of 36 ((5-amino-2,2-dimethyl-1,3-dioxan-5-yl)methanol)72 
 
 
 
To a solution of tris(hy- droxymethyl)aminomethane hydrochloride (35) (20.0 g, 125 mmol, 1.0 
eq.) in dry DMF (140 mL), PTSA (1.8 g, 6.0 mmol, 0.050 equiv) was added followed by 2,2-
dimethoxypropane (16.9 mL, 138 mmol, 1.1 equiv) in one portion. After stirring the reaction 
mixture for 12 h, Et3N (1.0 mL, 7.0 mmol, 0.060 equiv) was added. After 10 min, the mixture 
was concentrated and more Et3N (13.7 mL, 98.0 mmol) and EtOAc (500 mL) was added. The 
white precipitate, which was formed after the addition of Et3N was removed via filtration and 
the filtrate was purified by FC (ethylacetate/ MeOH 4:1) to afford the desired product as a 
white solid (17.4 g, 108 mmol, 86 %).  
Analytical data were identical with the values reported in literature.72 
 
Synthesis of 37 (2,2-dimethyl-1,3-dioxan-5-one)72 
 
 
 
A solution of 5-amino-5-hydroxymethyl-2,2-dimethyl-1,3-dioxane (36) (9.7 g, 60 mmol, 1.0 eq) 
and KH2PO4 (8.2 g, 60 mmol, 1.0 eq) in water (200 mL) was cooled to 5°C and a solution of 
NaIO4 (12.8 g, 60.0 mmol, 1.0 eq) in water (175 mL) was added via dropping funnel during a 
period of 30 min. After 3 h, the starting material was consumed and the reaction mixture was 
allowed to stir for another hour at 5 °C and 5 h at room temperature. Then Na2S2O3 (14.8 g, 
60.0 mmol, 1.0 equiv) was added, and the resulting solution was stirred for 15 min. The 
reaction mixture was extracted with CH2Cl2 (5 x 50 mL). The combined organic phases were 
dried over MgSO4, filtered and concentrated. The crude product was purified by bulb-to-bulb 
distillation (5 mbar, 80°C) to afford the product as colorless oil (6.6 g, 51 mmol, 85 %). 
Analytical data were identical with the values reported in literature.72 
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Synthesis of 39 (D-Glyceraldehyde 3-phosphate)73  
 
 
 
A solution of D-fructose 6-phosphate disodium salt (38) (5,0 g, 15.5 mmol, 1 eq) in water 
(150 mL) was cooled to 0°C and a solution of periodic acid (12.6 g, 109 mmol, 7 eq) in water 
(50 mL) was added dropwise. After 1 h, ethylene glycol (5 mL) was added and the solution 
stirred for 30 min, before the pH was adjusted to 3.5 using aqueous NaOH (2 M) and acetone 
(150 mL) was added, whereupon a white precipitate was formed, which was removed by 
filtration after 90 min. Subsequently, Ca(OAc)2 (7.9 g, 43.5 mmol, 2.8 eq) in water (45 mL) 
was added. The suspension was stirred for 90 min at 0°C and the white solid was filtrated and 
washed with aceton, HCl (10 µM), HCl (1 mM) and again with acetone to obtain the product 
as white solid (1.8 g, 8.7 mmol, 56 %) 
Analytical data were identical with the values reported in literature.73 
 
 
Synthesis of aldehyde 4a 
 
Synthesis of 41 (5-(1,3-dioxolan-2-yl)-2-nitrophenol) 
 
 
 
In a 50 mL round-bottom flask, 3-hydroxy-4-nitrobenzaldehyde (40) (1.49 g, 8.93 mmol, 1 eq) 
and ethylene glycol (0.75 mL 13.39 mmol, 1.5 eq) were dissolved in toluene (25 mL) and 
pTsOH (0.17 g, 0.89 mmol, 0.1 eq) was added. The apparatus was fitted with a Dean-Sark 
water trap and the solution heated to reflux. The solution was stirred under reflux overnight. 
After purification by column chromatography (9:1:1 cyclohexane/EtOAc/MeOH) the product 
was obtained in quantitative yield (1.85 g, 8.93 mmol). 1H NMR (400 MHz, CDCl3) δ 10.59 (s, 
1H), 8.11 (d, J = 8.8 Hz, 1H), 7.27 (d, J = 6.5 Hz, 1H), 7.09 (d, J = 10.4 Hz, 1H), 5.82 (s, 1H), 
4.07 (d, J = 38.4 Hz, 4H). 13C NMR (101 MHz, CDCl3) δ 155.06, 148.35, 133.67, 125.31, 
118.14, 117.85, 101.87, 65.45. HRMS (ESI [M - H]-) m/z: calcd for (C9H8O5N) 210.04080, 
found 210.04059.  
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Synthesis of 42 (2-(5-(1,3-dioxolan-2-yl)-2-nitrophenoxy)ethanol (modified procedure of 
Lepore et al.74)  
 
 
Acetal 41 (1.85 g, 8.76 mmol, 1 eq) and PPh3 (2.98 g, 11.39 mmol, 1.3 eq) was dissolved in 
THF (20 ml). Upon dropwise addition of diisopropylazodicarboxylate (DIAD) (2.30, 2.24 ml, 
11.39 mmol, 1.3 eq) a red precipitate was formed. Addition of ethylene glycol (0.70 g, 
0.63 mL, 11.39 mmol, 1.3 eq) led to a red solution. The reaction mixture was heated to 55 °C 
and stirred for 3 h.  The product was obtained after purification by column chromatography 
(cyclohexane/EtOAC 1:1) in 46 % yield (1.03 g, 4.04 mmol). 1H NMR (400 MHz, CDCl3) δ 
7.87 (d, J = 8.3 Hz, 1H), 7.26 (s, 1H), 7.23 (d, J = 1.5 Hz, 1H), 7.16 (dd, 1H), 5.83 (s, 1H), 
4.28 – 4.25 (m, 2H), 4.12 – 4.03 (m, 4H), 4.00 – 3.96 (m, 2H). 13C NMR (101 MHz, CDCl3) δ 
152.29, 144.99, 139.93, 125.96, 118.88, 112.98, 102.06, 71.44, 65.40, 60.93. HRMS (ESI [M 
+ Na]+) m/z: calcd for (C11H13O6NNa) 278.06351, found 278.06344. 
 
 
Synthesis of 4a (3-(2-hydroxyethoxy)-4-nitrobenzaldehyde)  
 
 
 
To a solution of 42 (427.0 mg, 1.68 mmol, 1 eq) in a mixture of acetone/water 9:1 (10 mL), 
pTsOH (63.5 mg, 0.34 mmol, 0.2 eq) was added. The reaction mixture was heated to 55 °C 
and stirred overnight. The mixture was diluted by addition of EtOAc (20 ml) and extracted with 
NaHCO3 (3x20 mL). The combined organic phases were washed with brine (20 mL), dried 
over MgSO4 and the solvent removed in vacuo. Aldehyde 4a was obtained as a yellow solid in 
quantitative yield. 1H NMR (400 MHz, CDCl3) δ 10.05 (s, 1H), 7.97 (d, J = 8.1 Hz, 1H), 7.62 
(d, J = 1.5 Hz, 1H), 7.58 (dd, 1H), 4.35 – 4.31 (m, 2H), 4.05 – 3.99 (m, J = 19.8 Hz, 2H). 13C 
NMR (126 MHz, CDCl3) δ 188.47, 150.84, 141.93, 138.29, 124.58, 121.32, 112.70, 70.19, 
59.27. HRMS (EI [M]+) m/z: calcd for (C9H9O5N) 211.04752, found 211.04766. 
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Synthesis of 61 (2-(5-(1,3-dioxolan-2-yl)-2-nitrophenoxy)ethyl bis((9H-fluoren-9-
yl)methyl) phosphate) 
 
 
 
Fm-phosphoramidite (266 mg, 0.51 mol, 1.3 eq) was coevaporated with MeCN (3 x 1 mL). 
Pentafluorophenol (361 mg, 1.96 mmol, 5 eq) and MeCN (3 mL) was added and the mixture 
stirred at room temperature for 1 h. After complete acitivation, which was monitored by 31P-
NMR, the solvent was removed on high vacuum. A solution of 42 (100 mg, 0.39 mmol, 1 eq) 
in MeCN (3 mL) was added ant the reaction stirred over night at room temperature. Upon 
complete consumption of starting material (monitored by 31P-NMR), the reaction mixture was 
cooled to 0°C and mCPBA (70 %, 125 mg, 0.51 mmol, 1.3 eq.) was added. The crude product 
was purified by column chromatography (EtOAc/Chex) and the product was obtained as 
slightly yellow oil (169 mg, 0.25 mmol, 62 %). 1H NMR (400 MHz, CDCl3) δ 7.83 – 6.99 (m, 
1H), 5.68 (s, 1H), 4.32 – 4.12 (m, 1H), 4.10 – 4.02 (m, 1H), 3.98 – 3.86 (m, 1H), 1.96 (d, J = 
8.0 Hz, 1H), 1.26 – 1.13 (m, 1H). 13C NMR (101 MHz, CDCl3) δ 170.04, 150.62, 143.66, 
142.09, 142.05, 140.39, 140.38, 139.39, 134.03, 126.83, 126.12, 126.11, 124.61, 124.11, 
124.08, 118.93, 118.92, 118.07, 112.04, 101.04, 70.52, 68.32, 68.27, 67.59, 67.53, 64.23, 
64.19, 59.91, 59.33, 46.95, 46.89, 44.68, 28.68, 19.97, 13.18, 7.47. 31P {1H} NMR (162 MHz, 
CDCl3) δ -0.71. HRMS (ESI [M + Na]+) m/z: calcd for (C39H35O9N) 692.20439, found 
692.20475. 
 
 
2.5.1.5 Towards substrates for intramolecular aldol reactions 
 
Synthesis of 43 (3-bromo-6-nitroisobenzofuran-1(3H)-one)76 
 
 
 
In a 50 mL round bottom flask, 6-nitroisobenzofuran-1(3H)-one (42) (896 mg, 5.0 mmol, 
1.0 eq) was dissolved in benzene (20 mL). N-bromosuccinimide (890 mg, 5.0 mmol, 1.0 eq) 
and AIBN (41.0 mg, 0.25 mmol, 0.05 eq) were added and the reaction mixture was refluxed 
for 2 h. The reaction mixture was cooled to 0°C and stirred for 1 h before it was filtered and 
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the filtrate concentrated under reduced pressure. The crude product was purified by flash 
chromatography (cyclohexane/ ethylacetate 9:1) to give 3-bromo-6-nitroisobenzofuran-1(3H)-
one as a colourless oil (839 mg, 3.25 mmol, 65 %). 
Analytical data were identical with the values reported in literature.76 
 
 
Synthesis of 44 (2-formyl-5-nitrobenzoic acid)76 
 
 
 
A round bottom flask with 3-bromo-6-nitroisobenzofuran-1(3H)-one (43) (100 mg, 0.4 mmol, 
1.0 eq) and water (10 mL) was prepared and the suspension was stirred at reflux for 1 h. The 
resulting solution was cooled to room temperature and ethylacetate (10 ml) was added and 
the phases were separated. The aqueous phase was extracted with EtOAc (3 × 10 mL), the 
combined organic phases were dried over MgSO4. The solvent was evaporated to give 2-
formyl-5-nitrobenzoic acid (44) in quantitative yield.  
Analytical data were identical with the values reported in literature.76  
 
 
Synthesis of 55 (2-(1,3-dioxolan-2-yl)-5-nitrobenzoic acid) 
 
 
 
In a 50 mL round-bottom flask, 2-formyl-5-nitrobenzoic acid (44) (1.74 g, 8.93 mmol, 1 eq) 
and ethylene glycol (0.75 mL 13.39 mmol, 1.5 eq) were dissolved in toluene (25 mL) and 
pTsOH (0.17 g, 0.89 mmol, 0.1 eq) was added. The apparatus was fitted with a Dean-Sark 
water trap and the solution heated to reflux. The solution was stirred under reflux overnight. 
After purification by column chromatography (9:1 – 7:3 EtOAc/MeOH) the product was 
obtained in quantitative yield (2.13 g, 8.93 mmol). 1H NMR (400 MHz, Chloroform-d) δ 8.65 (d, 
J = 2.0 Hz, 1H), 8.53 (dd, J = 8.3, 2.0 Hz, 1H), 7.76 (dt, J = 8.3, 0.5 Hz, 1H), 6.46 (s, 1H), 4.10 
– 3.91 (m, 2H), 3.83 (dd, J = 5.1, 3.8 Hz, 2H).  
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2.5.1.6 Synthesis of nornicotine as reference catalyst  
 
Synthesis of 55 (ethyl 5-bromonicotinate)77 
 
 
 
To a solution of acid 54 (2.0 g, 10 mmol, 1 eq), DCC (2.06 g, 10 mmol, 1 eq) followed by 
DMAP (1.22 g, 10 mmol, 1 eq.) at 0°C. The solution was stirred for 1 h and EtOH (0.92 g, 
20 mmol, 2 eq) was added dropwise during a period of 10 min. The reaction mixture was 
stirred for 3 d at room temperature, then CH2Cl2 was added and the mixture was washed with 
a solution of saturated NaHCO3. The organic phase was separated and the aqueous phase 
extracted with DCM and the combined organic phase was washed with brine and dried over 
MgSO4. The solvent was evaporated under vacuo and the crude product was purified by 
column chromatography (cyclohexane/EtOAc 8:2) to give pure ester 55 (1.7 g, 7.5 mmol, 75 
%). 1H NMR (400 MHz, CDCl3) δ 9.12 (s, 1H), 8.83 (s, 1H), 8.43 (s, 1H), 4.44 (d, J = 7.1 Hz, 
2H), 1.42 (d, J = 7.1 Hz, 3H). 13C NMR (101 MHz, CDCl3) δ 164.02, 154.42, 148.85, 139.48, 
127.66, 120.58, 61.91, 14.23. HRMS (ESI [M + H]+) m/z: calcd for (C8H9O2NBr) 229.01583, 
found 229.01568. 
Analytical data were identical with the values reported in literature.77 
 
 
Synthesis of 56 (3-bromo-5-(3,4-dihydro-2H-pyrrol-5-yl)pyridine)77 
 
 
 
Sodium hydride (277 mg of a 60% dispersion in mineral oil, 6.92 mmol, 1.33 eq) in a 50 mL 
flask was washed with three portions of THF (10 mL). Then THF was added (25 mL) and a 
solution of ethyl 5- bromonicotinate (fd) (1.2 g, 5.2 mmol,1.0 eq.) and N-vinylpyrrolidinone 
(642 mg, 5.8 mmol, 1.1 eq.) in THF (10 mL) was added. After 10 min, an exothermic reaction 
started and gas formation was observed. The reaction mixture was allowed to stir for 1 h room 
temperature before it was heated up to reflux for 1 h and cooled to room temperature again. 
Conc. HCl (3 mL), diluted with H2O (5 mL), was added and THF was evaporated. Additional 
HCl conc. (5 mL) and H2O (10 mL) were added. The mixture was refluxed for 16 h. The 
solution was cooled to 0°C and concentrated aqueous NaOH (50 mL) was added. The crude 
product precipitated and the mixture was extracted with CH2Cl2 (3 x 50 mL). The combined 
organic phases were washed with H2O (20 mL), the solvent evaporated and the crude product 
N
Br
O
O
N
NBr
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purified by a bulb-to-bulb distillation (130°C, 3 mbar) to obtain the product as a yellow oil (772 
mg, 3.43 mmol, 66 %). 1H NMR (500 MHz, CDCl3) δ 8.87 (s, 1H), 8.70 (s, 1H), 8.36 (s, 1H), 
5.29 (s, 2H), 4.09 (t, J = 7.4 Hz, 2H), 2.93 (t, J = 8.2 Hz, 2H), 2.19 – 2.00 (m, 2H). 13C NMR 
(126 MHz, CDCl3) δ 169.97, 152.21, 147.04, 137.24, 131.61, 120.92, 61.62, 53.36, 34.82, 
22.53. HRMS (ESI [M + H]+) m/z: calcd for (C9H10N2Br) 226.07127, found 226.07093. 
Analytical data were identical with the values reported in literature.77 
 
 
Synthesis of 57 (3-bromo-5-(pyrrolidin-2-yl)pyridine)77 
 
 
 
To a solution of 5-bromomyosmine (1.0 g, 4.4 mmol, 1 eq) in 10 mL methanol/acetic acid (8:2) 
at -40°C, NaBH4 (0.38 g, 10.1 mmol, 2.3 eq) was added portionwise over a period of 10 min. 
The reaction temperature increased during the course of the addition to -20 °C. After the 
addition, the reaction mixture was allowed to warm to room temperature. The solvent was 
evaporated and aqueous NaOH (2 M, 25 mL) was added and extracted with CH2Cl2 (3 x 20 
mL). The combined organic phases were washed with brine (20 mL) dried over MgSO4 and 
the solvent evaporated. The crude product was purified by flash chromatography (pure 
ethylacetate) to obtain racemic bromo-nornicotine (57) as yellow oil (790 mg, 3.48 mmol, 79 
%). 1H NMR (500 MHz, CDCl3) δ 8.42 (d, 1H), 8.39 (s, 1H), 7.81 (s, 1H), 4.08 (t, J = 7.6 Hz, 
1H), 3.13 – 2.90 (m, 2H), 2.24 – 2.06 (m, J = 70.8 Hz, 1H), 1.93 (s, 1H), 1.88 – 1.70 (m, 2H), 
1.60 – 1.48 (m, 1H). 13C NMR (126 MHz, CDCl3) δ 147.59, 145.20, 141.35, 135.17, 119.30, 
57.74, 45.46, 33.12, 24.05. ESI [M + H]+) m/z: calcd for (C9H12N2Br) 227.01756, found 
227.01785. Analytical data were identical with the values reported in literature.77 
 
 
X-ray structure of 57a ((R)-3-bromo-5-(pyrrolidin-2-yl)pyridine)77 
 
 
 
The racemic mixture of 3-bromo-5-(pyrrolidin-2-yl)pyridine) (57) was resolved according to a 
reported procedure to obtain (R)-3-bromo-5-(pyrrolidin-2-yl)pyridine (-)MTPA salt. After 
filtration and washing, the crystalline salt was obtained. The crystal was determined by 
single crystal X-ray diffraction. (R)-3-bromo-5-(pyrrolidin-2-yl)pyridine (57a) was liberated from 
N
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the (-) MTPAsalt with K2CO3 according to a reported procedure. [α]D: 31° (3.8 mM, EtOH, 
20°C). Analytical data were identical with the values reported in literature.77 
 
 
Figure 10: ORTEP representation of 57a (50% probability ellipsoids; H-atoms given arbitrary 
displacement parameters for clarity). 
 
The structure of 57a has been solved and refined successfully with no unusual features.  The 
compound in the crystal is enantiomerically pure and the absolute configuration of the ions 
has been determined independently by the diffraction experiment.  The anion has the 
expected S-configuration and the cation has the R-configuration.  The optical resolution of the 
cation has thus been successful. The ammonium group forms hydrogen bonds with a 
carboxylate O-atom from each of two neighboring anions.  
 
A crystal of 57a, obtained from EtOAc, was mounted on a glass fibre and used for a low-
temperature X-ray structure determination.  All measurements were made on a Rigaku Oxford 
Diffraction SuperNova area-detector diffractometer using Cu Ka radiation (l = 1.54184 Å) 
from a micro-focus X-ray source and an Oxford Instruments Cryojet XL cooler.  The unit cell 
constants and an orientation matrix for data collection were obtained from a least-squares 
refinement of the setting angles of 12617 reflections in the range 9° < 2q < 153°.  A total of 
1809 frames were collected using w scans with k offsets, 2.0-15.0 seconds exposure time and 
a rotation angle of 19.0° per frame, and a crystal-detector distance of 55.0 mm. 
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X-ray structure of 57b ((S)-3-bromo-5-(pyrrolidin-2-yl)pyridine)77 
 
 
 
The racemic mixture of 3-bromo-5-(pyrrolidin-2-yl)pyridine) (57) was resolved according to a 
reported procedure to obtain (R)-3-bromo-5-(pyrrolidin-2-yl)pyridine (+)MTPA salt. After 
filtration and washing, the crystalline salt was obtained. The crystal was determined by single 
crystal X-ray diffraction. (S)-3-bromo-5-(pyrrolidin-2-yl)pyridine (57a) was liberated from the 
(+) MTPA salt with K2CO3 according to a reported procedure. [α]D: -67° (3.8 mM, EtOH, 20°C).  
Analytical data were identical with the values reported in literature.77 
 
 
Figure 11: ORTEP representation of 57b (50% probability ellipsoids; H-atoms given arbitrary 
displacement parameters for clarity). 
 
The crystal structure of 57b was obtained according to the above described procedure for 
57a. 
 
 
Synthesis of 58a and 58b (R-nornicotine and S-nornicotine) 
 
 
 
A solution of the corresponding bromo-nornicotine 57a or 57b (100 mg, 0.44 mmol, 1.0 eq) 
and THF (8 mL) was cooled to -78°C. By means of a syringe n-BuLi 2.5 M in hexane 
(0.35 mL, 0.88 mmol, 2.0 eq.) were added whereupon the color changed from brown to 
yellow. The solution was stirred for 5 min and water (0.1 mL) was added. The reaction mixture 
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was allowed to stir for 4 h at -78°C before it was quenched. The aqueous phase was 
extracted with DCM (3 x 30 mL), the combined organic phases were dried over MgSO4, the 
solvent evaporated and the crude product was purified by flash chromatography 
(ethylacetate/hexane 1:1) to get pure nornicotine in quantitative yield. 
Analytical data were identical with the values reported in literature.77 
 
 
Synthesis of 59 (tert-butyl 2-(5-bromopyridin-3-yl)pyrrolidine-1-carboxylate) 
 
 
 
To a solution of 57 (1 g, 4.4 mmol, 1 eq) and TEA (1.24 mL, 8.93 mmol) 
in CH2Cl2 (20 mL) (Boc)2O (0.96 g, 4.4 mmol, 1 eq) was added. The reaction mixture was 
stirred overnight at room temperature. Water (20 mL) was added and extracted 
with CH2Cl2 (2 x 20 mL). The combined organic phases were washed with brine, dried over 
MgSO4, and concentrated in vacuo. The crude product was purified by flash chromatography 
(pure ethylacetate and 1% NEt3) to the pure product as a yellow oil. 1H NMR (400 MHz, 
CDCl3) δ 8.54 (s, 1H), 8.38 (d, J = 1.8 Hz, 1H), 7.63 (s, 1H), 4.99 – 4.84 (m, 1H), 4.83 – 4.66 
(m, 1H), 3.70 – 3.51 (m, 2H), 2.48 – 2.24 (m, 1H), 1.97 – 1.76 (m, J = 23.9, 18.1 Hz, 3H), 1.44 
(s, 4H), 1.25 (s, 8H). 1H NMR (400 MHz, CDCl3) δ 8.57 (s, 1H), 8.41 (d, J = 1.8 Hz, 1H), 7.66 
(s, 1H), 4.94 (b-m, 1H), 4.77 (b-m, 1H), 3.72 – 3.52 (m, 2H), 2.46 – 2.33 (m, 1H), 2.01 – 1.80 
(m, 3H), 1.47 (s, 4H), 1.25 (s, 6H). LRMS (ESI [M + H]+) m/z: for (C14H20O2N2Br) 327.07. 
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2.5.1.7 Synthesis of aldol products using catalytic LCPs and cubosomes 
 
Synthesis of 5a (anti-isomer) ((S)-2-((R)-hydroxy(3-(2-hydroxyethoxy)-4-nitrophenyl) 
methyl)cyclohexanone) 
 
 
Synthesized according to the general procedure for the aldol reaction using catalytic LCPs or 
catalytic cubosomes. Anti-aldol product 5a was obtained after purification by column 
chromatography (EtoAc). 1H NMR (500 MHz, CDCl3) δ 7.76 (dd, J = 10.3, 4.7 Hz, 1H), 7.04 
(s, 1H), 6.87 (d, J = 8.3 Hz, 1H), 4.73 (d, J = 8.2 Hz, 1H), 4.24 – 4.09 (m, 2H), 4.06 – 3.81 (m, 
2H), 2.56 – 2.19 (m, 3H), 2.09 – 1.96 (m, 1H), 1.75 (d, J = 12.9 Hz, 1H), 1.67 – 1.37 (m, 3H), 
1.37 – 1.10 (m, 1H). 13C NMR (126 MHz, CDCl3) δ 214.67, 152.48, 148.50, 139.03, 125.73, 
119.53, 113.48, 74.05, 71.41, 60.95, 57.20, 42.66, 30.76, 27.62, 24.69. HRMS (ESI [M + 
Na]+) m/z: calcd for (C15H19O6NNa) 332.11046, found 332.11037. 
 
 
Synthesis of 5a (syn-isomer) ((R)-2-((R)-hydroxy(3-(2-hydroxyethoxy)-4-
nitrophenyl)methyl)cyclohexanone and (S)-2-((S)-hydroxy(3-(2-hydroxyethoxy)-4-
nitrophenyl)methyl)cyclohexanone) 
 
 
 
Synthesized according to the general procedure for the aldol reaction using catalytic LCPs or 
catalytic cubosomes. Syn-aldol product 5a was obtained after purification by column 
chromatography (EtoAc). 1H NMR (500 MHz, CDCl3) δ 7.78 (d, J = 8.4 Hz, 1H), 7.07 (s, 1H), 
6.82 (d, J = 8.4 Hz, 1H), 5.37 – 5.30 (m, 1H), 4.18 (t, J = 4.2 Hz, 2H), 3.96 – 3.87 (m, 2H), 
3.08 (s br, OH), 2.56 – 2.46 (m, 1H), 2.43 – 2.37 (m, 1H), 2.35 – 2.27 (m, 1H), 2.07 – 1.99 (m, 
1H), 1.82 – 1.75 (m, 1H), 1.68 – 1.40 (m, 4H). 13C NMR (126 MHz, CDCl3) δ 214.06, 152.51, 
149.32, 138.04, 125.86, 117.81, 112.74, 71.39, 69.95, 60.96, 56.73, 42.60, 27.85, 25.95, 
24.78. HRMS (ESI [M + Na]+) m/z: calcd for (C15H19O6NNa) 332.11046, found 332.11037. 
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Synthesis of 5b (anti-isomer) ((S)-2-((R)-hydroxy(phenyl)methyl)cyclohexanonen)  
 
 
 
Synthesized according to the general procedure for the aldol reaction using catalytic LCPs or 
catalytic cubosomes. Anti-aldol product 5b was obtained after purification by column 
chromatography (Chex/EtoAc 9:1). 1H NMR (500 MHz, CDCl3) δ 7.30 – 7.20 (m, 5H), 4.72 
(dd, J = 8.8, 2.5 Hz, 1H), 3.87 (d, J = 2.7 Hz, 1H), 2.59 – 2.51 (m, 1H), 2.44 – 2.38 (m, 1H), 
2.33 – 2.25 (m, 1H), 2.05 – 1.98 (m, 1H), 1.75 – 1.68 (m, 1H), 1.65 – 1.42 (m, 3H), 1.28 – 
1.17 (m, 1H). 13C NMR (126 MHz, CDCl3) δ 215.52, 140.94, 128.37 (2C), 127.89, 127.02 
(2C), 74.77, 57.45, 42.69, 30.86, 27.81, 24.75. HRMS (ESI [M + Na]+) m/z: calcd for 
(C13H16O2Na) 227.10425, found 227.10402. 
 
 
Synthesis of 5b (syn-isomer) ((R)-2-((R)-hydroxy(phenyl)methyl)cyclohexanone and (S)-
2-((S)-hydroxy(phenyl)methyl)cyclohexanone) 
 
 
 
Synthesized according to the general procedure for the aldol reaction using catalytic LCPs or 
catalytic cubosomes. Syn-aldol product 5b was obtained after purification by column 
chromatography (Chex/EtoAc 9:1). 1H NMR (500 MHz, CDCl3) δ 7.30 – 7.21 (m, 4H), 7.20 – 
7.15 (m, 1H), 5.32 (s, 1H), 2.96 (d, J = 3.1 Hz, 1H), 2.57 – 2.49 (m, 1H), 2.41 – 2.35 (m, 1H), 
2.35 – 2.25 (m, 1H), 2.05 - 197 (m, 1H), 1.81 – 1.72 (m, 1H), 1.71 – 1.54 (m, 3H), 1.49 – 1.38 
(m, 1H). 13C NMR (126 MHz, CDCl3) δ 214.85, 141.42, 128.15 (2C), 126.97, 125.74 (2C), 
70.61, 57.18, 42.68, 27.96, 26.00, 24.88. HRMS (ESI [M + Na]+) m/z: calcd for (C13H16O2Na) 
227.10425, found 227.10402. 
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Synthesis of 5c (anti-isomer) ((S)-2-((R)-hydroxy(3-(2-
hydroxyethoxy)phenyl)methyl)cyclohexanone) 
 
 
 
Synthesized according to the general procedure for the aldol reaction using catalytic LCPs or 
catalytic cubosomes. Anti-aldol product 5c was obtained after purification by column 
chromatography (EtoAc). 1H NMR (500 MHz, CDCl3) δ 7.21 – 7.15 (m, 1 H), 6.87 – 6.81 (m, 
2H), 6.78 (dd, J = 8.2, 2.0 Hz, 1H), 4.69 (d, J = 8.7 Hz, 1H), 4.05 – 4.01 (m, 2H), 3.91 – 3.87 
(m, 2H), 2.56 – 2.45 (m, 1H), 2.44 – 2.36 (m, 1H), 2.34 – 2.24 (m, 1H), 2.06 – 1.98 (m, 1H), 
1.87 – 1.39 (m, 4H), 1.28 – 1.16 (m, 1H). 13C NMR (126 MHz, CDCl3) δ 215.44, 158.76, 
142.70, 129.41, 119.99, 113.96, 113.15, 74.66, 69.15, 61.51, 57.40, 42.69, 30.86, 27.79, 
24.75. HRMS (ESI [M + Na]+) m/z: calcd for (C15H20O4Na) 287.12538, found 287.12524. 
 
 
Synthesis of 5c (syn-isomer) ((R)-2-((R)-hydroxy(3-(2-
hydroxyethoxy)phenyl)methyl)cyclohexanone and (S)-2-((S)-hydroxy(3-(2-
hydroxyethoxy)phenyl)methyl)cyclohexanone) 
 
 
 
Synthesized according to the general procedure for the aldol reaction using catalytic LCPs or 
catalytic cubosomes. Syn-aldol product 5c was obtained after purification by column 
chromatography (EtoAc). 1H NMR (500 MHz, CDCl3) δ 7.23 – 7.12 (m, 1H), 6.85 (s, 1H), 6.80 
(d, J = 7.6 Hz, 1H), 6.73 (dd, J = 8.1, 2.2 Hz, 1H), 5.29 (s, 1H), 4.07 – 3.98 (m, 2H), 3.95 – 
3.85 (m, 2H), 2.98 (d, J = 2.5 Hz, 1H), 2.55 – 2.49 (m, 1H), 2.41 – 2.35 (m, 1H), 2.34 – 2.26 
(m, 1H), 2.15 – 1.95 (m, 2H), 1.81 – 1.74 (m, 1H), 1.72 – 1.54 (m, 2H), 1.50 – 1.39 (m, 1H), 
1.25 – 1.08 (m, 1H). 13C NMR (126 MHz, CDCl3) δ 214.73, 158.63, 143.34, 129.23, 118.39, 
112.92, 112.17, 70.38, 69.10, 61.47, 57.14, 42.64, 27.91, 26.01, 24.85. HRMS (ESI [M + 
Na]+) m/z: calcd for (C15H20O4Na) 287.12538, found 287.12524. 
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2.5.2 Preparation of catalytic LCPs 
 
MO (and in case of LCP C cholesterol) was weight into a pyrex glass tube and the 
corresponding amount of a catalyst stock-solution (catalyst in CH2Cl2) was added to obtain a 
homogeneous lipid mixture. The solvent was evaporated (at high vacuum 10-2 mbar for 24 h) 
and the lipidic mixture subsequently hydrated by adding appropriate volumes of buffer and 
mixed. To obtain homogeneous catalytic LCPs, samples were centrifuged in a Heraeus 
Megafuge 16R centrifuge (at 5 000 rpm) for 1 h at 23 °C. Samples were finally stored and left 
to equilibrate for 48 h in tightly closed glass tubes. 
LCP A: 0.0071 mmol catalyst (3.4 mg in case of catalyst 2), 66.6 mg MO, 53 µl PBS 1X, pH 
7.4. 
LCP B: 0.0071 mmol catalyst (3.4 mg in case of catalyst 2), 66.6 mg MO, 60 µl HEPES 20 
mM, pH 7.4. 
LCP C: 0.0071 mmol catalyst (3.4 mg in case of catalyst 2), 50.0 mg MO, 10 mg Cholesterol, 
63 µl HEPES 20 mM, pH 7.4. 
PT LCPs: 0.0071 mmol catalyst (4.5 mg in case of catalyst 2), 70 mg PT, 30 µl PBS 1X, pH 
7.4. 
 
 
2.5.3 Preparation of catalytic cubosomes 
 
MO (and in case of LCP C cholesterol) was weight into a glass vial and the corresponding 
amount of a catalyst stock-solution (catalyst in CH2Cl2) was added to obtain a homogeneous 
lipid mixture. The solvent was evaporated (at high vacuum 10-2 mbar for 24 h) and the lipidic 
mixture subsequently hydrated by adding appropriate volumes of stabilizer containing buffer 
(PF108, 1.65 mg / mL) to obtain the cubosome sample with the desired lipid concentration. 
The sample was vortex-mixed and then dispersed using an ultrasonic processor Brenson 
digital 250 (cycle 0.9 s on/ 0.9 s off, amplitude 50%, for 3 x 5 min). Subsequently, the 
cubosome dispersion was filtered through Acrodisc 450 nm filters.  
Cubosomes A: 0.0071 mmol catalyst (3.4 mg in case of catalyst 2), 66.6 mg MO, 2 mL 
PBS 1X, pH 7.4. 
Cubosomes B: 0.0071 mmol catalyst (3.4 mg in case of catalyst 2), 66.6 mg MO, 2 mL 
HEPES 20 mM, pH 7.4. 
Cubosomes C: 0.0071 mmol catalyst (3.4 mg in case of catalyst 2), 50.0 mg MO, 10 mg 
Cholesterol, 2 mL HEPES 20 mM, pH 7.4. 
Cubosomes D: 0.0071 mmol catalyst (3.4 mg in case of catalyst 2), 66.6 mg MO, 2 mL 
PBS 0.1X, pH 7.4. 
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2.5.4 Dynamic Light Scattering (DLS) 
 
Particle size of the cubosomes was performed after preparation, before the reaction was 
started, and after the reaction was terminated (1-2 d) with a Zeta Sizer Nano ZS (Malvern 
Instruments, Malvern, UK) at 25 ± 0.1 °C. The samples were measured in disposable 
polystyrene cuvettes of 1 cm optical path length with the corresponding buffer as solvent. 
Scattering angle was 90°. A triplicate of the samples was performed. The width of the DLS 
hydrodynamic diameter distribution is indicated by PDI (polydispersion index). The intensity 
size distribution of the cubosomes was typically unimodal; therefore the autocorrelation 
function was analyzed according to the cumulant method.  
 
Table 6: DLS data before and after the aldol reaction. 
Cubosomes phase 
identity 
size (nm) 
before 
reaction 
PDI before reaction size (nm) after 
reaction 
PDI after 
reaction 
A Im3m 177 ± 2 0.19 161± 2 0.20 
B Pn3m 174.4 ± 2 0.17 246.1 ± 5 0.28 
C Pn3m/Im3m 133.2 ± 1 0.17 139.7±14 0.31 
D Pn3m 234.9 ± 3 0.20 244 ± 2 0.26 
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2.5.5 Small angle X-ray scattering (SAXS)  
 
SAXS measurements were used to identify the symmetry of the catalytic LCPs and 
cubosomes and the fully hydration line of the catalytic LCPs. Experiments were performed on 
a Bruker AXS Micro, with a microfocused X-ray source, operating at voltage filament current 
of 50 kV and 1.000 µA, respectively. The Cu Kα radiation (λCu Kα =1.5418 Å) was collimated 
by a 2D Pilatus 100K detector. The scattering vector q = (4π/λ)sinθ, with 2θ being the 
scattering angle, was calibrated using silver behenate. Data were collected and azimuthally 
averaged using the Saxsgui software to yield one-dimensional intensity versus scattering 
vector q, with a q range from 0.004 – 0.5 Å-1. For all bulk measurements, the samples were 
placed inside a stainless-steel cell between two thin replaceable mica sheets and sealed by 
an O-ring, with a sample volume of 10 µL and a thickness of ~1 mm. Measurements were 
performed at 23°C, and samples were equilibrated for 15 min before measurements, whereas 
scattered intensity was collected over 30 min. For the cubosomes samples, the sample-to-
detector distance was 1 m, providing a q range from 0.005 to 0.77 Å-1. Samples were loaded 
into a quartz glass capillary (Hiligenberg, length: 80 mm; outside: 2.0 mm; wall thickness: 
0.01 mm). Measurements were performed at 23 °C, and samples were equilibrated for 10 min 
prior to measurements, while scattered intensity was collected over 4 hours.  
 
Mesophase identification and calculation of the aqueous channels 
Mesophases were identified by their specific Bragg peak positions. For the double diamond 
cubic phase (Pn3m) the relative positions in q of the Bragg reflections are at 
√2:√3:√4:√6:√8:√9…, whereas for the primitive cubic phase (Im3m)  the Bragg peaks are at 
q = √2:√4:√6:√8:√10:√12:√14:√16:√18… The mean lattice parameter, a, was deduced from 
the corresponding set of observed interplanar distances, d (d = 2π/q), using the appropriate 
scattering law for the phase structure. For cubic phases:  
 ; = @ ℎB + CB + DB	                                 (1) 
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By knowing from SAXS measurements the geometry and the lattice parameter a, and 
knowing the lipid volume fraction of the sample ϕ, the length of the lipid tail, l, can be 
calculated by solving the following cubic equation80:  
 Φ = 2$% &'()* + ,- ./ &'()* -                     (2) 
 
where $% is the area of the surface in the unit cell in which the lattice parameter is equal to 
unity, and / is the Euler-Poincare characteristic. Depending on the specific cubic phase they 
have the following values: $% = 3.091	and / = −8 for Ia3d; $% = 1.919	and / = −2 for Pn3m; 
and $% = 2.345	and / = −4	for Im3m. For the radius of the aqueous channels, r the following 
equations are valid for the Ia3d, Pn3m and Im3m phases, respectively17: 
 : = 0.248; − <=>?                       (3a) : = 0.391; − <=>?                       (3b) : = 0.3055; − <=>?                     (3c) 
 
 
 
Figure 12: SAXS pattern of cubosomes C at 23°C: 3.4 mg catalyst 2, 50.0 mg MO, 10 mg Cholesterol, 
2 mL HEPES 20 mM, pH 7.4. 
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Figure 13: SAXS pattern of cubosomes D at 23°C: 3.4 mg in case of catalyst 2, 66.6 mg MO, 2 mL 
PBS 0.1x, pH 7.4. 
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2.5.5.1 Control experiments: SAXS before and after catalysis 
 
SAXS spectra of catalytic LCPs and cubosomes were acquired before and after catalysis. The 
cubic structure was maintained in all cases. In Figure 14, an exemplary SAXS spectrum of 
both, catalytic LCPs (LCP vc) and cubosomes (cubosomes xy) is depicted. 
 
 
 
Figure 14: SAXS pattern of catalytic LCP C at 23 °C. 0.0071 mmol catalyst (3.4 mg in catalyst 2, 50.0 
mg MO, 10 mg Cholesterol, 63 µl HEPES 20 mM, pH 7.4 (top panel) and cubosomes C 0.0071 mmol 
catalyst (3.4 mg catalyst 2), 50.0 mg MO, 10 mg Cholesterol, 2 mL HEPES 20 mM, pH 7.4 (bottom 
panel) before and after catalysis.  
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2.5.6 Chiral stationary phase HPLC 
 
Reagents: Hexane (gradient HPLC grade from Honeywell (Art. No.65801)), EtOH (gradient 
grade from J.T. Baker (Art. No84462)). 
Sample solvent: MeOH, 2.0 mg/mL, injection volume: 5 µL, column: Chiralpak AD-H, 250 x 
4.6 mm, 5 µm (Daicel), flow rate: 0.6 mL/min, run time: 50.0 min, column temperature: 30°C, 
detection (DAD) at 214 nm (BW16nm), mobile phase: hexane/EtOH (8:2) 
 
Table SI2: Retention times of the major and minor aldol products. 
Nr. Isomer Retention (min) 
5a Anti, major enantiomer 41.739 
Anti, minor enantiomer 35.246 
Syn, major enantiomer 33.492 
Syn, minor enantiomer 29.664 
5b Anti, major enantiomer 18.320 
Anti, minor enantiomer 17.193 
5c Anti, major enantiomer 33.712 
Anti, minor enantiomer 28.056 
 
 
2.5.7 Cryogenic transmission electron microscopy (cryo-TEM)  
 
The microscopical characterization of the particles in their hydrated state was carried out in a 
Tecnai F20 cryo-TEM (FEI, USA). 300-mesh lacey carbon-coated copper grids (Quantifoil, 
Germany) were glow discharged (Emitech K100X, GB) for 30 s. 3 μl of sample solution were 
applied onto the grids in a Vitrobot Mark II (FEI, USA) and the excess of the dispersion was 
removed by controlled blotting. A mixture of liquid ethane/propane was used for sample 
vitrification. The grids were then transferred on a Gatan cryo-holder into the microscope and 
kept at -180°C during observation. Micrographs were recorded under low dose conditions 
(<500e− /nm2) using a 4k x 4k Gatan CCD camera, operating the microscope at 200 kV 
acceleration voltage in bright field mode. 
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Lipidic mesophases as novel nanoreactor scaffolds for metal complex 
catalysts: Degradation of pesticides 
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3.1 Introduction 
 
Phosphate esters like paraoxon (67) or parathion (68) are pesticides with hundred thousands 
of tons annual world production.1 Due to their toxicity and chemical stability, their 
accumulation in the environment is ecologically problematic. Some chemical warfare agents, 
also called G-type nerve agents, like sarin, soman and tabun are chemically related. Both 
classes possess phosphate ester bonds.2 These compounds are highly potent acetylcholine 
esterase inhibitors. Acetylcholin is a neurotransmitter that triggers muscular response and its 
accumulation leads to asphyxiation.3 Considerable efforts have been undertaken towards the 
safe, efficient and controlled decomposition of such compounds, usually through oxidation or 
hydrolysis.4,5 Thermally robust and water-stable metal-organic-frameworks (MOFs) have been 
functionalized and used to hydrolyze such compounds very efficiently.2 Katz et al., developed 
a zirconium(IV)-cluster containing MOF catalyst. The combination of the strong Lewis acid 
Zr(IV) and the bridging hydroxide anions leads to a highly efficient catalyst. The system is 
inspired by nature; the enzyme phosphotriesterase contains a hydroxyl-anion-bridged 
binuclear Zn(II) active site.6 König et al. for example, used vesicles and micelles to catalyze 
hydrolytic cleavage of organophosphates with amphiphilic cyclen-zinc(II) complexes.7,8 The 
same group used lanthanide coated liposomes to hydrolyze phosphodiesters and DNA.7 
Interestingly, these Eu(III) coated liposomes showed up to 17-fold hydrolysis activity as 
compared to the aqueous europium salt. Furthermore, methoxides of La(III) and Zn(II) have 
been successfully applied to the methanolysis of phosphateseter. Gunnlaugson et al. used 
cyclen based lanthanide complexes with pyridine as a cofactor for phosphodiester hydrolysis.9 
Ryabov et al. developed a platinum aryl oxime metallacycle that enables efficient degradation 
of thiophosphate pesticides like parathion (68).1 Catalyst 69 hydrolyzes parathion (68) by a 
factor of 106-107 faster than hydroxide. Due to this remarkable catalytic performance and the 
potential possibility for lipidic modification, this catalyst was chosen for our model system. 
Added guest catalysts can affect significantly the structural and dynamic properties of the 
ensuing host mesophases, depending on the additives’ molecular structure.10–13  
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Figure 1: Top: Examples of acetylcholine esterase inhibitors. Sarin (66), is a chemical warfare agent, 
paraoxon (67) and parathion (68) are pesticides. Bottom: Hydrolysis reaction of parathion. Right: Pt-
metallacycle 69. 
 
 
3.2 Results and discussion 
3.2.1 Synthesis of Pt-complexes 
 
To investigate the impact of the catalyst’s structure on its catalytic performance, structural 
motifs were varied. To that end, three different lipidic platinum catalysts were designed and 
synthesized (Scheme 1). Modifications were introduced at the lipidic chain and at the linker 
that connects the Pt-metallacycle headgroup to the lipidic chain. Thus, catalysts with a stearyl, 
a lauryl and an oleyl (75, 81 and 82), saturated (75 and 81) and unsaturated (82) lipidic 
chains, as well as catalysts in which the metallacycle is linked to the lipids via an amide (81 
and 82), or to an amine (75) were synthesized. The lipidic chain of catalyst 75 was installed at 
commercially available 1-(4-bromophenyl)ethanone (72) via Buchwald-Hartwig amination 
using stearyl amine. The subsequent steps, oxime formation and cycloplatination, were 
performed analogous to the synthesis of the original catalyst 84 (Scheme 1). The lauryl and 
oleyl lipid chains of catalyst 81 and 82, respectively were installed by coupling the 
corresponding acyl chlorides to commercially available 1-(4-aminophenyl)ethanone (76). The 
subsequent steps, oxime formation and cycloplatination were also performed analogous to 
the original catalyst 84, which was synthesized as well and serves as a reference catalyst. 
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Scheme 1: Syntheses of different lipidically modified Pt-catalysts and Ryabov’s catalyst which was 
used as reference. Conditions: a) Pd(OAc)2 0.05 eq, XPhos 0.1 eq, NatBuO, toluene, 50°C. b) NH2OH 
x HCl, EtOH/pyridine 2:1, reflux. c) Pt(DMSO)2Cl2 (86), MeOH, reflux. d) Lauroyl or oleoyl chloride, 
DIPEA, CH2Cl2, r.t.. e) DMSO, H2O, r.t..  
 
 
3.2.2 Parathion hydrolysis using Pt-catalyst 82 in LCPs 
 
Having catalysts 75, 81 and 82 successfully synthesized, first Pt-complex containing LCPs 
was prepared in order to test the stability of the mesophases and to determine the highest 
possible catalyst loading. Stable and transparent LCPs were obtained with catalyst 75 with a 
maximum catalyst loading of 3 % (w/w of the lipidic content). With catalyst 81 (stearyl) a 
similar additive loading could be achieved; 3.5 % (w/w of the lipidic content), whereas a 
significant higher loading of 7.0 % (w/w of the lipidic content) was achieved with catalyst 82. 
The oleyl lipidic chain of catalyst 82 leads to a better packing of host- and guest-lipids due to 
the compatibility of the lipidic chains. Thus, LCPs containing catalyst 82 were used for initial 
hydrolysis experiments using parathion as the substrate (Figure 2). 
The proposed mechanism of this platinum catalyst mediated P-ester hydrolysis is depicted in 
Scheme 2.1 Once the catalyst is in aqueous environment, the chloro ligand is replaced by a 
water molecule. Subsequently, the water ligand is substituted by parathion, which coordinates 
to the platinum center via its sulfur atom. Intramolecular nucleophilic attack by the oximate 
leads to cleavage of the P-ester bond releasing a phenolate. Upon hydrolysis of the metallo-
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phosphorus complex, the active species is recovered and the next catalytic cycle can be 
launched. 
 
Scheme 2: Proposed hydrolysis mechanism of parathion with Pt-metallacycles. Adapted from Ref. (1).  
 
Catalyst 82-containing LCP was produced directly in an NMR-tube (with 3 % catalyst w/w of 
the lipidic content, 20 mol % relative to the substrate, 100 mg LCP total weight). To the NMR 
tube with the catalytic LCP at the bottom, a buffer solution (0.005 M Na2B4O7/NaOH, pH 8.5, 
0.01 M NaClO4) with parathion (68) (6.5 mM) was added on top as an overlay. The reaction 
mixture was gently shaken and the reaction was monitored by 31P-NMR. Figure 2 shows the 
31P-NMR spectra acquired during the reaction and photographs of the respective NMR tubes. 
The top panel is at the start just after addition of the parathion solution; only the signal of 
parathion is present: The spectrum in the middle, which was taken after 9 h, shows a 
significant amount of decomposition product (ca. 50%). The 31-P-NMR on the bottom panel 
was acquired after 26 h and shows only the signal of the decomposition product. The color 
change from colorless to an intense yellow is a second indication for the formation of the 
decomposition product, since it arises from increasing phenolate concentration.  
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Figure 2: 31P-NMR spectra of parathion hydrolysis using Pt-catalyst 82 in LCP. Top: Reaction start. 
Middle: After 9h. Bottom: after 26 h with the corresponding photographs of the experimental set-up. 
The yellow color intensifies with increasing phenolate concentration. 
 
However, the system has a major drawback: Parathion (68) was found to accumulate in the 
lipidic compartment of the LCP, where the catalyst cannot reach it. After dissolving the LCP in 
EtOH, the total amount of parathion was determined to be 30 %. In addition, an NMR tube 
containing reference parathion solution, which did not contain any catalyst, was used as a 
control. As expected, no hydrolysis product was detected after 26 h by 31P-NMR. 
Furthermore, a control experiment was carried out in which the same amounts of LCP-
compatible catalyst 82 and parathion solution were mixed (and sonicated for 5 min) without 
LCP present. The resulting suspension was analyzed after 30 h and no significant amount of 
decomposition product was detected. This experiment shows the necessity of the LCP in this 
set up. This experiment proves the basic functionality of our concept: The catalyst, which is 
incorporated into LCP destroys parathion. However, the rate with which the substrate is 
destroyed is far too low as compared to our reference system.1 Thus, optimization is needed. 
Several parameters can be changed to achieve this goal: Catalyst loading and surface area 
between LCP and overlay could be increased, and the aqueous channels of the mesophase 
could be swollen with additives like cholesterol and sucrose stearate. Additionally, the use of 
dispersed mesophase nanoparticles, i.e. cubosomes might increase the efficiency of our 
system. This approach is described in the next paragraph. 
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3.2.3 Parathion hydrolysis using Pt-catalyst 82 in cubosomes 
 
In order to compare the catalytic performance of these two mesophase modes, the same 
model reaction and lipidic Pt-catalyst 82 as in the previously described LCP experiments were 
applied using cubosomes as the catalyst immobilization platform. In contrast to bulk LCPs, 
which are malleable and exhibit a gel-like consistency and adhesive properties, cubosome 
nanoparticles have a much lower viscosity.14 Such self-assembled fluid dispersions allow 
therefore running reactions in classical reaction flasks applying stirring, and therefore 
potentially increase reaction rates. Cubosomes are obtained upon ultra-sonication of the 
parent bulk LCP and show identical packing arrangement and phase identity to those of the 
parent gel LCP (see chapter 1). Since bulk LCPs are thermodynamically favored, cubosomes 
need to be stabilized in order to prevent them from reassembling to bulk LCPs. Pluronics,15 
are the most frequently used stabilizers for such systems. The most efficient stabilizer was 
found to be Pluronic F108 (PF 108),16 which was consequently used in this study. Cubosomes 
with a lipid concentration of 33 mg/mL in a buffer solution (0.005 M Na2B4O7/NaOH, pH 8.5, 
0.01 M NaClO4) and uniform particle size of 210 ± 3 nm were prepared using a standard 
sonication process (see experimental section). Subsequently, parathion (6.5 mM) was added 
to the nanoparticle dispersion and the reaction mixture was stirred. The progress of the 
reaction was again monitored by 31P-NMR. To this end, aliquots were removed, cubosomes 
filtered off and 31P-NMR spectra were acquired. After 2 hours, no parathion could be detected 
and only the decomposition product was present according to 31P-NMR. However, after 
destroying the cubosomes by dissolving them with EtOH after 20 h and subsequent analysis, 
it was found that parathion, like in the LCP case, was accumulated in the lipidic compartment 
of the cubosomes where it could not be hydrolyzed by the Pt-catalyst, which resides in the 
aqueous compartment. After 20 hours ca. 50% of the parathion is still present. The relatively 
high hydrophobicity of parathion (ClogP value: 3.648) is responsible for this accumulation 
effect. 
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Several attempts to overcome this problem were undertaken by lowering the parathion 
concentration in the buffer solution. A similar extent of accumulation occurred even at 
0.325 mM and at 0.163 mM parathion. We expected that replacing parathion with more 
hydrophilic phosphate esters might solve this problem. Therefore, bis(4-
nitrophenyl)phosphate (BNPP) (86), 4-nitrophenylphosphate (87) and paraoxon (67) (Figure 
3) were tested as hydrolysis substrates with Pt-catalyst-containing cubosomes.  
 
 
Figure 3: Structures of bis(4-nitrophenyl)phosphate (BNPP, 86), 4-nitrophenylphosphate (87) and 
paraoxon (67). 
 
In the case of BNPP (86) and 4-nitrophenylphosphate (87), no decomposition product was 
detected by 31P-NMR. A possible explanation might be the negative charges which interfere 
with the oxime-oxygen and makes intramolecular nucleophilic attack impossible (compare 
hydrolysis mechanism, Scheme 2). Hydrolysis using paraoxon (67), in which sulfur is replaced 
by oxygen, occurred, but significantly slower, thereby only 10 % of paraoxon (67) was 
hydrolyzed after 20 h. 
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3.3 Conclusion 
 
Lipidic Pt-catalyst 75, 81 and 82 were synthesized and successfully incorporated into LCPs 
and cubosomes. Especially catalyst 82, with its oleyl chain enables a relatively high additive 
loading of 7 % (w/w lipid). The catalytic performance of LCPs and cubosomes containing 
catalyst 82 on the hydrolysis of paraoxon, a phosphate-ester derived pesticide that is 
structurally related to chemical warfare agents like sarin was compared: It was shown that 
cubosomes are more efficient, after 2 h parathion was destroyed, whereas it took 26 h to 
achieve the same with LCPs. However, in both systems parathion was accumulated within the 
lipidic compartment of the mesophase. Whereas in cubosomes 50 % of the parathion was 
found to be accumulated in the lipidic compartment, this value was lower in the case of LCPs 
(30 %). More hydrophilic substrates were tested to circumvent this problem. However, 
hydrolysis of BNPP (86) and 4-nitrophenylphosphate (87) did not occur. Hydrolysis of 
paraoxon (67) was inefficient, only 10 % was decomposed after 20 h. These results indicate 
that such Pt-metallacycles hydrolyze specifically parathion (68). Non-sulfur-containing or 
charged substrates cannot be hydrolyzed efficiently. In summary, parathion (68) can be 
destroyed with our detoxing mesophases. Cubosomes are preferable to LCPs for this purpose 
due to the higher reaction rate. However, due to its lipophilicity, parathion (68) tends to 
accumulate in the lipidic compartment of the mesophases, which constiturtes a major 
drawback in these experiments.  
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3.4 Outlook 
 
The lipidic Pt-metallacycles seem to hydrolyze parathion (68) relative specifically, which 
turned out to be too lipophilic for our system. Therefore, catalysts that enable hydrolysis of a 
broad range of phosphate esters are needed, thereby providing a more general approach. 
Zinc(II)-cyclen complexes have been shown to hydrolyze BNPP (86) and DNA efficiently.8 
Lipidic modification of cyclen-derivatives is a promising approach. First precursors have 
already been synthesized by coupling one and four equivalents of oleyl chloride to Boc-
protected cyclen 88 or cyclen (91), respectively (Scheme 3). The target catalysts can be 
obtained after three synthetic steps: After Boc-deprotection, the amide will be reduced using 
LiAlH4 to the tertiary amines to allow coordination of Zinc(II), which will be achieved adding 
Zn(ClO4)2. 
 
 
Scheme 3: Synthesis of lipidic cyclen precursor 89 and 92 as Zn(II)-ligands and the proposed 
synthesis of the lipidic Zn(II)-cyclen complexes. One and four oleyl chains, respectively have 
successfully been installed. Boc-deprotection, reduction of the amide to the tertiary amines followed by 
Zn(II) complex formation will lead to the target catalysts 90 and 93. Conditions: a) Oleoyl chloride, 
DIPEA, CH2Cl2, r.t.. 
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3.5 Experimental section 
 
General Information  
1-Monooleoyl-sn-glycerol C18:1 (monoolein, MO) was purchased from Nu-Chek Prep, Inc. 
(MN, USA), and phosphate buffer solution (PBS (1X) pH 7.4) was purchased from Invitrogen. 
N-(3- dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride (EDC) was purchased from 
TCI, and all other reagents and solvents were purchased from Sigma Aldrich. All chemicals 
and solvents were used as received, unless otherwise stated. Reactions were carried out 
under an inert atmosphere of argon in dry solvents. Dichloromethane was degassed with 
argon and purified by passage through activated alumina solvent column (MC Brown solvent 
system) prior to use. Column chromatography was performed using silica gel Merck 60 
(particle size 0.040–0.063 mm). Analytical thin- layer chromatography (TLC) was performed 
using Merck pre-coated silica gel plates 60 F254; visualization by UV absorption and/or by 
dipping in a solution of KMnO4 (1 g), K2CO3 (2 g) in H2O (100 mL) and subsequent heating. 
1H-NMR spectra were recorded on a Bruker AV2-500 (500MHz) spectrometer. Chemical 
shifts are given in parts per million (ppm) relative to the internal standard TMS (δ = 0 ppm). 
Coupling constants J are expressed in Hz and multiplicities are abbreviated as follows: s 
(singlet), br (broad), d (doublet), t (triplet), q (quadruplet), quint (quintet), m (multiplet). 13C-
NMR chemical shifts are reported relative to the solvent residual peaks: CDCl3 = 77.00 ppm. 
Mass spectra were recorded by the Mass Spectroscopy Service of UZH on Finnigan MAT95 
MS, BrukerLC MS and Finnigan TSQ700 MS machines.  
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3.5.1 Synthesis  
 
Synthesis of 86 (PtCl2(DMSO)2) 
 
An aqueous solution (2.5 mL) of K2(PtCl4) (100 mg, 0.24 mmol, 1 eq) was prepared and 
DMSO (56 mg, 0.72 mmol, 3 eq) was added with a syringe. The solution was allowed to stand 
at room temperature until yellow crystals precipitated (24 h). The precipitate was filtered, 
washed with water (1 mL), ethanol (1 mL), and ether (1 mL). After drying at high vacuum, the 
product was obtained as yellow crystals in quantitative yield. Analytical data were identical 
with the values reported in literature.17 
 
 
Synthesis of 84 ((E)-acetophenone oxime) 
 
 
 
Acetophenone (22 mg, 0.18 mmol, 1 eq) and hydroxylamine hydrochloride (14 mg, 0.2 mmol, 
1.1 eq) were dissolved in a mixture of ethanol absolute and pyridine (1:1, 5 mL). The solution 
was refluxed until the starting material was consumed (2 h). The solvent was evaporated to 
give a transparent oil, which was treated with distilled water and lyophilized. The crude 
product was purified by flash chromatography (ethylacetate/CH2Cl2) to give the desired pure 
product in quantitative yield. Analytical data were identical with the values reported in 
literature.18 
 
 
Synthesis of catalyst 69  
 
 
 
The platinum precursor 86 cis-Pt[(DMSO)Cl2] (315 mg, 0.75 mmol, 1 eq) and MeOH (30 mL) 
were stirred at 40°C for 2.5 h. Acetophenone oxime 84 (90 mg, 0.75 mmol, 1 eq.) was added 
and the mixture was stirred for 2 h before it was heated up to reflux and stirred for another 20 
h. The solvent was evaporated until a precipitate was formed, then the mixture was allowed to 
stand for 2 h at 5°C, filtrated and washed with cold MeOH. A second batch was isolated from 
N
OH
NPtS
OH
ClO
Me
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the mother liquor to get the product as a brown solid (170 mg, 0.383 mmol, 51 %). Analytical 
data were identical with the values reported in literature.18 
 
 
Synthesis of 73 (1-(4-(octadecylamino)phenyl)ethan-1-one)19 
 
 
 
A round bottom flask with Pd(OAC)2 (11.3 mg, 0.05 mmol, 0.05 eq), XPhos (95 mg, 0.1 mmol, 
0.1 eq) and 4-bromoacetophenon (200 mg, 1 mmol, 1 eq), stearyl amine (320 mg, 1.5 mmol, 
1.5 eq) and NatBuO (190 mg, 2 mmol, 2 eq) was prepared and degased toluene (10 mL) was 
added. The yellow reaction mixture was heated up to 100°C whereupon the colour turned 
from brown to black. After 6 h, the oil bath was removed and the reaction mixture was allowed 
to cool to room temperature. Then the mixture was filtered over celite and the solvent 
evaporated. The crude product was purified by flash chromatography (ethylacetate/ hexane 
2:8) to give the product as slightly yellow oil (280 mg, 0.72 mmol, 28 %). 1H NMR (500 MHz, 
Chloroform-d) δ 7.81 (d, J = 8.7, 2H), 6.53 (d, J = 8.7, 2H), 4.14 (s, 1 H, NH), 3.17 (q, J = 5.5, 
7.0, 2H) 2.48 (s, 3H), 1.61 (quint., J = 7.1, 7.4, 2H); 1.25 (m, 31H); 0.87 (t, J = 7.0, 3H). 13C 
NMR (126 MHz, Chloroform-d) δ 196.27, 152.31, 130.83 (2C), 111.25 (2C), 43.35, 31.93, 
29.69─29.33 (m, 14C), 27.06, 25.97, 22.69, 14.12. HRMS (ESI [M + H]+) m/z: calcd for 
(C26H46ON) 388.35739, found 388.35691. 
 
 
Synthesis of 74 ((E)-1-(4-(octadecylamino)phenyl)ethan-1-one oxime)18 
 
 
 
In a round bottom flask equipped with a reflux condenser, 73 (40 mg, 0.103 mmol, 1 eq) and 
NH2OH x HCl (9.3 mg, 0.134 mmol, 1.3 eq) were added and dissolved in ethanol (5 mL). 
Pyridine (2.5 mL) was added and the solution was heated to reflux. After full conversion of 10, 
which was monitored by TLC, the solvent was evaporated in vacuo. The crude solid was 
purified by column chromatography (EtOAc/ cyclohexane 15:85). The purified product 27 was 
obtained as a clear liquid (41 mg, 0.101 mmol, 98%). 
1H NMR (500 MHz, Chloroform-d) δ 7.48 (d, J = 8.7, 2H), 6.61 (d, J = 8.4, 2H), 3.13 (t, J = 5.5, 
7.0, 2H), 2.23 (s, 3H), 1.63 (quint., J = 7.1, 7.4, 2H), 1.26 (m, 31H), 0.88 (t, J = 7.0, 3H). 13C 
O
N
H
N
N
H
OH
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NMR (126 MHz, Chloroform-d) δ 142.31, 127.28 (2C), 111.25 (2C), 43.35, 31.93, 29.67 - 
29.31 (m, 14C), 27.08, 25.97, 22.69, 14.11. HRMS (ESI [M + H]+) m/z: calcd for (C26H47ON2) 
403.36829, found 403.36858. 
 
 
Synthesis of catalyst 7518 
 
 
 
The platinum precursor cis-Pt[(DMSO)Cl2] (31.5 mg, 0.075 mmol, 1 eq) and MeOH (3 mL) 
were stirred at 40°C for 2.5 h. The acetophenone oxime derivative (30 mg, 0.075 mmol, 1 eq) 
was added and the mixture stirred for 2 h at before it was heated up to reflux and stirred for 
another 20 h. The solvent was evaporated until precipitate was formed, then the mixture was 
allowed to stand for 2 h at 5°C, filtrated, washed with cold MeOH. A second batch was 
isolated from the mother liquor to get the product as a brown solid (yield: 31%). 1H NMR (500 
MHz, DMSO-d6) δ 7.20 (s, 1H), 7.03 (d, J = 7.9 Hz, 1H), 6.29 (s, 1H), 2.98 (t, J = 6.6 Hz, 2H), 
2.46 (s, 6H), 2.23 (s, 2H), 1.57 – 1.42 (m, 2H), 1.19 (s, 32H), 0.81 (t, J = 6.2 Hz, 3H). 13C 
NMR (126 MHz, DMSO-d6) δ 170.6, 141.7, 129.4, 110.3, 41.49, 32.35, 30.09 (15C), 29.91, 
29.76, 27.62, 23.15, 15.02, 12.19. HRMS (ESI [M + H]+) m/z: calcd for (C28H52ClN2O2PtS) 
710.30805, found 710.30852. 
 
 
Synthesis of 77 (N-(4-acetylphenyl)dodecanamide) 
 
 
 
To a solution of 4-aminoacetophenone (0.506 g, 3.69 mmol, 1eq) in CH2Cl2 (15 mL) 
diisopropylethylamin (0.6 mL, 3.69 mmol, 1 eq) was added. The solution was cooled to 0 °C 
with an ice bath. Lauroylchloride (1.2 mL, 5.54 mmol, 1.5 eq.) was dissolved in CH2Cl2 (5 mL) 
and added dropwise to the reaction mixture. The solution was allowed to warm up to room 
temperature and stirred overnight. The solution was poured into brine and extracted three 
times with CH2Cl2 (3x 20 mL). The combined organic phases were washed with brine and 
dried over MgSO4. After evaporation of the solvent, the crude product was purified by column 
chromatography (EtOAc/ cyclohexane 4:6). The desired product 77 was obtained as a white 
solid (1.02 g, 3.21 mmol, 87%). 1H NMR (500 MHz, Chloroform-d) δ 7.93 (d, J = 8.5, 2H), 7.61 
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(d, J = 8.5, 2H), 2.57 (s, 3H); 2.38 (t, J = 7.7, 2H), 1.74 (quint, 2H), 1.36─ 1.26 (m, 17H), 0.88 
(t, J = 6.9, 3H). 13C NMR (126 MHz, Chloroform-d) δ 196.99, 171.69, 142.39 (2C), 133.01, 
129.92, 116.91 (2C), 60.52, 38.09, 32.05, 29.74─29.38 (6C), 26.56, 25.57, 22.82, 14.25. 
HRMS (ESI [M + H]+) m/z: calcd for (C20H32O2N) 318.24276, found 318.24247. 
 
 
Synthesis of 79 ((E)-N-(4-(1-(hydroxyimino)ethyl)phenyl)dodecanamide)  
 
 
 
To a solution of ketone 77 (1.0 g, 3.15 mmol, 1 eq) in ethanol (70 mL) NH2OH x HCl (0.291 g, 
4.095 mmol, 1.3 eq) and pyridine (20 mL) was added and the solution was heated to reflux. 
After full conversion of 77, which was monitored by TLC, the solvent was evaporated in 
vacuo. The crude solid was purified by column chromatography (EtOAc/ cyclohexane 3:7). 
The purified product 79 was obtained as a white solid (1.01 g, 3.01 mmol, quant.). 1H NMR 
(500 MHz, Chloroform-d) δ 7.62 (d, J = 8.7, 2H), 7.55 (d, J = 8.9, 2H), 2.36 (t, J = 7.5, 2H), 
2.28 (s, 3H), 1.71 (quint, 2H), 1.36─1.25 (m, 18H), 0.88 (t, J = 6.9, 3H). 13C NMR (126 MHz, 
Chloroform-d) δ 171.79, 142.40, 129.92 (2C), 128.17, 127.22, 119.53 (2C), 38.05, 32.06, 
29.75─29.41 (6C), 26.57, 25.58, 22.83, 14.26. HRMS (ESI [M + H]+) m/z: calcd for 
(C20H33O2N2) 333.25365, found 333.25336. 
 
 
Synthesis of catalyst 81  
 
 
 
A solution of Pt(II)(DMSO)2Cl2 (161.7 mg, 0.383 mmol, 1 eq) in methanol (26 mL) was stirred 
at 40 °C for 2 hours. Oxime 79 (123.5 mg, 0.383 mmol, 1 eq) was dissolved in methanol 
(6 mL) and added to the reaction mixture, which was stirred for 2 h. The reaction mixture was 
refluxed for 36 h and the solvent was evaporated and the crude product was filtered and 
washed with cold methanol. The desired product 81 was obtained as yellow crystals (110.3 
mg, 0.172 mmol, 45 %). 1H NMR (500 MHz, Chloroform-d) δ 9.96 (s, 1H), 7.97 (d, J = 8.1, 
1H), 7.64 (d, J =2.2, 1H), 7.19 (s, 1H), 7.15 (d, J = 8.8, 1H), 3.55 (s, 6H), 2.37 (s, 3H), 2.32 
(t, J = 7.5, 2H), 1.71 (quint, 2 H); 1.39─1.25 (m, 17 H) 0.87 (t, J = 6.9, 3H). 13C NMR (126 
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MHz, Chloroform-d) δ 171.59, 168.32, 139.78, 138.73, 127.22 (2C), 122.56, 115.47 (2C), 
47.36, 38.02, 31.91, 29.47─29.28 (6C) 25.49, 22.69, 14.12, 11.42. HRMS (ESI [M + H]+) m/z: 
calcd for (C22H38O3N2ClPtS) 640.19339, found 640.19337. 
 
 
Synthesis of 78 (N-(4-acetylphenyl)oleamide) 
 
 
 
To a solution of 4-aminoacetophenone 76 (0.499 g, 3.69 mmol, 1 eq) in anhydrous CH2Cl2 
(15 mL) diisopropylethylamin (0.6 mL, 3.69 mmol, 1 eq) was added. The reaction mixture was 
cooled to 0 °C with an ice bath and a solution of oleylchloride (1.82 mL, 5.54 mmol, 1.5 eq) in 
CH2Cl2 (5 mL) was added dropwise. The solution was allowed to warm to room temperature 
and stirred for 90 minutes. After complete conversion of the starting material the solution was 
poured into brine and extracted with CH2Cl2 (3x 20 mL). The combined organic phases were 
washed with brine and dried over MgSO4. After evaporation of the solvent in vacuo, the crude 
product was purified by column chromatography (EtOAc/ cyclohexane 2:8). The desired 
product 78 was obtained as a white solid (1.37 g, 3.43 mmol, 93%). 1H NMR (500 MHz, 
Chloroform-d) δ 7.93 (d, J = 8.9, 2H), 7.61 (d, J = 8.7, 2H), 7.24 (s, 1H), 5.34 (m, 2H), 2.57 (s, 
3H), 2.38 (t, J = 7.7, 2H), 2.00 (m, 4H), 1.73 (quint, 2 H), 1.41-1.26 (m, 20H), 0.87 (t, J = 6.9, 
3H). 13C NMR (126 MHz, Chloroform-d) δ 196.93, 171.59, 142.30 (2C), 132.82, 130.07, 
129.78, 129.70, 118.77 (2C), 37.92, 31.91, 29.77─29.11 (m, 8C); 27.24, 27.16, 26.44, 25.42, 
22.69, 14.13. HRMS (ESI [M + H]+) m/z: calcd for (C26H42O2N) 400.32101, found 400.32064. 
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Synthesis of 80 (N-(4-((E)-1-(hydroxyimino)ethyl)phenyl)oleamide) 
 
 
 
To a solution of ketone 78 (1.0 g, 2.502 mmol, 1 eq) in ethanol (40 mL), NH2OH x HCl (0.23 g, 
3.253 mmol, 1.3 eq) and pyridine (20 mL) was added and the solution was heated to reflux. 
After full conversion of 78, which was monitored by TLC, the solvent was evaporated in 
vacuo. The crude solid was purified by column chromatography (EtOAc/ cyclohexane 3:7). 
The purified product 80 was obtained as a white solid (0.89 g, 2.146 mmol, 95%). 1H NMR 
(500 MHz, Chloroform-d) δ 7.61 (d, J = 8.8, 2H), 7.54 (d, J = 8.8, 2H), 7.14 (s, 1H), 5.34 (m, 
2H), 2.57 (s, 3H), 2.38 (t, J = 7.6, 2H), 2.00 (m, 4 H), 1.73 (quint, 2H), 1.41 - 1.26 (m, 20H), 
0.87 (t, J = 6.9, 3H). 13C NMR (126 MHz, Chloroform-d) δ 171.48, 155.77, 139.02, 132.19, 
130.17, 129.85, 126.95 (2C), 119.47 (2C), 38.01, 32.03, 29.90─29.24 (10C); 27.36, 27.30, 
25.66, 22.81, 14.24, 12.03. HRMS (ESI [M + H]+) m/z: calcd for (C26H43O2N2) 415.33191, 
found 415.33221. 
 
 
Synthesis of 82 (N-(4-((E)-1-(hydroxyimino)ethyl)phenyl)oleamide- 
Pt(II)(dimethylsulfoxid)chlorid) 
 
 
 
A solution of Pt(II)(DMSO)2Cl2 (277 mg, 0.65 mmol, 1 eq) in methanol (50 mL) was stirred at 
40 °C for 2 hours. Oxime 80 (270 mg, 0.65 mmol, 1 eq) was dissolved in methanol (10 mL) 
and added to the reaction mixture, which was stirred for 2 h. The reaction mixture was 
refluxed for 36 h and the solvent was evaporated and the crude product was filtered and 
washed with cold methanol. The desired product 82 was obtained as a brown solid (178.15 
mg, 0.247 mmol, 38 %). 1H NMR (500 MHz, Chloroform-d) δ 9.95 (s, 1H), 7.96 (d, J = 8.8, 
1H), 7.69 (d, J = 7.5, 1H) 7.20 (s, 1H), 7.14 (d, J = 8.8, 1H); 5.35 (m, 2H), 3.65 (s, 6H), 2.60 
(s, 3H), 2.31 (m, 2H), 1.99 (m, 4H), 1.55 (m, 2H), 1.24 (m, 20H), 0.87 (t, J = 6.9, 3H). 13C 
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NMR (126 MHz, Chloroform-d) δ 171.48, 155.77, 139.02, 132.19, 130.17, 129.85 (2C), 
126.95, 119.47 (2C); 38.01, 32.03, 29.90─29.24 (10C), 27.36, 27.30, 25.66, 22.81, 14.24, 
12.03. HRMS (ESI [M + Na]+) m/z: calcd for (C28H47O3N2NaPtS) 744.25360, found 744.25342. 
 
 
Synthesis of 89 (tri-tert-butyl(E)-10-(octadec-9-enoyl)-1,4,7,10-tetraazacyclododecane-
1,4,7-tricarboxylate) 
 
 
 
1,4,7-tris-Boc-1,4,7,10-tetraaza-cyclododecane 88 (128.8 mg, 0.27 mmol, 1eq) was dissolved 
in anhydrous CH2Cl2 (5 mL) and diisopropylethylamin (0.35 mL, 0.27 mmol, 1 eq.) was added. 
The solution was cooled to 0 °C and oleylchloride (0.2 mL, 0.408 mmol, 1.5 eq) was dissolved 
in CH2Cl2 (2 mL) was added dropwise. The solution was allowed to warm up to room 
temperature and was stirred for 90 minutes. The reaction mixture was poured into brine and 
extracted with CH2Cl2 (3 x 10 mL). The combined organic phases were washed with brine and 
dried over MgSO4. After evaporation of the solvent in vacuo, the crude product was purified by 
column chromatography (EtOAc/ cyclohexane 2:8) to obtain the desired product 89 as a 
yellow oil (190 mg, 0.25 mmol, 93%). 1H NMR (500 MHz, Chloroform-d) δ 5.29 (m, 2H), 3.47- 
3.35 (m, 14H), 2.27 (t, J = 7.6, 2H), 1.99 (m, 4 H), 1.60 (m, 2H), 1.46-1.44 (m, 22 H), 1.28-
1.22 (m, 27H) 0.86 (t, J = 7.0, 3H). 13C NMR (126 MHz, Chloroform-d) δ 173.69, 157.43 (2C), 
155.49, 130.04, 129.84, 80.45, 80.28, 80.16, 51.49, 50.50 (2C), 49.62, 31.98, 29.85─29.27 
(14C); 28.58 (9C), 27.30, 25.49 22.75, 14.19. HRMS (ESI [M + H]+) m/z: calcd for 
(C41H77O7N4) 737.57868, found 737.57829. 
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Synthesis of 92 ((9Z,9'Z,9''Z,9'''Z)-1,1',1'',1'''-(1,4,7,10-tetraazacyclododecane-1,4,7,10-
tetrayl)tetrakis - (octadec-9-en-1-one)) 
 
 
 
A solution of cyclen tetrahydrochloride 91 (250.2 mg, 0.79 mmol, 1eq) and 
diisopropylethylamin (0.7 mL, 3.0 mmol, 4 eq) in CH2Cl2 (15 mL) was cooled to 0 °C. 
Subsequently, a solution of oleylchloride (1.5 mL, 3.95 mmol, 5 eq.) in CH2Cl2 (5 mL) was 
added dropwise. The solution was warmed up to room temperature and stirred for 1.5 h. Brine 
(50 mL) was added and the mixture was extracted with ethylacetate (3 x 30 mL). The 
combined organic phases were washed with brine and dried over MgSO4. After evaporation of 
the solvent in vacuo, the crude product was purified by column chromatography (EtOAc/ 
cyclohexane 4:6). The product 37 was obtained as a white solid (737 mg, 0.60 mmol, 76%). 
1H NMR (500 MHz, Chloroform-d) δ 5.33 (m, 8H), 3.51 (m, 16H); 2.32 (m, 7H), 2.00 (m, 
14 H), 1.62 (m, 9H), 1.29-1.26 (m, 84H), 0.87 (t, J = 7.1, 12H). 13C NMR (126 MHz, 
Chloroform-d) δ 176.86 (2Cs), 173.85 (2C), 130.11 (4C), 129.76 (4C), 50.31 (8C), 32.00 (4C), 
29.86─29.28 (XC); 27.32 (4C); 22.77 (4C); 14.20 (4C). HRMS (ESI [M + Na]+) m/z: calcd for 
(C80H148O4N4Na) 1252.13928, found 1252.13954. 
 
 
3.5.2 Preparation of catalytic mesophases 
 
Catalytic LCPs 
MO was weight into a pyrex glass tube and the corresponding amount of a catalyst stock-
solution (catalyst in CH2Cl2) was added to obtain a homogeneous lipid mixture. The solvent 
was evaporated (at high vacuum 10-2 mbar for 24 h) and the lipidic mixture subsequently 
hydrated by adding appropriate volumes of buffer and mixed. To obtain homogeneous 
catalytic LCPs, samples were centrifuged in a Heraeus Megafuge 16R centrifuge (at 5 000 
rpm) for 1 h at 23 °C. Samples were finally stored and left to equilibrate for 48 h in tightly 
closed glass tubes. 
 
  
N N
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3.5.3 Preparation of catalytic cubosomes 
 
MO was weight into a glass vial and the corresponding amount of a catalyst stock-solution 
(catalyst in CH2Cl2) was added to obtain a homogeneous lipid mixture. The solvent was 
evaporated (at high vacuum 10-2 mbar for 24 h) and the lipidic mixture subsequently hydrated 
by adding appropriate volumes of stabilizer containing buffer (PF108, 1.65 mg / mL) to obtain 
the cubosome sample with the desired lipid concentration. The sample was vortex-mixed and 
then dispersed using an ultrasonic processor Brenson digital 250 (cycle 0.9 s on/ 0.9 s off, 
amplitude 50%, for 3 x 5 min). Subsequently, the cubosome dispersion was filtered through 
Acrodisc 450 nm filters.  
 
 
3.5.4 Dynamic Light Scattering (DLS) 
 
Particle size of the cubosomes was performed after preparation, before the reaction was 
started, and after the reaction was terminated (1-2 d) with a Zeta Sizer Nano ZS (Malvern 
Instruments, Malvern, UK) at 25 ± 0.1 °C. The samples were measured in disposable 
polystyrene cuvettes of 1 cm optical path length with the corresponding buffer as solvent. 
Scattering angle was 90°. A triplicate of the samples was performed. The width of the DLS 
hydrodynamic diameter distribution is indicated by PDI (polydispersion index). The intensity 
size distribution of the cubosomes was typically unimodal; therefore the autocorrelation 
function was analyzed according to the cumulant method.  
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Palladium nanoparticles synthesized, templated and supported by lipidic cubic 
phases as catalysts of Suzuki-Miyaura cross coupling reactions 
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4.1 Introduction 
4.1.1 Suzuki-Miyaura cross coupling reactions 
 
Among other palladium catalyzed cross coupling reactions,1–3 the discovery of the Suzuki-
Miyaura cross coupling reaction in 1979 revolutionized the capabilities for building carbon-
carbon bonds. 4,5 Further development of these cross coupling reactions allowed for their 
versatile application, including the coupling of sp2-sp3 and sp3-sp3 carbons.6,7 The chemistry 
noble prize awarded in 2010 to the discoverer of the palladium catalyzed cross coupling 
reactions underlines the significance of the Suzuki-Miyaura reaction, which is an extensively 
used method to build-up complex molecules that finds broad application in industry as well as 
in academic research.  
Breslow’s discovery of the positive effect of water on the reaction rate and selectivity of Diels-
Alder reactions in the 1980s led to a renaissance of water as reaction medium for chemical 
transformations.8,9 This work has initiated widespread interest in the field of green chemistry, 
and the repertoire of chemical transformations that can efficiently be carried out in water is 
ever growing.10 As early as 1990, a first example of a water tolerant Suzuki-Miyaura cross 
coupling catalyst has been reported.11 Ever since, many examples of water soluble palladium 
catalysts have been developed12,13 including systems using organic co-solvents14,15, phase 
transfer catalysts and surfactants.16–18  
The fact that commonly used phosphine-based ligands for homogeneous catalysis of these 
reactions are expensive and their recovery is tedious, led to the development of 
heterogeneously catalyzed systems. Furthermore, by developing heterogeneous catalytic 
systems that are more easily recyclable, the actual life-time is extended, which improves the 
efficiency of the catalysts.19 The heterogenization of established catalysts to different supports 
is ineffective and many phosphine-free systems are known to leach catalytically active 
species to the solution.20 Recent discoveries revealed the potential of palladium nanoparticles 
(PdNPs) in catalysis,20,21 which might be a possible approach to overcome earlier mentioned 
difficulties. Various types of materials have been used for immobilization of PdNPs and their 
subsequent application in catalysis: Mesoporous silica, polymer supports, carbon nanotubes 
and metal organic frameworks, only to mention a few.21 By tuning morphology, shape and size 
of PdNPs, tailored heteregeneous catalytic systems can be designed.22,23 Therefore, the 
method for the synthesis of the PdNPs is a crucial step for the design of such heteregeneous 
catalytic systems. Not surprisingly, there is a myriad of procedures for the preparation of 
PdNPs described in literature, many of them require sophisticated reducing steps, are energy-
inefficient, or do not allow control over the particle size distribution.24 
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4.1.2 Synthesis of PdNPs 
 
Procedures for the preparation of PdNPs described in the literature will be shortly summarized 
(without being complete). They can be separated into physical and chemical methods. 
Physical methods include ion and electron beam deposition,25,26 laser ablation27,28 and 
sputtering.29,30 They are based on molecular rearrangements; palladium metal precursors do 
not undergo any chemical transformation. The hydrothermal method is a chemical approach 
for the synthesis of PdNPs in which the alternated properties of water as solvent at high 
temperature and high pressure are exploited.24 Often PdCl2 is used as the palladium 
precursor, and ammonium formate, formaldehyde and ethylene glycol are used as reducing 
agents.24 Electrochemical deposition is another efficient method. In general, the electrolyte 
serves as the palladium source in a three- or two-electrode cell set up,24 and several 
techniques are described in the literature: cyclic voltammetry, square-wave voltammetry, 
chronoamperometry, chronopotentiometry, chronocoulometry to mention a few examples.24 
Whereas for these methods external current is applied, this is not the case for electroless 
deposition methods, which can be separated into two categories: displacement deposition (or 
galvanic replacement) and autocatalytic deposition. the latter requires chemical reducing 
agents like ethylene glycol, sodium borohydride, ascorbic or citric acid.24 Additionally, there 
has been much effort recently to develop more sustainable methods for the synthesis of 
PdNPs, leading to an entirely new research field called biogenic synthesis of nanoparticles, in 
which the reductive properties of compounds which are present in plants (polyphenols, 
alkaloids and terpenoids) is exploited.31 Liposomes have also been used as nanoreactors to 
synthesize ultra-small and mono-disperse PdNPs with glycerol as the reducing agents.32  
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4.1.3 Medical applications 
 
Recently, palladium nanoparticles have attracted attention due to their use in the nanomedical 
field.33 Weiss et al. showed that supported Pd(0) particles were able to bioorthogonally 
activate 5-fluoro-1-propargyluracil and N4-propargyloxycarbonylgemcitabine, which in 
combination are cytotoxic to colorectal and pancreatic cancer cells.34,35 Huang et al. used 
hexagonal palladium nanosheets for phototermal therapy: They were able to kill liver cancer 
cells after only 5 min irradiation time.36 Furthermore, Balbin et al. treated four different human 
cancer cell lines with mesoporous silica supported PdNPs and reported high cytotoxicity of 
these PdNPs on these cell lines.37 Additionally, the same particles were successfully applied 
in Suzuki-Miyaura cross coupling- thus a dual application was reported.  
 
 
4.1.4 PdNP synthesis within LCPs 
 
Puvvada et al.38 used for the first time MO-based LCPs to synthesize PdNPs. The concept is 
based on a polyol type reduction of Pd2+ and allows PdNP synthesis at benign conditions - 
neither solvent, nor high temperature, high pressure and expensive equipment are needed. 
Furthermore, the size of the nanoparticles can be controlled as the LCP plays a dual role as 
reductant and template with controllable water pore sizes. However, this remains the only 
such report, and no further investigations with such PdNP-containing LCPs have been carried 
out. Due to the great potential of this method, we took up the concept and adapted it for our 
research: the investigation of mesophases as catalyst scaffolds.  
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Figure 1: Schematic representation of the PdNPs formed in the aqueous channels of LCPs and 
subsequent swelling of the aqueous channels. Top panel: The growth of PdNPs is limited by the size of 
the aqueous channels. This prevents the substrates from diffusing efficiently into the LCP, and thus no 
product is formed. Bottom panel: The size of the aqueous channels increases upon adding a swelling 
agent, resulting in the entry of substrates into the LCP and enabling the reaction to take place. 
 
We use this method to directly catalyze cross-coupling reactions in LCPs. Following 
nanoparticle formation as described by Puvvada et al.38 the aqueous channels were found to 
be blocked, and diffusion is therefore “switched off”. * To overcome this drawback, a “switching 
on” modification of the LCP is required in order to enable diffusion and allow the reaction to 
take place (Figure 1). The mesophases thus play a threefold role: they act as a reducing 
agent for Pd2+, as a template for their growth, and as a support in one. The LCP modifications, 
material characterization and kinetics of the Suzuki-Miyaura cross couplings carried out in 
bulk LCP, as well as in dispersed palladium lipid hybrid nanoparticles are described herein. 
Catalyzing Suzuki-Miyaura cross couplings with PdNPs synthesized and stabilized in LCPs is 
a novel approach which is different from our previous work, in which we have developed 
catalytic LCPs and cubosomes with tunable activity for investigating aldol reactions,39 
demonstrating the broad applicability of these materials in aqueous catalysis. 
                                                
* An assumption: It was found that the PdNPs size is controlled by the diameter of the aqoueus pores of the LCP. 
Furthermore, no product is formed applying the LCP before modification. 
	
Swelling: Aqueous channel diameter increases
Diffusion off: No reaction
Diffusion on: Reaction takes place
in-meso grown Pd-nanoparticles
Pd
Pd
94 95
96
94 95
96
Chapter 4 
 
 
 
120 
4.2 Results and discussion 
4.2.1 Investigation of in meso-PdNP synthesis 
 
The previously reported method to produce PdNP-containing lipidic cubic phases was 
successfully reproduced: Monoolein was hydrated with a 20 mM solution of K2PdCl4, mixed, 
centrifuged and equilibrated for 24 h.38 The data of several analytical methods prove the 
formation of PdNPs within the LCP. The LCP undergoes color change from orange to black 
(Figure 2A) and the maximum at 420 nm of the UV spectrum of K2PdCl4 disappears after the 
PdNP synthesis. The lipid fraction of the LCP was isolated after PdNP synthesis and analyzed 
by 1H-NMR. The signal at 9.66 ppm appeared after PdNP synthesis and might originate from 
an aldehyde formed during the redox process (Figure 2B and 2C). Puvvada et al. reported 
already the corresponding FTIR bands.38  
 
 
Figure 2: A) Pictures of a LCP directly after hydration with a K2PdCl4 solution (left), and after 24 h 
(right). The characteristic brown color of K2PdCl4 disappears and the LCP turns black. B) 1H-NMR 
spectrum in CDCl3 of the lipid fraction (MO) after PdNP synthesis; a signal which has a typical chemical 
shift (9.67 ppm) of an aldehyde proton, was detected. C) Proposed redox process leading to PdNP 
formation. D) UV/Vis spectra of K2PdCl4 (blue) and PdNPs (orange). 
 
The kinetics of the PdNP formation was carefully analyzed using small angle X-ray scattering 
(Figure 3). The slope of the signal at low q value increases in the first 15 h (indicated by the 
blue arrow), indicating formation of smaller particles. Since the slope does not increase 
further, the PdNP synthesis is probably completed. Interestingly, shortly before the increase of 
the slope stagnates, the Pn3m LCP undergoes a phase transition to a Ia3d cubic phase. It is 
not clear whether the phase transition is induced, directly or indirectly, by the PdNPs since 
reduction of the Pd-precursor K2PdCl4 brings along the oxidation of MO to aldehyde 97 
(Figure 2B and 2C), which might change the lipidic packing. However, the amount of K2PdCl4 
present in the sample can oxidize no more than 0.47 % of to the aldehyde 97. 
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Figure 3: SAXS profile of the time-resolved intensity vs. scattering vector q during the PdNP synthesis 
in MO LCPs at room temperature.  
 
In a next step, PdNPs were analyzed after lipid removal using transmission electron 
microscopy (TEM) and DLS. TEM micrographs were taken after adding Pd-LCP on a grid and 
removing the lipid by simply rinsing the grid with ethyl acetate. PdNPs of 5.3 ± 2.5 nm 
diameter were found (Figure 4B). For DLS measurements, dodecanethiol was added to the 
Pd-LCP and mixed. The lipid precipitate was removed by centrifugation, and ethanol was 
added to the supernatant, which contains PdNPs. This procedure was repeated three times 
before DLS was measured. Nanoparticles from 3 – 5 nm were detected (Figure 4C). 
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Figure 4: A) TEM micrograph of PdNPs after removal of lipid with ethyl acetate B) Size distribution of 
PdNPs in A, obtained using ImageJ. C) DLS analysis of PdNPs after removal of lipids with ethanol and 
PdNP stabilization with dodecanethiol. 
 
Initially, we intended to apply these unmodified mesophases directly for the catalysis of 
Suzuki-Miyaura cross couplings. Catalysis in LCPs and cubosomes requires water-soluble 
substrates to enable diffusion of substrates from the bulk water into the aqueous channels of 
the LCPs. To this end, 5-iodo-2’-deoxyuridine (95) and phenylboronic acid (94) were chosen 
as substrates for the model reaction to be investigated (Figure 1). A maximum concentration 
of 95 of ca. 5 mM was identified to be the highest one tolerated by the LCP, as higher 
concentrations led to destruction of the cubic structure of the material. As already mentioned 
earlier, only traces (3 %) of the corresponding product was formed (Table 1, entry 5). 
Puvvada et al. suggested that the size of the PdNPs corresponds to the size of the aqueous 
channels of the LCPs which were used for their synthesis.38 Hence, the aqueous channels are 
blocked by the PdNPs, which leads to strongly reduced diffusion, an thus the substrates do 
not get into contact with the catalyst and no product is formed.   
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4.2.2 Swelling of Pd-containing LCPs 
 
We set out to address this problem by swelling the LCP following the PdNP synthesis, thereby 
“switching on” the diffusion and allowing for the formation of the corresponding cross coupling 
product (Figure 1). The swelling can be induced via modification of the lipidic compartment, or 
of the aqueous phase. Hence, our system has two different “switches” to turn on reactivity and 
to tune it, as has been shown in a previous paper of our group.39 Cholesterol was chosen as a 
lipidic swelling agent. Following PdNP synthesis, cholesterol was added and the LCP was 
equilibrated for at least 4 days before being used for catalysis. The full hydration line with 4 % 
chlolesterol (w/w lipid) was reached at a hydration degree of 47 %. The diameter of this LCP 
was calculated to be 5.5 nm (see experimental part for equations and references). In 
comparison, Puvvada et. al. reported an aqueous channel diameter of 5 nm for pure MO 
LCPs containing PdNPs.38 Polyethylene glycol (PEG 4000), on the other hand, was used to 
induce swelling via the aqueous phase and was added simultaneously with the substrates. 
Since PEG 4000 is water-soluble, it can be removed from the mesophase. This approach 
allows not only the “on-switching”, but also the “off-switching” of the system. 
 
 
4.2.3 Catalysis of Suzuki-Miyaura cross coupling reactions with PdNP-
containing LCPs 
 
Using this approach, LCPs can be applied for catalysis directly following PdNP synthesis. 
Both approaches led to successful conversion of the starting materials to the desired Suzuki-
Miyaura product. When cholesterol was used to modify the LCP, 95 % of 5-iodo-2’-
deoxyuridine (94) was converted to the product (96) in 24 h (Table 1, entry 1), whereas 87 % 
of 5-iodo-2’-deoxyuridine was transformed in 32 h when PEG 4000 was used (Table 1, entry 
4). In a next step, the influence of the base on this PdNP-LCP catalysis was investigated. 
Three bases were tested; K2CO3, KOH and NEt3. Beside the impact of the base on the 
reaction itself, the tolerance of the LCP toward the base needs to be considered. K2CO3 and 
KOH showed very similar results and allowed for efficient catalysis: after 24 h, 95 % and 98 
%, respectively, of 94 was converted (Table 1, entry 1 and 2). When NEt3 was used as a 
base, the reaction was significantly slower: after 72 h, 84 % of 94 was consumed (Table 1, 
entry 3). All these experiments were carried out with 3 mol % Pd with respect to 5-iodo-2’-
deoxyuridine (94), and only entry 5 was carried out with 1 mol % Pd, which resulted in slower 
conversion (76 % after 48 h). The reaction progress of Pd-LCP with a catalyst loading of 
3 mol % and with K2CO3 as base (Table 1, entry 1) is depicted in Figure 5.  
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Table 1: Comparison of the catalytic efficiencies of PdNP-containing LCPs with different bases, Pd 
concentrations and swelling approaches on the model Suzuki-Miyaura reaction of 5-iodo-2’-
deoxyuridine (94) and phenylboronic acid (95). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Conditions: Reactions were carried out in special, home built metal holders at room temperature in 
miliQ H2O with 2 eq of base and 2 eq of phenyl boronic acid (95). aDetermined by 1H-NMR. The NMR 
shows the shift of H1 (blue) and H2 (red) when transformed from starting material to product. b % w/w of 
lipid content. c Reaction carried out with Pd-LCP containing 1 mol % Pd. dControl experiment: Aqueous 
phase was separated from PdNP-containing LCP and controlled for catalytic activity by 1H-NMR. 
  
NH
O
ON
O
HO
HO
I
B(OH)2 NH
O
ON
O
HO
HO
Pd mesophase 
3 mol % Pd
H2O
Base (2 eq.)H2
H1 H1
H2
H1 of 94
H1 of  96
H2 of  96
H2 of  94
94 95 96
Entry Swelling agent Base Time [h] Conv.a [%] 
1 Cholesterol, 4 %b K2CO3 24 95 
2 Cholesterol, 8 %b K2CO3 19 97 
3 Cholesterol, 4 %b KOH 24 98 
4 Cholesterol, 4 %b Et3N 72 84 
5 Cholesterol, 4 %c K2CO3 48 95 
6 PEG 4000 K2CO3 32 87 
7 - K2CO3 24 3 
8d - K2CO3 24 0 
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Figure 5: Left: Progress of the Suzuki-Miyaura cross coupling reaction of phenyl boronic acid (95) with 
5-iodo-2’-deoxyuridine (94) in Pd-LCP with 3 mol % Pd. Right: Recycling efficiency of PdNP-containing 
LCPs. Conditions: Reactions were carried out in special, home built metal holders at room temperature 
in miliQ H2O with 2 eq. of base and phenyl boronic acid (95). Conversions determined by 1H-NMR. 
 
Overall, the best results were obtained when K2CO3 was used as base with 3 mol % 
palladium (Table 1, entry 1). Therefore, this system was used for further investigations such 
as lowering Pd concentration (Table 1, entry 5), PEG-swelling and recycling of Pd-LCPs. 
K2CO3 is a weaker base compared KOH and nearly as efficient. Weaker bases are preferred 
due to the better tolerance towards LCPs (e.g. due to hydrolysis of ester group of monoolein). 
To prove that the reaction takes place in the aqueous compartment of the LCP rather than in 
the aqueous overlay, the aqueous phase was checked for its catalytic activity by 1H-NMR. 
However, no product was observed, indicating that PdNPs remain in the mesophase. ICP-MS 
analyses supported this finding. Only low Pd-concetrations of 75.2 ng/mL (less than 0.05 % of 
total Pd) were found in the aqueous phases. 
In principle, PdNP-containing LCPs can easily be reused by just removing the crude product 
and by decanting the aqueous phase. After rinsing with water, a new substrate solution can 
be added to the LCP as an overlay. However, only two cycles could be achieved without 
significant loss of activity. The conversion drops slightly in the second cycle from 95 % to 
88 % conversion and then drops dramatically to 12 % conversion during the third cycle. This 
is not consistent with comparable, previous reports on in-meso enzymatic and organocatlaytic 
reactions that are recyclable multiple times.39,40 The assembly of PdNPs to bigger aggregates 
might be a reason for the loss of activity. A second reason might be the physical sinking of the 
PdNPs towards the bottom of the sample. The observation that the upper part of Pd-LCPs 
turn colorless after two weeks of storage in some cases, supports this hypothesis. 
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In the initial studies only one substrate pair (phenyl boronic acid (95) with 5-iodo-2’-
deoxyuridine (94) was used. To enlarge the substrate scope of our system, several halogen 
derivatives were tested, coupling them with phenylboronic acid. The coupling of 4-iodo-
benzoeic acid (98) and phenyl boronic acid (3) delivered the product in traces (Table 2, entry 
1). However, the substrates in combination with the products dissolve the LCP, which made 
completion of the reaction impossible. Bisphospho 5-iodo-2’-deoxyuridine (100) is much more 
hydrophilic than 5-iodo-2’-deoxyuridine (94) but leads to similar results (Table 2, entry 2). 
Adding Boc-4-iodo-L-phenylanaline (102) to the Pd-LCP destroyed the latter, and no product 
was detected (Table 2, entry 3). A stable Pd-LCP was observed upon adding 5-bromo-2’-
deoxyuridine (104) and phenylboronic acid, but also here no product was detected (Table 1, 
entry 4). To sum up, the substrate scope of Pd-LCPs is so far limited to deoxyuridine 
derivatives. Other nucleoside derivatives and small peptides are potential candidates to 
enlarge the scope. 
 
Table 2: Attempts to enlarge the substrate scope for Suzuki-Miyaura cross coupling reaction catalyzed 
by Pd-LCPs by testing different halogen-aryls. 
Entry 
Halogen- 
derivatives 
Suzuki- product Outcome 
1 
  
Traces of product detecteda, LCP is 
destroyed 
2 
  
91 % conversion after 24 hb 
3 
  
No product formed, LCP is destroyed 
already at low concentrations  
4 
  
No product formed, LCP remains 
stable 
Conditions: Reactions were carried out in special, home built metal holders (see experimental part) at 
room temperature in miliQ H2O with 2 eq. of base and 2 eq. of phenyl boronic acid (95). a Determined 
by ESI-MS. b Determined by 1H-NMR. 
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4.2.4 Preparation and characterization of PdNP/lipid nanoparticles  
 
Since PdNPs need to be grown in bulk LCP, only a top down approach for the formation of 
lipidic dispersions can be applied. Attempts to synthesize PdNPs in cubosomes after their 
preparation failed. MO- and PT-based LCPs have been prepared and their aqueous channels 
were swollen using cholesterol or 1,2-distearoyl-sn-glycero-3-phospho-rac-(1-glycerol) 
(DGPG). Interestingly, by varying lipid composition, different Pd/lipidic hybrid nanoparticles 
can be obtained (Table 3).  
 
Table 3: Formation of various Pd/lipidic hybrid nanoparticles as a function of lipid composition and their 
catalytic performance in the model reaction of 5-iodo-2’-deoxyuridine (94) and phenylboronic acid (95). 
(Cf. Table 1). 
 
 
 
 
 
Conditions: Reactions were carried out in special, home built metal holders (see experimental part) at 
40°C with 2 eq. of base and 2 eq. of phenyl boronic acid (95), and stopped after 72 h. a Determined by 
SAXS. b Determined by 1H-NMR after 24 h. c Cubosomes underwent phase transition to hexosomes 
during the reaction dSubstrate concentration: 1.1 mM (5-iodo-2’-deoxyuridine), Pd loading: 12 mol %. e 
Control experiment: Aqueous phase was separated from the lipid dispersion and controlled for catalytic 
activity by 1H-NMR. 
 
Dispersion of monoolein/cholesterol LCP, which form cubosomes in the absence of Pd,39 led 
to liposomes (Figure 6A), probably due to interactions of the double bond of MO with PdNPs. 
These samples did not scatter when analyzed by SAXS, but the liposomal structure can be 
detected by TEM (Figure 6A). The Pd-liposomes are catalytically active and recyclable 
(3 cycles, Figure 7). The dispersion of phytantriol/cholesterol LCP led to hexosomes which 
are catalytically active (slightly less than liposomes, Table 2, entry 2). Cubosomes could be 
obtained upon dispersion of PT/DGPG LCPs (Figure 6B and 6C). Interestingly, a phase 
transition from the cubic Pn3m to HII occurred (Figure 6C) when applied to Suzuki-Miyaura 
cross coupling reaction of phenyl boronic acid (95) with 5-iodo-2’-deoxyuridine (94) using our 
standard substrate concentrations (4.3 mM) (Table 2, entry 3). SAXS spectra of the resulting 
hexosomes were acquired at 22 °C, 40 °C, 50 °C and 60 °C, proving their stability up to 
50-°C, while the lattice parameter shifts to higher q values. The sample loses its structure at 
60 °C (Figure 6D). The cubic structure could only be retained if the substrate concentration (5-
iodo-deoxyuridine) was substantially reduced from 4.3 to 1.1 mM. 
Entry Lipid Additive Nanoparticlea Conversion [%]b 
1 MO Cholesterol Liposomes 68 
2 PT Cholesterol Hexosomes 51 
3 PT DGPG Cubosomesc 35  
4 PT DGPG Cubosomesd 54 
5 -  -e - 
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Figure 6: A) TEM micrograph of Pd-liposomes B) TEM micrograph of Pd-cubosomes C) SAXS pattern 
of Pd-cubosomes before and after reaction at 40 °C D) SAXS pattern of Pd-hexosomes at 22 °C, 40 
°C, 50 °C and 60 °C, where the sample starts to lose its hexagonal structure. 
 
 
4.2.5 Catalysis of Suzuki-Miyaura cross coupling reactions with PdNP/lipid 
hybrid-nanoparticles 
 
The catalytic activity of Pd-liposomes, Pd-hexosomes and Pd-cubosomes hybrid-
nanoparticles were compared using the model coupling reaction 5-iodo-2’-deoxyuridine (94) 
and phenylboronic acid (95). In contrast to bulk Pd-LCPs, which are catalytically active at 
ambient temperatures, the lipid dispersions require elevated temperatures (40 °C) to 
transform the substrates to the products. Pd-liposomes (Table 3, entry 1), exhibited the best 
catalytic activity after 48 h, whereby 68 % of the starting material was converted to the 
product (and 87 % after 78 h, see Figure 4). Using Pd-hexosomes, 51 % of 5-iodo-2’-
deoxyuridine (94) was consumed (Table 3, entry 2). The lowest catalytic activity was 
observed with Pd-cubosomes, only 35 % of 5-iodo-2’-deoxyuridine (94) were transformed to 
A B
DC
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the product after 48 h (Table 3, entry 3). These cubosomes underwent phase transitions, 
resulting in hexosomes when applied to the Suzuki-Miyaura coupling of 5-iodo-2’-
deoxyuridine (94) and phenylboronic acid (95). This problem could only be circumvented by 
reducing the substrate concentration to ca. 25 % of the usual concentration (from 4.3 to 1.1 
mM). Since the cubosomes including Pd concentration were kept constant, this led to an 
increase of Pd to 12 mol % relative to the substrates 5-iodo-2’-deoxyuridine (95). After 72 h, 
54 % of the substrate was transformed to the product (Table 3, entry 4). We proposed that 
this problem could be solved if a more hydrophilic substrate was used. To this end, 
bisphospo-5-iodo-2’-deoxyuridine (100) was synthesized (see 4.2.6). However, phase 
transitions to HII was still observed when 100 was applied as a substrate. 
 
To control if the PdNPs remain inside the lipidic particles, the catalytic activity of the aqueous 
phase was investigated by adding the substrates 5-iodo-2’-deoxyuridine (94) and 
phenylboronic acid (95) (including K2CO3). No product was formed after 24 h or after 48 h. 
ICP-MS analysis of the aqueous phase revealed that the Pd-concentration was 5.2 ng/mL, 
which corresponds to 0.00325 % of total Pd in the system. To recycle Pd-dispersions, the lipid 
is separated from the water by filtration, a new stabilizer solution is added, and the sonication 
process is repeated. Pd-liposomes could be recycled, albeit with a certain loss of catalytic 
activity after every cycle (Figure 7). Whereas in cycle 1 the conversion was 68 %, it dropped 
to 59 % in cycle 2 and finally to 45 % in cycle 3 (Figure 7). In general, the coupling reactions 
catalyzed by Pd/lipid dispersion are slower compared to bulk Pd LCPs and need to be 
performed at 40 °C. Noteworthy, this is the first report on PdNP-containing hexosomes and 
cubosomes.  
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Figure 7: Left: Progress of the Suzuki-Miyaura cross coupling reaction of phenyl boronic acid (95) with 
5-iodo-2’-deoxyuridine (94) using Pd-liposomes with 3 mol % Pd. Right: Recycling efficiency of PdNP-
containing liposomes. Conditions: Reactions were carried at 40 °C with 2 eq. of base and phenyl 
boronic acid (95). Conversions determined by 1H-NMR. 
 
 
4.2.6 Synthesis of bisphospho 5-iodo-2’-deoxyuridine (100) 
 
The initial substrates and the product of the model Suzuki-Miyaura cross coupling reaction are 
water-soluble. However, the product with its phenyl group bears a hydrophobic moiety that is 
introduced in this reaction. During the coupling reaction, an unexpected phase transition from 
the cubic Pn3m to the HII phase was observed. This phase transition might be induced by the 
formation of this hydrophobic compound, which would interfere with the self-assembled 
architecture of the cubosomes. To test this assumption, more hydrophilic substrates are 
required, which were obtained by phosphorylation of 5-iodo-2’-deoxyuridine (94). Two 
different strategies were applied. In a first approach, 5-iodo-2’-deoxyuridine (94) was bis-
phosphitylated using a Fm-phosphor-amidite, and subsequently oxidized with tBuOOH to 
obtain 105. The Fm-protecting group was cleaved in a second step using piperidine 
(Scheme-1). The second approach includes only one step; 5-iodo-2’-deoxyuridine (94) was 
treated with phosphorus oxychloride to obtain bis-phosphorylated 5-iodo-2’-deoxyuridine 
(100). Initially, mono-phosphorylated 5-iodo-2’-deoxyuridine was targeted via phosphitylation 
of the primary alcohol with Fm-P-amidite. However, a non-separable mixture of mono- and 
bis-phosphorylated product was obtained. Since two phosphates are more favorable than 
one, no further attempts towards monophosphorylation have been undertaken. 
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Scheme 1: Diphosphorylation of 5-iodo-2’-deoxyuridine (94) in two steps (upper scheme) using Fm-P-
amidite followed by oxidation and deprotection, or in one step (procedure c) using phosphorus 
oxychloride. Conditions: a) Fm-P-amidite, tetrazole, MeCN, 0°C, tBuOOH. b) DMF/Piperidine 10:1, r.t. 
c) phosphorus oxychloride, water, pyridine, acetonitrile, 0°C. 
 
 
4.2.7 Towards Suzuki-Miyaura cross coupling reactions with lipidic Pd-
complexes immobilized in mesophases 
 
In addition to the previously described approach using PdNP-containing LCPs to catalyze 
Suzuki-Miyaura cross coupling reactions, a lipidic Pd-catalyst was synthesized that can be 
incorporated into the mesophases. Gayakhe et al. and Kapdi et. al. developed water-soluble 
Pd-imidate complexes that enable chemical modification of nucleoside derivatives via Suzuki-
Miyaura cross couplings in water as solvent.41,42 This system served as orientation for the 
design of an LCP-compatible Pd-complex that can be incorporated into LCPs. In the above-
mentioned work, 1,3,5-triaza-7-phosphaadamantane (PTA) served as hydrophilic phosphine 
ligand that, together with imidate ligands assures the water-solubility of the catalyst. Since for 
incorporation into LCPs a catalyst with amphiphilic character is required, a lipidic 
triphenylphosphine ligand 107 was prepared by coupling oleylamine to 4-
(diphenylphosphino)benzoic acid (106) (Scheme 2). Phtalimidate Pd-complex cv was 
obtained upon treatment of Pd(OAc)2 in dimethyl sulfide (SMe2) with phthalimid.43 The desired 
lipidic Pd-complex 110 was synthesized by treating the Pd-precursor 109 with phosphine 
ligand 107 in CH2Cl2 at reflux for 1 h.41 
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Scheme 2: Synthesis of LCP-compatible Pd-complex 110. Conditions: a) Oleyl amine 1.2 eq, 
EDC/DMAP, 0°C, CH2Cl2/DMF. b) Phthalimid (2 eq.), Me2S, r.t. c) 109 1 eq, 107 2 eq, CH2Cl2, reflux. 
 
Lipidic catalyst 110 was incorporated into MO-based LCPs (3 % w/w lipid). The LCP was then 
tested in our model Suzuki-Miyaura cross coupling reaction. The product was formed very 
efficiently after 24 h, and no starting material was left. However, as the control experiments 
revealed that the aqueous phase was also catalytically active, research was focused in the 
PdNP approach. 
 
 
4.3 Conclusion 
 
Puvvada et al, who reported the only PdNP synthesis in LCPs so far, analyzed the 
mesophases after the PdNP synthesis with SAXS, and the PdNPs after lipid removal using 
solvents with TEM.38 By carefully investigating the PdNP synthesis in LCPs, we were able to 
provide additional information on the kinetics of this process by using time resolved SAXS 
analysis, which revealed that the synthesis was completed after 14 h, and induced a phase 
transition of the LCP from the Pn3m to the Ia3d cubic phase. Furthermore, we could confirm 
the formation of aldehyde 97 by means of 1H-NMR, which was proposed based on IR data.38 
In addition to the analysis of isolated PdNPs with TEM, we were able to perform DLS 
measurements on these particles. The Pd LCPs were used to catalyze a model Suzuki-
Miyaura cross coupling reaction. The bulk Pd LCPs need to be activated to enable catalysis. 
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This was achieved by swelling the aqueous channels of the LCPs with a lipidic additive 
(cholesterol or DGPG) or with PEG 4000, thereby providing two different switches to initiate 
the reaction. The model cross coupling substrates were transformed to the product with yields 
as high as 98 % within 24 h, with Pd loading of 3 mol %. Pd-containing liposomes, 
hexosomes and cubosomes could be prepared from bulk LCPs. By carefully combining the 
host lipid MO and PT with cholesterol or DGPG as swelling agent, the desired lipidic 
nanoparticles can be obtained. To the best of our knowledge, PdNP hexosomes and 
cubosomes are novel, and have not yet been reported. Analogous the parent bulk phase, the 
dispersed lipid/Pd hybrid nanoparticles are catalytically active as well. However, they are less 
efficient than bulk Pd LCPs, and thus the reaction needs to be performed at 40 °C.  
 
 
4.4 Outlook 
 
The narrow substrate scope and the limited recycling are weak points of our approach, which 
need to be improved. The recycling might be improved by additional stabilization of the 
PdNPs, using thiols for example.44 The substrate scope can be extended using small peptides 
or different nucleosides and nucleotides. Furthermore, these novel Pd/lipid hybrid 
nanoparticles have potential medical applications. PdNPs have been successfully tested 
against cancer cell lines.34,35 Our Pd cubosomes and hexosomes are thus potential delivery 
vehicles for PdNPs. This would be a very elegant approach, since the PdNPs are in-situ 
synthesized by its drug delivery vehicle. 
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4.5 Experimental section 
 
General Information  
1-Monooleoyl-sn-glycerol C18:1 (monoolein, MO) was purchased from Nu-Chek Prep, Inc. 
(MN, USA), and phytantriol was purchased from DSM. All other reagents and solvents were 
purchased from Sigma Aldrich. All chemicals and solvents were used as received, unless 
otherwise stated. Reactions were carried out under an inert atmosphere of argon in dry 
solvents. Dichloromethane was degassed with argon and purified by passage through 
activated alumina solvent column (MC Brown solvent system) prior to use. Column 
chromatography was performed using silica gel Merck 60 (particle size 0.040–0.063 mm). 
Analytical thin- layer chromatography (TLC) was performed using Merck pre-coated silica gel 
plates 60 F254; visualization by UV absorption and/or by dipping in a solution of KMnO4 (1 g), 
K2CO3 (2 g) in H2O (100 mL) and subsequent heating. 1H-NMR spectra were recorded on a 
Bruker AV2-500 (500MHz) spectrometer. Chemical shifts are given in parts per million (ppm) 
relative to the internal standard TMS (δ = 0 ppm). Coupling constants J are expressed in Hz 
and multiplicities are abbreviated as follows: s (singlet), br (broad), d (doublet), t (triplet), q 
(quadruplet), quint (quintet), m (multiplet). 13C-NMR chemical shifts are reported relative to the 
solvent residual peaks: CDCl3 = 77.00 ppm. Mass spectra were recorded by the Mass 
Spectroscopy Service of UZH on Finnigan MAT95 MS, BrukerLC MS and Finnigan TSQ700 
MS machines. 
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4.5.1 Dynamic Light Scattering (DLS) 
 
Particle size of the cubosomes was performed after preparation, before the reaction was 
started, and after the reaction was terminated (1-2 d) with a Zeta Sizer Nano ZS (Malvern 
Instruments, Malvern, UK) at 25 ± 0.1 °C. The samples were measured in disposable 
polystyrene cuvettes of 1 cm optical path length with the corresponding buffer as solvent. 
Scattering angle was 90°. A triplicate of the samples was performed. The width of the DLS 
hydrodynamic diameter distribution is indicated by PDI (polydispersion index). The intensity 
size distribution of the cubosomes was typically unimodal; therefore the autocorrelation 
function was analyzed according to the cumulant method.  
 
Table 4: DLS data before and after the aldol reaction. 
Particles SAXS Size (nm) PDI 
Liposomes - 226 ± 11 0.272 
Hexosomes HII 176 ± 5 0.237 
Cubosomes Pn3m  210 ± 9 0.190 
 
 
4.5.2 Small angle X-ray scattering (SAXS)  
 
SAXS measurements were used to identify the symmetry of the catalytic LCPs and 
cubosomes and the fully hydration line of the catalytic LCPs. Experiments were performed on 
a Bruker AXS Micro, with a microfocused X-ray source, operating at voltage filament current 
of 50 kV and 1.000 µA, respectively. The Cu Kα radiation (λCu Kα =1.5418 Å) was collimated 
by a 2D Pilatus 100K detector. The scattering vector q = (4π/λ)sinθ, with 2θ being the 
scattering angle, was calibrated using silver behenate. Data were collected and azimuthally 
averaged using the Saxsgui software to yield one-dimensional intensity versus scattering 
vector q, with a q range from 0.004 – 0.5 Å-1. For all bulk measurements, the samples were 
placed inside a stainless-steel cell between two thin replaceable mica sheets and sealed by 
an O-ring, with a sample volume of 10 µL and a thickness of ~1 mm. Measurements were 
performed at 23°C, and samples were equilibrated for 15 min before measurements, whereas 
scattered intensity was collected over 30 min. For the cubosomes samples, the sample-to-
detector distance was 1 m, providing a q range from 0.005 to 0.77 Å-1. Samples were loaded 
into a quartz glass capillary (Hiligenberg, length: 80 mm; outside: 2.0 mm; wall thickness: 0.01 
mm). Measurements were performed at 23 °C, and samples were equilibrated for 10 min prior 
to measurements, while scattered intensity was collected over 4 hours.  
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Mesophase identification and calculation of the aqueous channels 
Mesophases were identified by their specific Bragg peak positions. For the double diamond 
cubic phase (Pn3m) the relative positions in q of the Bragg reflections are at 
√2:√3:√4:√6:√8:√9…, whereas for the primitive cubic phase (Im3m)  the Bragg peaks are at q 
= √2:√4:√6:√8:√10:√12:√14:√16:√18… The mean lattice parameter, a, was deduced from the 
corresponding set of observed interplanar distances, d (d = 2π/q), using the appropriate 
scattering law for the phase structure. For cubic phases:  
 ; = @ ℎB + CB + DB	                                 (1) 
 
By knowing from SAXS measurements the geometry and the lattice parameter a, and 
knowing the lipid volume fraction of the sample ϕ, the length of the lipid tail, l, can be 
calculated by solving the following cubic equation45:  
 Φ = 2$% &'()* + ,- ./ &'()* -                     (2) 
 
where $% is the area of the surface in the unit cell in which the lattice parameter is equal to 
unity, and / is the Euler-Poincare characteristic. Depending on the specific cubic phase they 
have the following values: $% = 3.091	and / = −8 for Ia3d; $% = 1.919	and / = −2 for Pn3m; 
and $% = 2.345	and / = −4	for Im3m. For the radius of the aqueous channels, r the following 
equations are valid for the Ia3d, Pn3m and Im3m phases, respectively46: 
 : = 0.248; − <=>?                       (3a) : = 0.391; − <=>?                       (3b) : = 0.3055; − <=>?                     (3c) 
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Figure 8: Pn3m SAXS pattern of fully hydrated Pd LCP with 47 % w/w water (10 mM K2CO3), 4 % 
cholesterol of the lipid content at 23°C.  
 
 
4.5.3 General procedures for PdNP-mesophases synthesis 
 
MO and PT LCPs 
MO or PT (60 mg) was weight into an eppendorf tube and molten with a heating gun (40°C). 
The lipid was subsequently hydrated by adding appropriate volumes of a solution of K2PdCl4 
(20 mM) and K2CO3 (10 mM) in miliQ H2O (50 µL). To obtain homogeneous palladium particle 
containing LCPs, samples were centrifuged in an eppendorf 5415 R centrifuge for at least 1 h 
at 23 °C at 13’000 rpm. Samples were stored and left to equilibrate for at least 48 h in tightly 
closed eppendorf tubes. The color of the LCP changes during this time from brown to black. 
In order to swell the LCP, a suspension of cholesterol (2.5 mg or 1.25 mg) in 10 mM aqueous 
K2CO3 solution (50 µL) was added, stirred with a needle and centrifuged again in an 
eppendorf 5415 R centrifuge for at least 1 h at 23 °C at 13’000 rpm. Samples were finally 
stored and left to equilibrate for at least 5 days in tightly closed eppendorf tubes in the dark. 
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PT cubosomes 
Cubosomes were prepared using a top down approach; after production of bulk PT LCP, a 
swelling agent (1,2-distearoyl-sn-glycero-3-phospho-rac-(1-glycerol) sodium salt) was added 
and the sample was dispersed in a stabilizer solution (PF-127) by ultra sonication. PT (60 mg) 
was weight into a eppendorf tube and the lipid was subsequently hydrated by adding 
appropriate volumes of a solution of K2PdCl4 (20 mM) in miliQ H2O (50 µL). To obtain 
homogeneous palladium particle containing LCPs, the samples were centrifuged in an 
eppendorf 5415 R centrifuge for 1 h at 23 °C at 13’000 rpm. Samples were stored and left to 
equilibrate for 48 h in tightly closed eppendorf tubes. The color of the LCP changes during this 
time from brown to black. In order to swell the LCP, a suspension of 1,2-distearoyl-sn-glycero-
3-phospho-rac-(1-glycerol) sodium salt (2.0 mg) in miliQ H2O (50 µL) was added, stirred with 
a needle and centrifuged again in an eppendorf 5415 R centrifuge for at least 1 h at 23 °C at 
13’000 rpm. After the sample was stirred and centrifuged a second time, they were finally 
stored and left to equilibrate for at least 5 days in tightly closed eppendorf tubes in the dark. 
The lipidic mixture was subsequently hydrated by adding appropriate volumes of stabilizer 
containing buffer (PF-127, 1% w/w) to obtain the cubosome sample with the desired lipid 
concentration. The sample was vortex-mixed and then dispersed using an ultrasonic 
processor Brenson digital 250 (cycle 0.9 s on/ 0.9 s off, amplitude 50%, for 3 x 5 min). 
Subsequently, the cubosome dispersion was filtered through Acrodisc 450 nm filters.  
 
 
PT hexosomes 
Hexosomes were prepared using a top down approach; after production of bulk LCP, a 
swelling agent (cholesterol) was added. The sample was dispersed in a stabilizer solution 
(PF-127) by ultra sonication. PT (60 mg) was weight into a eppendorf tube and the lipid was 
subsequently hydrated by adding appropriate volumes of a solution of K2PdCl4 (20 mM) in 
miliQ H2O (50 µL). To obtain homogeneous palladium particle containing LCPs, the samples 
were centrifuged in an eppendorf 5415 R centrifuge for 1 h at 23 °C at 13’000 rpm. The 
samples were stored and left to equilibrate for 48 h in tightly closed eppendorf tubes. The 
color of the LCP changes during this time from brown to black. In order to swell the LCP, a 
suspension of cholesterol (5.0 mg) in miliQ H2O (50 µL) was added, stirred with a needle and 
centrifuged again in an eppendorf 5415 R centrifuge for at least 1 h at 23 °C at 13’000 rpm. 
After the sample was stirred and centrifuged a second time, they were finally stored and left to 
equilibrate for at least 5 days in tightly closed eppendorf tubes in the dark. The lipidic mixture 
was subsequently hydrated by adding appropriate volumes of stabilizer containing buffer (PF-
127, 1% w/w) to obtain the hexosome sample with the desired lipid concentration. The sample 
was vortex-mixed and then dispersed using an ultrasonic processor Brenson digital 250 (cycle 
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0.9 s on/ 0.9 s off, amplitude 50%, for 3 x 5 min). Subsequently, the hexosome dispersion was 
filtered through Acrodisc 450 nm filters. 
 
 
MO liposomes 
MO (60 mg) was weight into an eppendorf tube and molten with a heating gun (40°C). The 
lipid was subsequently hydrated by adding appropriate volumes of a solution of K2PdCl4 (20 
mM) and K2CO3 (10 mM) in miliQ H2O (50 µL). To obtain homogeneous palladium particle 
containing LCPs, samples were centrifuged in an eppendorf 5415 R centrifuge for at least 1 h 
at 23 °C at 13’000 rpm. Samples were stored and left to equilibrate for at least 48 h in tightly 
closed eppendorf tubes. The color of the LCP changes during this time from brown to black. 
In order to swell the LCP, a suspension of cholesterol (5.0 mg or 2.5 mg) in 10 mM aqueous 
K2CO3 solution (50 µL) was added, stirred with a needle and centrifuged again in an 
eppendorf 5415 R centrifuge for at least 1 h at 23 °C at 13’000 rpm. Samples were finally 
stored and left to equilibrate for at least 5 days in tightly closed eppendorf tubes in the dark. 
The lipidic mixture was subsequently hydrated by adding appropriate volumes of stabilizer 
containing buffer (PF-127, 1% w/w or PF-108, 1.65 mg / mL) to obtain the liposome sample 
with the desired lipid concentration. The sample was vortex-mixed and then dispersed using 
an ultrasonic processor Brenson digital 250 (cycle 0.9 s on/ 0.9 s off, amplitude 50%, for 3 x 5 
min). Subsequently, the liposome dispersion was filtered through Acrodisc 450 nm filters.  
 
 
4.5.4 General procedures for the Suzuki-Miyaura couplings in LCP 
 
Previously prepared LCP (containing PdNPs, prepared as described above) was added on 
homemade metal holders and the plastic container for the aqueous phase was attached. 
Subsequently, a solution of the desired aryl halide (2 mL, 4.3 mM, 1 eq) and phenyl boronic 
acid (8.6 mM, 2eq) in 2 mL miliQ H2O was carefully poured on top of the catalytic LCP. The 
set-up was gently shaken on a laboratory shaker. The reaction was monitored by 1H-NMR. 
After completion of the reaction, the aqueous phase was removed and the LCP rinsed with 
2-mL of miliQ H2O. The aqueous phases were extracted with EtOAc (5 x 3 mL). The 
combined organic phases were washed with brine and dried over MgSO4. The solvent was 
removed and the crude product was purified by column chromatography (silica gel, 
cyclohexane/EtOAc) to obtain the pure Suzuki-Miyaura product. 
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4.5.5 General procedures for the Suzuki-Miyaura couplings in cubosomes, 
hexosomes and liposomes  
 
The halogen derivative (3 mg, 0.0085 mmol, 1 eq) and phenyl boronic acid (2.1 mg, 0.017 
mmol, 2 eq) were added to previously prepared lipidic nanoparticles (containing PdNPs, 
prepared as described above) and the reaction mixture was stirred at 40 °C. The reaction was 
monitored by 1H-NMR. After completion of the reaction, the lipidic nanoparticles were 
separated from the aqueous phase by centrifugation with vivacon 500 filter. The lipidic part 
was rinsed with 2 mL miliQ H2O. The aqueous phases were extracted with EtOAc (5 x 3 mL). 
The combined organic phases were washed with brine and dried over MgSO4. The solvent 
was removed and the crude product was purified by column chromatography (silica gel, 
cyclohexane/EtOAc) to obtain the Suzuki-Miyaura products. 
 
 
Synthesis of 96 (1-((2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-
phenylpyrimidine-2,4(1H,3H)-dione) 
 
 
 
Synthesized using PdNP-containing LCPs and lipid/Pd hybrid nanoparticles. 
1H NMR (500 MHz, DMSO-d6) δ 11.51 (s, 1H), 8.20 (s, 1H), 7.81 – 7.76 (m, 3H), 7.55 (d, J = 
7.4 Hz, 3H), 7.34 (ddq, J = 29.0, 14.5, 7.3 Hz, 9H), 6.24 (t, J = 6.6 Hz, 1H), 5.26 (d, J = 3.8 
Hz, 2H), 5.12 (t, J = 4.4 Hz, 2H), 3.82 (d, J = 3.1 Hz, 1H), 3.66 – 3.55 (m, 4H), 2.28 – 2.12 (m, 
4H). 13C NMR (126 MHz, DMSO-d6) δ 162.09, 149.92, 138.01, 134.07, 130.02, 128.12 (2C), 
127.90 (2C), 127.36 (2C), 113.46, 87.50, 84.47, 70.24, 60.98. HRMS (ESI [M + Na]+) m/z: 
calcd for (C15H16O5N2Na) 327.09514, found 327.09503. 
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4.5.6 Synthesis of Suzuki-Miyaura substrates 
 
Synthesis of 105 (Fm-protected bisphosphorylated iodo-deoxyuridine) modified from47 
 
 
 
Fm-phosphoramidite (266 mg, 0.510 mmol, 2.6 eq) was coevaporated with MeCN (3 x 1 mL). 
Pentafluorophenol (380 mg, 2 mmol, 5 eq.) in MeCN (3 mL) were added and the mixture 
stirred at room temperature for one hour. The activation was checked by 31P-NMR. 
Subsequently, the solvent was removed and a solution of 5-iodo-2’-deoxyuridine (95) (71 mg 
0.2 mmol, 1 eq) in MeCN (3 mL) was added and the reaction stirred overnight at room 
temperature. As soon as the starting material was consumed, the reaction mixture was cooled 
in an ice/water bath and mCPBA (70 %, 65 mg, 0.510 mmol, 1.3 eq.) was added. The crude 
product was purified by column chromatography (cyclohexane/EtOAc) to obtain the desired 
product as a yellow oil (148 mg, 0.122 mmol, 61 %). 1H NMR (500 MHz, Chloroform-d) δ 8.60 
(s, 1H), 8.06 – 7.98 (m, 1H), 7.61 (m, 7.68 – 7.56, 8H), 7.48 – 7.02 (m, 24H), 5.88 (dd, J = 
8.5, 5.6 Hz, 1H), 4.45 (t, J = 6.2 Hz, 1H), 4.30 – 4.11 (m, 10H), 4.04 – 3.94 (m, 4H), 3.76 (s, 
1H), 3.67 – 3.47 (m, 2H). 13C NMR (126 MHz, Chloroform-d) δ 171.21, 159.53 (2C), 149.27, 
145.33, 143.69, 142.86 – 142.54 (m, 8C), 141.69 – 141.21 (m, 8C), 129.44, 129.37, 127.97 
(2C), 127.31 – 126.99 (m, 8C), 124.97 (m, 8C), 124.90 – 124.77 (m, 8C), 120.28 – 119.84 (m, 
8C), 116.46, 116.28, 86.02, 84.85, 83.21, 69.27, 68.84, 68.26, 66.04, 61.57, 60.42, 47.97 – 
47.61 (m, 4C), 21.06, 14.19. 31P NMR {1H} (203 MHz, Chloroform-d) δ -1.46, -2.78. 31P NMR 
(203 MHz, Chloroform-d) δ -1.46, -2.78 (q, J = 5.3 Hz). HRMS (ESI [M + H]+) m/z: calcd for 
(C65H54O11N2IP2) 1227.22420, found 1227.22592. 
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Synthesis of 100 (Diphosphorylated iodo-deoxyuridine) 
 
 
 
Method A 
Fm-protected 5-iodo-2’-deoxyuridine bis-phosphate 105 (148 mg, 0.122 mmol) was dissolved 
in 5 mL of a mixture of DMF/piperidine (5:1) and stirred overnight. The solvent and excess 
piperidine was was removed at high vacuum to obtain the product as piperidine salt in 
quantitative yield. 
Method B, modified procedure from Sowa et al.48 
A mixture of phosphoroxy chloride (675 mg, 4.4 mmol, 4.4 eq.), water (500 mg, 2.8 mmol, 
1.4-eq), pyridine (380 mg, 4.8 mmol, 4.8 eq) was cooled to 0°C and 5-iodo-2’-deoxyuridine 
(360 mg, 1.0 mmol, 1 eq) was added. The mixture was stirred for 4 h at 0 °C whereupon the 
reaction mixture was quenched with cold water and stirred for 1 h. The pH was adjusted to 9 
with aq. NaOH (0.1 M) and the solvent was removed. The desired product was obtained as 
white solid (408 mg, 0.71 mmol, 71 %). 
1H NMR (400 MHz, Deuterium Oxide) δ 8.20 (s, 1H), 7.84 (s, 1H), 6.25 – 6.14 (m, 1H), 4.60 
(s, 1H), 4.19 (s, 1H), 4.05 (d, J = 4.1 Hz, 1H), 3.94 – 3.68 (m, 1H), 2.52 – 2.20 (m, 2H). 13C 
NMR (126 MHz, DMSO-d6) δ 160.92, 150.58, 145.09, 85.02, 73.87, 70.39, 49.05. 31P NMR 
{1H} (162 MHz, Deuterium Oxide) δ 3.52, 3.02. 31P NMR (162 MHz, Deuterium Oxide) δ 3.51, 
3.02 (d, J = 7.6 Hz). HRMS (ESI [M + H]+) m/z: calcd for (C9H12O11N2IP2) 512.89665, found 
512.89680. 
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4.5.7 Synthesis of lipidic Pd Complex 
 
Synthesis of 107 ((Z)-4-(diphenylphosphino)-N-(octadec-9-en-1-yl)benzamide) 
 
 
 
To a stirred solution of 4-(diphenylphosphino)benzoic acid (106) (710 mg mg, 2.32 mmol, 
1-eq) in 50 mL of a mixture of dry CH2Cl2 and dry DMF (1:1) was added EDC (466 mg mg, 
3.00 mmol, 1.3 eq) and DMAP (28 mg, 0.232 mmol, 0.1 eq) at 0 °C under an inert 
atmosphere. The solution was stirred for 1 h at 0 °C and then the oleylamine amine (930 mg, 
3.48 mmol, 1.5 eq.) was added dropwise over a period of 10 min. The reaction mixture was 
stirred for 14 h at room temperature and then CH2Cl2 (50 mL) was added, the mixture was 
washed with a saturated solution of NaHCO3. The organic phase was separated and the 
aqueous phase was extracted with CH2Cl2 (50 mL). The combined organic phases were 
washed with brine and dried over MgSO4. The solvent was removed and the crude product 
was purified by column chromatography. After evaporated the solvent, the desired product 
was obtained as slightly yellow oil (1.01 g, 1.81 mmol, 78 %). 1H NMR (400 MHz, Chloroform-
d) δ 7.61 (d, J = 8.0 Hz, 2H), 7.32 – 7.20 (m, 12H), 6.06 (s, 1H), 3.36 (q, J = 6.7 Hz, 2H), 1.51 
(q, J = 7.1 Hz, 2H), 1.33 – 1.11 (m, 30H), 0.80 (t, J = 6.7 Hz, 3H). 13C NMR (126 MHz, 
Chloroform-d) δ 167.15, 141.70, 136.36, 136.28, 134.87, 133.91 (2C), 133.75 (2C), 133.60, 
133.45, 129.03 (2C), 128.65 (2C), 128.59, 126.74, 126.66, 31.91, 29.68 (5C), 29.65 (5C), 
29.58, 29.54, 29.35, 26.99, 22.68, 14.11. 31P {1H} NMR (203 MHz, Chloroform-d) δ -5.60. 31P 
NMR (203 MHz, Chloroform-d) δ -5.40 – -5.80 (m). HRMS (ESI [M + H]+) m/z: calcd for 
(C37H53ONP) 558.38593, found 558.38604. 
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Synthesis of 109 (trans-[Pd(Succinimidate)2(DMSO)2])43 
 
 
 
To a mixture of SMe2 (20 mL) and Pd(OAc)2 (0.5 g, 2.23 mmol, 1 eq), phthalimide (0.66 g, 
4.46 mmol, 2 eq) was added and stirred at room temperature. The resulting yellow 
suspension was filtered and the precipitate washed with a mixture of MeOH and Et2O. After 
drying at high vacuum, Pd-complex 109 was obtained (0.74 g, 1.36 mmol, 61 %). 
Analytical data were identical with the values reported in literature.43 
 
 
Synthesis of 11041 
 
 
 
Pd-complex 109 (74 mg, 0.136 mmol, 1 eq) was dissolved in CH2Cl2 (10 mL) and phosphine 
ligand 107 (152 mg, 0.272 mmol, 2 eq) was added. The reaction mixture was then refluxed for 
1 h, the solvent removed under vacuum and the resulting crude product washed with Et2O (3 
x 5 mL) and dried at high vacuum to obtain the Pd-complex 110 (76 mg, 0.052 mmol 38 %). 
1H NMR (400 MHz, Benzene-d6) δ 8.36 – 8.28 (m, 4H), 8.14 (q, J = 5.8 Hz, 10H), 7.75 (d, J = 
7.6 Hz, 4H), 7.09 (t, J = 7.5 Hz, 10H), 7.02 – 6.95 (m, 8H), 5.79 – 5.64 (m, 4H), 3.43 (q, J = 
7.0 Hz, 4H), 2.30 (p, J = 8.9, 7.4 Hz, 4H), 1.68 – 1.35 (m, 54H), 1.14 – 0.99 (m, 6H). 
31P-NMR-{1H} (162 MHz, Benzene-d6) δ 32.74. ESI-MS (ESI [M + H]+) m/z: 1509.68824 
(C90H109O6N4P2Pd). 
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4.5.8 Inductively coupled plasma mass spectrometry (ICP MS) 
 
ICP-MS measurements were performed with an Agilent QQQ 8800 Triple quad ICP-MS 
spectrometer, equipped with a standard x-lens setting, nickel cones and a “micro-mist” quartz 
nebulizer.  
All solutions were prepared from 60% HNO3 (Merck 1.1518.1000 ultrapur) and 18.2 MΩ 
Millipore water. Palladium was measured against a serial dilutions of single element standard 
(Palladium: Merck 1.70339.0100	 2%	 HNO3). Antimony (100 ppb in 2% HNO3) was used as 
internal standard. 
Tune settings were based on the Agilent General Purpose method and only slightly modified 
by an autotune procedure using an Agilent 1 ppb tuning solution containing Li, Y, Ce and Tl.  
Palladium was determined as m/z 105 Pd+ in a “no gas” mode, where the instrument is set to 
a single quadrupole setting. 
The feed was 0.1 ml/min, the RF power 1550 W. Values are reported as the average of 10 
sweeps x 3 replicates. 
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5 Chapter 5 
 
Enzyme immobilization in lipidic mesophases by ionic interactions and lipidic 
modification 
 
 
 
 
 
 
 
 
 
 
  
5.1 Introduction 
 
Enzymes are versatile and sophisiticated catalysts that perform chemical reactions with high 
substrate specificity and stereoselectivity under benign conditions. Thus, enzymes find 
applications in research laboratories as well as in industry. Immobilizing enzymes facilitates 
their recovery and enables efficient recycling. Additionally, immobilization often increases the 
stability and prevents hydrophobic enzymes from aggregation.1 In general, potential 
immobilization platforms should have a large surface area. This can be achieved by using 
porous materials or small particles. The most common immobilization approaches use one of 
the following approaches:1 
 
• Noncovalent adsorption such as van der Waals interaction or hydrogen bonding 
• Ionic interactions via deprotonated carboxylic acids or protonated lysins 
• Covalent fixation using activated linkers 
• Cross-linking of enzymes 
• Entrapment in capsules 
 
LCPs show a plethora of properties that render these materials suitable as immobilization 
matrices for enzymes. The large surface area of ca. 400 m2 g-1 lipid2 between the well-defined 
aqueous channels and the lipidic bilayer in these structures promises efficient catalysis. The 
feasibility of doping LCPs with tailored additives enables a broad variety of potential anchoring 
approaches. Furthermore, the diameter of the aqueous channels can be modified, which 
allows tuning of the enzyme kinetics, not only before but even while catalysis is ongoing. Sun 
et al., for example, used LCPs to encapsulate horseradish peroxidase (HRP) and investigated 
enzyme kinetics in LCPs with different aqueous channel diameters. They could show that 
HRP encapsulated in swollen LCPs can achieve up to 92.1 % of its native activity.3 In another 
study, the same group showed that not only the diameter of the aqueous channels is an 
important parameter for efficient enzyme catalysis, but also the topology of the mesophases.4 
In this work, HRP was encapsulated and thus immobilized in LCPs to some extent. However, 
HRP was not fixed to the lipidic bilayer and could diffuse to an excess water reservoir, if 
present. We plan to circumvent this issue by fixing enzymes permanently to the lipidic bilayer 
of the mesophases. Two different approaches with two different enzymes have been applied. 
The first is deoxyribose-5-phosphate aldolase (DERA, EC 4.1.2.4, 259 amino acids, 27.7 
kDa)5, which reversibly transforms D-glyceraldehyde 3-phosphate and acetaldehyde to 2-
deoxyribose 5-phosphate.6 DERA is an unusual aldolase, being the only one known to 
condense two aldehydes, as opposed to other aldolases that have a ketone and an aldehyde 
as substrates.7 DERA has been used as a catalyst for asymmetric aldol condensation of a 
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broad range of aliphatic aldehydes.7,8 It possesses several solvent-exposed lysins, whose 
amino groups are protonated at physiological pH, and are therefore positively charged. By 
using an additive that bears a negative charge, DERA can be bound to the LCP based on 
ionic interactions.  
The second enzyme, tobacco etch virus (TEV) protease has been chemically modified with 
lipid chains, which should anchor the enzyme at the lipidic bilayer of the mesophase, leading 
to a supramolecular enzyme-LCP-complex. Proteases, among them also TEV protease, are 
being used to remove affinity tags of recombinant proteins. TEV protease is highly specific 
and remains active in a broad range of conditions.9 With these enzyme-containing LCPs, a 
novel class of biocatalytic material is being introduced.  
 
 
5.2 Results and discussion 
5.2.1 Deoxyribose-5-phosphate aldolase 
5.2.1.1 Immobilization by ionic interactions 
 
As already mentioned in Chapter 2, the aldol reaction is a powerful method to form new 
carbon-carbon bonds by forming ß-hydroxy carbonyl moieties. Whereas in Chapter 2 aldol 
reactions catalyzed by proline-derived lipids were described, we report herein the same 
reaction type performed enzymatically, using DERA-containing LCPs. The solvent exposed 
lysins present at the surface of DERA constitute an ideal opportunity for the immobilization of 
the enzyme by ionic interactions. The amino groups of these lysins are positively charged 
since they are protonated at pH 7.4. We hypothesized that mesophases doped with an 
additive bearing a negative charge will enable efficient immobilization of the enzyme by virtue 
of electrostatic attraction. According to the pKa of oleic acid (OA, 6), which is 4.8,10 the 
carboxylic acid is mostly deprotonated at pH 7.4 and constitutes therefore a suitable ionic 
counterpart to the lysins of DERA for binding to the mesophase bilayer by ionic interactions. 
Reversed hexagonal phases (HII) and Pn3m cubic phases based on mixtures MO and OA (6) 
have been described previously.11,12 The immobilization principle and the experimental set-up 
are illustrated in Figure 1. Substrates from an excess water reservoir diffuse into the aqueous 
channels of the mesophase and are transformed to the corresponding aldol products, which 
then can diffuse back to the bulk water. The product can then easily be separated from the 
catalyst by simply removing the overlaid water. 
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Figure 1: Schematic representation of the immobilization principle and the experimental set up 
including the structure of the host-guest H(II) phase. The H(II) phase, composed of host MO lipids 
(white), guest lipid oleic acid (red), water (blue) and DERA, is placed in an Eppendorf tube, and is 
overlaid with an aqueous substrate solution. The substrates (dark blue) are transformed by the enzyme 
DERA to the products (green). The reaction takes place at the lipid-water interface of the catalytic 
mesophase. The proportions of lipids and enzyme do not match reality. 
 
The immobilization efficiency of the MO/OA reverse hexagonal phase was tested by 
determining the DERA release to the overlaid excess water. As a control, a HII phase with the 
uncharged additive tetradecane was used, which has been described previously.13 Due to the 
lack of charges of this additive, the enzyme should be released from the control HII phase 
much faster. The two HII phases were overlaid with buffer solution. The DERA-release of the 
HII phase to the excess water reservoir was measured by UV/Vis spectroscopy over four 
days, and the results are shown in Figure 2. A concentration of 100 % in the overlaid buffer 
solution corresponds to release of the all the enzyme molecules from the HII phase to the 
excess water reservoir. The oleic acid-doped HII phase is depleted by ca. 10 % of its DERA 
within the first 24 h, and the enzyme concentration remains almost constant thereafter- this 
value only slightly increasing to 13 % after 96 h. The tetradecane-doped HII phase, on the 
other hand, loses 18 % of its DERA within the first 24 h and the release rate is subsequently 
only slightly reduced and reaches 37 % after 96 h. The significantly different release rates are 
the basis for further experiments and proves our immobilization hypothesis.  
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Figure 2: A) DERA immobilization study of oleic acid- and tetradecane-doped H(II) phases. Uncharged, 
tetradecane-doped H(II) phase (red curve) releases DERA much faster and to a greater extent than 
oleic acid-doped H(II) phase (blue curve). B) Molecular structures of oleic acid (top) and tetradecane 
(bottom). C) X-ray surface structure of DERA with solvent exposed lysine residues shown in blue. 
DERA crystal structure reprinted with permission from Ref. 5. 
 
 
5.2.1.2 Activity assays of immobilized DERA 
 
The activity of native and immobilized DERA was determined using a previously reported 
coupled enzymatic assay which allows to follow the oxidation of nicotinamide adenine 
dinucleotide (NADH) by UV/Vis spectroscopy.14 After cleaving 2-deoxy-D-ribose 5-phosphate 
(DRP) to glyceraldehyde 3-phosphate (G-3-P) and acetaldehyde (ACH) with DERA, G-3-P is 
transformed to dihydroxy acetone phosphate (DHAP) by a triose-phosphate isomerase (TPI) 
and further reduced to glycerol 3-phosphate with glycerol 3-phosphate isomerase (GDH). The 
oxidation of NADH can be monitored by UV/Vis spectroscopy at 340 nm and serves as the 
read-out of this assay. 
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for the isolated screening hits. DERAVar3 contained six nu-
cleotide changes, two of them resulting in silent muta-
tions, three mutations leading to amino acid substitutions
(N80S, E127G and M185V), and one leading to a frame
shift mutation (deletion of G773), resulting in the substi-
tution of the most C-terminal amino acid residues S258
and Y259 by threonines and in the addition of ten addi-
tional amino acid residues (KTQLSCTKW), due to the lack
of a stop codon in the new reading frame. The sequence,
coding for these additional C-terminal amino acid
residues, was derived from the pDEST14 expression vec-
tor used (Invitrogen). The sequencing of DERAVar5 identi-
fied two nucleotide changes, resulting in the substitution
of D84 by glycine, and one leading (insertion of an addi-
tional A at nucleotide position 777) to a premature stop
codon, resulting in the loss of the C-terminal Y259 residue.
Analysis of additional stability of DERA variants resulted
in the identification of at least four independent muta-
tions resulting in the loss of the terminal Y259 residue, or
in its substitution, and the addition of additional C-termi-
nal amino acid residues. Variant DERAVar2 contained
three nucleotide changes, two of them silent and one re-
sulting in the amino acid substitution M185V. Analysis 
of DERAVar2 for (3R,5S)-6-chloro-2,4,6-trideoxyhexapyra-
noside formation showed that the mutation resulted in an
about 5-fold increase in product formation compared to
wild-type E. coli DERA, under the applied synthesis con-
ditions (Table 1). We did not observe significant differ-
ences in protein expression levels compared to wild-type
DERA with any of the DERA variants examined here in
the SDS-PAGE analyses of the cell-free extracts (data not
shown).
3.3 Directed random mutation of individual lysine residues
Loss of enzymatic activity due to aldehyde exposure is
mainly attributed to imine formation and subsequent fur-
ther modifications of accessible lysine residues [25, 26].
Examination of chloroacetaldehyde exposed E. coli
DERA, by peptic digestion and LC-MS analysis of ob-
tained fragments, indicated that several of the 19 lysine
residues of E. coli DERA were modified by the exposure
to chloroacetaldehyde. Molecular modeling studies based
on the published DERA X-ray structure [27] showed that
these modified lysine residues coincided as expected
with solvent-exposed surface positions. In particular, one
of the identified modified lysine residues (K172) is located
at the substrate entry point to the active site of DERA (Fig.
3), and thus could explain the inactivation of DERA by
chloroacetaldehyde. To examine the role of the lysine
residues in the inactivation of DERA by chloroacetalde-
hyde, we decided to target all DERA lysine residues, ex-
cept lysine residue 167 (active site lysine involved in the
Schiff-base formation during the catalytic cycle), individ-
ually by site-directed mutagenesis. Using oligonu-
cleotides with completely randomized nucleotide posi-
tions corresponding to the individual lysine codons in 18
separate mutagenesis experiments, these lysine posi-
tions were targeted for amino acid substitution. For each
site-directed lysine mutagenesis experiment, the variant
deoC genes were subcloned into expression vector, and
200–300 randomly chosen clones were then screened for
enzymatic activity using 2-deoxy-D-ribose 5-phosphate
as substrate. From the obtained active clones, the deoC
genes were sequenced to verify the amino acid alteration.
The variant DERA enzymes were then tested for im-
proved chloroacetaldehyde tolerance. For all lysine posi-
tions except lysines 167 and 201, amino acid substitutions
were identified resulting in enzymatically active DERA
proteins. However, using our established high-through-
put DERA stability screening protocol, no amino acid sub-
stitution was identified that led to a detectable improve-
ment in chloroacetaldehyde tolerance of the tested vari-
ant DERA variants. Even the K172I amino acid substitu-
tion showed no improvement of chloroacetaldehyde
resistance of the variant DERA enzyme compared to wild-
type DERA (Fig. 4).
3.4 Identification of mutations improving the catalytic activi-
ty of DERA towards chloroacetaldehyde as substrate
Besides the inherent low tolerance to chloroacetaldehyde,
wild-type E. coli DERA shows a rather low affinity toward
chloroacetaldehyde as acceptor substrate for its catalyzed
stereoselective aldol reaction. Therefore, to improve the
catalytic activity of DERA for (3R,5S)-6-chloro-2,4,6-
trideoxyhexapyranoside production, we devised a high-
throughput GC-MS-based product-screening protocol.
This allowed the direct quantification of the condensation
product of chloroacetaldehyde and acetaldehyde, (S)-4-
chloro-3-hydroxybutanal. The deep-well expression cul-
tures yielded concentrations of wild-type DERA enzyme
that were too low (~ 1–2 U DERA enzyme) to result in the
Biotechnol. J. 2006, 1, 537–548 www.biotechnology-journal.com
Figure 3. DERA X-ray structure-based model, highlighting solvent ex-
posed lysine residues in blue and bound 2-deoxy-D-ribose 5-phosphate
substrate in the active site. Lysine residue 172 is located at the substrate
entry channel close to the active site.
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Scheme 1: Coupled enzymatic assay to determine DERA-activity. The consumption of NADH is 
directly related to the activity of DERA and can be monitored by UV/Vis spectroscopy at 340 nm.14 
Abbreviations: 2-deoxy-D-ribose 5-phosphate (DRP), glyceraldehyde 3-phosphate (G-3-P), 
acetaldehyde (ACH), deoxyribose-5-phosphate aldolase DERA, dihydroxy acetone phosphate (DHAP), 
triose-phosphate isomerase (TPI), glycerol 3-phosphate (glycerol-3-P), glycerol 3-phosphate isomerase 
(GDH). Adapted from Ref. 22. 
 
Despite several optimization attempts, e.g. varying oleic acid and DERA concentration in 
LCPs or changing their ratio, enzyme leaking was observed in all DERA-LCPs that were 
prepared. However, the in-meso enzyme activity of DERA-LCP could be determined be 
subtracting the activity of the proportion of released enzyme from the total enzyme activity. 
The enzyme activity arising from released DERA was determined by removing the overlay 
and repeating the assay without DERA-LCP. The actual DERA-LCP activity was found to be 
22 % relative to the native DERA activity (Table 1, entry 1 and 2). The activity of DERA-HII 
was with 3 % relative to native DERA significantly lower (Table 1, entry 3). This can be 
explained by the smaller lattice parameter and the different mesophase topology as compared 
to LCPs.4 Whereas DERA was found to leak from all LCPs that were prepared, this was not 
the case for HII phases when a washing step was conducted. 
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Table 1: Catalytic activity of native DERA, DERA-LCP and DERA-HII. 
 
 
 
 
 
 
Conditions: Reactions were carried out in special, home built metal holders in UV/Vis cuvettes at 25°C. 
a Oleic acid concentration in the mesophase in w/w % of the lipid fraction. b The activity was normalized 
for native DERA to 100 %. 1 mg native DERA consumes 6 mmol DRP/min.  
Lipidic modification of enzymes for immobilization in mesophases 
 
Chemical modification of proteins after translation is a ubiquitous process that is responsible 
for the broad protein chemodiversity present in nature. These post-translational modifications 
play important roles in cellular processes such as signaling, trafficking or differentiation, and 
include among others acylation, methylation, phosphorylation, sulfation, farnesylation, 
ubiquitination, and glycosylation. Together with the possibility of unnatural biorthogonal 
modifications developed by chemists, a broad range of chemical modifications are available 
which allow to study proteins and to control their properties by design.15,16  
 
 
5.2.2 TEV protease 
5.2.2.1 Synthesis of lipidic linkers 114 and 115 
 
Attaching lipidic chains to water-soluble enzymes will render these enzymes more 
hydrophobic and might enable their immobilization by anchoring them at the lipidic bilayer of 
the mesophase. To this end, two differently functionalized lipidic linkers (114 and 115, 
Scheme 2) have been synthesized. Although procedures to couple such compounds to 
enzymes have been reported earlier,17,18 the linker had to be customized for our purposes, i.e. 
incorporating oleyl residues to allow anchoring of the enzyme to the lipidic bilayer. Linker 114 
was obtained by coupling commercially available 2-(2-bromoethyl)-1,3-dioxolane (112) and 
oleic chloride (10) via Grignard reaction. In a subsequent step, the acetal was cleaved with 
acetic acid to obtain linker 114, which forms a pyrrole ring upon coupling to a lysine amine via 
Paal-Knoor synthesis.17,19 Linker 115 was obtained by simply activating oleic acid with N-
hydroxysuccinimide to obtain the NHS-ester thereof. The modification of enzymes occurs at 
the exposed lysines as well. Initially, several attempts were undertaken to modify HRP. 
However, the coupling that was performed according to reported procedures17,18 was not 
successful, and we decided to exchange the enzyme and to work with a TEV protease 
instead. Linker vc was coupled in a mixture DMF and PBS buffer (1:4) in the presence of 
Entry Catalyst OAa Activity [%]b 
1 Native DERA - 100  
2 DERA-LCP 2 % 22 
3 DERA-HII 20 % 3  
Chapter 5 
 
 
 
156 
DBU as a base.17 NHS-activated linker 115 was coupled under similar conditions, but without 
DBU. 
We have some evidence for the successful lipidic modification of a TEV protease for both 
linkers. For linkers 115 MALDI-MS data indicates that a mixture of TEV protease with several 
modifications was obtained, whereas the coupling of 114 to TEV protease was only proven 
indirectly by comparing the release of modified and unmodified TEV protease from LCPs. 
Unmodified TEV protease was released significantly faster from a LCP than its modified 
analogue.20 
 
 
Scheme 2: Synthesis of three different lipidic linkers and their coupling to a TEV protease. Conditions: 
a) Oleylchloride, Mg, THF, - 78°C. b) AcOH/H2O, r.t.. c) TEV protease, DMF/PBS (1:4), DBU, d) DCC, 
NHS, EtOAc/dioxane 1:1, r.t e) TEV protease, DMF/PBS 1:4, pH 7.4. 
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5.3 Conclusions 
 
The immobilization of DERA within HII phases based on ionic interactions was shown, albeit 
with a strongly reduced activity of the enzyme as compared to the native form (3 % vs. 100 %, 
Table 1, entries 1 and 3). In contrast, using LCPs to immobilize DERA only works partially 
using the same approach, as a fraction of the enzyme content was released to the excess 
water reservoir. The activity of 22 % relative to the native enzyme is reasonable (Table 1, 
entry 2). Thus, even though the principle was shown to work, both cases have a strong 
drawback and optimization is necessary in order to obtain a robust and reliable catalytic 
system that can be used to study aldol reactions. 
Finally, two different linkers to modify enzymes chemically with a lipidic chain have been 
successfully synthesized. Both linker 114 and 115 enable modifications at lysins residues. 
There is evidence for the successful lipidic modification of a TEV protease with both linkers.20 
 
 
5.4 Outlook 
 
Optimal conditions at which DERA is immobilized in the mesophase but still shows high 
activity need to be established. Therefore, a comprehensive screening of conditions is 
needed. Varying systematically the oleic acid, monoolein and DERA concentration might be a 
successful approach. The aqueous channel diameter is an important parameter that might be 
crucial and could be varied as well.  
Marco Etter and Philipp Ansorge from our group are continuing the project and are currently 
investigating the immobilization of TEV protease and its in-meso activity.  
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5.5 Experimental section 
 
General Information  
1-Monooleoyl-sn-glycerol C18:1 (monoolein, MO) was purchased from Nu-Chek Prep, Inc. 
(MN, USA). All other reagents and solvents were purchased from Sigma Aldrich. All 
chemicals and solvents were used as received, unless otherwise stated. Reactions were 
carried out under an inert atmosphere of argon in dry solvents. Dichloromethane was 
degassed with argon and purified by passage through activated alumina solvent column (MC 
Brown solvent system) prior to use. Column chromatography was performed using silica gel 
Merck 60 (particle size 0.040–0.063 mm). Analytical thin- layer chromatography (TLC) was 
performed using Merck pre-coated silica gel plates 60 F254; visualization by UV absorption 
and/or by dipping in a solution of KMnO4 (1 g), K2CO3 (2 g) in H2O (100 mL) and subsequent 
heating. 1H-NMR spectra were recorded on a Bruker AV2-500 (500MHz) spectrometer. 
Chemical shifts are given in parts per million (ppm) relative to the internal standard TMS (δ = 
0 ppm). Coupling constants J are expressed in Hz and multiplicities are abbreviated as 
follows: s (singlet), br (broad), d (doublet), t (triplet), q (quadruplet), quint (quintet), m 
(multiplet). 13C-NMR chemical shifts are reported relative to the solvent residual peaks: CDCl3 
= 77.00 ppm. Mass spectra were recorded by the Mass Spectroscopy Service of UZH on 
Finnigan MAT95 MS, BrukerLC MS and Finnigan TSQ700 MS machines.  
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5.5.1 Preparation of DERA mesophases 
 
MO was weight into an Eppendorf vial and a corresponding amount of additive was added to 
obtain a homogeneous lipidic mixture. The lipidic mixture was subsequently hydrated by 
adding appropriate volumes of PBS buffer (pH = 7.4) and mixed. To obtain homogeneous 
LCPs, the samples were centrifuged at 5000 rpm for 85 minutes at 23 °C. The samples were 
finally stored to equilibrate for at least 24 h in a closed Eppendorf tube. The ratio of 
components was chosen on the basis of the reported phase diagrams.11,21  
 
 
5.5.2 DERA Activity assay 
 
The catalytic assay was conducted as described by Dean et al.14 and Subrizi et al.22	 The 
phase with 8.4 µg DERA was transferred to a metal holder inside a glass cuvette and PBS 
buffer (2 mL) was added. DR-5-P (39.5 μL, 1.97 μmol), α-GPD (2 μL, 3.2 μmol) and NADH 
(39.75 μL, 0.59 μmol) were added to start the reaction. The assay was monitored by UV-Vis 
spectroscopy. Therefore, the absorbance of NADH at λ = 340 nm was measured. The overlay 
of this assay was drained to another glass cuvette and measured with the same reagents. 
This procedure was repeated two to five times.  
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5.5.3 Synthesis 
 
Synthesis of 113 ((Z)-1-(1,3-dioxolan-2-yl)icos-11-en-3-one)17 
 
 
 
To a flask with Magnesium turnings (150 mg, 6.25 mmol, 1.33 eq.) and dry THF (4 mL) a 
solution of 2-(2-bromoethyl)-1,3-dioxolane (1 g, 5.5 mmol, 1.17 eq.) in dry THF (2 mL) was 
added dropwise. A small amount of iodine was used to initiate the reaction. Subsequently, 
THF (5 mL) was added and as soon as the reaction was completed, more THF (15 mL) was 
added. The reaction mixture stirred for 1 h and then cooled to -78 °C. A solution of oleyl 
chloride (1.41 g, 4.7 mmol, 1 eq.) in dry THF (5 mL) was then added slowly via dropping 
funnel. The reaction mixture was stirred for 40 min before it was quenched with saturated 
aqueous NH4Cl (30 mL). The phases were separated and the aqueous phase was extracted 
with ethylacetate (4 x 15 mL) and the combined organic phases were washed with brine, dried 
over MgSO4, and the solvents removed in vacuo. The resulting crude product was purified by 
flash chromatography (hexane/ethylacetate 8:2) to obtain the product as colourless oil (1.12 
g, 3.06 mmol, 65%). 1H NMR (500 MHz, Chloroform-d) δ 5.49 – 5.19 (m, 2H), 4.84 (t, J = 4.4 
Hz, 1H), 3.92 – 3.84 (m, 2H), 3.81 – 3.74 (m, 2H) 2.44 (t, J = 6.9 Hz, 2H), 2.35 (t, J = 6.9 Hz, 
2H), 2.12 – 1.75 (m, 6H), 1.57 – 1.44 (m, 2H), 1.42 – 0.98 (m, 20H), 0.81 (t, J = 6.9 Hz, 3H). 
13C NMR (126 MHz, Chloroform-d) δ 210.25, 129.96, 129.74, 103.36, 64.95 (2C), 42.81, 
36.43, 31.89, 29.76, 29.69, 29.51, 29.31 (2C), 29.20, 29.11, 27.58, 27.20, 27.16, 23.86, 
22.67, 14.11. HRMS (ESI [M + Na]+) m/z: calcd for (C23H42O3Na) 389.30262, found 
389.30200. 
 
  
O
O
O
Chapter 5 
 
 
 
161 
Synthesis of 114 ((Z)-4-oxohenicos-12-enal)17 
 
 
 
Acetal (100 mg, 0.27 mmol, 1 eq.) was dissolved in a mixture of AcOH and H2O (3:1, v/v) and 
stirred for 5 h at 50 °C when TLC showed completion of the reaction. The solvent was 
removed and the desired product was obtained without further purification in quantitative 
yield. 1H NMR (500 MHz, Chloroform-d) δ 9.73 (s, 1H), 5.38 – 5.19 (m, 2H), 2.71 – 2.61 (m, 
4H), 2.39 (t, J = 7.5 Hz, 2H), 2.02 – 1.85 (m, 4H), 1.57 – 1.44 (m, 2H), 1.30 – 1.14 (m, 20H), 
0.81 (t, J = 6.9 Hz, 3H). 13C NMR (126 MHz, Chloroform-d) δ 208.83, 200.47, 129.91, 129.67, 
42.68, 37.39, 34.54, 31.84, 29.70, 29.63, 29.46, 29.26 (2C), 29.23, 29.10, 29.04, 27.15, 
27.10, 23.79, 22.62, 14.05. HRMS (ESI [M + Na]+) m/z: calcd for (C21H38O2Na) 345.27640, 
found 345.27633. 
 
 
Synthesis of 115 (2,5-dioxopyrrolidin-1-yl oleate)18 
 
 
 
Oleic acid (1.0 g, 3.4 mmol, 1 eq.) was dissolved in a mixture of ethyl acetate/dioxane (1:1, 10 
mL) and cooled to 0°C. Subsequently, N-hydroxysuccinimide (0.424 g, 3.68 mmol, 1.04 eq) 
and DCC (0.76 g, 3.68 mmol, 1.04 eq.) was added. The mixture was stirred at room 
temperature for 5 h and the precipitate was filtered off and the solvent was evaporated in 
vacuo. The resulting oil was dissolved in ethyl acetate (35 mL) and washed with aqueous 
NaHCO3 5% (3 × 5 mL) and brine (10 mL). The combined organic phases were dried over 
MgSO4 and the solvent removed. The crude product was purified by flash chromatography 
(cyclohexane/ethylacetate 5:1) to give the product as slightly yellow oil (981 mg, 2.58 mmol, 
76%). 1H NMR (400 MHz, Chloroform-d) δ 5.64 – 4.94 (m, 2H), 2.76 (s, 4H), 2.53 (t, J = 7.5 
Hz, 2H), 1.98 – 1.88 (m, 4H), 1.68 (p, J = 7.5 Hz, 2H), 1.42 – 1.08 (m, 20H), 0.87 – 0.74 (m, 
3H). 13C NMR (126 MHz, Chloroform-d) δ 169.20 (2C), 168.67, 130.02, 129.68, 31.89, 30.92, 
29.75, 29.62, 29.50, 29.30 (2C), 28.98 (2C), 28.75, 27.20, 27.13, 25.57 (2C), 24.54, 22.66, 
14.10. HRMS (ESI [M + Na]+) m/z: calcd for (C22H37O4NNa) 402.26153, found 402.26106. 
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5.5.4 Protein modifications 
 
Enzyme modification with linker 114  
(Procedure adapted from Lu et al.17) 
Oleyl linker 114 (2 mg, 0.006 mmol) was dissolved in DMF (0.5 mL) and added to 1.5 mL to a 
0.08 mM solution of HRP or TEV protease. The reaction mixture was stirred under argon for 4 
days. DBU (0.2 mL) was then added and the mixture was stirred overnight. The reaction 
mixture was submitted to MALDI-MS after dialysis (12 h, Mr cutoff 14’000, against 500 mL 20 
% DMF in 10 mM PBS, pH 7.4). 
 
Enzyme modification with linker 115 
NHS-activated oleyl linker 115 (2 mg, 0.005 mmol) was dissolved in DMF (0.5 mL) and added 
to 1.5 mL to a 0.08 mM solution of HRP or TEV protease. The reaction mixture was stirred for 
4 days. The reaction mixture was submitted to MALDI-MS after dialysis (12 h, Mr cutoff 
14’000, against 500 mL 20 % DMF in 10 mM PBS, pH 7.4). 
 
TEV protease was expressed and purified by Philipp Ansorge according to the procedure 
described in his PhD thesis.23 
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6.1 Introduction - Polymerization of LCPs 
 
The development of catalytic LCPs and cubosomes during this thesis revealed both the huge 
potential of this approach, as well as its limitations and drawbacks. For example, the major 
drawback of the aldol LCPs and cubosomes described in Chapter 2 is the limitation to water-
soluble substrates. Similarly, the detoxifying hydrolysis of parathion in Chapter 3 suffered from 
substrate accumulation in the lipidic compartment, which seems to be too hydrophobic. The 
recycling of PdNP-containing LCPs described in Chaper 4 is restricted to few cycles. A 
possible explanation is the gravity-induced migration of the PdNPs over time, leading to the 
loss of substrate-accessible PdNPs in the aqueous compartment. However, these 
complications can potentially be overcome by polymerizing LCPs. In an ideal case, LCPs can 
be designed with customized properties, which can then be “frozen” to obtain more stable 
LCPs that are even compatible with organic solvents. To address these possibilities, a 
polymerizable catalytic LCP based on reported technology1,2 was designed, and its lipid 
building blocks synthesized.  
Generally, two strategies to achieve polymerization of three-dimensional, supramolecular 
structures such as LCPs are available: First by hydrating lipids that contain polymerizable 
moieties to form the corresponding mesophases and subsequent linear or cross-linked 
polymerization. Second, the inverse approach by pre-polymerization in organic solvents, 
subsequent evaporation of the solvent and purification of the polymer followed by hydration.3 
The research using the first approach is briefly introduced herein. The overall objective is to 
develop more stable LCPs (and HII phases) with enhanced temperature and concentration 
ranges, and therefore achieve a much broader application area of these biomaterials.3 A very 
crucial part for the success of this research is the rational design of lipid monomers. 
Polymerizable moieties which allow photo or redox initiation, such as dienes, styrenes and 
acryloyls are favored over thermal inducible groups, since temperature affects the phase 
behavior. The position of the polymerizable moiety in the lipid needs to be considered; linking 
lipids between the tail and head groups should interfere the least with the forces required for 
self-assembly.3,4 Lee et al. polymerized a pre-formed LCP and HII phase using a mixture of 
mono-dienoyl-substituted phosphoethanolamine and bis-dienoyl-substituted phosphocholine, 
which exhibited a Pn3m cubic phase at 60 °C. The polymer was insoluble in several organic 
solvents.4 Srisiri et al. synthesized polymerizable monoacylglycerols and 1,2-diacyl-sn-
glycerols and studied their mesophases. A mixture of 9/1 molar ratio of polymerizable 
monoacylglycerol 116 and 1,2-diacyl-sn-glycerol 117 formed an Ia3d cubic phase which was 
found to be stable from 5 – 45 °C. A similar 1,2-diacyl-sn-glycerol lipid was used to prepare 
polymerized cubosomes.5 
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6.2 Results and discussion 
 
The work of Srisiri et al.1,2 serves as the basis for our polymerized catalytic LCPs. These lipids 
bear the polymerizable moiety just below the head group (Figure 1). This prevents 
hydrophobic substrates from accumulation in the lipidic compartment and does not interfere 
with the forces required for self-assembly. To functionalize, i.e. render the LCP catalytically 
active, polymerizable proline-derived lipid 118 was designed and synthesized, with the aim of 
using it as an additive that should co-polymerize with 116 and 117. The polymerization 
process is schematically illustrated in Figure 1, together with the molecular structures of the 
three required polymerizable lipids.  
 
 
Figure 1: A) Schematic representation of the polymerization process. B) Molecular structure of the 
three polymerizable lipids 116, 117 and 118. C) Schematic representation of the resulting polymer. 
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6.2.1 Synthesis of polymerizable lipids 
 
Fatty acid 122 is the key compound and is required in the synthesis of all three lipids 116, 117 
and 118, it introduces the polymerizable moiety. Fatty acid 122 was obtained in two synthetic 
steps. Commercially available decanal (119) was transformed to methyl 2,4-
tetradecadienoate (121) in a Wittig-Horner reaction using trimethyl 4-phosphocrotonate (120) 
(Scheme 1).6 Methylester 121 was obtained as a mixture of the (E,E)-isomer (80 %) and the 
(E,Z)-isomer (20 %) according to 1H-NMR. Methyl ester hydrolysis was carried out in a KOH 
solution in methanol at reflux to obtain a mixture of the (E,E)- and (E,Z)-acids 122.2 
Separation of the (E,E)- and (E,Z)-acids was accomplished using urea inclusion in methanol 
(Scheme 1). Urea crystallizes in methanol in a helical lattice with a narrow cylindrical channel 
of 5.3 Å due to hydrogen bonding.2,7 Whereas the (E,E)-isomer is included in this crystals, the 
(E,Z)-isomer remains outside. 
 
Scheme 1: Synthesis of the polymerizable building blocks for catalytic LCPs. Lipids 116 and 117 are 
known to form LCPs when mixed 9:1 and hydrated (25 %). Catalyst 118 is planned to be incorporated 
as an additive to the LCP. Conditions: a) 120 (1.2 eq), NaH (1.5 eq), THF, 0 °C. b) KOH (1.5 eq), 
MeOH, reflux. c) Urea (8.5 eq), MeOH, 0 °C. d) EDC (1.1 eq), DMAP (0.1 eq), glycerol (6 eq), 
CH2Cl2/DMF (1:1), 0 °C. e) 122 (2 eq.), EDC (2.2 eq), DMAP (0.2 eq), 128 (1 eq), CH2Cl2, 0 °C. f) 122 
(1 eq), EDC (1.1 eq), DMAP (0.1 eq), 123 (1.1 eq), CH2Cl2, 0 °C. g) TFA/CH2Cl2 (1:9), 0 °C. h) HCl 
(1 M), MeOH, r.t. i) 4-methoxybenzyl chloride (1 eq), NaH (1.7 eq), DMF, reflux. k) HCl (0.1 M), MeOH, 
r.t.. 
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Polymerizable monoacylglycerol 116 was obtained by esterification with an excess of glycerol 
(Scheme 1). The synthesis of 1,2-diacyl-sn-glycerol 117 including a specific glycerol 
protecting strategy and was achieved in four steps. The free hydroxyl group of acetal-
protected glycerol (126) was reacted with para-methoxy-benzyl (PMB) chloride to obtain 127. 
After cleaving the acetal, PMB-protected 1,2-diacyl-sn-glycerol was obtained upon 
esterification with fatty acid 122. In a final step, the PMB group was removed to obtain 117 
(Scheme 1). Polymerizable proline catalyst was available after coupling fatty acid 122 to (S)-
2-(Aminomethyl)-1-Boc-pyrrolidine (123) using EDC/DMAP followed by BOC deprotection 
with trifluoro acetic acid (Scheme 1). 
 
 
6.2.2 Polymerization experiments 
 
In a first experiment, the polymerization of a 9:1 hydrated mixture of 116 and 117 in 25 % 
H2O2/H2O according to the procedure of Srisiri et al. was reproduced.1 To this end, a lipid film 
consisting of polymerizable lipids 116 and 117 in a molar ratio of 9:1 was prepared and 
hydrated with 25 % (w/w) aqueous H2O2 30 % (w/w). The sample was centrifuged and 
equilibrated at 5 °C in the dark, and subsequently polymerized at 45 °C. comparison of the 1H-
NMR spectra of 116 (Figure 2, top panel) and the hydrated lipid mixture of 116 and 117 
(Figure 2, bottom panel) indicates that the polymerization took place. The 1H-NMR signals of 
the protons at the two trans carbon-carbon double bonds of 116 (Figure 2, top panel) are 
absent after incubation of the sample at 45 °C (Figure 2, bottom panel). However, attempts to 
verify this by ESI-MS and MALDI-TOF-MS failed. As an alternative, determination of the 
polymerization degree using size exclusion chromatography is planned. Since the obtained 
mesophase was not transparent, SAXS analysis was not carried out. The LCP preparation 
procedure thus requires optimization. 
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Figure 2: 1H-NMR spectra in CDCl3 of polymerizable lipid 116 (top panel, blue) and of the hydrated (25 
% H2O2/H2O) mixture of polymerizable lipids 116 and 117 (9:1) after incubation at 45 °C for 48 h and 
subsequent lyophylization (bottom panel, red). The hydrogen atoms attached to the two carbon-carbon 
double bonds of 116 (colored in red) in the ppm range of 5.5 – 7.5 (top panel, box) disappear after 
incubation at 45 °C (bottom panel, box), which suggests that polymerization occurred.  
 
 
6.3 Conclusions and Outlook 
 
The polymerizable lipid reported by Srisiri et al.2 were successfully resynthesized. Acid 122 is 
available in gram scale for future polymerization experiments. Additionally, polymerizable 
proline-derived catalyst 118 was synthesized, which is used as an additive and allows to test 
the polymerized LCP for aldol reactions. 1H-NMR data indicate that polymerization of a 9:1 
mixture of 116 and 117 took place. However, the mesophase was not transparent and was 
therefore not analyzed by SAXS. This experiment needs to be repeated and optimized. If the 
reported Pn3m LCP can be reproduced, catalyst 118 can be incorporated to the LCP as an 
additive and aldol organocatalysis will be investigated. Finally, we plan to prepare cubosomes 
consisting of polymerizable lipids and to apply them to catalysis as well. 
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6.4 Experimental section 
 
General Information  
N-(3- dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride (EDC) was purchased from 
TCI, and all other reagents and solvents were purchased from Sigma Aldrich. All chemicals 
and solvents were used as received, unless otherwise stated. Reactions were carried out 
under an inert atmosphere of argon in dry solvents. Dichloromethane was degassed with 
argon and purified by passage through activated alumina solvent column (MC Brown solvent 
system) prior to use. Column chromatography was performed using silica gel Merck 60 
(particle size 0.040–0.063 mm). Analytical thin- layer chromatography (TLC) was performed 
using Merck pre-coated silica gel plates 60 F254; visualization by UV absorption and/or by 
dipping in a solution of KMnO4 (1 g), K2CO3 (2 g) in H2O (100 mL) and subsequent heating. 
1H-NMR spectra were recorded on a Bruker AV2-500 (500MHz) spectrometer. Chemical 
shifts are given in parts per million (ppm) relative to the internal standard TMS (δ = 0 ppm). 
Coupling constants J are expressed in Hz and multiplicities are abbreviated as follows: s 
(singlet), br (broad), d (doublet), t (triplet), q (quadruplet), quint (quintet), m (multiplet). 13C-
NMR chemical shifts are reported relative to the solvent residual peaks: CDCl3 = 77.00 ppm. 
Mass spectra were recorded by the Mass Spectroscopy Service of UZH on Finnigan MAT95 
MS, BrukerLC MS and Finnigan TSQ700 MS machines. 
 
 
6.4.1 Synthesis of polymerizable lipids 
 
Synthesis of 121 (methyl tetradeca-2,4-dienoate)2 
 
 
 
A solution of NaH 60% in mineral oil (0.8 g, 22.5 mmol, 1.4 eq) in THF (50 mL) was cooled to 
0°C and a solution of trimethyl 4-phosphonocrotonate (4 g, 19 mmol, 1.2 eq) in THF (50 mL) 
was added dropwise. The reaction mixture was then stirred for 1 h at 0°C before a solution of 
decanal (2.5 g, 16 mmol, 1 eq) was added slowly via dropping funnel. The cooling bath was 
removed and the reaction was monitored by TLC. After completion of the reaction, excess 
NaH was quenched using cold water. The reaction mixture was concentrated in vacuo, diluted 
with ethyl acetate and extracted with water (1x 100 mL) and brine (1x 100 mL) and dried over 
MgSO4. After removal of the solvent in vacuo, the crude product was purified by column 
chromatography (cyclohexane/ethyl acetate 10:0 – 9:1) to obtain the desired product as a 
yellow oil as an isomeric mixture (3.34 g, 14.63 mmol, 65 %). 1H NMR (500 MHz, Chloroform-
MeO
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d) δ 7.62 – 7.45 (m, 1H), 7.28 – 7.01 (m, 1H), 6.57 – 6.28 (m, 1H), 6.16 – 5.23 (m, 2H), 3.79 – 
3.46 (m, 3H), 2.78 – 2.47 (m, 1H), 2.30 – 1.84 (m, 2H), 1.45 – 0.95 (m, 14H), 0.81 (t, J = 6.7 
Hz, 3H). 13C NMR (126 MHz, Chloroform-d) δ 172.77 (d, J = 11.4 Hz), 168.35 – 166.19 (m), 
145.37, 145.10, 145.06, 144.97, 141.85, 139.72 (2 C), 126.33, 125.19, 120.60, 118.58, 52.27 
– 50.52 (4C), 32.46 – 31.56 (2C), 30.16 – 28.90 (5C), 22.65, 14.07. HRMS (ESI [M + H]+) m/z: 
calcd for (C15H27O2) 229.20056, found 229.20038. 
 
 
Synthesis of 122 ((2E,4E)-tetradeca-2,4-dienoic acid) modified procedure2  
 
 
 
To a solution of methyl ester (2.5 g, 10 mmol, 1 eq) in methanol (50 mL) an aqueous solution 
of KOH (85 %, 1.5 eq) was added. The solution was then stirred at reflux until the methyl 
ester was disappeared (ca. 3 h). Methanol was removed and water (30 mL) was added, the 
solution was acidified to pH 3 with aqueous HCl 10 % and extracted with ethyl acetate (5 x 50 
mL). The combined organic phases were washed with brine and dried over MgSO4. The 
solvent evaporated in vacuo to get the crude product. A solution of acid (1.35 g, 6 mmol) in 
methanol (50 mL) was treated with a solution of urea (3 g, 50 mmol) and stored in the fridge 
(4°C) for 3 days. The precipitated crystals were filtered off and washed with ethyl acetate. The 
filtrate was then concentrated and stored in the fridge (4 °C) for 3 days. The procedure was 
repeated 3 times. The pure product (tran-trans isomer) was obtained as a urea adduct (0.3 g), 
which was treated with HCl (5 %, 30 mL). The solution was extracted with ethyl acetate (3x 50 
mL), dried over MgSO4 and the solvent evaporated in vacuo to get the pure product (1.6 g, 7 
mmol, 70 %). 1H NMR (400 MHz, Chloroform-d) δ 7.36 – 7.21 (m, 1H), 6.17 – 6.06 (m, 2H), 
5.71 (d, J = 15.3 Hz, 1H), 2.11 (q, J = 7.1 Hz, 2H), 1.43 – 1.27 (m, 1H), 1.20 (s, 13H), 0.81 (t, 
J = 6.7 Hz, 3H). 13C NMR (126 MHz, Chloroform-d) δ 173.22, 148.59, 147.26, 128.12, 117.53, 
33.11, 31.86, 29.49, 29.41, 29.28, 29.18, 28.57, 22.66, 14.09. HRMS (ESI [M + H]+) m/z: 
calcd for (C14H25O2) 225.18491, found 225.18522. 
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Synthesis of 122B (2E,4Z)-pentadeca-2,4-dienoic acid (not reported by Srisiri et al.)2 
 
 
 
The trans-cis isomer was obtained after evaporating the filtrate after three crystallization 
cycles. The product was treated with aqueous HCl (5 %, 30 mL). The solution was extracted 
with ethyl acetate (3x 50 mL), dried over MgSO4 and the solvent evaporated in vacuo to 
obtain the free acid (0.23 g, 1 mmol, 70 %). 1H NMR (500 MHz, Chloroform-d) δ 7.63 (dd, J = 
15.2, 11.8 Hz, 1H), 6.18 – 6.04 (m), 5.91 – 5.82 (m), 5.79 (d, J = 15.2 Hz, 1H), 3.44 – 3.16 (m, 
impurity), 2.24 (q, J = 7.6, 6.9 Hz, 1H), 1.44 – 1.00 (m, 13H), 0.81 (t, J = 6.9 Hz, 3H). 13C NMR 
(126 MHz, Chloroform-d) δ 172.54, 143.09, 141.81, 126.23, 120.17, 31.86, 29.50, 29.43, 
29.30, 29.27, 29.18, 28.34, 22.65, 14.09. HRMS (ESI [M + H]+) m/z: calcd for (C14H25O2) 
225.18491, found 225.18522. 
 
 
Synthesis of 116 ((2E,4E)-2,3-dihydroxypropyl tetradeca-2,4-dienoate) (modified 
procedure of Ref. 9) 
 
 
 
To a stirred solution of acid (100 mg, 0.45 mmol, 1 eq) in 50 mL of a mixture of dry 
CH2Cl2/DMF (3:1) was added EDC (250 mg, 0.59 mmol, 1.3 eq) followed by DMAP (15 mg, 
0.045 mmol, 0.01 eq) at 0 °C under argon. The solution was stirred for 1 h at 0 °C and then 
was added dropwise over a period of 30 min to a solution of glycerol (250 mg, 2.7 mmol, 6 
eq.) in 50 mL of dry DMF at 0 °C. The mixture was stirred for 12 h at room temperature and 
then washed with a saturated solution of NaHCO3. The organic phase was separated and the 
aqueous phase was extracted with CH2Cl2 (3 x 100 mL). The combined organic phases were 
washed with brine and dried over MgSO4. The solvent was removed under reduced pressure 
and the residue was purified by column chromatography on silica gel and eluted with a 
mixture of cyclohexane/ethylacetate 8:2 to 4:6. The solvent was removed to give colorless 
solid product (84 mg, 0.28 mmol, 63 %). 1H NMR (400 MHz, Chloroform-d) δ 7.29 – 7.20 (m, 
1H), 6.11 (d, J = 6.4 Hz, 2H), 5.74 (d, J = 15.3 Hz, 1H), 4.25 – 4.12 (m, 2H), 4.05 (q, J = 7.2 
Hz, 1H), 3.89 (p, J = 5.2 Hz, 1H), 3.80 (s, 1H), 3.66 – 3.61 (m, 1H), 3.58 – 3.52 (m, 1H), 2.33 
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– 2.07 (m, 3H), 1.35 (d, J = 7.0 Hz, 1H), 1.19 (s, 12H), 0.81 (t, J = 6.6 Hz, 3H). 13C NMR (126 
MHz, Chloroform-d) δ 167.74, 146.46, 145.95, 128.11, 117.96, 70.34, 65.08, 63.31, 33.03, 
31.84, 29.48, 29.39, 29.26, 29.16, 28.62, 22.64, 14.08. HRMS (ESI [M + Na]+) m/z: calcd for 
(C17H30O4Na) 321.20363, found 321.20351. 
 
 
Synthesis of 127 (4-(((4-methoxybenzyl)oxy)methyl)-2,2-dimethyl-1,3-dioxolane)2 
 
 
 
To a suspension of NaH 60 % in mineral oil (1.0 g, 25 mmol, 1.66 eq) in DMF (100 mL) a 
solution of 1,2-O-isopropylidene glycerol (2.0 g, 15 mmol, 1 eq) in DMF (50 mL). The reaction 
mixture was heated to reflux and after 30 min, 4-methoxybenzyl chloride (2.4 g, 15 mmol, 1 
eq) was added dropwise. After completion of the reaction, the mixture was allowed to warm 
up to room temperature and the excess NaH was quenched with cold water. The mixture was 
concentrated and the residue dissolved in ethyl acetate. The organic phase was washed with 
water (3x 50 mL) and brine (50 mL), dried over MgSO4 and the solvent was evaporated in 
vacuo to obtain the crude product, which was purified by column chromatography 
(cyclohexane/ethyl acetate 3:1) to obtain the desired product (5.17 g, 20.5 mmol, 82 %). 
Analytical data were identical with the values reported in literature. 
 
 
Synthesis of 128 (3-((4-methoxybenzyl)oxy)propane-1,2-diol)2 
 
 
 
PMB protected 1,2-O-isopropylidene glycerol (0.5 g, 1.98 mmol) was dissolved in methanol 
(50 mL) and an aqueous solution of 10% HCl was added and the reaction mixture stirred for 3 
h. The solvent was evaporated in vacuo to obtain the crude product, which was purified by 
column chromatography (cyclohexane/ethyl acetate 3:1) to obtain the desired product in 
quantitative yield (0.42 mmol, 1.98 mmol). 1H NMR (400 MHz, CDCl3) δ 7.28 – 7.22 (m, 2H), 
6.93 – 6.86 (m, 2H), 4.49 (s, 2H), 3.88 (s, 1H), 3.82 (s, 3H), 3.74 – 3.58 (m, 2H), 3.57 – 3.47 
(m, 2H). 13C NMR (75 MHz, CDCl3) δ 159.35, 129.73 (2C), 129.53 (2C), 113.87, 73.22, 71.44, 
70.70, 64.05, 55.30. Analytical data were identical with the values reported in literature. 
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Synthesis of 125 ((2E,2'E,4E,4'E)-3-((4-methoxybenzyl)oxy)propane-1,2-diyl 
bis(tetradeca-2,4-dienoate))2 
 
 
 
To a stirred solution of acid (100 mg, 0.45 mmol, 1 eq) in 50 mL of a mixture of dry 
CH2Cl2/DMF (3:1) was added EDC (250 mg, 0.59 mmol, 1.3 eq.) followed by DMAP (15 mg, 
0.045 mmol, 0.01 eq.) at 0 °C under argon. The solution was stirred for 1 h at 0 °C and then 
was added dropwise over a period of 30 min to a solution of PMB-protected glycerol 128 
(113-mg, 0.45 mmol, 1 eq.) in 50 mL of dry DMF at 0 °C. The mixture was stirred for 12 h at 
room temperature and then washed with a saturated solution of NaHCO3. The organic phase 
was separated and the aqueous phase was extracted with CH2Cl2 (3 x 100 mL). The 
combined organic phases were washed with brine and dried over MgSO4. The solvent was 
removed under reduced pressure and the residue was purified by column chromatography on 
silica gel and eluted with a mixture of cyclohexane/ethylacetate 8:2 to 4:6. The solvent was 
removed to give the product (106 mg, 0.17 mmol 38 %) as a slightly yellowish oil. 1H NMR 
(300 MHz, CDCl3) δ 7.41 – 7.18 (m, 4H), 6.94 – 6.85 (m, 2H), 6.29 – 6.03 (m, 4H), 5.87 – 5.71 
(m, 2H), 5.39 – 5.28 (m, 1H), 4.58 – 4.27 (m, 4H), 3.81 (s, 3H), 3.71 – 3.55 (m, 2H), 2.18 (dd, 
J = 12.1, 5.8 Hz, 4H), 1.53 – 1.19 (m, 28H), 0.90 (t, J = 6.7 Hz, 6H). 13C NMR (75 MHz, 
CDCl3) δ 166.86, 166.52, 159.27, 146.01, 145.79, 145.41, 145.30, 129.85, 129.33 (2C), 
128.27 (2C), 118.58, 118.44, 113.82 (2C), 72.96, 70.18, 67.89, 62.77, 55.24, 33.03 (2C), 
31.88 (2C), 29.52 (2C), 29.43 (2C), 29.30 (2C), 29.19 (2C), 28.69 (2C), 22.67 (2C), 14.11 
(2C). HRMS (ESI [M + Na]+) m/z: calcd for (C39H60O6Na) 647.52821, found 647.42765. 
Analytical data were identical with the values reported in literature. 
 
 
Synthesis of 117 ((2E,2'E,4E,4'E)-3-hydroxypropane-1,2-diyl bis(tetradeca-2,4-
dienoate))2 
 
 
 
A solution of PMB-protected glycerol 125 (100 mg, 0.16 mmol) in CH2Cl2 (5 mL) was cooled to 
-0 °C and TFA (0.25 mL) was added. The reaction mixture was stirred for 4 h at 0 °C before 
the solvent was evaporated. In order to remove residual TFA, CH2Cl2 (3 x 3 mL) was added 
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and evaporated. The product was obtained as colorless oil (36 mg, 0.072 mmol, 45 %) 
Analytical data were identical with the values reported in literature. 
 
 
Synthesis of 124 ((S)-tert-butyl 2-((2E,4E)-tetradeca-2,4-dienamidomethyl)pyrrolidine-1-
carboxylate) 
 
 
 
To a stirred solution of acid 122 (63 mg, 0.27 mmol, 1 eq) in 10 mL of a mixture of dry CH2Cl2 
and dry DMF (1:1) was added EDC (165 mg, 0.35 mmol, 1.3 eq) and DMAP (3.3 mg, 
0.027-mmol 0.1 eq) at 0 °C under an inert atmosphere. The solution was stirred for 1 h at 0 °C 
and then 123 (64 mg, 0.32 mmol,1.2 eq.) was added dropwise over a period of 10 min. The 
reaction mixture was stirred for 14 h at room temperature and then CH2Cl2 (50 mL) was 
added, the mixture was washed with a saturated solution of NaHCO3. The organic phase was 
separated and the aqueous phase was extracted with CH2Cl2 (50 mL). The combined organic 
phases were washed with brine and dried over MgSO4. The solvent was removed and the 
crude product was purified by column chromatography to obtain the product (81 mg, 
0.20-mmol,75 %) 1H NMR (500 MHz, Chloroform-d) δ 7.42 (s, 1H), 7.15 – 7.00 (m, 1H), 6.09 
– 5.91 (m, 2H), 5.70 (d, J = 15.1 Hz, 1H), 3.44 – 3.15 (m, 4H), 2.06 (q, J = 7.0 Hz, 2H), 1.97 – 
1.58 (m, 4H), 1.40 (s, 9H) 1.32 (q, J = 6.9 Hz, 2H), 1.21 (s, 14H), 0.81 (t, J = 6.9 Hz, 3H). 13C 
NMR (126 MHz, Chloroform-d) δ 166.72, 156.65, 142.43, 140.37, 128.34, 122.26, 79.90, 
56.25, 46.98, 46.01, 32.83, 31.79, 29.43, 29.35 (2C), 29.20, 29.07, 28.74, 28.36 (3C), 23.78, 
22.57, 14.02. HRMS (ESI [M + H]+) m/z: calcd for (C24H43O3N2) 407.32682, found 407.32684. 
 
 
Synthesis of 118 ((2E,4E)-N-((S)-pyrrolidin-2-ylmethyl)tetradeca-2,4-dienamide) 
 
 
 
Boc-protected catalysts 124 (89 mg, 0.22 mmol) were dissolved in CH2Cl2 (5 mL), cooled to 
0-°C and trifluoro acetic acid (TFA) (3 mL) was added slowly. The solution was stirred for 3 h 
at 0 °C while the reaction was monitored by TLC. Upon completion of the reaction, the solvent 
was evaporated in vacuo. In order to remove residual TFA, CH2Cl2 (3 x 3 mL) was added and 
N
O
O
H
N
O
NH
H
N
O x CF3COOH
Chapter 6 
 
 
 
177 
evaporated to obtain the product quantitatively (67 mg, 0.22 mmol). 1H NMR (500 MHz, 
Chloroform-d) δ 7.03 (dd, J = 15.1, 9.7 Hz, 1H), 6.11 – 5.91 (m, 2H), 5.76 (d, J = 15.1 Hz, 
1H), 3.86 – 3.11 (m, 6H), 2.08 – 1.86 (m, 4H), 1.75 – 1.60 (m, 1H), 1.36 – 1.25 (m, 2H), 1.16 
(s, 14H), 0.78 (t, J = 6.8 Hz, 3H). 13C NMR (126 MHz, Chloroform-d) δ 169.29, 144.84, 
142.80, 128.02, 120.27, 60.57, 45.25, 41.05, 33.00, 31.85, 29.50, 29.42, 29.28, 29.20, 28.73, 
27.52, 24.10, 22.64, 14.07. HRMS (ESI [M + H]+) m/z: calcd for (C19H35ON2) 307.27439, found 
307.27456. 
 
 
6.4.2 Polymerization of lipidic cubic phases1 
 
Polymerizable lipids 116 and 117 were mixed in a molar ratio of 9:1. The lipids were dissolved 
in CH2Cl2 to obtain a homogeneous mixture. After removal of the solvent at high vacuum, the 
lipid mixture was hydrated with a degassed aqueous solution of H2O2 (30 % w/w) at a 
concentration of 25 % w/w. The mixture was centrifuged at room temperature and 
subsequently stored for 24 hours at 5 °C in the dark to equilibrate. Polymerization was carried 
out at 45 °C for 48 hours.  
 
 
  
Chapter 6 
 
 
 
178 
Bibliography 
 
(1)  Srisiri, W.; Benedicto, A.; O’Brien, D. F.; Trouard, T. P.; Orädd, G.; Persson, S.; Lindblom, G. Stabilization 
of a Bicontinuous Cubic Phase from Polymerizable Monoacylglycerol and Diacylglycerol. Langmuir 1998, 
14, 1921–1926. 
(2)  Srisiri, W.; Lamparski, H. G.; O’Brien, D. F. Syntheses of Polymerizable Monoacylglycerols and 1,2-Diacyl- 
Sn -Glycerols. J. Org. Chem. 1996, 61, 5911–5915. 
(3)  Mueller, A.; O’Brien, D. F. Supramolecular Materials via Polymerization of Mesophases of Hydrated 
Amphiphiles. Chem. Rev. 2002, 102, 727–757. 
(4)  Lee, Y. S.; Gleeson, J. T.; Yang, J. Z.; Sisson, T. M.; Frankel, D. A.; O’Brien, D. F.; Keller, S. L.; Aksay, E.; 
Gruner, S. M. Polymerization of Nonlamellar Lipid Assemblies. J. Am. Chem. Soc. 1995, 117, 5573–5578. 
(5)  Yang, D.; O’Brien, D. F.; Marder, S. R. Polymerized Bicontinuous Cubic Nanoparticles (Cubosomes) from 
a Reactive Monoacylglycerol. J. Am. Chem. Soc. 2002, 124, 13388–13389. 
(6)  Dorn, K.; Klingbiel, R. T.; Specht, D. P.; Tyminski, P. N.; Ringsdorf, H.; O’Brien, D. F. Permeability 
Characteristics of Polymeric Bilayer Membranes from Methacryloyl and Butadiene Lipids. J. Am. Chem. 
Soc. 1984, 106, 1627–1633. 
(7)  Smith, A. E. The Crystal Structure of the Urea–hydrocarbon Complexes. Acta Crystallogr. 1952, 5, 224–
235. 
 
  
Chapter 7 
 
 
 
179 
7 Chapter 7 
 
Homochiral lipidic cubic phases 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
OH
HO
OHS,S-Phytantriol
OH
HO
OHR,R-Phytantriol
 180 
 
7.1 Introduction 
 
Our world is full of objects that are incongruent with their mirror images. These objects are 
called chiral. Examples are hands, snails, shoes and most significantly, many molecules. In 
the living world, chirality is unbalanced and molecules of life such as proteins and their amino 
acid building blocks, sugars, and nucleic acids appear in only one handed form. This has 
profound consequences, since two enantiomers interact differently with the human body, for 
example. The pharmaceutical properties of one enantiomer can be different from the other, 
and in some cases the enantiomer of a drug can be highly toxic, demonstrating the 
importance of chirality and hence stereoselective synthesis. Enantioselective heterogeneous 
catalysis has initiated widespread interest in chirality at solid surfaces. For example, achiral 
compounds were aligned and pre-organized on a chiral surface so that hydrogenation of 
carbon-carbon or carbon-oxygen bonds occurred selectively.1,2 Mesoporous organosilica 
materials (PMO),3 or metal organic frameworks (MOF) have been applied for asymmetric 
heterogeneous catalysis as well.4 Catalytic LCPs and cubosomes based on lipidic proline 
catalysts have been developed in our group and are described in Chapter 2 of this thesis.5 
However, in this case, the chiral information originates from the chiral lipidic proline catalysts. 
A chiral surface within pure lipid-water LCPs can be obtained by preparing these mesophases 
from chiral lipid building blocks, leading to novel chiral materials which have, to the best of our 
knowledge, not yet been described. In contrast, chiral lipid monolayers6 and chiral 
thermotropic cubic phases have been reported.7,8 MO, the most common lipid that forms 
LCPs is in principle chiral. However, once in contact with water MO, which is an ester, is in a 
transesterification equilibrium which leads to loss of chiral information. Commercial MO is 
available as a racemic mixture. Phytantriol (PT) (Scheme 1) lacks the ester moiety and is 
therefore a more suitable chiral target lipid. PT is often used as additive in the cosmetic 
industry, and its binary phase behavior upon hydration is very similar to that of hydrated MO. 
However, it is based on a mixture of diastereoisomers. A major difference between these 
phase diagrams is the lower hydration degree, and smaller lattice parameter of the Pn3m 
cubic phase of PT at excess water conditions as compared to MO.9 The absence of the ester 
group renders PT chemically more stable, as compared to MO, since ester groups are prone 
to hydrolysis. The same is true for in vivo applications in the presence of digestive enzymes. 
The goal of this project is to synthesize two different PT diastereoisomers and to study their 
mesophases. Furthermore, their impact on catalysis and has been investigated and 
experiments towards chiral recognition and separation were performed. 
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7.2 Results and discussion 
7.2.1 Synthesis of two different phytantriol diastereoisomers 
 
Commercially available phytol is a suitable precursor to obtain two pure phytantriol 
diastereoisomers via Sharpless asymmetric dihydroxylation (Scheme 1).10 With this approach, 
using the corresponding AD-Mix-α or AD-Mix-ß, (2S,3S,7R,11R)-3,7,11,15-
tetramethylhexadecane-1,2,3-triol (130), denoted herein R,R-PT, and (2R,3R,7R,11R)-
3,7,11,15-tetramethylhexadecane-1,2,3-triol (131), denoted herein S,S-PT, can be obtained in 
one synthetic step with ca. 70 % yield in each case. 
 
Scheme 1: Synthesis of S,S-PT (130) and R,R-PT (131) from commercial phytol using AD-Mix-α or 
AD-Mix-ß, respectively. 
 
The 1H-NMR spectra of commercially available PT (blue), R,R-PT (brown) and S,S-PT (green) 
are compared in Figure 1. A closer look at the proton at position 2 indicates that commercial 
PT consist of four diastereoisimers, two of them are R,R-PT and S,S-PT (Figure 1C). The 
other two are (2R,3S,7R,11R)-3,7,11,15-tetramethylhexadecane-1,2,3-triol and 
(2S,3R,7R,11R)-3,7,11,15-tetramethylhexadecane-1,2,3-triol, which would be referred to S,R-
PT and R,S-PT in the nomenclature used before. 
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Figure 1: A) Stacked 1H-NMR spectra of commercially available PT (blue), S,S-PT (green) and R,R-PT 
(brown). B) Structures of S,S-PT (green) and R,R-PT (brown). C) Superimposed sections of 1H-NMR 
spectra of commercial PT (blue), S,S-PT (green) and R,R-PT (brown) showing the triplet arising from 
the hydrogen at position 2. 
 
With these two diastereomeric moldecules R,R-PT and S,S-PT in hand, novel chiral LCPs can 
be produced and potentially applied for catalysis and chiral recognition. As a model system, 
the aldol reaction described in Chapter 2 will be used. Two important questions will be 
addressed: Firstly, can stereochemical information be induced to the aldol reaction applying a 
nonchiral catalyst but a chiral supporting LCP? And secondly, is it possible to enhance the 
stereoselectivity of a chiral catalyst with a chiral LCP?  
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7.2.2 Applications of chiral LCPs 
7.2.2.1 Catalysis 
 
LCPs based on S,S-PT, R,R-PT, and commercially available PT, each containing lipidic aldol 
catalyst 2 (40 mol % relative to aldehyde 4a) were prepared and used to catalyze the model 
aldol reaction described in Chapter 2. The goal of these experiments was to determine 
whether the chiral surfaces of the ensuing S,S-PT and R,R-PT LCPs, respectively, would 
support the catalyst by preorganizing the substrates specifically and thus affecting the 
stereochemical outcome of the reaction. Furthermore, the kintics of these were compared, as 
preliminary data suggest that the phase diagrams of the individual PT diastereomers are 
different from the mixture, which is reported in literature.11 However, neither the reaction rates 
nor the stereochemistry were found to be significantly different for one of the three PT-based 
LCPs, as shown in Figure 2, which has already been shown in Chapter 2.  
 
 
Figure 2: Progress of the aldol reaction of cyclohexanone 3 with aldehyde 4a in three different 
phytantriol LCP systems (determined by 1H-NMR). Comparison of LCP media consisting of racemic PT, 
S,S-PT and R,R-PT with 40 mol % cat. loading.  
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7.2.2.2 Characterization of S,S-PT and R,R-PT monolayers and mesophases 
 
Monolayers of commercially available PT, S,S-PT, and R,R-PT were prepared in a trough at 
at the air-water interface, and their Langmuir-Blodgett isotherms and Brewster-angle-
microscopic images compared. No significant differences were found between the three 
systems (results not shown). However, initial comparison of the phase behavior indicates 
differences between that of the single diastereoisomers with the one of commercially available 
PT. In the pure form at room temperature, the single diastereoisomers S,S-PT and R,R-PT 
form white crystals, whereas commercial PT appears as a viscous liquid. Polarized light 
micrographs and SAXS analysis of S,S-PT (Figure 3A and 3C) reveal the presence of a Lc 
phase, which gives rise to anisotropy, whereas polarized light micrographs and SAXS 
analysis of commercial PT show an isotropic sample (Figure 3B and 3D). The detailed phase 
diagram of the hydrated S,S-PT and R,R-PT systems are currently being elucidated in our 
group. 
 
 
Figure 3: A) Polarized light micrograph of S,S-PT. B) Polarized light micrograph of commercially 
available PT. C) SAXS pattern of S,S-PT. D) SAXS pattern of commercially available PT. 
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7.3 Conclusions 
 
The two diastereoisomers of phytantriol, S,S-PT and R,R-PT were synthesized from 
commercially available phytol within one synthetic step using Sharpless asymmetric 
dihydroxylation. With these lipids in hand, homochiral LCPs are accessible. Such materials 
are potentially interesting for catalysis or for chiral recognition. Homochiral LCPs of both S,S-
PT and R,R-PT have been prepared and used for catalysis of a model aldol reaction. 
However, neither kinetic nor stereochemical differences have been found in preliminary 
experiments. Whereas the Langmuir monolayers of commercially available PT, S,S-PT, and 
R,R-PT show identical behavior, differences in their hydrated phase behavior was observed 
using SAXS and light microscopy. 
 
 
7.4 Outlook 
 
A project in our group was started to investigate the properties of such homochiral LCPs. 
Elucidation of the phase diagrams of the single diastereoisomers is in progress. Furthermore, 
experiments towards chiral recognition/separation will be performed. In order to exploit the 
chiral surface of these LCPs, metals could be coordinated to the lipids. The resulting catalytic 
LCP complex can then be used for asymmetric catalysis. 
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7.5 Experimental section 
 
General information 
Phytantriol was purchased from DSM. All other reagents and solvents were purchased from 
Sigma Aldrich. All chemicals and solvents were used as received, unless otherwise stated. 
Reactions were carried out under an inert atmosphere of argon in dry solvents. 
Dichloromethane was degassed with argon and purified by passage through activated 
alumina solvent column (MC Brown solvent system) prior to use. Column chromatography 
was performed using silica gel Merck 60 (particle size 0.040–0.063 mm). Analytical thin- layer 
chromatography (TLC) was performed using Merck pre-coated silica gel plates 60 F254; 
visualization by UV absorption and/or by dipping in a solution of KMnO4 (1 g), K2CO3 (2 g) in 
H2O (100 mL) and subsequent heating. 1H-NMR spectra were recorded on a Bruker AV2-500 
(500MHz) spectrometer. Chemical shifts are given in parts per million (ppm) relative to the 
internal standard TMS (δ = 0 ppm). Coupling constants J are expressed in Hz and 
multiplicities are abbreviated as follows: s (singlet), br (broad), d (doublet), t (triplet), q 
(quadruplet), quint (quintet), m (multiplet). 13C-NMR chemical shifts are reported relative to the 
solvent residual peaks: CDCl3 = 77.00 ppm. Mass spectra were recorded by the Mass 
Spectroscopy Service of UZH on Finnigan MAT95 MS, BrukerLC MS and Finnigan TSQ700 
MS machines.  
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7.5.1 Synthesis 
 
Synthesis of 130 ((2S,3S,7R,11R)-3,7,11,15-tetramethylhexadecane-1,2,3-triol)12 
 
 
 
To a round-bottomed flask, tert-butyl alcohol (5 mL), water (5 mL), and 1.4 g of AD-mix-α 
were added. The yellow mixture was allowed to stir at room temperature whereupon two clear 
phases were obtained. Methanesulfonamide (95 mg, 1 mmol, 1eq) was added. The reaction 
mixture was cooled to 0 °C which led to the precipitation of salts.	 Phytol (296 mg, 1 mmol, 
1  eq) was added and the reaction mixture was stirred for 22 h. Sodium sulfite (1.5 g) was 
added and the mixture was allowed to warm to room temperature. After 60 min, DCM (20 mL) 
was added and the phases were separated. The aqueous phase was extracted with DCM 
(3 x 20 mL) and the combined organic phases were washed with aqueous KOH 2 M (30 mL), 
dried over MgSO4 concentrated. The crude product was purified by flash chromatography 
(cyclohexane/ethylacetate 9:1) to give the product as colourless oil (235 mg, 0.71 mmol, 
71%). 1H NMR (400 MHz, Chloroform-d) δ 3.70 (d, J = 4.9 Hz, 2H), 3.46 (t, J = 4.3 Hz, 1H), 
2.07 (s, br, OH), 1.55 – 0.93 (m, 24H), 0.82 – 0.75 (m, 12H). 13C NMR (101 MHz, Chloroform-
d) δ 75.12, 70.55, 63.43, 39.81, 39.36, 37.53, 37.42, 37.39, 37.27, 32.79, 27.98, 24.79, 24.48, 
22.72, 22.62, 22.35, 21.05, 19.74, 19.68. HRMS (ESI [M + Na]+) m/z: calcd for (C20H42O3) 
353.30262, found 353.30224. 
 
 
Synthesis of 131 ((2R,3R,7R,11R)-3,7,11,15-tetramethylhexadecane-1,2,3-triol)12 
 
 
 
To a round-bottomed flask, tert-butyl alcohol (5 mL), water (5 mL), and 1.4 g of AD-mix-β 
were added. The yellow mixture was allowed to stir at room temperature whereupon two clear 
phases were obtained. Methanesulfonamide (95 mg, 1 mmol, 1eq) was added. The reaction 
mixture was cooled to 0 °C which led to the precipitation of salts.	 Phytol (296 mg, 1 mmol, 
1 eq) was added and the reaction mixture was stirred for 22 h. Sodium sulfite (1.5 g) was 
added and the mixture was allowed to warm to room temperature. After 60 min, DCM (20 mL) 
was added and the phases were separated. The aqueous phase was extracted with DCM 
(3 x 20 mL) and the combined organic phases were washed with aqueous KOH 2 M (30 mL), 
OH
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dried over MgSO4 concentrated. The crude product was purified by flash chromatography 
(cyclohexane/ethylacetate 9:1) to give the product as colourless oil (225 mg, 0.68 mmol, 68%) 
1H NMR (400 MHz, Chloroform-d) δ 3.70 (d, J = 4.9 Hz, 2H), 3.45 (t, J = 4.3 Hz, 1H), 2.07 (s, 
br, OH), 1.55 – 0.93 (m, 24H), 0.82 – 0.75 (m, 12H). 13C NMR (101 MHz, Chloroform-d) δ 
75.18, 74.58, 63.43, 39.80, 39.37, 37.53, 37.43 (2C), 37.28, 32.79 (2C), 27.97, 24.79, 24.49, 
22.71, 22.62, 22.34, 21.04, 19.74, 19.66. HRMS (ESI [M + Na]+) m/z: calcd for (C20H42O3) 
353.30262, found 353.30318. 
 
 
Commercial phytantriol (mixture of diastereoisomers) 
 
1H NMR (400 MHz, Chloroform-d) δ 3.70 (d, J = 4.9 Hz, 2H), 3.47 – 3.40 (m, 1H), 2.07 (s, br, 
OH), 1.55 – 0.93 (m, 24H), 0.82 – 0.75 (m, 12H). 13C NMR (126 MHz, Chloroform-d) δ 76.53, 
76.51, 75.67, 75.64, 74.69, 74.68, 74.52, 74.51, 63.34, 63.19, 39.61, 39.64, 39.35, 38.32, 
38.36, 37.81, 37.72, 37.62, 37.44, 37.41, 37.38, 37.27, 32.78, 27.95, 24.79, 24.78, 24.49, 
23.47, 23.44, 22.70, 22.61, 22.19, 22.16, 20.99, 20.95, 19.72, 19.67, 19.64, 19.61, 19.57, 
19.55. HRMS (ESI [M + Na]+) m/z: calcd for (C20H42O3) 353.30318. 
 
 
7.5.2 Langmuir Blodgett 
 
Surface pressure versus molecular area isotherms were recorded using the KSV LB through 
5000 equipped hydrophilic barriers. The experiment was controlled with software version KSV 
5000. A Wilhelmy balance was used as a surface pressure sensor. Surface pressure was 
recorded as function of molecular area. The accuracy of measurements of area per molecule 
was 1 Å2 and that of surface pressure was 1 mN/m. After the solution was spread, it was left 
for 15 min for solvent evaporation. Compression was accomplished with a barrier speed of 
7.5 cm2/min. Temperature was kept at 22 ± 1 °C. 
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7.5.3 Brewster Angle Microscopy 
 
Brewster angle microscopy experiments were performed using a Nanofilm Ep3 instrument 
(Accurion GmbH, Germany) equipped with an UltraBam objective (10 x magnification), 
50 mW solid-state laser emitting p-polarized light at a wavelength of 658 nm and a CCD 
camera. The lateral resolution of the UltraBam objective is 2 µm. Images were captured 
during the compression of the monolayers at the air-water interface and each picture 
represents the area of 320 µm x 410 µm. 
 
 
7.5.4 Small angle X-ray scattering (SAXS)  
 
Experiments were performed on a Bruker AXS Micro, with a microfocused X-ray source, 
operating at voltage filament current of 50 kV and 1.000 µA, respectively. The Cu Kα radiation 
(λCu Kα =1.5418 Å) was collimated by a 2D Pilatus 100K detector. The scattering vector 
q = (4π/λ)sinθ, with 2θ being the scattering angle, was calibrated using silver behenate. Data 
were collected and azimuthally averaged using the Saxsgui software to yield one-dimensional 
intensity versus scattering vector q, with a q range from 0.004 – 0.5 Å-1. The samples were 
placed inside a stainless-steel cell between two thin replaceable mica sheets and sealed by 
an O-ring, with a sample volume of 10 µL and a thickness of ~1 mm. Measurements were 
performed at 23°C, and samples were equilibrated for 15 min before measurements, whereas 
scattered intensity was collected over 30 min.  
 
 
7.5.5 Light microscopy 
 
Images were taken under cross-polarized light using a Zeiss Axioskop 2 mot microscope. 
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Cyclopropanated lipids: Synthesis and mesophases 
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8.1 Introduction 
 
Due to their unique properties, LCPs find applications in a wide range of fundamental and 
applied fields. Landau and Rosenbusch introduced the concept of LCPs for the solubilization, 
stabilization, and crystallization of membrane proteins.1 Ca. 31% of all X-ray structures of 
membrane proteins currently available were obtained with this method.2 However, many 
membrane proteins are unstable at ambient temperature and should preferentially be studied 
at low temperatures. Available LCPs are inapplicable in such cases, as they undergo phase 
transitions at low temperatures. A research program to address this problem was launched in 
our group, yielding to MDS, a first cyclopropanated lipid which showed extended cubic phase 
boundary to lower temperature and enabled crystallization of bacteriorhodopsin at 4 °C.3 Lipid 
polymorphism is a complex phenomenon based on a variety of parameters. Correlating 
molecular structures of lipids with the ensuing mesophase is therefore a major challenge.4 
Phase transitions are strongly governed by the lipid’s molecular structure, i.e. on the nature of 
the head group and the length and curvature of the chain. It has been shown that the chain 
splay plays a pivotal role affecting the phase behavior of monoacylglycerols.5 Varying 
systematically structural elements of the lipids might allow to gain information on how such 
changes affect phase behavior. To this end, a series of naturally occurring cis-
monoacylglycerols that are known to form LCPs have been modified by replacing the cis-
double bond with a cyclopropyl ring to obtain a small library of novel designer lipids (Figure 1).  
 
 
Figure 1: The most common monoacylglycerols (left column) and their cyclopropyl-analogues (right 
column). 
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Olefins and cyclopropanes have some characteristics in common; their chemical properties 
and the curvature of the cis-monoacylglycerols and their cyclopropyl analogues are similar, 
since the two functional groups have their residues attached in similar angles. However, the 
main difference is the change from sp2 to sp3 hybridized carbon atoms at the corresponding 
functional group. In contrast to classical cis-monoacylglycerols, our designer lipids protrude 
out of the plane of the molecule due to the tetrahedral geometry of the sp3 carbon atoms at 
the cyclopropyl ring, resulting in a kink in the molecule that locks the cis geometry. 
The cyclopropane modification is naturally inspired; cyclopropanated phospholipids are 
prevailed among the realm of bacteria. Their presence improves survival of bacterial 
pathogens like M. tuberculosis6 and leads to resistance of the E. coli cell membrane against 
acid and cold shock.7 Furthemore, cyclopropanated phospholipids seem to play an important 
role in membrane property regulation.7 
 
 
8.2 Results and discussion 
 
We hypothesized that the rigidity of the lipidic chain of the target compounds can be modified 
by varying the position and the number of the cyclopropyl moiety as well as the length of the 
lipidic tail. Cyclopropanated analogues of cis-monoacylglycerols that are known to exhibit 
lipidic cubic phases were targeted. By systematically substituting the carbon-carbon double 
bond with a cyclopropyl ring, a library of cyclopropanated lipids with variying lipidic tail length, 
location of cyclopropanation and number of cycloproanation have been prepared (Figure 1): 
monodihydrosterculin (MDS, 132),3 cyclopropyl monopalmitolein (CPMP, 134), 
monolactobacillin (MLB, 136), dicyclopropyl monolinolein (DCPML, 138) and tricyclopropyl 
monolinolenin (TCPMLN, 140). In summary, these comprise: 
 
• Lipids with with modification at C9 position and C16 and C18 chains (CPMP, C16) and 
(MDS, C18). 
 
• The location of the cyclopropyl ring of lipids with a C18 was shifted from position C9 
(MDS) to position C11 (MLB). 
 
• Lipids with one (MDS, CPMP, MLB), two (DCPML) and three cyclopropyl groups 
(TCPMLN). 
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8.2.1 Synthesis of cyclopropanated lipids 
 
Cyclopropanation of olefins 1, 133, 135, 137 and 139 was performed using diethyl zinc and 
diiodomethane in the presence of 2,4,6-trichlorophenol according to a reported procedure8 to 
afford the corresponding cyclopropanated acids 141 - 145 with yields ranging from 61 to 73 
%. Due to safety concerns, this procedure was not scaled up, although a great quantity of lipid 
was required. The maximum amount of lipid that was cyclopropanated was 3 g in one batch to 
ensure efficient cooling. However, up to three batches were conducted in parallel. 
 
 
Scheme 1: Two step synthesis of cyclopropanated lipids MDS, CPMP, MLB, DCPML and TCPMLN 
from commercially available olefins. Conditons: a) 2,4,6-Trichlorophenol, CH2I2, ZnEt2, CH2Cl2, -40 °C. 
b) EDC/DMAP, DMF/ CH2Cl2 (1:1), r.t.. 
 
The esterification underwent an optimization process, since initial yields below 50 % were 
obtained when using EDC/DMAP in CH2Cl2. Transesterification was tried starting from 
methylesters of 141 using P1-phosphazen. However, the high reported yields could not be 
reproduced.9 Therefore, the initially applied method using EDC/DMAP was modified. First, a 
mixture of DMF and CH2Cl2 was used instead of pure CH2Cl2, since glycerol is only 
moderately soluble in CH2Cl2. The rate of glycerol addition to the activated acid is crucial; the 
formation of di-esterified product (Figure 2) was almost completely prevented when glycerol is 
added over a period of 2 h, leading to better yields between 55 and 78 %.  
 
 
Figure 2: Structures of di-esterified side products DCPDL (146) and TCPDLN (147).  
 
Since mesophases of multiple cyclopropanated lipids DCPML and TCPLN show highly 
interesting properties (see page 196), the di-esterified side products were isolated as well and 
characterized for future investigations (Figure 2). 
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The final products also contain the 2-substituted products that are formed upon 
transesterification. In equilibrium, these amount to 6 – 10 % of the 1-substituted products. 
 
 
8.2.2 Phase behavior of the designer cyclopropyl lipids 
 
The following paragraph summarizes the data obtained from investigations of the 
mesophases of cyclopropanated lipids. This work was performed in collaboration with the 
group of Prof. Raffaele Mezzenga.10 After successfully synthesizing the five designed 
cyclopropyl analogues MDS (132),3 CPMP (134), MLB (136), DCPML (138) and TCPMLN 
(140), their phase behavior was investigated using small angle X-ray scattering (SAXS). The 
phase diagrams were built by systematically varying temperature and hydration degree of the 
water/lipid system. The MDS/water phase diagram, together with a first membrane protein 
crystallization therein, has been published by Salvati Manni et al.3 The most important results 
are briefly summarized: The MDS/water phase diagram shows some important differences to 
its MO/water analogue, which arise from the structural difference of the lipids. The cubic 
phases appear in a broader range, i.e. to a higher water content and can therefore 
accommodate more water. Remarkably, MDS was shown to form cubic phases at lower 
temperatures than MO. A comparable effect was found for the corresponding 
phosphatidylethanolamines.11,12 The fact that the installation of a cyclopropyl moiety has a 
profound effect on the phase behavior of the lipid reinforced our hypothesis and led to a 
further investigation of this phenomenon by studying the phase diagrams of the remaining 
cyclopropylated lipids CPMP (134), MLB (136), DCPML (138) and TCPMLN (140). CPMP and 
MLB show similar phase diagrams like the corresponding monoacylglycerols. DCPML, on the 
other hand, exhibits an unusual and highly remarkable phase behavior. The typical sequence 
of phase transitions at ambient temperatures for most hydrated monoacylglycerols, including 
unmodified ML is Lα, Ia3d, Pn3m. However, DCPML showed a phase transition from Ia3d to 
HII instead. A stable HII phase at room temperature and 37 °C is a novelty, and can usually 
only obtained by adding hydrophobic molecules like tetradecane or oleic acid to other 
monoacylglycerols13,14 or if the ester group of the lipid is replaced with an ether linkage.15 
Moreover, the release of hydrophilic molecules from HII phases is slower as compared to 
LCPs, which makes this phase interesting for several applications. HII phases have been used 
as membrane protein reconstitution16 matrix and for drug delivery.17,18 Thus, with our DCPML 
HII phases a simpler binary system is introduced, thereby avoiding the difficulties of available 
ternary systems. Having a stable HII phases present at room temperature indicates that the 
entire phase diagram is shifted to lower temperatures and hydration. Therefore, low 
temperature phase behavior was investigated as well. 
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8.2.3 Low temperature phase behavior of DCPML 
 
Investigating the phase behavior of DCPML yielded highly interesting results; a cubic 
phase was observed at lower temperature than expected. A DCPML sample with 12 % w/w of 
water was analyzed by SAXS at low temperature. The sample was slowly cooled to -20 
°C (1 °C/min) and kept there for 3 h. Subsequently, the temperature was slowly increased 
from -20 to 22 °C while SAXS spectra were acquired. The phase transition from Lα to Ia3d 
phase at -15 °C and -10 °C when heating and cooling the sample, proves the presence of a 
stable cubic phase at sub-zero temperatures. This observation is remarkable, as all other 
known synthetic or natural monoacylglycerols crystallize in a lamellar crystalline (Lc) phase at 
low temperatures. MO, the most common monoacylglycerol exhibits a Lc phase below 10 °C 
and coexists at any water concentration below 0 °C as a Lc and ice.19 
A possible explanation for this phenomenon is the presence of bound water that is formed 
within the confined aqueous channels of this mesophase. To test this hypothesis, differential 
scanning calorimetry (DSC) was performed. This technique allows to resolve the first-order 
transitions of confined and free water, which usually differ from each other. In a reference 
sample of pure water, a sharp first-order peak appears at 0 °C, when heated up from -70 °C. 
The water in this DCPML mesophases is confined in planes (Lα) or channels (Ia3d, HII) which 
change their thickness and radii, respectively, while altering the lipid/water composition. Using 
DSC, the changes of the freezing temperature can be monitored depending on the lipid/water 
composition. Remarkably, the first-order peak is completely absent in DCPML samples with 5 
and 10 % w/w of water while a sharp peak appears in the sample of 20 and 25 % w/w water. 
When the water content is lowered, a peak broadening occurs, indicating the presence of 
confined water which is of a different nature. The absence of the first order peak at low 
hydration degrees of 5 and 10 % w/w in Ia3d and Lα mesophases suggests that the water is 
confined, which prevents it from freezing. The fact that water confined in space from 1 to 
100 nm might not freeze has been reported.20 In confined space, the orientation of water 
molecules is restricted, and they are prevented from forming a tetrahedral ice structure. 
Freezing is thus hindered, which leads to a state of super-cooled water.20 Control experiments 
were carried out on commercial monolinolein (ML), the natural analogue of DCPML. A first 
order transition at all water/lipid compositions was observed. This phenomenon was further 
confirmed by temperature dependent neutron elastic and inelastic scattering on a sample with 
7.5 % w/w water, in which no phase transition was observed at 0 °C. Wide angle X-ray 
scattering (WAXS) measurements showed that the ice is present in hexagonal structure in the 
samples with higher hydrations (20 and 25 % w/w of water), while there is absence of 
crystalline structures for the other samples. Furthermore, diffusion NMR on a DCPML sample 
with 10 % w/w water revealed water mobility down to -11 °C.  
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8.3 Conclusions 
 
In addition to the previously reported MDS, four new cyclopropanated monoacylglycerol 
derivatives have been synthesized. Both steps of the synthesis of these compounds - 
cyclopropanation and esterification - could be optimized, and disubstituted side products 146 
and 147 were isolated and characterized. The phase diagrams of MLB and DCPML have 
been completed. DCPML shows a highly interesting and unusual phase behavior, especially 
at sub-zero temperatures, where confined liquid water was found. This is an extremely 
important property, not only from a fundamental science perspective but also for applications 
in various fields such as membrane protein crystallization. Furthermore, such mesophases, in 
which water is liquid until -11 °C constitute unprecedented matrices to study the kinetics of 
chemical or biochemical reactions. 
 
 
8.4 Outlook 
 
Increasing the number of cyclopropane rings at the C18 carbon chain from one (MDS) to two 
(DCPML) led to significantly different phase behavior of the corresponding mesophases. 
Therefore, threefold cyclopropanate TCPMLN (140) was synthesized and its phase behavior 
will be studied. Furthermore, the cyclopropanation of arachidonic acid to obtain a fourfold 
cyclopropanated C20 lipid is planned. 
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8.5 Experimental Section 
 
General Information 
Natural fatty acids were purchased from Nu-Chek Prep, Inc. (MN, USA). N-(3- 
dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride (EDC) was purchased from TCI, and 
all other reagents and solvents were purchased from Sigma Aldrich. All chemicals and 
solvents were used as received, unless otherwise stated. Reactions were carried out under 
an inert atmosphere of argon in dry solvents. Dichloromethane was degassed with argon and 
purified by passage through activated alumina solvent column (MC Brown solvent system) 
prior to use. Column chromatography was performed using silica gel Merck 60 (particle size 
0.040–0.063 mm). Analytical thin- layer chromatography (TLC) was performed using Merck 
pre-coated silica gel plates 60 F254; visualization by UV absorption and/or by dipping in a 
solution of KMnO4 (1 g), K2CO3 (2 g) in H2O (100 mL) and subsequent heating. 1H-NMR 
spectra were recorded on a Bruker AV2-500 (500MHz) spectrometer. Chemical shifts are 
given in parts per million (ppm) relative to the internal standard TMS (δ = 0 ppm). Coupling 
constants J are expressed in Hz and multiplicities are abbreviated as follows: s (singlet), br 
(broad), d (doublet), t (triplet), q (quadruplet), quint (quintet), m (multiplet). 13C-NMR chemical 
shifts are reported relative to the solvent residual peaks: CDCl3 = 77.00 ppm. Mass spectra 
were recorded by the Mass Spectroscopy Service of UZH on Finnigan MAT95 MS, BrukerLC 
MS and Finnigan TSQ700 MS machines.  
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Synthesis of 141 (8-(2-octylcyclopropyl)octanoic acid, Cp-oleic acid)3 
 
 
 
To a stirred solution of 2,4,6-trichlorophenol (8.60 g, 43.5 mmol, 4 eq) in 200 mL of dry CH2Cl2 
at -40 °C under argon was added a 0.9 M hexane solution of diethyl zinc (49 mL, 44 mmol, 
4.04 eq). The solution was stirred for 15 min at -40 °C and then diiodomethane (11.66 g, 
3.50 mL, 43.5 mmol, 4 eq) was slowly added over a period of 10 min. After stirring for 15 min 
at the same temperature oleic acid (3.07 g, 3.46 mL, 10.88 mmol, 1 eq) was added. The 
reaction mixture was stirred at -40 oC for an additional 1 h and then allowed to warm to r.t. 
and stirred overnight. The mixture was washed with 300 mL of 10 % HCl. The organic phase 
was separated and the aqueous phase was extracted with CH2Cl2 (3 x 150 mL). The 
combined organic phases were washed with a saturated solution of NaCl and dried over 
MgSO4. The solvent was removed under reduced pressure and the residue was purified by 
column chromatography on silica gel, starting with CH2Cl2, and after elution of excess 2,4,6-
trichlorophenol with CH2Cl2/MeOH 95:5 to get the product as colourless solid (2.11 g, 
7.1 mmol, 65 %). Analytical data were identical with the values reported in literature.3 
 
 
Synthesis of 132 (2,3-dihydroxypropyl 8-(2-octylcyclopropyl)octanoate, MDS) 
 
 
 
To a stirred solution of acid (660 mg, 2.23 mmol, 1 eq) in 50 mL of a mixture of dry 
CH2Cl2/DMF (3:1) was added EDC (556 mg, 2.90 mmol, 1.3 eq) followed by DMAP (27 mg, 
0.223 mmol, 0.01 eq) at 0 °C under argon. The solution was stirred for 1 h at 0 °C and then 
was added dropwise over a period of 30 min to a solution of glycerol (1.23 g, 13.38 mmol, 
6 eq) in 50 mL of dry DMF at 0 °C. The mixture was stirred for 12 h at room temperature and 
then washed with a saturated solution of NaHCO3. The organic phase was separated and the 
aqueous phase was extracted with CH2Cl2 (3 x 100 mL). The combined organic phases were 
washed with brine and dried over MgSO4. The solvent was removed under reduced pressure 
and the residue was purified by column chromatography on silica gel and eluted with a 
mixture of cyclohexane/ethylacetate 8:2 to 4:6. The solvent was removed to give the product 
(571 mg, 1.54 mmol 69 %) as a slightly yellowish oil. Analytical data were identical with the 
values reported in literature.3 
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Synthesis of 142 (8-(2-hexylcyclopropyl)octanoic acid, Cp-palmitoleic acid)3 
 
 
 
To a stirred solution of 2,4,6-trichlorophenol (8.60 g, 43.5 mmol, 4 eq) in 250 mL of dry CH2Cl2 
at -40 °C under argon was added a 0.9 M hexane solution of diethyl zinc (49 mL, 44 mmol, 
4.04 eq). The solution was stirred for 15 min at -40 °C and then diiodomethane (11.66 g, 
3.50 mL, 43.5 mmol, 4 eq) was slowly added over a period of 10 min. After stirring for 15 min 
at the same temperature, palmitoleic acid (2.77 g, 3.10 mL 10.88 mmol, 1 eq) was added. The 
reaction mixture was stirred at -40 oC for an additional 1 h and then allowed to warm to r.t. 
and stirred overnight. The mixture was washed with 300 mL of 10 % HCl. The organic phase 
was separated and the aqueous phase was extracted with CH2Cl2 (3 x 150 mL). The 
combined organic phases were washed with a saturated solution of NaCl and dried over 
MgSO4. The solvent was removed under reduced pressure and the residue was purified by 
column chromatography on silica gel, starting with CH2Cl2, and after elution of excess 2,4,6-
trichlorophenol with CH2Cl2/MeOH 95:5 to get the product as a slightly yellow oil (2.13 g, 7.94 
mmol, 73 %). 1H NMR (500 MHz, CDCl3) δ 2.28 (t, J = 7.5 Hz, 2H), 1.57 (q, J = 7.5 Hz, 2H), 
1.14 – 1.36 (m, 18H), 1.01 – 1.12 (m, 2H), 0.82 (t, J = 7.0 Hz, 3H), 0.46 – 0.62 (m, 3H), - 0.39 
- -0.42 (m, 1H). 13C-NMR (125 MHz, CDCl3) 179.22, 33.91, 31.95, 30.18, 30.12, 29.42, 29.34, 
29.28, 29.07, 28.72, 28.66, 24.70, 22.69, 15.77, 15.73, 14.11, 10.91. HRMS (ESI [M - H]-) 
m/z: calcd for (C17H31O2) 267.23295, found 267.23271. 
 
 
Synthesis of 134 (2,3-dihydroxypropyl 8-(2-hexylcyclopropyl)octanoate, CPMP) 
 
 
 
To a stirred solution of acid (600 mg, 2.23 mmol, 1 eq) in 50 mL of a mixture of dry 
CH2Cl2/DMF (3:1) was added EDC (556 mg, 2.90 mmol, 1.3 eq) followed by DMAP (27 mg, 
0.223 mmol, 0.01 eq) at 0 °C under argon. The solution was stirred for 1 h at 0 °C and then 
was added dropwise over a period of 30 min to a solution of glycerol (1.23 g, 13.38 mmol, 
6 eq) in 50 mL of dry DMF at 0 °C. The mixture was stirred for 12 h at room temperature and 
then washed with a saturated solution of NaHCO3. The organic phase was separated and the 
aqueous phase was extracted with CH2Cl2 (3 x 100 mL). The combined organic phases were 
washed with brine and dried over MgSO4. The solvent was removed under reduced pressure 
and the residue was purified by column chromatography on silica gel and eluted with a 
mixture of cyclohexane/ethylacetate 8:2 to 4:6. The solvent was removed to give colourless 
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solid product (420 mg, 1.23 mmol, 55 %). 1H-NMR (500 MHz, CDCl3) δ 4.86 (quint, J = 4.7 
Hz, 1H of 2-NMH), 4.13 (dd, J = 11.7, 4.6 Hz, 1H), 4.08 (dd, J = 11.6, 6.2 Hz, 1H), 3.84 – 3.89 
(m, 1H), 3.76  (t, J = 5.2 Hz, 4H of 2-NMH), 3.59 – 3.68 (m, 1H), 3.50 – 3.56 (m, 1H), 2.64 (br 
d, OH), 2.26 – 2.34 (m, 2H), 2.18 – 2.25 (m, 1 H), 1.52 – 1.60 (m, 2H), 1.14 – 1.35 (m, 18H), 
1.01 – 1.12 (m, 2H), 0.82 (t, J = 6.8 Hz, 3H), 0.46 – 0.62 (m, 3H), -0.40 (q, J = 5.1 Hz, 1H). 
13C-NMR (125 MHz, CDCl3) δ 174.34, 70.27, 65.16, 63.35, 34.15, 31.94, 30.16, 30.11, 29.42, 
29.33, 29.28, 29.13, 28.71, 28.65, 24.91, 22.68, 15.76, 15.71, 14.10, 10.91. HRMS (ESI [M + 
Na]+) m/z: calcd for (C20H38O4Na) 365.26623, found 365.26647 
 
 
Synthesis of 143 (10-(2-hexylcyclopropyl)decanoic acid, Cp-vaccenic acid)3 
 
 
 
To a stirred solution of 2,4,6-trichlorophenol (8.60 g, 43.5 mmol, 4 eq) in 200 mL of dry CH2Cl2 
at -40 °C under argon was added a 0.9 M hexane solution of diethyl zinc (49 mL, 44 mmol, 
4.04 eq). The solution was stirred for 15 min at -40 °C and then diiodomethane (11.66 g, 
3.50 mL, 43.5 mmol, 4 eq) was slowly added over a period of 10 min. After stirring for 15 min 
at the same temperature vaccenic acid (3.07 g, 3.46 mL, 10.88 mmol, 1 eq) was added. The 
reaction mixture was stirred at -40 oC for an additional 1 h and then allowed to warm to r.t. 
and stirred overnight. The mixture was washed with 300 mL of 10 % HCl. The organic phase 
was separated and the aqueous phase was extracted with CH2Cl2 (3 x 150 mL). The 
combined organic phases were washed with a saturated solution of NaCl and dried over 
MgSO4. The solvent was removed under reduced pressure and the residue was purified by 
column chromatography on silica gel, starting with CH2Cl2, and after elution of excess 2,4,6-
trichlorophenol with CH2Cl2/MeOH 95:5 to get the product as colourless solid (2.29 g, 
7.72 mmol, 71 %). 1H-NMR (500 MHz, CDCl3) δ 2.28 (t, J = 7.5 Hz, 2H), 1.56 (quint, J = 7.4 
Hz, 2H), 1.14 – 1.37 (m, 22H), 1.01 – 1.15 (m, 2H), 0.82 (t, J = 6.9 Hz, 3H), 0.47 – 0.61 (m, 
3H), -0.40 (q, J = 5.1 Hz, 1H). 13C-NMR (125 MHz, CDCl3) δ 179.63, 33.97, 31.95, 30.19 (2C), 
29.63 (2C), 29.44, 29.36, 29.25, 29.07, 28.73, 28.71, 24.69, 22.70, 15.77, 15.76, 14.12, 
10.91. HRMS (ESI [M - H]-) m/z: calcd for (C19H35O2) 295.26425, found 295.26394. 
 
 
  
OH
O
Chapter 8 
 
 
 
202 
Synthesis of 136 (2,3-dihydroxypropyl 10-(2-hexylcyclopropyl)decanoate, MLB) 
 
 
 
To a stirred solution of acid (660 mg, 2.23 mmol, 1 eq) in 50 mL of a mixture of dry 
CH2Cl2/DMF (3:1) was added EDC (556 mg, 2.90 mmol, 1.3 eq) followed by DMAP (27 mg, 
0.223 mmol, 0.01 eq) at 0 °C under argon. The solution was stirred for 1 h at 0 °C and then 
was added dropwise over a period of 30 min to a solution of glycerol (1.23 g, 13.38 mmol, 
6 eq) in 50 mL of dry DMF at 0 °C. The mixture was stirred for 12 h at room temperature and 
then washed with a saturated solution of NaHCO3. The organic phase was separated and the 
aqueous phase was extracted with CH2Cl2 (3 x 100 mL). The combined organic phases were 
washed with brine and dried over MgSO4. The solvent was removed under reduced pressure 
and the residue was purified by column chromatography on silica gel and eluted with a 
mixture of cyclohexane/ethylacetate 8:2 to 4:6. The solvent was removed to give the product 
(480 mg, 1.29 mmol, 58 %) as a slightly yellowish oil. 1H-NMR (500 MHz, CDCl3) δ 4.86 
(quint, 1H of 2-MLB), 4.13 (dd, J = 11.7, 4.7 Hz, 1H), 4.09 (dd, J = 11.7, 6.1 Hz, 1H), 3.83 – 
3.89 (m, 1H), 3.75 – 3.78 (m, 4H of 2-MLB), 3.62 (dd, J = 11.4, 4.0 Hz, 1H), 3.53 (dd, J = 
11.5, 5.8 Hz, 1H), 2.24 – 2.35 (m, 2H), 2.04 (br s, 2H, OH), 1.52 – 1.61 (m, 2H), 1.15 – 1.37 
(m, 22H), 1.01 – 1.12 (m, 2H), 0.82 (t, J = 7.8 Hz, 3H), 0.45 – 0.67 (m, 3H), -0.35 – -0.46 (m, 
1H). 13C-NMR (125 MHz, CDCl3) δ 174.34, 70.26, 65.16, 63.32, 34.15, 31.94, 30.19, 30.17, 
29.62 (2C), 29.45, 29.34, 29.24, 29.13, 28.71, 28.70, 24.91, 22.69, 15.76, 15.74, 14.12, 
10.90. HRMS (ESI [M + Na]+) m/z: calcd for (C22H42O4Na) 393.29753, found 393.29757. 
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Synthesis of 144 (8-(2-((2-pentylcyclopropyl)methyl)cyclopropyl)octanoic) acid, 2-Cp-
linoleic acid)3 
 
 
 
To a stirred solution of 2,4,6-trichlorophenol (8.60 g, 43.5 mmol, 4 eq) in 200 mL of dry CH2Cl2 
at -40 °C under argon was added a 0.9 M hexane solution of diethyl zinc (49 mL, 44 mmol, 
4.04 eq). The solution was stirred for 15 min at -40 °C and then diiodomethane (11.66 g, 
3.50 mL, 43.5 mmol, 4 eq) was slowly added over a period of 10 min. After stirring for 15 min 
at the same temperature linoleic acid (1.53 g, 1.70 mL, 5.44 mmol, 0.5 eq) was added. The 
reaction mixture was stirred at -40 oC for an additional 1 h and then allowed to warm to r.t. 
and stirred overnight. The mixture was washed with 300 mL of 10 % HCl. The organic phase 
was separated and the aqueous phase was extracted with CH2Cl2 (3 x 150 mL). The 
combined organic phases were washed with a saturated solution of NaCl and dried over 
MgSO4. The solvent was removed under reduced pressure and the residue was purified by 
column chromatography on silica gel eluted, starting with CH2Cl2, and after elution of excess 
2,4,6-trichlorophenol with CH2Cl2/MeOH 95:5 to get the product as a slightly yellow oil as a 
mixture of diastereoisomers (1.16 g, 3.75 mmol, 69 %). 1H-NMR (500 MHz, CDCl3) δ 2.28 (t, 
J = 7.5 Hz, 1H), 1.51 – 1.62 (m, 2H), 1.17 – 1.46 (m, 17H), 0.91 – 1.15 (m, 3H), 0.82 (t, J = 
6.8 Hz, 3H), 0.67 – 0.75 (m, 2H), 0.51 – 0.66 (m, 4H), -0.30 – -0.40 (m, 2H). 13C-NMR (125 
MHz, CDCl3) δ 179.90, 34.06, 31.90, 30.13, 29.89, 29.42, 29.30, 29.08, 28.88, 28.87, 28.72, 
28.70, 28.02, 27.87, 24.70, 22.72, 16.05, 15.93, 15.91, 15.88, 15.66, 15.61, 14.12, 11.02, 
10.84. HRMS (ESI [M - H]-) m/z: calcd for (C20H35O2) 307.26425, found 307.26407. 
 
 
Synthesis of 138 (2,3-dihydroxypropyl 8-(2-((2-
pentylcyclopropyl)methyl)cyclopropyl)octanoate, DCPML) 
 
 
 
To a stirred solution of acid (688 mg, 2.23 mmol, 1 eq) in 50 mL of a mixture of dry 
CH2Cl2/DMF (3:1) was added EDC (556 mg, 2.90 mmol, 1.3 eq.) followed by DMAP (27 mg, 
0.223 mmol, 0.01 eq) at 0 °C under argon. The solution was stirred for 1 h at 0 °C and then 
was added dropwise over a period of 30 min to a solution of glycerol (1.23 g, 13.38 mmol, 
6 eq) in 50 mL of dry DMF at 0 °C. The mixture was stirred for 12 h at room temperature and 
then washed with a saturated solution of NaHCO3. The organic phase was separated and the 
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aqueous phase was extracted with CH2Cl2 (3 x 100 mL). The combined organic phases were 
washed with brine and dried over MgSO4. The solvent was removed under reduced pressure 
and the residue was purified by column chromatography on silica gel and eluted with a 
mixture of cyclohexane/ethylacetate 8:2 to 4:6. The solvent was removed to give the product 
(605 mg, 1.58 mmol, 71 %) as a slightly yellowish oil. 1H NMR (400 MHz, CDCl3) δ 4.86 
(quint, J = 4.8 Hz, 1H of 2-subst), 4.13 (dd, J = 11.7, 4.7 Hz, 1H), 4.09 (dd, J = 11.6, 6.1 Hz, 
1H), 3.83 – 3.90 (m, 1H), 3.75 – 3.78 (m, 4H of 2-subst), 3.62 (dd, J = 11.5, 4.0 Hz, 1H), 3.54 
(dd, J = 11.5, 5.8 Hz, 1H), 2.25 – 2.34 (m, 2H), 2.18 (br s, 2H, OH), 1.52 – 1.61 (m, 2H), 1.17 
– 1.47 (m, 17H), 0.91 – 1.13 (m, 3H), 0.82 (t, J = 7.0 Hz,  3H), 0.68 – 0.77 (m, 2H), 0.51 – 
0.65 (m. 4H) -0.29 – -0.39 (m, 2H). 13C-NMR (125 MHz, CDCl3) δ 174.34, 70.25, 65.13, 
63.32, 34.14, 31.88, 30.11, 29.87, 29.41, 29.28, 29.12, 28.86, 28.84, 28.69, 28.68, 28.01, 
27.85, 24.90, 22.70, 16.03, 15.91, 15.91, 15.89, 15.85, 15.64, 15.58, 14.10, 11.01, 10.82. 
HRMS (ESI [M + Na]+) m/z: calcd for (C23H42O4Na) 405.29753, found 405.29715. 
 
 
Synthesis of 146 (2-hydroxypropane-1,3-diyl bis(8-(2-((2-
pentylcyclopropyl)methyl)cyclopropyl)octanoate), DCPDL) 
 
 
 
Isolated as a side product of 138. 
1H NMR (500 MHz, Chloroform-d) δ 4.19 – 3.93 (m, 5H), 2.28 (t, J = 7.6 Hz, 4H), 1.60 – 1.52 
(m, 4H), 1.46 – 1.38 (m, 1H), 1.37 – 1.16 (m, 32H), 1.13 – 1.01 (m, 4H), 0.96 (dt, J = 14.3, 7.9 
Hz, 1H), 0.82 (t, J = 6.8 Hz, 6H), 0.76 – 0.67 (m, 4H), 0.66 – 0.57 (m, 4H), 0.56 – 0.51 (m, 
4H), -0.31 – -0.38 (m, 4H). 13C NMR (126 MHz, Chloroform-d) δ 173.89 (2C), 68.42, 65.04 
(2C), 34.10 (2C), 31.89 (2C), 30.13 (2C), 29.89 (2C), 29.43 (2C), 29.30 (2C), 29.14 (2C), 
28.87 (2C), 28.70 (2C), 28.03 (2C), 27.87 (2C), 16.05 (2C), 15.91 (2C), 15.87 (2C), 15.66 
(2C), 15.60 (2C), 14.12 (2C), 11.02 (2C), 10.84 (2C). HRMS (ESI [M + H]+) m/z: calcd for 
(C43H77O5) 673.57655, found 673.57643. 
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Synthesis of 145 (8-(2-((2-((2-
ethylcyclopropyl)methyl)cyclopropyl)methyl)cyclopropyl)octanoic acid, (3-Cp-linolenic 
acid)3  
 
 
 
To a stirred solution of 2,4,6-trichlorophenol (8.60 g, 43.5 mmol, 4 eq) in 200 mL of dry CH2Cl2 
at -40 °C under argon was added a 0.9 M hexane solution of diethyl zinc (49 mL, 44 mmol, 
4.04 eq). The solution was stirred for 15 min at -40 °C and then diiodomethane (11.66 g, 
3.50 mL, 43.5 mmol, 4 eq) was slowly added over a period of 10 min. After stirring for 15 min 
at the same temperature α-linolenic acid (1.01 g, 1.10 mL, 3.63 mmol) was added. The 
reaction mixture was stirred at -40 oC for an additional 1 h and then allowed to warm to r.t. 
and stirred overnight. The mixture was washed with 300 mL of 10 % HCl. The organic phase 
was separated and the aqueous phase was extracted with CH2Cl2 (3 x 150 mL). The 
combined organic phases were washed with a saturated solution of NaCl and dried over 
MgSO4. The solvent was removed under reduced pressure and the residue was purified by 
column chromatography on silica gel, starting with CH2Cl2, and after elution of excess 2,4,6-
trichlorophenol with CH2Cl2/MeOH 95:5 to get the product as a mixture of diastereoisomers as 
a slightly yellow oil (0.71 g, 2.21 mmol, 61 %). 1H NMR (500 MHz, Chloroform-d) δ 2.27 (t, J = 
7.5 Hz, 2H), 1.56 (p, J = 7.4 Hz, 2H), 1.50 – 1.40 (m, 1H), 1.39 – 1.02 (m, 15H), 1.02 – 0.95 
(m, 1H), 0.92 (td, J = 7.2, 2.1 Hz, 3H), 0.83 – 0.66 (m, 4H), 0.65 – 0.50 (m, 4H), -0.24 – 0.39 
(m, 3H). 13C NMR (126 MHz, Chloroform-d) δ 180.61, 34.12, 30.11, 29.40, 29.27, 29.06, 
28.85, 28.69, 28.21, 28.11, 28.05, 27.97, 27.95, 27.90, 27.79, 24.65, 22.12, 21.96, 17.85, 
17.57, 16.25, 16.17, 16.09, 16.05, 15.92, 15.88, 15.82, 15.62, 14.46, 11.11, 11.02, 10.91, 
10.84, 10.76, 10.72, 10.60. HRMS (ESI [M - H]-) m/z: calcd for (C21H35O2) 319.26425, found 
319.26403. 
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Synthesis of 140 (2,3-dihydroxypropyl 8-(2-((2-((2-
ethylcyclopropyl)methyl)cyclopropyl)methyl)cyclopropyl)octanoate, TCPMLN) 
 
 
 
To a stirred solution of acid (688 mg, 2.23 mmol, 1 eq) in 50 mL of a mixture of dry 
CH2Cl2/DMF (3:1) was added EDC (556 mg, 2.90 mmol, 1.3 eq) followed by DMAP (27 mg, 
0.223 mmol, 0.01 eq) at 0 °C under argon. The solution was stirred for 1 h at 0 °C and then 
was added dropwise over a period of 30 min to a solution of glycerol (1.23 g, 13.38 mmol, 
6 eq) in 50 mL of dry DMF at 0 °C. The mixture was stirred for 12 h at room temperature and 
then washed with a saturated solution of NaHCO3. The organic phase was separated and the 
aqueous phase was extracted with CH2Cl2 (3 x 100 mL). The combined organic phases were 
washed with brine and dried over MgSO4. The solvent was removed under reduced pressure 
and the residue was purified by column chromatography on silica gel and eluted with a 
mixture of cyclohexane/ethylacetate 8:2 to 4:6. The solvent was removed to give the product 
as a mixture of diastereoisomers (687 mg, 1.74 mmol, 78 %) as a slightly yellowish oil. 1H 
NMR (500 MHz, Chloroform-d) δ 4.14 (dd, J = 11.7, 4.6 Hz, 1H), 4.08 (dd, J = 11.7, 6.2 Hz, 
2H), 3.87 (s, 1H), 3.80 – 3.75 (m, 1H), 3.67 – 3.60 (m, 1H), 3.65 – 3.60 (m, 1H), 2.32 – 2.26 
(m, 2H), 1.61 – 0.95 (m, 18H), 0.92 (td, J = 7.4, 2.1 Hz, 3H), 0.82 – 0.69 (m, 4H), 0.67 – 0.49 
(m, 4H), -0.15 – -0.29 (m, 3H). 13C NMR (126 MHz, Chloroform-d) δ 174.34, 70.27, 65.17, 
63.32, 34.15, 30.12, 29.42, 29.28, 29.13, 28.85, 28.69, 28.22, 28.11, 28.09, 28.06, 27.97, 
27.95, 27.91, 27.79, 24.91, 22.04, 17.86, 17.58, 16.26, 16.18, 16.10, 16.05, 15.92, 15.88, 
15.84, 15.80, 15.62, 14.50, 11.12, 11.02, 10.92, 10.85, 10.77, 10.73, 10.61. HRMS (ESI [M + 
Na]+) m/z: calcd for (C24H42O4Na) 417.29753, found 417.29748. 
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Synthesis of 147 (2-hydroxypropane-1,3-diyl bis(8-(2-((2-((2-
ethylcyclopropyl)methyl)cyclopropyl)methyl)cyclopropyl)octanoate)) (TCDPLN) 
 
 
 
Isolated as a side product of 140. 
1H NMR (500 MHz, Chloroform-d) δ 5.01 (p, J = 5.0 Hz, 1H, 2-subst.), 4.25 (dd, J = 11.9, 4.5 
Hz, 1H, 2-subst), 4.20 – 3.97 (m, 4H), 3.71 – 3.62 (m, 1H), 2.27 (dt, J = 12.0, 7.6 Hz, 4H), 
1.55 (q, J = 7.0 Hz, 4H), 1.50 – 1.40 (m, 2H), 1.39 – 0.95 (m, 32H), 0.92 (td, J = 7.3, 2.2 Hz, 
6H), 0.82 – 0.67 (m, 8H), 0.66 – 0.49 (m, 8H), -0.24 – -0.38 (m, 6H). 13C NMR (126 MHz, 
Chloroform-d) δ 173.88, 173.75, 173.39, 72.08, 68.33, 65.01, 61.99, 61.49, 34.26, 34.08, 
30.11 (2C), 29.42 (2C), 29.28 (2C), 29.10 (2C), 28.84, 28.67, 28.20, 28.07, 28.04, 27.93, 
27.89, 27.77, 24.86 (2C), 22.11, 21.94, 17.84, 17.56, 16.24 (2C), 16.17, 16.15, 16.08 (2C), 
16.05, 16.03, 15.94, 15.90 (2C), 15.86 (2C), 15.82, 15.78, 15.61 (2C), 14.47 (2C), 11.10, 
11.01 (2C), 10.90, 10.83, 10.75, 10.71, 10.59. HRMS (ESI [M + NH4]+) m/z: calcd for 
(C45H80O5N) 714.60310, found 714.60311. 
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9.1 Introduction 
9.1.1 Tissue engineering 
 
Tissue engineering is an important medical field in which significant progress was made in 
the last three decades.1 The replacement or regeneration of damaged tissue using artificially 
grown grafts is a powerful approach. The method is based on the isolation of donor cells, 
often from the patient, which then are proliferated in vitro. These cells are then seeded on a 
matrix to form a graft, which subsequently is implanted into the patient. A bottleneck in 
current cell-based transplantation therapies is the poor donor cell survival.2,3 The implanted 
tissue is not connected to the blood vessel system of the patient’s body, leading to oxygen 
and nutrition deficiencies. Since vascularization, i.e. the development of new blood vessels is 
a slow process, the cells often suffer from necrosis,4 caused by insufficient oxygen supply.5,6 
Several studies on different tissues have revealed that most cells die within the first 24 h 
after transplantation.7,8 Some studies show that 70-80 % of injected cells die within three 
days; 93 % of skeletal myoblasts were lost after 2 days.9 Pathological processes or local 
immune and inflammatory responses causes early donor cell death.10 Several approaches 
have been reported to address the problem of insufficient oxygen supply by delivering 
oxygen artificially to the cells. For example, the biodegradable polymer poly(lactic-co-glycolic 
acid) (PLGA) was loaded with sodium percarbonate. The application of the sodium 
percarbonate system led to a decrease of necrosis and enhanced cell viability for several 
days.11 A hydrogen peroxide/catalase system as oxygen source has been introduced as 
well.12 Pedreza et al. developed a system that generates oxygen from calcium peroxide 
encapsulated in polydimethylsiloxane.13 However, these methods suffer from drawbacks 
such as generation of cytotoxic reactive oxygen species (ROS) and uncontrolled oxygen 
release.14,15 Benz et al. treated fibroblasts and rat smooth muscle cells (SMCs) under 
hypoxic conditions with pyridone endoperoxides and could show that cell survival was 
improved.16 These water-soluble methylated pyridone-derived endoperoxides undergo a 
retro-Diels-Alder reaction when exposed to aqueous environment, thereby releasing oxygen. 
Lipid-based cubosomes have attracted considerable attention in the field of nanomedicine as 
tunable drug-nanocarriers. The nanoparticles protect their cargo from digestion by enzymes, 
thereby improving their bioavailability, and can enter cells very efficiently.17 Combining this 
elegant approach of producing oxygen via retro-Diels-Alder reaction of pyridone 
endoperoxides, with its efficient delivery into cells using cubosome nanoparticles, results in a 
novel and promising concept addressing the issue of oxygen deficiency in freshly 
transplanted cells, which is introduced herein. 
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9.1.2 Drug delivery and cubosomes 
 
An ideal drug delivery system should be biodegradable, biocompatible and should be able to 
incorporate a variety of different cargo molecules, may they be proteins, nucleic acids or 
small molecules that are positively charged, negatively charged or neutral. It should deliver 
the incorporated active agents without loss of activity to the specific location in vivo in an 
efficient and controlled manner. Lipidic mesophases, specifically lipidic cubic phases (LCPs) 
constitute an attractive delivery system that can be triggered by external stimuli.18  
To exploit the large potential of nano-medicinal techniques, the development and 
investigation of state-of-the-art drug delivery nanoparticles is required. These nanoparticles 
need to be tunable for distinct applications and need to consist of non-toxic and 
biocompatible compounds.19 Whereas polymers and liposomes are well established drug 
delivery systems, the application of cubosomes is still at its infancy. Cubosomes, introduced 
in Chapter 1 of this thesis in more detail, are dispersions of LCPs which are formed by ultra 
sonication of the bulk parent phase. Undesirable biological responses such as opsonization 
of the colloidal lipidic cubic phases and subsequent clearance are reduced due to the 
polyethylene glycol layer around the particles, the so-called stealth corona. The resulting 
increase of the biological half-life depends on both the thickness and density of the stealth 
corona which mask the cubosomes.20 
Innovation in the field of nanomedicine can be achieved by developing drug delivery systems 
which are rationally designed, with features like side-effect reduction, targeting, continuous 
drug release and imaging tools.20 The application of a self-assembly approach to generate 
these drug-delivery vehicles allows to combine the required elements from toolboxes, for 
example fluorescently labelled lipids, to create tailored nanoparticles for specific 
applications.20  
Whereas progress in the field of bioactive cubosomes and their in-vitro applications is quite 
advanced, transfer to clinics is still at an early stage.21 Thus, the huge potential of 
cubosomes has not yet been fully exploited. Their application as multifunctional delivery 
vehicles for hydrophobic, hydrophilic, and amphiphilic drugs or imaging agents, as well as 
their tunable drug release properties and potential surface functionalization for targeted drug 
delivery provide great promise for their clinical applications.21 
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9.1.3 Pyridone endoperoxides 
 
The fact that 2-pyridones can reversibly bind singlet oxygen22,23 is the underlying principle of 
our oxygen supply strategy to engineered tissue.14,16 Pyridone endoperoxides are obtained 
upon [4+2] cycloaddition of 1O2 acting as dienophile and the 2-pyridone derivative as diene 
(Scheme 1). This type II photooxigenation requires the more reactive singlet oxygen for the 
Diels-Alder reaction to occur. A photosensitizer (ps) is excited by photons to the excited state 
(ps*). Upon energy transfer from the excited photosensitizer to triplet oxygen (3O2), singlet 
oxygen (1O2) is formed, which undergoes [4+2] cycloaddition with the 2-pyridone derivative to 
form the corresponding pyridone endoperoxide.24 
 
 
Scheme 1: General mechanism of type II photooxygenation using the example of a 2-pyridone 
derivative resulting in a 2-pyridone endoperoxide. Abbreviations: photosensitizer in the ground state 
(ps) and in the excited state (ps*), photons (hν). 
 
This [4+2] cycloaddition is a reversible process. Pyridone endoperoxides can therefore 
release singlet oxygen via retro-Diels-Alder reaction when in contact with water. However, 
singlet oxygen is cytotoxic and cannot be delivered to cells in this form. The use of vitamin C, 
among others, is a known method to physically quench singlet oxygen to obtain triplet 
oxygen25 and was thus previously used to quench singlet oxygen released from pyridone 
endoperoxides.16  
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9.2 Results and discussion 
 
Benz et al. showed that the stability and thus the 1O2-release of such pyridone 
endoperoxides is tunable by varying the substitution pattern of the pyridone core, especially 
at position 1 and 3 (Scheme 1), leading to half-lives (t1/2) on different time scales. Since 
vascularization of transplanted tissue is a lengthy process, taking up to weeks, artificial 
oxygen supply should ideally proceed on a similar time scale.5,16 The development of 
compounds with very long half-lives remains a challenge, and the best available pyridone-
based candidate shows a half-life of 8.5 h at 37 °C in water.16  
 
 
Figure 1: Structures of water-soluble pyridone endoperoxide 148 used by Benz et al.16 (left), and 
lipidic pyridone endoperoxide 149 that allows incorporation into MO-cubosomes upon self-assembly 
(right). The relevant substitutions at positions 1 and 3 for the stability (in blue) were not altered, 
whereas the triethyleneglycol residue in the water-soluble molecule was replaced by an oleyl chain (in 
green), leading to significant increase of the CLogP value. 
 
 
9.2.1 Synthesis of lipidic pyridone endoperoxides 
 
The beneficial effects on survival of anoxic 3T3 fibroblasts and rat SMCs achieved by Benz 
et al. using water-soluble pyridone endoperoxides16 might even be more efficient if the 
oxygen bearing precursors were delivered into the cells using cubosomes as nanocarriers. 
To this end, pyridone endoperoxides were lipidated to enable their incorporation via self-
assembly into lipid-based cubosomes. Two lipidic pyridone endoperoxides bearing a 
saturated and an unsaturated lipidic chain were synthesized (Scheme 2), with the aim of 
optimal incorporation of these additives into cubosomes that are based on the saturated lipid 
PT, and on the unsaturated lipid MO, thereby enabling the use of both phytantriol (PT)- and 
MO-based cubosomes. In a first step, 2-bromoacetate (150) was coupled to dodecanol or 
oleyl alcohol, respectively, at -78 °C to obtain the required linker 151 and 152 bearing the 
corresponding lipidic tails. The synthesis was performed according to the procedure of 
Morrissey et al.26 Alkylation of pyridones can occur at the nitrogen or the oxygen atom, 
depending on the conditions. Selective N-alkylation of commercially available 2-
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methylpyridone was achieved using K2CO3 as a base in DMF and yielded the lipidated 
pyridone dienes 154 and 155. 27 O-alkylation was not observed. Lipidated pyridone dienes 
154 and 155 were subsequently photooxigenized using compressed air in the presence of 
meso-tetraphenylporphyrin as photosensitizer in CH2Cl2 and under irradiation with an LED at 
627 nm.22 Lipidic pyridone endoperoxides 156 and 157 were obtained in good yields in three 
synthetic steps each. 
 
Scheme 2: A) Syntheses of the two lipidic pyridone endoperoxides. The saturated derivative was 
designed to be incorporated into PT-based cubosomes, the unsaturated derivative for MO-based 
cubosomes. B) Synthesis of a fluorescently labelled lipid from commercially available NHS-fluorescein 
and oleylamine. Conditions: a) Dodecanol or oleyl alcohol in CH2Cl2, -78 °C. b) 151 or 152, K2CO3, 
DMF, -78 °C. c) compressed air, cat. meso-tetraphenylporphyrin, CH2Cl2, hν (LED, 627 nm), 0 °C. d) 
Oleylamine, 1.5 eq., NEt3, 1.5 eq, DMF, r.t. 
 
Several studies on the uptake mechanism and the intracellular fate of the nanoparticles have 
been published.28–32 The results are, however restricted to the system under investigation.33 
In order to allow in vitro tracking of the cubosomes and to gain knowledge about the uptake 
mechanism and the intracellular fate of the nanoparticles in our study, a fluorescently 
labelled lipid was synthesized which can be incorporated as an additive into the cubosomes. 
Commercially available NHS-fluorescein 158, was coupled to oleylamine to obtain 
fluorescently labelled lipid 159 in one step (Scheme 2 B). 
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9.2.2 Cubosome preparation, characterization and O2-release kinetics 
 
Cubosomes were prepared by evaporating dichloromethane from a solution with the 
corresponding lipid and additive in the required ratio. The lipidic was subsequently hydrated 
and ultrasonicated. The particle size and the polydispersion index (PDI) of the cubosomes 
were determined by DLS. Monoolein-based cubosomes were found to be 238 ± 4 nm with a 
PDI of 0.33, whereas phytantriol-based cubosomes were 218 ± 3 with a PDI of 0.21. 
 
 
Figure 2: Kinetic measurements of O2-release from cubosomes: A) Decay of lipidic pyridone 
endoperoxide 157 upon release of O2 over time. B) Evolution of the retro-Diels-Alder product 2 over 
time. C) Relevant section of the 1H-NMR spectrum of a cubosome dispersion during the reaction. 
D) NMR tube with O2-releasing cubosome dispersion. 
 
Following their preparation, the cubosomes were added to a NMR tube (Figure 2D) and their 
O2-release was monitored directly by 1H-NMR to prove the function of the system and to 
determine the half-lives of the O2-releasing compound, which was found to be ca. 7 h, 
whereas the O2-release is completed after ca. 30 h. Decay of the lipidic pyridone 
endoperoxide 157 and generation of the retro-Diels-Alder product 155 was plotted versus 
time (Figure 2 A and B) by integration of the corresponding signals in the NMR spectra (an 
example: Figure 2, C) at 37°C. One of the challenges with such compound is the fact that 
oxygen release is induced once the pyridone endoperoxides are in contact with water. 
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Hence, the cubosome preparation step needs to be done as fast as possible. However, 
some oxygen release will take place before the cubosomes can be used for kinetic 
measurements or actual applications. This can be seen in Figure 2A, 37 % of 157 underwent 
already retro-Diels-Alder reaction at the time the measurement was started. By accelerating 
the cubosome preparation process and reducing the sonication power, this loss might be 
reduced. 
 
 
9.2.3 In vitro toxicity assessment and development of working concentration 
 
Previous experiments by Prange, Aleandri et al.17 served as orientation for the preparation of 
safe and non-toxic cubosome concentrations for in vitro studies. Therefore, we started with 
similar concentrations (0.1-0.2 mg/mL) to those used in these previous experiments. 
Surprisingly, it was found that empty MO- and PT-based cubosomes prepared in growth 
medium of the cells negatively influence the cell proliferation (Figure 4A left panel). However, 
when prepared in PBS and diluted in cell growth medium just before use for incubation, cell 
proliferation does not seem to be affected (Figure 3A right panel). Additionally, optimal 
vitamin C concentrations had to be found (Figure 3B/C). Vitamin C is required as a quencher 
of singlet oxygen (1O2) which is formed during the retro-Diels-Alder reaction, thereby 
obtaining non-cytotoxic triplet oxygen (3O2). It was also observed that higher vitamin C 
concentrations (Figure 3B) did not lead to better cell viability.  
To find an optimal ratio between vitamin C and cubosomes, vitamin C concentrations of 25, 
50 and 75 µg/mL were tested on 0.05, 0.1 and 0.2 mg/mL cubosomes (Figures 3C). The 
most stable cell proliferation was reached with either 25 or 50 µg/mL vitamin C for all tested 
cubosome concentrations. Hence, the working concentration for the in vitro tests was set to 
be 50 µg/mL vitamin C with 0.1 mg/mL cubosomes. 
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Figure 3: Toxicity determination of empty cubosomes (A), endoperoxide-loaded cubosomes (B), and 
vitamin C concentrations for non-toxic cubosome concentrations (C): MPCs were seeded 4 h prior to 
cubosomes treatment. Cubosomes were incubated on the cells for indicated times (A) or 24 h (B/C) 
and a routine cell proliferation assay (WST) was performed thereafter. (A) Preparation of empty 
cubosomes in PBS seems to affect cell proliferation less, independent of their lipidic basis, than 
preparation directly in growth medium. (B) Endoperoxide-loaded cubosomes need to be co-incubated 
with vitamin C as oxygen radical scavenger. Higher cubosome concentration leads to increased cell 
death despite parallel vitamin C increase. (C) Non-toxic concentrations of endoperoxide-loaded 
cubosomes could not be further expanded using different vitamin C concentrations. 
 
 
9.2.4 The effect of endoperoxide-loaded cubosomes under hypoxic conditions 
in vitro 
 
Preliminary test runs were performed with the muscle precursor cells (MPCs) under normal 
and reduced oxygen conditions. Following the observation with basic culture that hypoxic 
conditions affect the proliferation of the MPCs, cubosome samples were added under 
hypoxic and normoxic conditions to compare their potential effect on the Hypoxia-inducible 
factor-1a (Hif1a) protein expression. Hif1a is induced under hypoxia and is a key 
transcription factor which is regulated by a proline hydroxylase.34 Proline hydroxylase 
requires 2-oxoglutarate, iron and oxygen for its activity, and it modifies Hif1a post-
translationally by hydroxylation.35 The post-translationally modified Hif1a interacts with the 
Von Hippel-Lindau protein which then leads to degradation of Hif1a.34 However, this post-
Chapter 9 
 
 219 
translational modification does not occur under hypoxic conditions, which leads to 
accumulation of Hif1a. 34  
As can be seen in Figure 6C, Hif1a expression was reduced after cubosome treatment 
compared to its expression under untreated hypoxic conditions. Normoxia conditions did not 
show any Hif1a expression. These first results support our hypothesis that cubosomes 
loaded with endoperoxide could influence cellular reactivity to hypoxia by delivering oxygen. 
 
 
Figure 4: The impact of cubosome treatment on MPCs under hypoxic conditions: MPCs were cultured 
under normoxic and hypoxic conditions (representative images shown in A) and their proliferation was 
monitored (B). Protein analysis of these samples showed a reduced relative Hif1a expression after 
cubosome treatment under hypoxic conditions compared to untreated hypoxia samples (C). 
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9.3 Conclusions 
 
Lipidic pyridone endoperoxides 156 and 157 have been prepared in good yields in three 
synthetic steps. In addition, fluorescein-derived lipid (159) was synthesized that allows in 
vitro tracking of the cubosome, thereby gaining information about the uptake mechanism and 
the intracellular fate of the nanoparticles. Cubosomes with lipidic pyridone endoperoxides 
156 and 157 have been prepared and characterized using SAXS and DLS. Non-toxic 
cubosome concentrations were found to be up to 0.2 mg/mL with vitamin C concentrations of 
25 or 50 µg/mL. The O2-release kinetics of lipidic pyridone endoperoxide 157 in cubosomes 
at 37 °C was investigated by 1H-NMR, and the half-live time of lipidic pyridone endoperoxide 
157 was found to be ca. 7 h. Preliminary data on the effect of the O2-releasing cubosomes 
on MPCs are available. Hif1a expression was reduced after cubosome treatment compared 
to its expression under untreated hypoxic conditions. This indicates that cubosomes loaded 
with endoperoxides could affect cellular reactivity to hypoxia by providing oxygen.  
 
 
9.4 Outlook 
 
Lipidic endoperoxides with prolonged half-lives are required to bridge oxygen supply until 
vascularization has taken place. Naphthalene-based endoperoxides seem to be a suitable 
compound class to achieve this goal.36 Furthermore, novel lipids with several endoperoxide 
groups (two or three) within the same molecule will be developed to enable a maximal O2-
release potential. Moreover, the fluorescently labelled lipid 159 will be incorporated into 
cubosomes and used to investigate the cubosome uptake mechanism microscopically. In 
order to proceed with the first step towards clinical application of cubosomes in human trials, 
the cubosome effect has to be tested in animal models. For this purpose, we plan to apply 
cubosomes and MPCs after cubosome treatment in vivo into a mouse model to evaluate the 
potential toxic effect and to find proof on its positive effect on muscle regeneration. 
Preliminary data were already collected while injecting albumin-loaded cubosomes into the 
blood stream of endocytosis deficient mice.17  
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9.5 Experimental section 
 
General Information 
1-Monooleoyl-sn-glycerol C18:1 (monoolein, MO) was purchased from Nu-Chek Prep, Inc. 
(MN, USA), and phytantriol was purchased from DSM. Phosphate buffer solution (PBS (1X) 
pH 7.4) was purchased from Invitrogen. N-(3- dimethylaminopropyl)-N′-ethylcarbodiimide 
hydrochloride (EDC) and 3-methyl pyridone was purchased from TCI, and all other reagents 
and solvents were purchased from Sigma Aldrich. All chemicals and solvents were used as 
received, unless otherwise stated. Reactions were carried out under an inert atmosphere of 
argon in dry solvents. Dichloromethane was degassed with argon and purified by passage 
through activated alumina solvent column (MC Brown solvent system) prior to use. Column 
chromatography was performed using silica gel Merck 60 (particle size 0.040–0.063 mm). 
Analytical thin- layer chromatography (TLC) was performed using Merck pre-coated silica gel 
plates 60 F254; visualization by UV absorption and/or by dipping in a solution of KMnO4 (1 g), 
K2CO3 (2 g) in H2O (100 mL) and subsequent heating. 1H-NMR spectra were recorded on a 
Bruker AV2-500 (500MHz) spectrometer. Chemical shifts are given in parts per million (ppm) 
relative to the internal standard TMS (δ = 0 ppm). Coupling constants J are expressed in Hz 
and multiplicities are abbreviated as follows: s (singlet), br (broad), d (doublet), t (triplet), q 
(quadruplet), quint (quintet), m (multiplet). 13C-NMR chemical shifts are reported relative to 
the solvent residual peaks: CDCl3 = 77.00 ppm. Mass spectra were recorded by the Mass 
Spectroscopy Service of UZH on Finnigan MAT95 MS, BrukerLC MS and Finnigan TSQ700 
MS machines.  
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9.5.1 Synthesis 
 
Synthesis of 151 ((dodecyl 2-bromoacetate))26 
 
 
 
A stirred solution of dodecanol (2 g, 12.63 mmol, 1 eq) and triethylamine (1.4 g, 1.9 mL, 
13.9 mmol, 1.1 eq) in CH2Cl2 (20 mL) was cooled to -78°C whereupon bromoacetyl bromide 
(2.5 g (1.08 mL), 1 eq) was added dropwise. The reaction mixture was stirred for 3 h and 
reaction mixture was allowed to warm up to -20°C and carefully quenched with water (5 mL). 
The organic phase was extracted with water (2 x 10 mL), ammonium chloride sat. (2 x 
10 mL), sodium bicarbonate sat. (2 x 10 mL) and brine (2 x 10 mL) and dried over MgSO4, 
filtered and the solvent removed by rotary evaporation. The crude product was purified by 
column chromatography (95:5 cyclohexane/ethylacetate) to yield the product as a colorless 
oil (3.3 g, 10.74 mmol 85 %). 1H NMR (500 MHz, Chloroform-d) δ 4.10 (t, J = 6.7 Hz, 2H), 
3.76 (2, 1H), 1.59 (p, J = 6.8 Hz, 2H), 1.40 – 1.05 (d, J = 11.4 Hz, 18H), 0.81 (t, J = 6.8 Hz, 
3H). 13C NMR (126 MHz, Chloroform-d) δ 167.30, 66.45 (2C), 29.60 (2C), 29.53, 29.46, 
29.32, 29.16, 28.39, 25.92, 25.72, 22.67, 14.10. HRMS (ESI [M + Na]+) m/z: calcd for 
(C14H27BrO2) 329.10866, found 329.10849. 
 
 
Synthesis of 154 (dodecyl 2-(3-methyl-2-oxopyridin-1(2H)-yl)acetate)16 
 
 
 
A solution of 3-methyl-2-pyridone (153) (160 mg, 1.46 mmol, 1.0 eq), dodecyl 2-
bromoacetate (151) (600 mg, 1.95 mmol, 1.5 eq), and potassium carbonate (600 mg, 
4.4 mmol, 3 eq) in DMF (20 mL) was stirred at room temperature for 16 h. The reaction 
mixture was concentrated in vacuo, the residue was dissolved in ethyl acetate and extracted 
with water (30 mL) and brine (30 mL). The organic phases were dried over MgSO4 and 
concentrated in vacuo. The product was obtained after purification by column 
chromatography (cyclohexane/ethyl acetate 9:1) as a colorless oil (462 mg, 1.3 mmol, 89 %). 
1H NMR (500 MHz, Chloroform-d) δ 7.16 (d, J = 6.7 Hz, 1H), 7.02 (d, J = 6.7 Hz, 1H), 6.05 (t, 
J = 6.8 Hz, 1H), 4.56 (s, 2H), 4.10 (t, J = 6.7 Hz, 2H), 2.08 (s, 3H), 1.56 (q, J = 7.4, 6.8 Hz, 
2H), 1.30 – 1.11 (m, 18H), 0.81 (t, J = 6.8 Hz, 3H). 13C NMR (126 MHz, Chloroform-d) δ 
O
O
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N O
O
O
Chapter 9 
 
 223 
167.93, 162.85, 137.23, 135.16, 130.05, 105.79, 65.90, 50.75, 31.90, 29.63, 29.61, 29.54, 
29.47, 29.33, 29.18, 28.44, 25.76, 22.67, 17.10, 14.11. HRMS (ESI [M + H]+) m/z: calcd for 
(C20H34O3N) 336.25332, found 336.25302. 
 
 
Synthesis of 156 (dodecyl 2-(1-methyl-6-oxo-2,3-dioxa-5-azabicyclo[2.2.2]oct-7-en-5-
yl)acetate) 
 
 
 
Dodecyl 2-((3-methyl-1,2-dihydropyridin-2-yl)oxy) acetate (154) (30 mg, 0.09 mmol) and 
meso-tetraphenylporphyrin (1 mg) were dissolved in CH2Cl2 (10 mL) and stirred vigorously. 
Compressed air (or oxygen) were bubbled through the reaction mixture, which was cooled to 
0°C. The reaction mixture was kept under oxygen atmosphere and irradiated with an LED 
lamp at 627 nm for 1.5 h. The solvent was removed in vacuo and the crude product purified 
by column chromatography (cyclohexane/ethyl acetate 9:1) to obtain the product in 
quantitative yield (33 mg, 0.09 mmol). 1H NMR (500 MHz, Chloroform-d) δ 6.85 (dd, J = 7.8, 
5.4 Hz, 1H), 6.39 (dd, J = 7.8, 1.5 Hz, 1H), 5.66 (dd, J = 5.2, 1.5 Hz, 1H), 4.61 (d, J = 18.0 
Hz, 1H), 4.13 – 4.00 (m, 2H), 3.80 (d, J = 18.0 Hz, 1H), 1.60 – 1.52 (s, 4H), 1.30 – 0.94 (m, 
19 H), 0.81 (t, J = 6.8 Hz, 3H. 13C NMR (126 MHz, Chloroform-d) δ 169.57, 168.99, 134.31, 
132.80, 84.73, 81.43, 65.92, 44.21, 31.89, 29.61, 29.57, 29.54, 29.47, 29.33, 29.17, 28.45, 
25.78, 22.67, 14.54, 14.11. HRMS (ESI [M + Na]+) m/z: calcd for (C20H33O5NNa) 390.22509, 
found 390.22534.  
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Synthesis of 152 ((Z)-octadec-9-en-1-yl 2-bromoacetate)26  
 
 
 
A stirred solution of oleyl alcohol (3.4 g, 12.63 mmol, 1 eq) and triethylamine (1.4 g, 1.9 mL, 
13.9 mmol, 1.1 eq) in CH2Cl2 (20 mL) was cooled to -78°C whereupon bromoacetyl bromide 
(2.5 g (1.08 mL), 1 eq) was added dropwise. The reaction mixture was stirred for 3 h and 
reaction mixture was allowed to warm up to -20°C and carefully quenched with water (5 mL). 
The organic phase was extracted with water (2 x 10 mL), ammonium chloride sat. (2 x 
10 mL), sodium bicarbonate sat. (2 x 10 mL) and brine (2 x 10 mL) and dried over MgSO4, 
filtered and the solvent removed by rotary evaporation. The crude product was purified by 
column chromatography (95:5 cyclohexane/ethylacetate) to yield the product as a colorless 
oil (3.98 g, 10.23 mmol, 81%). 1H NMR (500 MHz, Chloroform-d) δ 5.42 – 5.21 (m, 2H), 4.10 
(t, J = 6.7 Hz, 2H), 3.76 (s, 2H), 1.97 – 1.86 (m, 4H), 1.59 (p, J = 6.8 Hz, 2H), 1.38 – 1.09 (m, 
22H), 0.81 (t, J = 6.9 Hz, 3H). 13C NMR (126 MHz, Chloroform-d) δ 166.29, 128.97, 128.73, 
65.43, 30.89, 28.75, 28.70, 28.51, 28.35, 28.31, 28.16, 28.13 (2C), 27.39, 26.20, 26.16, 
24.91, 24.72, 21.67, 13.10. HRMS (ESI [M + Na]+) m/z: calcd for (C20H37BrO2) 411.18691, 
found 411.18663. 
 
 
Synthesis of 155 ((Z)-octadec-9-en-1-yl 2-(3-methyl-2-oxopyridin-1(2H)-yl)acetate)16 
 
 
 
A solution of 3-methyl-2-pyridone (153) (200 mg, 1.83 mmol, 1.0 eq), (Z)-octadec-9-en-1-yl 
2-bromoacetate (152) (1.07 g, 2.75 mmol, 1.5 eq), and potassium carbonate (760 mg, 
5.5 mmol, 3 eq) in DMF (20 mL) was stirred at room temperature for 16 h. The reaction 
mixture was concentrated in vacuo, the residue was dissolved in ethyl acetate and extracted 
with water (30 mL) and brine (30 mL). The organic phases were dried over MgSO4 and 
concentrated in vacuo. The product was obtained after purification by column 
chromatography (cyclohexane/ethyl acetate 9:1) as a colorless oil (597 mg, 1.43 mmol, 
78 %). 1H NMR (500 MHz, Chloroform-d) δ 7.15 (d, J = 6.8 Hz, 1H), 7.03 (d, J = 6.8 Hz, 1H), 
O
Br
O
N O
O
O
Chapter 9 
 
 225 
6.05 (t, J = 6.8 Hz, 1H), 5.38 – 5.22 (m, 2H), 4.56 (s, 2H), 4.09 (t, J = 6.7 Hz, 2H), 2.08 (s, 
3H), 1.97 – 1.86 (m, 4H), 1.57 (p, J = 6.6 Hz, 2H), 1.38 – 1.09 (m, 22H), 0.81 (t, J = 6.8 Hz, 
3H). 13C NMR (126 MHz, Chloroform-d) δ 167.88, 162.80, 137.19, 135.15, 129.97, 129.91, 
129.71, 105.74, 65.82, 50.72, 31.85, 29.71, 29.69, 29.47, 29.33, 29.26 (2C), 29.14, 29.11, 
28.40, 27.16, 27.14, 25.71, 22.63, 17.05, 14.06. HRMS (ESI [M + H]+) m/z: calcd for 
(C26H44O3N) 418.33157, found 418.33164. 
 
 
Synthesis of 157 ((Z)-octadec-9-en-1-yl 2-(1-methyl-6-oxo-2,3-dioxa-5-
azabicyclo[2.2.2]oct-7-en-5-yl)acetate)  
 
 
 
(Z)-octadec-9-en-1-yl 2-(3-methyl-2-oxopyridin-1(2H)-yl)acetate (30 mg, 0.072 mmol) and 
meso-tetraphenylporphyrin (1 mg) were dissolved in CH2Cl2 (10 mL) and stirred vigorously. 
Compressed air (or oxygen) were bubbled through the reaction mixture, which was cooled to 
0°C. The reaction mixture was kept under oxygen athmoesphere and irradiated with an LED 
lamp at 627 nm for 4 h. The solvent was removed in vacuo and the crude product purified by 
column chromatography (cyclohexane/ethyl acetate 9:1) to obtain the product as colorless oil 
(24 mg, 0.054 mmol, 75 %). 1H NMR (500 MHz, Chloroform-d) δ 6.96 – 6.79 (m, 1H), 6.39 
(d, J = 7.8 Hz, 1H), 5.66 (d, J = 5.2 Hz, 1H), 5.33 – 5.23 (m, 2H), 4.61 (d, J = 18.0 Hz, 1H), 
4.11 – 4.01 (m, 2H), 3.80 (d, J = 18.0 Hz, 1H), 1.99 – 1.86 (m, 4H), 1.59 – 1.47 (s, 5H), 1.34 
– 1.07 (m, 22H), 0.81 (t, J = 6.5 Hz, 3H). 13C NMR (126 MHz, Chloroform-d) δ 169.57, 
134.31, 129.99, 129.72, 84.72, 81.43, 65.89, 44.20, 31.89, 29.75, 29.71, 29.53, 29.51, 29.37, 
29.31 (2C), 29.18 (2C), 29.15, 28.45, 27.19, 27.14, 25.78, 22.67, 14.55, 14.11. HRMS (ESI 
[M + Na]+) m/z: calcd for (C26H43O5NNa) 472.30334, found 472.30340. 
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Synthesis of 159 ((Z)-3',6'-dihydroxy-N-(octadec-9-en-1-yl)-3-oxo-3H-
spiro[isobenzofuran-1,9'-xanthene]-5-carboxamide) 
 
 
 
Commercially available NHS-fluorescein (158) (20 mg, 0.422 mmol, 1 eq) oleylamine (17 mg, 
0.633 mmol, 1.5 eq), and triethylamine (39 mg, 3.8 mmol, 9 eq) in CH2Cl2 (5 mL). The 
reaction mixture was let to stir overnight at room temperature. The solvent was removed in 
vacuo and the crude product purified by column chromatography (cyclohexane/ethyl acetate 
1:9) to obtain the product as a mixture of isomers (41 mg, 0.659 mmol, 64 %). 1H NMR (500 
MHz, DMSO-d6) δ 10.15 (s, 1H??), 8.78 (t, J = 5.3 Hz, 1H), 8.64 (t, J = 5.4 Hz, 1H), 8.45 (s, 
1H), 8.23 (d, J = 8.1 Hz, 1H), 8.16 (d, J = 8.1 Hz, 1H), 8.06 (d, J = 8.0 Hz, 1H), 7.66 (s, 1H), 
7.36 (d, J = 8.0 Hz, 1H), 6.77 – 6.65 (m, 2H), 6.61 – 6.51 (m, 2H), 5.48 – 5.18 (m, 2H), 2.07 
– 1.84 (m, 2H), 1.61 – 1.12 (m, 4H), 0.91 – 0.76 (m, 1H). 13C NMR (126 MHz, DMSO-d6) δ 
168.20, 168.05, 164.42, 164.27, 159.60, 154.56, 152.66, 151.83, 140.84, 136.41, 134.66, 
129.65, 129.62, 129.21, 129.12, 128.11, 126.43, 124.81, 124.18, 123.18, 122.19, 112.71, 
112.64, 109.16, 109.10, 102.27, 102.24, 83.28, 83.24, 28.4 – 29.1 (m, 10C), 26.51, 26.55, 
26.45, 22.09, 13.94. HRMS (ESI [M + H]+) m/z: calcd for (C39H48O6N) 626.34706, found 
626.34687. 
 
 
9.5.2 Cubosome preparation  
 
MO or PT was weight into a glass vial and the corresponding amount of a lipidic pyridone 
endoperoxide stock-solution (in CH2Cl2) was added to obtain a homogeneous lipid mixture. 
The solvent was evaporated (at high vacuum 10-2 mbar for 24 h) and the lipidic mixture 
subsequently hydrated by adding appropriate volumes of stabilizer containing buffer (PF108, 
1.65 mg / mL, and required vitamin C concentration) to obtain the cubosome sample with the 
desired lipid concentration. The sample was vortex-mixed and then dispersed using an 
ultrasonic processor Brenson digital 250 (cycle 0.9 s on/ 0.9 s off, amplitude 50%, for 3 x 
5 min). Subsequently, the cubosome dispersion was filtered through Acrodisc 450 nm filters 
and directly used. 
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9.5.3 Dynamic light scattering (DLS) 
 
Particle size of the cubosomes was performed after preparation, before the reaction was 
started, and after the reaction was terminated (1-2 d) with a Zeta Sizer Nano ZS (Malvern 
Instruments, Malvern, UK) at 25 ± 0.1 °C. The samples were measured in disposable 
polystyrene cuvettes of 1 cm optical path length with the corresponding buffer as solvent. 
Scattering angle was 90°. A triplicate of the samples was performed. The width of the DLS 
hydrodynamic diameter distribution is indicated by PDI (polydispersion index). The intensity 
size distribution of the cubosomes was typically unimodal; therefore the autocorrelation 
function was analyzed according to the cumulant method.  
 
 
9.5.4 Small angle X-ray scattering (SAXS) 
 
SAXS measurements were used to identify the symmetry of the cubosomes. Experiments 
were performed on a Bruker AXS Micro, with a microfocused X-ray source, operating at 
voltage filament current of 50 kV and 1.000 µA, respectively. The Cu Kα radiation (λCu Kα 
=1.5418 Å) was collimated by a 2D Pilatus 100K detector. The scattering vector q = 
(4π/λ)sinθ, with 2θ being the scattering angle, was calibrated using silver behenate. Data 
were collected and azimuthally averaged using the Saxsgui software to yield one-
dimensional intensity versus scattering vector q, with a q range from 0.004 – 0.5 Å-1. The 
sample-to-detector distance was 1 m, providing a q range from 0.005 to 0.77 Å-1. Samples 
were loaded into a quartz glass capillary (Hiligenberg, length: 80 mm; outside: 2.0 mm; wall 
thickness: 0.01 mm). Measurements were performed at 23 °C, and samples were 
equilibrated for 10 min prior to measurements, while scattered intensity was collected over 4 
hours.  
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SAXS spectrum of MO-cubosomes containing pyridone endoperoxide 157 
 
Figure 5: Pn3m SAXS pattern of cubosomes containing pyridone endoperoxide 157 (2 mg vc, 31 mg 
MO/ mL PBS 1X containing 1.65 mg/mL PF-108). 
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The experiments described in the following paragraphs have been performed by Jenny 
Prange at the University Hospital of Zurich. 
 
9.5.5 Toxicity assessment and development of optimal ex vivo application 
conditions 
 
hMPCs were isolated and expanded until passage 2/3 and frozen as stock. hMPCs were 
then thawed for each cubosome experiment, seeded in a cellular density of 3000-5000 
cells/cm2 and performed always in the same passage to avoid passaging effects. Cells were 
seeded at least 4h prior to cubosome treatment under both, normoxic and hypoxic 
conditions, to allow settling. Cubosome treatment was performed for 24 h, as the target 
treatment would be a slow release of the load, and hMPCs were cultured after cubosome 
treatment for maximum one week, which represents the time needed by the blood vessels to 
re-vascularize transplanted tissue. Analysis of the cubosome effect will be performed visually 
(light microscopy images), by cell proliferation assay (WST) and by cell counting.  
Cell culture: single cells were isolated from human muscle biopsies (> 0.2 g) from patients 
(different sex and age) undergoing abdominal surgery. Ethical approval was achieved and 
inform consent will be obtained from each patient. Cells will be isolated for research 
purposes only and not used for cell therapy afterwards. All muscle biopsies were transported 
in PBS + 1 % penicillin/streptomycin at 2-8 °C and processed immediately after removal. 
Human MPC isolation procedure is as follows: the biopsy is clean from other tissues, such as 
tendons or fat, weighed and disinfected with 100% and 50% betadine solution for 5 min. After 
three times washing, the muscle tissue is minced and cut into a viscous mix which is then 
mixed with collagenase/ dispase enzymatic solution and incubated for about 1 h at 37 °C. 
After stopping the digestion, the tissue suspension is centrifuged, filtered and distributed on 
collagen-coated 6-well plates for 24 h. After 1 day, the suspension is transferred into the 
neighboring well to remove fibroblasts which have been settled already. In the following 
days, medium is changed every two to three days and growing hMPCs will be split and 
expanded when confluency reaches 80 %.  
The growth medium is based on DMEM/F12 Nutirent Mix (1:1) supplemented with 1 % 
Penicillin/ streptomycin, 18 % FBS, 10 ng/mL hEGF, 1 ng/mL hbFGF, 10 μg/mL human 
Insulin, and 0.4 μg/mL dexamethasone and changed every two to three days. If confluency 
reaches 80 % hMPCs are split using 0.25 % trypsin (Gibco) and reseeded on new culture 
supports.  
Differentiation medium contains DMEM/F12 Nutrient Mix (1:1), 10 % FBS, 1 % Penicillin/ 
Streptomycin and is changed every two to three days. If not directly used, hMPCs are stored 
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in 50 % FBS (Sigma), 40 % DMEM/F12 Nutrient Mix (Gibco) and 10 % Dimethylsulfoxide 
(Sigma) in liquid nitrogen.  
Cubosome treatment: For the cubosome treatment, passage 2-5 hMPCs are seeded 4 h 
prior to the cubosome treatment to allow the cells to settle. Then various concentrations of 
cubosomes will be tested and incubated for 24 h before removal and replacement with fresh 
medium.	
Hypoxia experiments: hMPCs were prepared in suspension (40.000±10.000 cells/mL) and 
seeded directly under hypoxic conditions, at least 4 h prior to cubosome treatment. Medium 
will be stored already 1 day prior to use under hypoxic conditions to ensure the lack of 
oxygen during the procedure. All materials and substances used under hypoxic conditions 
have to pass through the air lock system of the hypoxic chamber.  
Cell proliferation assay: hMPCs were pre-seeded, treated and after treatment suspension 
is removed and replaced with a 1:10 dilution of the WST reagent (Roche) in DMEM/F12 
Nutrient Mix (1:1). WST reagent is incubated for 1-4 h. After incubation, the supernatant was 
removed from the cells and transferred into a 96-well plate (flat bottom) and measured with 
an Epoch2 plate reader (Biotek) at 450 nm.  
Mitochondria assessments: hMPCs treated with/ without cubosomes under hypoxic and 
normoxic conditions were stained for mitochondria morphology using immunofluorescence 
staining with Mitotracker or similar protocols (according to the manufacturers protocol).	Cell 
Counting: For automated cell counting 10 μL of cell suspension was mixed with 10μl of 
trypan blue and loaded in the two chambers of a counting chamber for the Countess 
(Invitrogen). Cell number were reported directly from the machine. Countings were 
performed in triplicates to reduce intra-sampling variability.  
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9.5.6 Application and assessment of cubosome effect on hMPC morphology, 
survival and muscle-specific protein expression under hypoxic 
conditions  
 
Protein Simple WES Analysis 
Cells with different treatments were lysed with modified lysis buffer plus protease inhibitor-
cocktail (Sigma-Aldrich). Samples were centrifuged for 20 min at 13’000 rpm, and the 
supernatant was taken for protein determination. Total protein will be measured using BCA 
protein assay kit (Thermo Scientific, Lausanne, Switzerland). 1 mg/mL of protein will be used 
for the WES sample preparation using 12-230 KDa cartridge kit and the proteins will be 
separated in WES with a capillary cartridge according to the manufacturer protocols (Protein 
Simple WES, Germany). The primary antibodies will be HIf1a (1:100), PHD2 (1:100), 
GAPDH (1:100), Desmin (1:50), Pax7 (1:100), MyoD (1:20), Actinin (1:10). Mouse anti-
GAPDH (1:100, Novus Biologicals Europe) served as internal control.  
Real time PCR: Cells will be mixed with RNA lysis buffer provided in the kit (SV Total RNA 
isolation system, Promega, Dübendorf, Switzerland). Total RNA will be isolated using a kit 
according to the manufacturer's protocol, which includes DNase digestion. RNA will be 
reverse transcribed using random primers (Retro- transcription RNA to cDNA, Applied 
Biosystem). Predesigned primers for EGLN1, Hif3A, Hif1A, ERO1A, DDIT3, MyHC1, desmin 
and human cytochrome c will be purchased from Applied Biosystem. The GAPDH was used 
to normalize cDNA concentrations. For quantification, expression in untreated control cells 
for each gene was taken as a 100% reference value. Negative controls were included as no 
template control and RNA control to check for genomic DNA contamination.  
Fiber formation assay: The formation of muscle fibers was evaluated after 10 days, 
differentiation of hMPCs, seeded in a density of 3000-5000 cells/cm2, in differentiation 
medium which was changed every two to three days. At day 10, culture supports were fixed 
in methanol for 7 min, air dried and stained with Giemsa (Sigma, 1:20 dilution) for 1 h at 
room temperature. After washing, samples were air dried and pictures taken with a Zeiss 
Axio imager M1 microscope. Five high power fields (HPF) were analyzed to calculate the 
average number of fiber per HPF. The data were expressed as fused cells per high power 
field, number of fibers per HPF and number of nuclei per fiber.  
FACS: 500.000 cells will be fixed for 10 min with 2 % paraformaldehyde, permeabilized for 7 
min with 0.5 % Triton X-100, blocked for 20 min with 5 % BSA + 0.1 Triton X-100 and each 
time washed with PBS in between. Samples were then immunolabelled with anti- Annexin V 
(apoptosis marker), anti- PI (necrosis marker), anti-desmin, anti-myosin heavy chain, anti-
MyoD, anti-PAX7 and anti-sarcomeric actinin (hMPC markers, Sigma) at 4 °C before 
secondary labelling were done with a PE- (or equivalent) secondary antibody. Samples were 
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measured using a Becton FACS Calibur flow cytometer of the FACS Core Facility and 
analyzed with FlowJo software. Cell apoptosis/ Necrosis assays: Cell pellet were 
resuspended in cold PBS and pelleted by centrifugation at 1400 rpm for 7 min. Cell pellet 
were gently resuspended in 100 µL of 1x binding buffer (1 x 105 cells/100 µL Binding buffer). 
1 µL of FITC / Annexin V (BD Pharmingen) were added and tubes were incubated for 15 min 
in the dark at room temperature. 350 µL 1 x binding buffer were added to each tube. Just 
before analyzing, 10 µL probidium iodide (100 µg/ml) was added and samples were analyzed 
by flow cytometry within 1 h.  
 
  
Chapter 9 
 
 233 
Bibliography 
 
(1)  Vacanti, C. A. The History of Tissue Engineering. J. Cell. Mol. Med. 2006, 10 (3), 569–576. 
(2)  Müller-Ehmsen, J.; Whittaker, P.; Kloner, R. A.; Dow, J. S.; Sakoda, T.; Long, T. I.; Laird, P. 
W.; Kedes, L. Survival and Development of Neonatal Rat Cardiomyocytes Transplanted into 
Adult Myocardium. J. Mol. Cell. Cardiol. 2002, 34 (2), 107–116. 
(3)  Haider, H. K.; Ashraf, M. Strategies to Promote Donor Cell Survival: Combining Preconditioning 
Approach with Stem Cell Transplantation. J. Mol. Cell. Cardiol. 2008, 45 (4), 554–566. 
(4)  Rivron, N. C.; Liu, J.; Rouwkema, J.; De Boer, J.; Van Blitterswijk, C. A. Engineering 
Vascularised Tissues in Vitro. Eur. Cells Mater. 2008, 15, 27–40. 
(5)  Tremblay, P. L.; Hudon, V.; Berthod, F.; Germain, L.; Auger, F. A. Inosculation of Tissue-
Engineered Capillaries with the Host’s Vasculature in a Reconstructed Skin Transplanted on 
Mice. Am. J. Transplant. 2005, 5 (5), 1002–1010. 
(6)  Auger, F. A.; Gibot, L.; Lacroix, D. The Pivotal Role of Vascularization in Tissue Engineering. 
Annu. Rev. Biomed. Eng. 2013, 15 (1), 177–200. 
(7)  Guérette, B.; Skuk, D.; Célestin, F.; Huard, C.; Tardif, F.; Asselin, I.; Roy, B.; Goulet, M.; Roy, 
R.; Entman, M.; Tremblay, J. P. Prevention by Anti-LFA-1 of Acute Myoblast Death Following 
Transplantation. J. Immunol. 1997, 159 (5), 2522–2531. 
(8)  Snyder, B. R.; Chiu, A. M.; Prockop, D. J.; Chan, A. W. S. Human Multipotent Stromal Cells 
(MSCs) Increase Neurogenesis and Decrease Atrophy of the Striatum in a Transgenic Mouse 
Model for Huntington’s Disease. PLoS One 2010, 5 (2). 
(9)  Qu, Z.; Balkir, L.; Van Deutekom, J. C. T.; Robbins, P. D.; Pruchnic, R.; Huard, J. Development 
of Approaches to Improve Cell Survival in Myoblast Transfer Therapy. J. Cell Biol. 1998, 142 
(5), 1257–1267. 
(10)  Hodgetts, S. I.; Beilharz, M. W.; Scalzo, A. A.; Grounds, M. D. Why Do Cultured Transplanted 
Myoblasts Die in Vivo? DNA Quantification Shows Enhanced Survival of Donor Male 
Myoblasts in Host Mice Depleted of CD4+ and CD8+ Cells or NK1.1+ Cells. Cell Transplant. 
2000, 9 (4), 489–502. 
(11)  Harrison, B. S.; Eberli, D.; Lee, S. J.; Atala, A.; Yoo, J. J. Oxygen Producing Biomaterials for 
Tissue Regeneration. Biomaterials 2007, 28 (31), 4628–4634. 
(12)  Li, Z.; Guo, X.; Guan, J. An Oxygen Release System to Augment Cardiac Progenitor Cell 
Survival and Differentiation under Hypoxic Condition. Biomaterials 2012, 33 (25), 5914–5923. 
(13)  Pedraza, E.; Coronel, M. M.; Fraker, C. A.; Ricordi, C.; Stabler, C. L. Preventing Hypoxia-
Induced Cell Death in Beta Cells and Islets via Hydrolytically Activated, Oxygen-Generating 
Biomaterials. Proc. Natl. Acad. Sci. 2012, 109 (11), 4245–4250. 
(14)  Jaimes, E. A.; Sweeney, C.; Raij, L. Effects of the Reactive Oxygen Species Hydrogen 
Peroxide and Hypochlorite on Endothelial Nitric Oxide Production. 2001, 877–883. 
(15)  Yang, L.; Zhu, L.; Dong, W.; Cao, Y.; Rong, Z. Oxygen-Generating Scaffolds: A New Strategy 
for Bone Tissue Engineering. Bone 2013, 57 (1), 322–323. 
(16)  Benz, S.; Nötzli, S.; Siegel, J. S.; Eberli, D.; Jessen, H. J. Controlled Oxygen Release from 
Pyridone Endoperoxides Promotes Cell Survival under Anoxic Conditions. J. Med. Chem. 
Chapter 9 
 
 234 
2013, 56 (24), 10171–10182. 
(17)  Aleandri, S.; Prange, J. Unpublished Results. 2018. 
(18)  Rahanyan-Kägi, N.; Aleandri, S.; Speziale, C.; Mezzenga, R.; Landau, E. M. Stimuli-
Responsive Lipidic Cubic Phase: Triggered Release and Sequestration of Guest Molecules. 
Chem. - A Eur. J. 2015, 21 (5), 1873–1877. 
(19)  Farokhzad, O. C.; Langer, R. Impact of Nanotechnology on Drug\nDelivery. ACS Nano 2009, 3 
(1), 16–20. 
(20)  Mulet, X.; Boyd, B. J.; Drummond, C. J. Journal of Colloid and Interface Science Advances in 
Drug Delivery and Medical Imaging Using Colloidal Lyotropic Liquid Crystalline Dispersions. 
2013, 393, 1–20. 
(21)  Zhang, L.; Gu, F. X.; Chan, J. M.; Wang, A. Z.; Langer, R. S.; Farokhzad, O. C. Nanoparticles 
in Medicine: Therapeutic Applications and Developments. Clin. Pharmacol. Ther. 2008, 83 (5), 
761–769. 
(22)  Sato, E.; Ikeda, Y.; Kanaoka, Y. Photochemistry of Conjugated Nitrogen-Carbonyl Systems. III 
Photosensitized Oxygenation of 3- and 6-Substituted 2-Pyridones. Chem. Pharm. Bull. 1987, 
35 (2), 507–513. 
(23)  Matsumoto, M.; Yamada, M.; Watanabe, N. Reversible 1,4-Cycloaddition of Singlet Oxygen to 
N-Substituted 2-Pyridones: 1,4-Endoperoxide as a Versatile Chemical Source of Singlet 
Oxygen. Chem. Commun. 2005, No. 4, 483. 
(24)  DeRosa, M. C.; Crutchley, R. J. Photosensitized Singlet Oxygen and Its Applications. Coord. 
Chem. Rev. 2002, 233–234, 351–371. 
(25)  Chou, P. T.; Khan, A. U. L-Ascorbic Acid Quenching of Singlet Delta Molecular Oxygen in 
Aqueous Media: Generalized Antioxidant Property of Vitamin C. Biochem. Biophys. Res. 
Commun. 1983, 115 (3), 932–937. 
(26)  Morrissey, S.; Pegot, B.; Coleman, D.; Garcia, M. T.; Ferguson, D.; Quilty, B.; Gathergood, N. 
Biodegradable, Non-Bactericidal Oxygen-Functionalised Imidazolium Esters: A Step towards 
“greener” Ionic Liquids. Green Chem. 2009, 11 (4), 475. 
(27)  Liu, H.; Ko, S. B.; Josien, H.; Curran, D. P. Selective N-Functionalization of 6-Substituted-2-
Pyridones. Tetrahedron Lett. 1995, 36 (49), 8917–8920. 
(28)  Chithrani, B. D.; Ghazani, A. A.; Chan, W. C. W. Determining the Size and Shape Dependence 
of Gold Nanoparticle Uptake into Mammalian Cells. Nano Lett. 2006, 6 (4), 662–668. 
(29)  Dausend, J.; Musyanovych, A.; Dass, M.; Walther, P.; Schrezenmeier, H.; Landfester, K.; 
Mailänder, V. Uptake Mechanism of Oppositely Charged Fluorescent Nanoparticles in Hela 
Cells. Macromol. Biosci. 2008, 8 (12), 1135–1143. 
(30)  Banquy, X.; Suarez, F.; Argaw, A.; Rabanel, J.-M.; Grutter, P.; Bouchard, J.-F.; Hildgen, P.; 
Giasson, S. Effect of Mechanical Properties of Hydrogel Nanoparticles on Macrophage Cell 
Uptake. Soft Matter 2009, 5 (20), 3984. 
(31)  Saha, K.; Kim, S. T.; Yan, B.; Miranda, O. R.; Alfonso, F. S.; Shlosman, D.; Rotello, V. M. 
Surface Functionality of Nanoparticles Determines Cellular Uptake Mechanisms in Mammalian 
Cells. Small 2013, 9 (2), 300–305. 
(32)  Verma, A.; Uzun, O.; Hu, Y.; Hu, Y.; Han, H. S.; Watson, N.; Chen, S.; Irvine, D. J.; Stellacci, F. 
Chapter 9 
 
 235 
Surface-Structure-Regulated Cell-Membrane Penetration by Monolayer-Protected 
Nanoparticles. Nat. Mater. 2008, 7 (7), 588–595. 
(33)  Deshpande, S.; Singh, N. Influence of Cubosome Surface Architecture on Its Cellular Uptake 
Mechanism. Langmuir 2017, 33 (14), 3509–3516. 
(34)  Harris, A. L. Hypoxia — a Key Regulatory Factor in Tumour Growth. Nat. Rev. Cancer 2002, 2 
(1), 38–47. 
(35)  Masson, N.; Willam, C.; Maxwell, P. H.; Pugh, C. W.; Ratcliffe, P. J. Independent Function of 
Two Destruction Domains in Hypoxia-Inducible Factor-?? Chains Activated by Prolyl 
Hydroxylation. EMBO J. 2001, 20 (18), 5197–5206. 
(36)  Klaper, M.; Linker, T. New Singlet Oxygen Donors Based on Naphthalenes: Synthesis, 
Physical Chemical Data, and Improved Stability. Chem. - A Eur. J. 2015, 21 (23), 8569–8577. 
 
  
Acknowledgements 
 
 236 
10 Acknowledgements 
 
I would like to express my appreciation to Prof. Dr. Ehud M. Landau, for giving me the 
chance to pursue my PhD in his group and for his support during this time. He was a very 
encouraging advisor, especially when things did not work according to plan. I really 
appreciate his openness to new ideas and projects and to collaborations with groups from 
different fields. This made my PhD extremely interesting and interdisciplinary. 
I want to thank Prof. Dr. Henning J. Jessen for mentoring this project and for his help to find 
my PhD position. Henning gave very important inputs for this project to work out. He still 
supported me after his move to Freiburg, which I appreciate very much. 
I also thank Prof. Dr. Oliver Zerbe for being a part of my PhD committee. 
 
I would like to thank all the present members of the Landau Group: 
Marco Etter, who is the social and organizational heart of our group. I thank him for his help 
with the polymerizable lipids, a project that we started together and for his help with the 
enzyme catalysis project, that he is continuing together with Philipp. We went together 
through almost the whole PhD time and became true friends. 
Nicole Kieliger, who is a very friendly colleague. I thank her for the help with the Pd-
complexes.  
Dr. Jijo Vallooran, he brought a lot of mesophase-related know-how into the group. I want to 
thank him for his contributions to the PdNP- and the chiral PT-project. 
Dr. Philipp Ansorge, our biochemistry expert, thanks for your help in the enzyme catalysis 
project. 
We had a wonderful working athmosphere in the group and I will miss the coffee breaks with 
you. 
The former members of the Landau Group: 
Dr. Livia Salvati Manni, with whom I have inspiring scientific, and private discussions. I thank 
her for the contributions on the aldol paper and the PdNP project. 
Dr. Simone Aleandri for introducing me into the lipidic mesophase field. 
Dr. Marek Komisarski and Dr. Yazmin Osornio 
I want to thank the students whose Master or Bachelor theses I supervised: 
Laurent Moser for his work on nornicotine organocatalysts, Giann Wieprächtiger for his work 
on phosphate ester hydrolysis, Daria Dällenbach for her contributions to the enzyme 
catalysis project. It was a pleasure to have you in the lab.  
 
I want to thank Prof. Dr. Raffaele Mezzenga, who allowed us to use his facilities. Stephan 
Handschin for patiently taking TEM images of cubosomes and palladium nanoparticles. 
Acknowledgements 
 
 237 
Chiara Speziale for measuring SAXS and Dr. Salvatore Assenza for his help with some 
figures. 
 
I want to thank Dr. Jenny Prange and Prof. Dr. Dr. med. Daniel Eberli for the collaboration on 
the oxygen-delivery project. 
And I would like to thank Dr. Esther Gottwald and Prof Dr. Andrew Hall for the collaboration 
on kidney diseases. It was a pleasure to work with Esther. 
These collaborations truly enriched my PhD thesis. I am very glad that I could work with 
people from the ETH, from the University Hospital of Zurich and from other groups here at 
UZH. Zurich is an amazing research city. 
 
I would like to thank PD Laurent Bigler and Yvonne Forster for the MS service and Irene 
Lehmann for her analytical help.  
And the people from the NMR facilities: Nadja Bross and especially Simon Jurt, who 
acquired NMR spectra of our Cp-mesophases and of our endoperoxide cubosomes  
 
I would like to thank the Graduate School of Chemical and Molecular Science and to the 
Forschungskredit UZH for their financial support. 
 
This PhD thesis would not have been possible without a very strong private support. 
I want to thank the most important people in my life. Steffi, you are a wonderful woman, I am 
very happy to have you by my side. I admire you for how you are caring for Sebastian, how 
you handle the work load in your office and how you finish your MAS. All at the same time. I 
want to thank Sebastian, who reveals the important things in life. 
My parents Rita and Niklaus, for their support in so many ways, and to my brothers David 
and Alexander, to Lotti and Thomas, who became a second pair of parents to me, and to Adi 
and Mary.  
 
 
 
                                          
 
Curriculum Vitae 
 
Personal information 
First Name, Name Michael DUSS 
Address   Scheuchzerstrasse 223  
    8057 Zurich 
Mobile Phone   +41 79 565 84 14 
Email    michael.duss@chem.uzh.ch 
Date of Birth   05/29/1985 
Place of Origin   Entlebuch LU  
 
Education 
PhD, Chemistry, University of Zurich, Department of Chemistry 11/2013 – 06/2018 
Supervisor: Prof. Ehud M. Landau 
Thesis title: Design of Novel Functionalized Lipidic  
Mesophases and their Applications in Catalysis, Water  
Confinement and Cellular Oxygen Delivery 
MSc, Chemistry, University of Zurich, Department of Chemistry  09/2011 – 09/2013 
Supervisor: Prof. Henning J. Jessen 
Thesis title: Novel Applications of Phosphoramidites:  
Desymmetrization of meso-Compounds and  
Enrichment of Phosphorylated Proteins 
BSc, Chemistry, ZHAW Zurich University of Applied Sciences  09/2007 – 09/2010 
Bachelor Thesis at Givaudan Suisse SA 
Thesis title: Synthese von Benzophenondiethern und  
Benzophenondiacetalen als UV-Präkursoren für die Riechstoffindustrie 
Preparatory course for the entrance examination  10/2006 – 07/2007 
at ZHAW Zurich University of Applied Sciences 
Apprenticeship as Chemical Laboratory Technician,  08/2002 – 08/2005 
Dottikon Exclusive Synthesis AG   
 
Professional experience  
PhD, Chemistry, University of Zurich, Department of Chemistry 11/2013 – 06/2018 (expected) 
Supervisor: Prof. Ehud M. Landau 
Chemical Laboratory Technician, Dottikon Exclusive Synthesis AG  09/2005 – 09/2006 
Supervisor: Dr. Frank Wierschem 
Apprenticeship as Chemical Laboratory Technician,  08/2002 – 08/2005 
Dottikon Exclusive Synthesis AG, Supervisor: Peter Huber 
 
Teaching activities and supervision of students 
Practical Organic chemistry, synthesis course for 2nd year chemistry students (4 semesters, 600 
hours). Students: Anaïs Troude (Internship), Laurent Moser (Master thesis), Giann Wiprächtiger 
(Bachelor thesis), Daria Dellenbach (Bachelor thesis). 
 
Membership in scientific societies 
Swiss Chemical Society 
 
Awards and honors 
- Nomination for an Albert Hofmann PhD Award for Excellence in Research, 2017 
- Forschungskredit Candoc UZH, 2015, (FK-15-083) 
 
Languages and software 
German (native speaker), English (working language, C1/C2), French (good knowledge, B2)  
MS Office, ChemDraw Ultra, Mestrenova, SciFinder 
 
Contributions to conferences and scientific schools 
• Swiss Summer School in Chemical Biology, September 1-5, 2014, Villars, Switzerland (poster 
presentation) 
• SCS Fall Meeting, September 11, 2014, Zurich, Switzerland (poster presentation) 
• 16th Tetrahedron Symposium, June 16-19, 2015, Berlin, Germany (poster presentation) 
• 18th Tetrahedron Symposium, June 27-30, 2017, Budapest, Hungary (poster presentation) 
 
Publications in peer-reviewed scientific journals 
• Michael Duss, Samanta Capolicchio, Anthony Linden, Nisar Ahmed, Henning J. Jessen, 
Desymmetrization of myo-inositol derivatives by lanthanide catalyzed phosphitylation with C2-
symmetric phosphites, 2015 Bioorganic & Medicinal Chemistry, 23, 12, 2854 – 2861. 
• Michael Duss, Livia Salvati Manni, Laurent Moser, Stephan Handschin, Raffaele Mezzenga, 
Henning J. Jessen, Ehud M. Landau, Lipidic mesophases as novel nanoreactor scaffolds for 
organocatalysts: Heterogeneously catalyzed asymmetric aldol reactions in confined water, 
ACS Applied Materials & Surfaces, 2018, 10, 5114 – 5124.  
• Esther M. Gottwald, Michael Duss, Milica Bugarski, Dominik Haenni, Claus D. Schuh, Ehud 
M. Landau, Andrew M. Hall. The targeted anti-oxidant MitoQ causes mitochondrial swelling 
and depolarization in kidney tissue, Physiological Reports, 2018, 1 – 9. 
 
 
 I 
Appendix: 1H-and 13C-NMR spectra 
 
 
Table of contents 
 
Chapter 2 II 
Chapter 3 XXI 
Chapter 4 XXIV 
Chapter 5 XXV 
Chapter 6 XXVIII 
Chapter 7 XXX 
Chapter 8 XXXIII 
Chapter 9 XLIII 
 
  
 II 
Chapter 2 
Compound 2, 1H 
 
 
Compound 2, 13C 
 
  
NH
O
N
H
x CF3COOH
NH
O
N
H
x CF3COOH
 III 
Compound 5a, anti-isomer, 1H 
 
 
Compound 5a, anti-isomer, 13C 
 
 
  
OHO
NO2
O
OH
OHO
NO2
O
OH
 IV 
Compound 5a, syn-isomer, 1H 
 
 
Compound 5a, syn-isomer, 13C 
 
  
OHO
NO2
O
OH
OHO
NO2
O
OH
OHO
NO2
O
OH
OHO
NO2
O
OH
 V 
Compound 5b, anti-isomer, 1H 
 
 
Compound 5b, anti-isomer, 13C 
 
  
OHO
OHO
 VI 
Compound 5b, syn-isomer, 1H 
 
 
Compound 5b, syn-isomer, 13C 
 
  
OHO OHO
OHO OHO
 VII 
Compound 5c, anti-isomer, 1H 
 
 
Compound 5c, anti-isomer, 13C 
 
  
OHO
O
OH
OHO
O
OH
 VIII 
Compound 5c, syn-isomer, 1H 
 
 
Compound 5c, syn-isomer, 13C 
 
 
 
 
 
OHO
O
OH
OHO
O
OH
OHO
O
OH
OHO
O
OH
 IX 
Compound 22, 1H 
 
 
Compound 22, 13C 
 
 
 
  
N
O
NH
O
HO
HO
HN
OMe
O
O
N
O
NH
O
HO
HO
HN
OMe
O
O
 X 
Compound 23, 1H 
 
 
Compound 23, 13C 
 
 
 
  
NH
O
NH
O
HO
HO
HN
OMe
x 2 CF3COOH
NH
O
NH
O
HO
HO
HN
OMe
x 2 CF3COOH
 XI 
Compound 26, 1H 
 
 
Compound 26, 13C 
 
 
  
NH
O
N
H
x CF3COOH
NH
O
N
H
x CF3COOH
 XII 
Compound 27, 1H 
 
 
Compound 27, 13C 
 
 
 
  
NH
x 2 CF3COOH
N
NH
x 2 CF3COOH
N
 XIII 
Compound 28, 1H 
 
 
 
Compound 28, 13C 
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Compound 29, 1H 
 
 
Compound 29, 13C 
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Compound 31, 1H 
 
 
 
Compound 31, 13C 
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 XVI 
Compound 60, 1H 
 
 
Compound 60, 13C 
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H
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O
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O
N
H
O
O
 XVII 
Compound 61, 1H 
 
 
Compound 61, 13C 
 
 
 
  
N
O
N
H
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O
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O
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H
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 XVIII 
Compound 62, 1H 
 
 
Compound 62, 13C 
 
 
  
Br
Br
 XIX 
Compound 63, 1H 
 
 
Compound 63, 13C 
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O
O
N
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O
O
O
 XX 
Compound 64, 1H 
 
 
Compound 64, 13C 
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O
O
N
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O
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 XXI 
Chapter 3 
Compound 78, 1H 
 
 
Compound 78, 13C 
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Compound 80, 1H 
 
 
 
Compound 80, 13C 
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Compound 82, 1H 
 
 
 
Compound 82, 13C 
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 XXIV 
Chapter 4 
Compound 96, 1H 
 
 
Compound 96, 13C 
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Chapter 5 
Compound 113, 1H 
 
 
Compound 113, 13C 
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Compound 114, 1H 
 
 
Compound 114, 13C 
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O
O
H
O
 XXVII 
Compound 115, 1H 
 
 
Compound 115, 13C 
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 XXVIII 
Chapter 6 
Compound 124, 1H 
 
 
Compound 124, 13C 
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H
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H
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 XXIX 
Compound 118, 1H 
 
 
Compound 118, 13C 
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 XXX 
Chapter 7 
Compound 130, 1H 
 
 
Compound 130, 13C 
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Compound 131, 1H 
 
 
 
Compound 131, 13C 
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 XXXII 
Commercial phytantriol (purchased from DSM), 1H 
 
 
 
 
Commercial phytantriol (purchased from DSM), 13C 
 
 XXXIII 
Chapter 8 
Compound 142, 1H 
 
 
Compound 142, 13C 
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O
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Compound 134, 1H 
 
 
Compound 134, 13C 
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O
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Compound 143, 1H 
 
 
Compound 143, 13C 
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O
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O
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Compound 136, 1H 
 
 
Compound 136, 13C 
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Compound 144, 1H 
 
 
Compound 144, 13C 
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O
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Compound 138, 1H 
 
 
Compound 138, 13C 
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Compound 146, 13C 
 
 
Compound 146, 13C 
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Compound 145, 1H 
 
 
Compound 145, 13C 
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Compound 140, 1H 
 
 
Compound 140, 13C 
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Compound 147, 1H 
 
 
Compound 147, 13C 
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Chapter 9 
Compound 151, 1H 
 
Compound 151, 13C 
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Compound 154, 1H 
 
Compound 154, 13C 
 
N O
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O
N O
O
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 XLV 
Compound 156, 1H 
 
Compound 156, 13C 
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O
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 XLVI 
Compound 152, 1H 
 
Compound 152, 13C 
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Compound 155, 1H 
 
Compound 155, 13C 
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 XLVIII 
Compound 157, 1H 
 
 
Compound 157, 13C 
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 XLIX 
Compound 159, 1H 
 
 
Compound 159, 13C 
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